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Abstract 
 
Osteoarthritis (OA) is a common degenerative disease of articular joints characterised by 
the enzymatic degradation of cartilage, mediated predominately by the collagenolytic 
matrix metalloproteinases (MMP)-1 and -13. Various stimuli have been identified as 
inducers of MMP expression in chondrocytes, including pro-inflammatory cytokines, 
abnormal mechanical load, and the activation of protease-activated receptor 2 (PAR2) by 
matriptase. Both PAR2 and matriptase are strongly implicated in OA. PAR2 is activated 
by cleavage at a distinct site to reveal the canonical tethered ligand, SLIGKV, which can 
bind and activate the receptor. PAR2 is also able to undergo non-canonical activation and 
receptor disarming by cleavage at different sites, revealing different tethered ligands or 
removing the extracellular domain. 
 
This project aimed to identify novel PAR2 cleavages by incubated recombinant proteases 
with a PAR2 peptide sequence. The classical collagenases, MMP-1, -8 and -13, as well 
as the cysteine proteases cathepsins V, K, L and B, were all identified as novel PAR2 
cleaving enzymes. The collagenases cleaved PAR2 at a distinct site a single amino acid 
to the C-terminus of the canonical site, and the putative tethered ligand, LIGKVD, was 
identified as a potential biased agonist for PAR2. The cathepsins generally cleaved PAR2 
further towards the cell membrane, and cathepsin V was found to disarm against 
canonical PAR2 activation. Enzyme kinetics were examined for all novel proteases and 
compared with matriptase, identifying MMP-13 as the most potent collagenase for PAR2 
cleavage, with all cathepsins exhibiting broadly similar kinetic profiles to each other. 
 
Canonical PAR2 activation was further explored by DNA microarray analysis which 
identified a pro-inflammatory expression profile. Multiple identified downstream targets 
had previously been identified as MMP regulators induced by pro-inflammatory cytokine 
stimulation of chondrocytes, such as activating transcription factor (ATF) 3, and early 
growth response (EGR) 2. Furthermore, work performed on the mechanical loading of 
chondrocytes in 3-dimensional hydrogel culture identified the same regulators to be 
induced by abnormal load, with subsequent MMP-1 expression. Taken together, disparate 
stimuli were identified as having common downstream elements suggesting overlapping 
pathways resulting in a common outcome: the induction of MMP expression, and an 
increased potential for cartilage catabolism. 
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1. Chapter 1. Introduction 
  Articular Cartilage 
 Structure and Function 
The human body contains numerous cartilaginous tissues, classified as being hyaline, 
elastic or fibrocartilage from a histological standpoint2. The most abundant of these is 
hyaline cartilage which is found on various surfaces such as in the nose, larynx, trachea 
and bronchi, as well as on articular joint surfaces where it is known as articular cartilage3. 
The major function of articular cartilage is joint protection4, by which it provides a low-
friction surface over the joints to protect them from the almost constant movement of the 
average human body. Furthermore, it provides a resistant surface for load-bearing joints 
such as those in the legs4. 
 
Articular cartilage is a unique tissue. It contains no vascular, lymphatic or nervous system, 
and harbours a relatively low number of resident cells known as chondrocytes2. These 
mesenchyme-originating cells produce and maintain a complex extracellular matrix 
(ECM) responsible for the unique properties of cartilage. The cartilage ECM contains 
three major components – collagen, aggrecan and hyaluronan – with a multitude of less 
abundant components. The major protein in all ECMs is fibrillar collagen, and in articular 
cartilage, this is of a specific type – type II collagen5. These collagen fibrils confer 
strength to the tissue, and are resistant to proteolysis. Following collagen, the most 
abundant proteins are the proteolgycans, in particular aggrecan2.  
 
Articular cartilage consists of four distinct zones which differ in cellular morphology and 
ECM structure (Figure 1.1). The top layer which faces the synovial cavity is known as 
the superficial zone and accounts for 10-20% of total cartilage thickness6. This zone is 
characterised by a low proteoglycan content, and densely packed collagen fibres parallel 
to the articular surface7. In the middle zone, the proteoglycan content begins to increase 
and in the deep zone the collagen forms thick fibres perpendicular to the subchondral 
bone, surrounded by high levels of proteoglycan. This zone is key for the structural role 
cartilage plays in the joints7. 
 
2 
 
 
 Chondrocytes 
The cartilage ECM is produced and maintained by the resident chondrocytes. It is thought 
that there is a slow turnover of cartilage, with the chondrocytes also producing enzymes 
which are able to break down the cartilage ECM, such as the collagenase Matrix 
Metalloproteinase (MMP)-13 and the aggrecanase, A Disintegrin And Metalloproteinase 
with Thrombospondin motifs (ADAMTS)-58.  
 
As the cartilage is avascular, chondrocytes are unable to receive their nutrition and 
oxygen from blood, rather they are sustained by diffusion from the synovium and the 
majority of their energy requirements are obtained by anaerobic glycolysis9. 
Chondrocytes are immediately surrounded in an ECM which differs in structure to the 
general cartilage ECM, which is known as the pericellular matrix (PCM). The 
chondrocyte and its associated PCM are together known as a chondron7. The morphology 
of the chondrocytes and chondrons varies depending on their location in the cartilage 
(Figure 1.1). Furthest away from the subchondral bone in the superficial layer, the 
chondrocytes are smaller and flatter “disc-shaped” cells than those deeper within the 
cartilage. Within the transitional zone, the chondrocytes are rounder and more sparsely 
populated, before aligning themselves in clustered columns in the deep zone of cartilage7. 
In the calcified zone, the chondrocytes are small hypertrophic cells in uncalcified lacunae 
anchored within a calcified matrix which acts to attach the cartilage to the subchondral 
bone7,10. 
 
Figure 1.1: The zones of articular cartilage 
Cartilage can be divided into 4 major zones: the superficial zone (STZ), the middle (or transitional zone), the deep 
zone and the calcified zone. Diagram taken from Buckwalter et al., (1994). 
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Despite having a very complex pathogenesis, one of the key concepts in osteoarthritis 
(OA) is an excessive level of ECM breakdown by chondrocyte-expressed proteinases, 
shifting the homeostatic balance away from ECM synthesis11. Type II collagen has an 
extremely long half-life, estimated to be around 117 years12, meaning that its degradation 
is essentially an irreversible process, whereas aggrecan can more readily be remodelled13.  
 
 The Extracellular Matrix 
 Collagen 
Collagens are a large family of crucially important structural proteins, which compose a 
third of all protein in the human body. The collagens are defined by their structure, which 
is composed of three polypeptide chains, forming a right-handed triple helical structure. 
In order to form this tight helix, every third residue in the amino acid sequence is a 
glycine, the smallest amino acid. The overall primary structure of collagens is Gly-Xaa-
Yaa, where Xaa is commonly a proline residue and Yaa is often a post-translationally 
modified hydroxyproline residue14. These collagen triple helices can then self-assemble 
together into microfibrils which can form huge macromolecular structures such as 
collagen fibres. Of particular interest to cartilage biology are the fibrallar collagens, 
especially the interstitial collagens (types I, II and III) which can form these fibres15.  
 
Collagen biosynthesis is a complicated process commencing with translation of collagen 
genes into proto-collagen strands. Type I collagen consists of two gene products, alpha 1 
and alpha 2 chains (COL1A1 or A2), whereas type II collagen consists of a single gene 
product, alpha 1 chain (COL2A1). Type I collagen forms helices with two alpha 1 chains 
and a single alpha 2 chain, whereas type II collagen forms trimers of alpha 1 chains14. 
 
 Proteoglycans 
Proteoglycans, as their name suggests, are heavily glycosylated proteins which usually 
consist of a core protein where the glycosylation occurs in the form of glycosaminoglycan 
(GAG) side chains5. The major proteoglycan in cartilage is aggrecan. 
 
Aggrecan consists of three globular domains (G1, G2 and G3) separated by a long core 
region of around 230 kDa, glycosylated with the GAGs chondroitin sulphate (CS) and 
keratan sulphate (KS). The GAG side chains are separated in to KS- and CS-rich regions. 
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G1 and G2 are N-terminal to the long core region, and are separated from each other by 
a short region known as the interglobular domain (IGD) (Figure 1.2)5. 
 
The GAG side chains carry a negative charge which attracts positively charged water 
molecules, saturating the tissue and rendering it resistant to compressive forces5. 
Furthermore, aggrecan also undergoes various interactions with other matrix components, 
forming large aggregates. An important non-covalent interaction occurs between G1 of 
aggrecan and hyaluronic acid (HA), a large non-sulphated GAG, which can bind up to 
one hundred individual aggrecan molecules2. 
 
 
 
 Mechanical Loading of Cartilage 
In performing their physiological roles within joints, many articular surfaces are subjected 
to great loads on a near constant basis. The structure of cartilage allows for this loading, 
and it is known that experiencing “normal loading” is important in the maintenance of 
joint homeostasis. Indeed, physiological loads on cartilage and chondrocytes stimulate 
the cells to express anabolic mediators and effectors such as aggrecan and type II 
collagen16,17. 
 
Physiological loading as a result of moderate physical exercise has been suggested to be 
protective against OA development in humans18, whereas moderate exercise may have 
positive effects on established OA19. 
 
Figure 1.2: Structure of aggrecan 
Aggrecan consists of three globular domains: G1, G2 at the N-terminus and G3 at the C-terminus, separated by a 
core region, heavily glycosylated by GAGs. KS Keratan sulphate-rich region, CS Chondroitin sulphate-rich region.  
IGD Interglobular domain. Diagram adapted from a figure in Heinegard (2009).  
CS KS 
G3 G2 G1 
IGD 
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Conversely, the non-physiological loading of cartilage (either excessive loading, or lack 
of physiological loading) has detrimental effects on cartilage health. Excess loading of 
cartilage in explant culture can lead to chondrocyte apoptosis20 and the stimulation of 
multiple pro-inflammatory pathways leading to the expression of proteins such as MMPs 
which can lead to cartilage destruction21,22 (Figure 1.3). 
 
 
 
 
 
 Arthritis 
“Arthritis” encompasses a huge range of diseases involving one or multiple joints with 
some level of inflammation. Indeed, the word arthritis comes from the greek “arthro-” 
meaning joint and “-itis” meaning inflammation. The most common forms of arthritis are 
osteoarthritis and rheumatoid arthritis (RA), however these also encompass many distinct 
sub-forms with differing aetiology and progression. 
 
Figure 1.3: Signalling pathways mediated by mechanical loading of cartilage 
Chondrocytes are responsive to both physiological and non-physiological loading, and multiple pathways have 
been identified as mechanosensitive. Diagram taken from Sun (2010). 
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 Rheumatoid Arthritis 
Rheumatoid arthritis is an autoimmune disease of synovial joints characterised by a strong 
inflammatory response. The causes of RA are incompletely understood, with links to both 
genetic and environmental factors23. Despite the lack of an initial trigger being identified, 
it is likely that RA results from the recognition of an auto-antigen. During subsequent 
disease progression, a variety of immune cells such as T cells, B cells, macrophages, 
neutrophils and mast cells infiltrate the synovial space, and with the resulting release of 
a multitude of pro-inflammatory mediators, joint and bone is degraded, and the synovial 
membrane proliferates forming a pannus23. 
 
 Osteoarthritis 
Osteoarthritis is a common disease in the aged population, with some symptoms of the 
disease prevalent in the majority of people over 65 years of age24. OA is a disease best 
characterised by the degradation of articular cartilage, although the disease is considered 
a disease of the whole joint25. The joints most often affected by OA include joints of the 
hands, knees, hips and spine, with the major symptoms including pain, mild 
inflammation, stiffness and general loss of mobility24. 
 
There is some evidence that aggrecan cleavage is involved in the initiation of cartilage 
degradation in OA, as aggrecan is able to protect the type II collagen26. Pratta et al. 
(2003)26, provide evidence that the selective inhibition of ADAMTS-4 and -5 (the 
aggrecanases) appears to offer protection against MMP-mediated collagen degradation in 
bovine explant cultures. In order to control for non-specific inhibition of MMPs by these 
aggrecanase inhibitors, the inhibitors were also added to the explant culture following 
aggrecan cleavage (but before collagen cleavage), and here they offered no protection, 
whereas MMP inhibition following aggrecan loss does offer collagen protection. The 
authors hypothesised that aggrecan offers the collagen physical protection from 
proteolytic attack via steric hindrance. Type II collagen is thought to bind to the KS-rich 
region of aggrecan27 which would place the larger CS-rich region into close proximity of 
the collagen fibrils, thus protecting the collagen. 
 
Conversely, there is opposing evidence which suggests that the cleavage of collagen is 
the initiating factor in cartilage degradation, with aggrecan loss being secondary to this. 
This idea was first suggested in the 1970s when it was noted that the breaking of the 
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collagen network results in localised swelling of the cartilage, as a result of the collagen 
no longer being able to partially “resist” the hydrophilic nature of the aggrecan28. Even 
though there is an eventual aggrecan loss in OA, and thus a loss of water, early disease 
phases are associated with an increase in hydration and swelling29. Furthermore, aggrecan 
loss has been shown to occur in areas where type II collagen fibrils are damaged30,31. 
Despite it not being definitively proven whether collagen or aggrecan cleavage are 
involved in the initiation of cartilage degradation, it is clear that a close interplay between 
these two key events is vital for disease initiation. 
 
Aggrecan is able to undergo multiple cleavages (Figure 1.4), however the most important 
pathological cleavages are thought to occur within the IGD as these cleavages result in 
rapid loss of the whole GAG attachment region and thus is derogatory to the whole 
structure of the cartilage32. The IGD is able to be cleaved by various MMPs, including 
MMP-333, -2, -934, -1, -835, and -1336 at asparagine-341 / phenylalanine-342. However, a 
key study in 1992 showed that these were unlikely to be the most pathologically relevant 
in OA. Sandy et al.37 found that the synovial fluid collected from OA patients contained 
aggrecan fragments cleaved at the glutamic acid-373 / alanine-274. Subsequent studies 
confirmed that this cleavage was not undertaken by MMPs38, and enzymes known as the 
aggrecanases (ADAMTS-4 and -5) were subsequently identified39,40. 
 
Mice studies using ADAMTS-4 and -5 null mice showed that the loss of ADAMTS-5 
(but not ADAMTS-4) protected against OA, suggesting that ADAMTS-5 is the key 
aggrecanase in mice41,42. The situation in humans is more complex however, with 
evidence suggesting that ADAMTS-4 is also involved aggrecan degradation43,44. 
 
8 
 
 
 
 Introduction to Proteases 
Proteases are a class of enzymes which have the ability to catalyse the hydrolysis of a 
peptide bond. There are five classes of proteases, categorised based on their mechanism 
of catalytic action: serine proteases, metalloproteases, cysteine proteases, threonine 
proteases, and aspartic proteases. The total spectrum of proteases encoded by humans is 
known as the degradome. 
 
There are currently 588 proteases identified within the human degradome: 192 
metalloproteases, 184 serine proteases, 164 cysteine proteases, 27 threonine proteases and 
21 aspartic proteases45.  
 
A nomenclature for naming substrate amino acid and protease enzymatic subsites was 
described in 1967 by Schechter and Berger46, where the amino terminal side of the 
cleavage site (the scissile bond) is known as the non-prime side and the carboxy terminal 
side is known as the prime side. The amino acids of the substrate are subsequently 
numbered P4-P4’, and the corresponding sites on the protease are numbered S4-S4’ 
(Figure 1.5) which allows for description and comparison of enzyme specificities. 
 
MMPs Aggrecanases (ADAMTS-4/ -5) 
Figure 1.4: Aggrecan and its cleavage sites 
Multiple cleavage sites have been identified on aggrecan mediated by both the MMPs and the aggrecanases 
(ADAMTS-4 and -5). Diagram adapted from a figure in Heinegard (2009).  
G3 G2 G1 
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 Metalloproteinases 
 Catalytic mechanism 
Much understanding of the metalloproteinase catalytic mechanism is based on studies of 
thermolysin47. Metalloproteinases are thought to employ a single-step catalytic 
mechanism utilising a metal ion, often zinc (as is the case with all metzincins, such as the 
MMPs), co-ordinated by two or three histidine residues. Metalloproteinases further 
require a free water molecule to co-ordinate with the metal ion which is hydrogen bonded 
to a glutamate residue. The catalytic mechanism is thought to entail the binding of the 
substrate into the active site which displaces the hydrogens of the water molecule towards 
the glutamate residue whereas the oxygen remains associated with the zinc ions. The zinc 
ion also associates with the carbonyl oxygen of the substrate, forming the ES complex. 
The polarising activity of the zinc by the glutamate allows the oxygen of the active site 
water to perform nucleophilic attack on the carbonyl carbon of the scissile bond (Figure 
1.6)47,48. 
 
Figure 1.5: Schechter and Berger nomenclature for protease cleavage 
The Schechter and Berger nomenclature describes the amino acids of the substrate as P4-P1 towards the amino 
terminus of the cleavage site, and P1’ to P4’ towards the carboxy terminus. These correspond to the subsites S4-
S4’ on the protease. 
 
        
 P4  P2  P1  P1’  P2’  P3’  P3  P4’ H2N COOH 
S4 S3 S2 S1 S1’ S2’ S3’ S4’ 
Protease 
Protein Substrate 
Scissile Bond 
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 The Metzincins 
The metzincins represent a superfamily of zinc-dependent metalloproteinases including 
the matrixins (MMPs), the astacins, the adamalysins and serralysin49. This superfamily 
shares certain features, most importantly the conserved zinc-binding motif 
(HEXXHXXGXXH, where the three conserved histidine residues bind the zinc ion) and 
a conserved methionine residue49 located 6-53 amino acids after the zinc-binding motif, 
known as the “met-turn”, a tight 1,4-β-turn which is thought to be key to the structural 
integrity of the metzincin active sites50. These two key features are indispensable to the 
metzincins; indeed, they lend their name to the superfamily49. Common to the metzincins 
is the presence of multiple non-catalytic domains51. Of the metzincins, the MMPs and the 
adamlysins play key roles in the remodelling of ECM components. 
 
 The Matrix Metalloproteinases 
The first MMP was identified by Gross & Lapiere in 196252 as a collagenolytic activity 
in tadpole tails during metamorphosis. Subsequently, multiple family members have been 
identified and subdivided into one of six groups according to substrate preference or 
domain structure. These are the classical collagenases (MMP-1, -8 and -13); the 
gelatinases (MMP-2 and -9); the stromelysins (MMP-3, -10 and -11); the matrilysins 
(MMP-7 and -26); the membrane-type MMPs (MT-MMPs); and ungrouped MMPs (such 
as MMP-12 and -19)53. Despite these groupings of the MMPs, it is important to note that 
they all have multiple substrates. For example, MMP-1 cleaves not only collagen, but 
Figure 1.6: Metalloproteinase catalytic mechanism 
Metalloproteinases require a co-ordinated metal ion (usually zinc) which is bound to two or three histidine residues 
as well as a water molecule. The water forms a hydrogen bond with a glutamate, which allows the water molecule 
to act as a nucleophile, able to attack the scissile bond of the substrate at the carbonyl carbon. Diagram taken from 
Erez et al., (2009). 
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other substrates such as protease activated receptor 1 (PAR1)54. Conversely, despite being 
classified as gelatinases, MMP-255 and MMP-956 further have the ability to cleave some 
collagens. 
 
 MMP Structure and activation 
The MMPs share a domain structure consisting of an N-terminal pro-domain, a catalytic 
domain, a hinge region and (with the exception of MMP-7, -23 and -26) a C-terminal 
haemopexin-like (Hpx) domain (Figure 1.7), although some family members have 
variations on this structure, for example, the “membrane type” MT-MMPs. These either 
contain a transmembrane domain or glycosylphophatidylinositol (GPI)-anchor to the C-
terminus of the Hpx domain53. 
 
 
The role of the pro-domain is to keep the MMPs in their inactive, latent pro-forms. This 
is achieved via a mechanism called the “cysteine switch” whereby a conserved cysteine 
residue in the cysteine switch motif (PRCGXPD) ligates to the zinc in the MMP active 
site, preventing catalytic activity57. The majority of secreted MMPs are secreted in their 
pro-form and are activated by a mechanism known as “stepwise activation” where a 
proteinase-susceptible “bait” region in the pro-domain is cleaved by various 
proteinases58. At this stage, the pro-domain is only partially removed and the pro-MMP 
is only partially active. In order to fully activate the pro-MMP, the activity of other active 
MMPs is required, or the pro-MMP may undergo auto-catalysis58.  
 
Various MMPs contain a furin-like enzyme recognition sequence (RX-(K/R)-R), such as 
MMP-11 and the MT-MMPs53. These enzymes are able to be activated intracellularly by 
furin-like enzymes and secreted59 or membrane bound60 in an active form. 
Haemopexin-like domain 
Hinge 
Catalytic Pro 
Figure 1.7: The basic structure of MMPs  
The majority of MMPs share this basic domain structure, including the collagenases (MMP-1, -8 and -13), the 
gelatinases (MMP-2 and -9) and the stromelysins (MMP-3, 10 and 11) although other family members contain 
additional features. For example, several “membrane-type” MMPs (MMP-14, -15, 16, and -17) have an additional 
membrane binding domain, C-terminal to the Hpx domain, whereas the matrilysins MMP-7, -23 and -26 lack the 
haemopexin-like domain. 
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The activation of proMMPs is of great biological significance and is considered a key 
limiting step in MMP activity61. Indeed, the inhibition of proMMP activation could hold 
therapeutic relevance62, which could be of particular importance as the therapeutic 
targeting of MMPs has to date been unsuccessful63. 
 
The Hpx domains of MMPs are thought to have a key role in ligand recognition of MMPs. 
For an excellent review on Hpx domains, the reader is directed to Piccard et al. (2007)64. 
 
 The Collagenases 
There are three “classical” collagenases: MMP-1, MMP-8 and MMP-13, with other 
MMPs also having identified collagenolytic activity such as MMP-14. The collagenases 
are defined by their ability to cleave fibrillar collagen and are all expressed in synovial 
joints65. 
 
The Hpx domains of the collagenases are indispensable for collagenolytic activity. MMP-
1, -8 and -13 are all relatively unstable and are thought to undergo autoproteolytic events, 
separating the Hpx domain from the catalytic domain. MMP-1 and MMP-8 are 
hydrolysed in the hinge region, with MMP-1 being hydrolysed at the proline-250 / 
isoleucine-251 peptide bond66 and MMP-8 is hydrolysed at the glycine-242 / leucine-243 
or proline-247 / isoleucine-248 peptide bonds67. The auto-catalysis of MMP-13 does not 
occur in the hinge region, rather the cleavage site is at the C-terminus of the catalytic 
domain, at the serine-245 / leucine-246 peptide bond68. Following these auto-cleavage 
events, the ability of the MMPs to cleave collagen is lost, however their ability to cleave 
other non-collagen substrates remains. This led to the development of various studies 
using MMP-Hpx chimeras to explore the role of the Hpx domains in collagen recognition. 
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MMP Hpx domains consist of around 210 amino acids, which form a four-blade propeller 
structure, with each blade consisting of four anti-parallel β-sheets64 (Figure 1.8). The first 
and fourth blades are connected together via a disulphide bond64. When the catalytic 
domain from MMP-1 is ligated to the Hpx domain from MMP-3 (an MMP with no 
collagenolytic ability), its ability to cleave collagen is lost, confirming a vital role for the 
Hpx of MMP-1 in collagenolytic activity69. This study further created a chimera 
containing the catalytic domain of MMP-3 and the Hpx domain of MMP-1, and this was 
not sufficient to give MMP-3 collagenolytic activity, suggesting interplay of both the 
catalytic and Hpx domain of MMP-1 is required for binding to and cleaving collagen. 
Another study replaced blades two to four of the propeller in the MMP-8 Hpx domain for 
the corresponding blades in the MMP-3 Hpx domain, and this chimera showed 16.1% of 
the collagenolytic activity of MMP-870. 
 
MMP-1 was the first MMP to be associated with pathological conditions when 
“collagenase” was detected in the synovium of patients with RA71. MMP-1 preferentially 
cleaves type III collagen, followed by type I and has its weakest activity on type II72,73. 
MMP-8 was originally purified from human neutrophils (and is thus often referred to as 
neutrophil collagenase), and has a similar cleavage profile to MMP-1, preferring to cleave 
Figure 1.8: Structure of MMP-2 
Crystal structure of MMP-2, with the Hpx domain boxed in red. The Hpx domain is formed by a four-bladed 
propeller structure with a co-ordinated calcium ion in the centre. Image adapted from a figure in Piccard et al. 
(2007). 
14 
 
type I collagen over type II collagen, however unlike MMP-1, MMP-8 has a much lower 
activity on type III collagen. Indeed, the catalytic efficiencies for MMP-8 on all 3 fibrillar 
collagens are lower than those of MMP-173. Furthermore, much lower levels of MMP-8 
are expressed within articular cartilage74, though higher expression levels are observed in 
OA75. Overall, MMP-8 is not considered to be a major contributor to cartilage degradation 
in arthritic conditions. 
 
MMP-13 is thought to be the most important pathological collagenase in OA76. Even 
though cartilage is thought to express lower levels of MMP-13 compared to MMP-177, it 
has a much higher activity against type II collagen which is its preferred substrate, 
followed by type I and type III collagen78. The Hpx domain from MMP-13 has been 
shown to interact with a whole host of other cartilage ECM components, such as 
fibronectin, type VI collagen, decorin, syndecan 4 and serglycin79, potentially 
highlighting a further role for this enzyme in the regulation of cartilage. 
 
Despite neither MMP-1 nor MMP-13 being completely specific for either OA or RA77, it 
is generally considered that MMP-1 is more important in RA whereas MMP-13 is more 
important in OA61. 
 
 The Gelatinases 
The gelatinase sub-family of MMPs consists of two members: MMP-2 and MMP-9 or 
gelatinase A and B, respectively. Despite being named for their ability to cleave gelatin, 
the mix of proteins and peptides generated from partial collagen hydrolysis, the 
gelatinases are able to cleave a much larger range of ECM components and have some 
roles identified in arthritic diseases80. 
 
Both MMP-255 and MMP-956 have been shown to also exhibit collagenolytic activity, 
with the ability to cleave type I collagen and both enzymes have had roles implicated in 
OA. The expression of both gelatinases is elevated in OA cartilage compared to normal 
adult human cartilage, with MMP-9 being expressed at a much lower level than MMP-
281-83. It is thought that in OA, gelatinase activity is higher in the subchondral bone, rather 
than in the cartilage84, with a role in OA-associated bone changes speculated for them80. 
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 The Stromelysins 
The stromelysin sub-family of MMPs consist of three members: MMP-3 (stromelysin-1), 
MMP-10 (stromelysin-2) and MMP-11 (stromelysin-3). None of the stromelysins are able 
to cleave fibrillar collagen, however are able to cleave several other cartilage components 
such as aggrecan85. 
 
MMP-3 and MMP-10 share 82% sequence homology with one another and have similar 
substrate specificities86, however MMP-3 has much higher expression levels in 
cartilage87. Both of these enzymes are able to activate several proMMPs, including 
proMMP-1, -8 and -1353,88,89, thus are able to initiate collagen degradation by activating 
the collagenases. Indeed MMP-3 is suspected to have an important role in cartilage 
turnover in both health and disease and elevated levels have been observed in synovial 
tissues of OA patients90. 
 
Despite being expressed at lower levels than MMP-3, MMP-10 expression can be induced 
by pro-inflammatory stimulation and subsequently induce collagen degradation by pro-
collagenase activation88.   
 
 The membrane-type MMPs 
The cell anchored membrane-type MMPs (MT-MMP) sub-family of MMPs consists of 
six members of which four are transmembrane proteins: MT1-MMP, MT2-MMP, MT3-
MMP and MT5-MMP, whilst two are glycosylphosphatidylinositol (GPI)-anchored: 
MT4-MMP and MT6-MMP91. These six MMPs may also be referred to as MMP-14, -15, 
-16, -24 -17 and -25, respectively. Whilst most soluble MMPs are secreted in an inactive 
pro-form, the MT-MMPs are activated intracellularly, and secreted to the cell surface in 
an active form. This activation is performed by furin-like proprotein convertases91. 
 
 The Tissue Inhibitors of Metalloproteinases (TIMPs) 
TIMPs are a family of endogenous metalloprotease inhibitors consisting of four members: 
TIMP-1, -2, -3 and -4, which are all 184-194 amino acids in length and consist of two key 
domains. The N-terminal domain is responsible for the inhibitory activity, and does so by 
folding into a “wedge-like” structure that is able to interact with the MMP active site53. 
TIMPs bind and inhibit MMPs in 1:1 stoichiometry53, thus can be used experimentally to 
active-site titrate recombinant MMP. All four TIMPs can inhibit all MMPs, with the 
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exception of TIMP-1 which has negligible levels of inhibition against MT1-MMP (MMP-
14)92. 
 
 The Adamalysins 
The adamalysin subfamily of the metzincins include the ADAM (A disintegrin and 
metalloproteinase) and the ADAMTS proteinases. 
 
 The ADAM family 
The ADAMs are transmembrane and secreted proteinases with multiple roles including 
cellular adhesion and the proteolytic processing and shedding of various membrane-
bound proteins, such as receptors and signalling molecules93. Despite not being key 
players in articular cartilage degradation, some ADAM members have been suggested to 
have roles in OA. For example, ADAM-8 has been identified in human OA cartilage as 
being able to cleave fibronectin, generating fragments that may then enhance collagenase 
and aggrecanase expression94. Furthermore, the serum levels of ADAM-12 appear 
increased in patients with knee OA95 and ADAM15 mRNA has been shown to be up-
regulated in human OA cartilage compared to normal cartilage96 whereas ADAM15-/- 
mice exhibit accelerated development of OA lesions97. 
 
 
 
The ADAM proteinases have a relatively complex domain structure, consisting of an N-
terminal pro-domain, followed by its metalloproteinase catalytic domain, a disintegrin-
like domain, a cysteine-rich domain and (apart from ADAM-10 and -17) and an epidermal 
growth factor (EGF)-like domain. They are transmembrane proteins, with a C-terminal 
transmembrane domain and a cytoplasmic tail which varies in length across the family 
members98 (Figure 1.9). As with the MMPs, the pro-domain maintains the enzyme in a 
latent form via a cysteine switch mechanism99, and activate intracellularly via the activity 
Catalytic Pro Dis Cys 
Figure 1.9: The basic structure of ADAM  proteinases 
The ADAM proteinases are integral membrane proteins, containing a transmembrane domain (TM) at their C-
terminus. Furthermore, the majority of ADAMs contain an epidermal growth factor-like (EGF) domain (ADAM-
10 and -17 lack this). They also contain a cysteine rich domain (Cys) and a disintegrin-like domain (Dis). 
EGF T
Cytoplasmic tail 
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of furin-like enzymes, similarly to some MMPs, ADAM pro-domains contain a RX-
(K/R)-R motif100. 
 
To date, 21 human ADAM genes have been identified, of which only 13 have a 
catalytically active metalloproteinase catalytic domain, containing the classical 
HEXXHXXGXXH active site motif93. This suggests that the remaining 8 family 
members have evolved functions dependent on their non-catalytic domains. 
 
 The ADAMTS family 
The ADAMTS family of proteinases are closely related to the ADAM proteinases, with 
two major differences. While the ADAMs are generally membrane-bound proteins, the 
ADAMTSs are secreted. Furthermore, the ADAMTSs have a thrombospondin type I 
repeat in between their disintegrin-like domain and cysteine-rich domain101. Following 
the cysteine-rich domain, ADAMTSs have a spacer region followed by a highly variable 
C-terminus (Figure 1.10). 
 
 
 
Nineteen members of the ADAMTS family have been identified to date, with the ability 
to cleave a wide range of substrates101. As with the other metzincins, the ADAMTSs have 
a pro-domain with a vital role in enzyme latency, however it is thought that these pro-
domains operate via a different mechanism as 13 members of the family lack a cysteine 
which would form the cysteine switch mechanism101. Like the ADAMs, the ADAMTSs 
are thought to be activated by furin-like enzymes102. 
 
ADAMTS-4 has the shortest ancillary domain out of the ADAMTS family, terminating 
following the spacer region, and containing no C-terminal thrombospondin type I 
Protease Domain Ancillary Domains 
(varies) 
Catalytic Pro Dis Cys  
Figure 1.10: The basic structure of ADAMTS  proteinases 
The ADAMTS proteinases share an N-terminal protease domain consisting of a pro domain, a metalloproteinase 
catalytic domain and a disintegrin-like domain (Dis). The ADAMTS family also all contain a C-terminal ancillary 
domain, though these vary in content. They all commence with a single central thrombospondin type I motif (TSP-
1) followed by a cysteine-rich domain (Cys) and a spacer region. Following this spacer, the family exhibits 
variation with either a few or several TSP-1 motifs and other domains such as CUB domains (ADAMTS13), mucin-
like domains (ADAMTS7 and 12) and gon-1-like motifs (ADAMTS9 and 20) 
TSP-1(n) TSP-1 
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motifs101. However, ADAMTS-4 has been suggested to interact via its ancillary domain 
to the cell surface protein, syndecan 1, in a chondrocytic cell line103 with the interaction 
requiring the central thrombospondin type I motif and the cysteine-rich domain. The 
ancillary domain is thought to undergo proteolytic processing which can alter 
aggrecanase specificity and activity, including a reduction in binding to GAGs and thus 
reduction in aggrecanolysis104. ADAMTS-5 has also been found to localise to the cell 
surface, and has been shown to interact with both GAGs105 and hyaluronan106, localising 
the enzyme to the chondrocytes with potential implications for OA. 
 
 
 Serine proteinases 
 Classification 
The human genome encodes a predicted 184 serine proteinases, which have a wide variety 
of functions in human biology, and they are generally considered as extracellular 
proteases45,107. Whilst the majority of serine proteinases are soluble secreted proteins, 
some serine proteinases are found membrane-bound, either by a C-terminal GPI-anchor, 
a C-terminal transmembrane domain (type I transmembrane serine proteinases) or an N-
terminal transmembrane domain (type II transmembrane serine proteinases, or TTSPs)108.  
 
Of particular interest to the current programme of research, matriptase is one of 17 
identified human TTSPs, a family of enzymes characterised by a C-terminal catalytic 
domain separated from the membrane by a highly variable non-catalytic “stem region”107. 
TTSPs may be categorised into one of four subfamilies based on this variable stem region: 
the HAT/DESC (human airway trypsin-like protease/ differentially expressed in 
squamous cell carcinoma)  subfamily, the hepsin/TMPRSS (transmembrane 
protease/serine) subfamily, the matriptase subfamily and the corin subfamily107. 
 
 Catalytic mechanism 
Common to the serine proteinases is the “catalytic triad”, the presence of three amino acid 
residues: aspartic acid, histidine and serine, in the catalytic domain which are responsible 
for catalysis of substrate109. Chymotrypsin is considered the archetypal serine protease on 
which much of our understanding of catalysis is derived. Indeed, chymotrypsin 
numbering (histidine-57, aspartic acid-102, and serine-195) is used in all serine proteases, 
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despite these three amino acids not always being at these exact positions. Serine proteases 
employ a two-step mechanism of catalysis whereby the protease initially binds to the 
substrate in a covalent manner, forming an acyl-enzyme intermediate. This intermediate 
subsequently breaks down in the second step into two products and the protease is 
restored. 
 
The substrate enters the active site and is initially held in position by non-covalent 
interactions. The hydroxyl group of serine-195 and the imidazole group of histidine-57 
are hydrogen bonded together, which allows the serine hydroxyl group to perform 
nucleophilic attack on the carbonyl carbon in the substrate. This forms the acyl-enzyme 
intermediate where serine-195 is covalently bound to the carbonyl carbon of the former 
peptide bond, allowing C-terminal peptide fragment to dissociate away from the protease 
active site. A water molecule is then able to enter the active site and forms a hydrogen 
bond with histidine-57. This allows the water to perform nucleophilic attack on the 
carbonyl carbon within the acyl-enzyme intermediate. Serine-195 and histidine-57 re-
form a hydrogen bond to restore the protease, and the second product is removed110 
(Figure 1.11). 
 
 
Figure 1.11: Serine protease catalytic mechanism 
The catalytic triad of serine proteases consists of a histidine, a serine and an aspartic acid. The histidine is stabilised 
by the aspartic acid by forming a hydrogen bond with it, and deprotonates the serine, producing a strong nucleophile 
able to attack the substrate carbonyl carbon. Diagram taken from Erez et al., (2009). 
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 Matriptase 
 Structure and Function 
Matriptase contains a single sea urchin sperm protein, enteropeptidase, agrin (SEA) 
domain, two Cls/Clr, urchin embryonic growth factor and bone morphogenic protein-1 
(CUB) domains, and four low density lipoprotein receptor class A (LDLRA) domains 
(Figure 1.12). 
 
 
 
Matriptase is best characterised as a proteinase expressed in epithelial tissues108. 
Matriptase null mice die shortly following birth as a result of dehydration from 
compromised skin integrity111. These mice exhibit an inability to process profilaggrin, a 
protein important in the arrangement of keratin filaments in the skin112. In humans, an 
important role in skin has been confirmed in patients with mutations in matriptase, such 
as G827R113, which results in autosomal recessive ichthyosis with hypotrichosis (ARIA). 
 SEA CUB CUB     Catalytic 
 
LDLRA 
N C 
Figure 1.12: The domain structure of matriptase 
Matriptase is a type II transmembrane serine proteinase consisting of an N-terminal transmembrane domain 
(orange), a C-terminal serine proteinase catalytic domain, as well as multiple non-catalytic domains in a stem 
region, including a SEA domain, two CUB domains and four LDLRA domains. Multiple processed forms of 
matriptase may be observed depending on progress through the maturation process. Full length matriptase is 
95kDa, and undergoes early N-terminal processing to a 70kDa form, however it is thought these remain bound 
together. Matriptase undergoes activation from the zymogen by cleavage at Arg 614, resulting in a two chain 
disulphide linked form. When run by reducing SDS-PAGE, a 26kDa band is observed for the active catalytic 
domain. 
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Matriptase has also been found to be overexpressed in a number of carcinomas (cancers 
derived from epithelial tissues), and correlations with negative prognostic outcomes have 
been identified114. 
 
A role for matriptase in OA was identified by Milner et al. (2010)1 where it was found to 
be more highly expressed in OA patient samples compared to control NOF (neck of femur 
fracture) samples. The addition of matriptase to bovine explant cultures in the presence 
of pro-inflammatory stimulation resulted in enhanced levels of observed collagenolysis. 
Furthermore, the addition of matriptase to OA cartilage explant cultures resulted in an 
increase in the level of metalloproteinase-dependent collagenolysis, as well as an increase 
in the gene expression of MMP-1 and MMP-13, likely through the activation of the PAR2 
receptor1, a known substrate for matriptase115, and will be further described in chapter 
1.7. 
 
 Activation 
The non-catalytic domains of matriptase are known to have several roles in the maturation 
and inhibition of matriptase, however it is likely they have further unidentified roles in 
matriptase activity. The successful maturation of matriptase is a complex and 
incompletely understood process, which is known to involve two sequential proteolytic 
cleavages as well as interactions with its cognate inhibitor, hepatocyte growth factor 
activator inhibitor (HAI)-1108. 
 
Matriptase is synthesised as a single chain 95kDa zymogen and enters the secretory 
pathway where it undergoes its first proteolytic cleavage, which occurs in the SEA 
domain after glycine 149 at a conserved GSVIA sequence, yielding a 70kDa zymogen 
form, although it is thought that the enzyme remains bound together116. It is unknown 
how this cleavage event occurs117. The second proteolytic cleavage event occurs after 
arginine 614, and is dependent on the first cleavage having occurred118. This is the 
cleavage which yields an active two-chain protease, and likely occurs as a result of a 
transactivation process on the cell surface as catalytic inactive mutants are unable to 
undergo this processing118. Furthermore, the zymogen form of rat matriptase has been 
shown to be able to cleave a synthetic peptide with sequence similarities to the arginine 
614 cleavage site119. Rat matriptase shares a high degree of homology with the human 
enzyme120. 
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 Other serine proteases in Osteoarthritis 
Aside from matriptase, multiple other serine proteases have been implicated in OA 
including the proteases involved in the complement and coagulation cascades (Figure 
1.13)121. Abnormal complement activation is particularly associated with RA122, however 
recent work has identified higher expression and activation of complement components 
in human osteoarthritic joints, such as activated fragments C3a and C5b-9123. 
Furthermore, mice deficient in either C5 or C6 protease are protected against OA, and 
CD59a (an endogenous complement inhibitor)-deficient mice experience more severe 
disease123. It is thought that this abnormal complement activation in OA could lead to 
cartilage damage by aberrant membrane-attack complex (MAC) deposition, the effector 
arm of the complement system, leading to production of inflammatory mediators or 
matrix-degrading proteases. Furthermore, the expression level of the competent proteases 
factor I, factor D and protease C2 have elevated expression levels in OA cartilage 
compared to normal1. 
 
Various proteases of the coagulation cascade have been linked to arthritic diseases, in 
particular RA124. One of the key proteases in coagulation, thrombin, has been implicated 
in arthritis. Thrombin is able to activate the PAR1 receptor (see chapter 1.7) which can 
instigate pro-inflammatory signalling. PAR1 deficiency in mice results in protection from 
antigen-induced arthritis, with a reduced expression of MMP13125. Furthermore, the 
inhibition of thrombin attenuates synovial hyperplasia in collagen-induced arthritis (CIA) 
in mice126. Coagulation factors X and VII have the ability to activate PAR2 (see chapter 
1.7)127, a pro-inflammatory receptor known to have an elevated expression in OA128. 
Furthermore, the expression of coagulation factor X is elevated in OA compared to 
normal cartilage1. 
 
The high-temperature requirement A (HTRA) family of serine proteases have been linked 
to arthritic diseases. Three out of the four family members (HTRA1, 3 and 4) have an 
elevated expression level in OA compared to normal cartilage1,129. These three members 
are all secreted proteases whereas HTRA2 functions within the mitochondria130. The 
expression of both HTRA1 and 3 is elevated in mouse models of arthritis131,132. HTRA1 
has the ability to degrade cartilage components such as aggrecan and HTRA1-digested 
fragments of aggrecan have been identified in OA cartilage133. HTRA1 has also been 
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shown to digest soluble type II collagen131, thus may act to further degrade partially 
digested collagen in cartilage. 
 
 
 
 Cysteine proteinases 
 Classification and Structure 
Cysteine proteases represent the third largest family of proteases, accounting for 164 
proteases out of the 588 currently identified within the human degradome45. Members 
from this family are generally considered to be intracellular proteases which share a 
common catalytic mechanism134. They can be grouped into two major superfamilies: 
cytoplasmic caspase-1-like enzymes, and endosomal/lysosomal papain-like enzymes135. 
The research presented here utilises only papain-like superfamily enzymes, thus only 
these will be focused on in this section. Indeed, despite sharing an active site cysteine and 
catalytic mechanism, the two superfamilies share no other sequence homology and are 
thought to be evolutionary distinct families of enzymes136. The papain-like superfamily 
Figure 1.13: Roles of serine proteases in cartilage turnover in arthritic joints 
Multiple serine proteases are expressed within the joint and are thought to play roles in arthritic diseases. Taken 
from Milner et al. (2008). 
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also includes a subfamily of calpain-like proteases which are calcium-dependent 
cytoplasmic enzymes which share homology with the papain-like proteases137. 
 
The lysosomal papain-like cysteine proteases are referred to as the “cathepsins”138, 
though this term is somewhat ambiguous as some enzymes such as cathepsin A, G (both 
serine proteases139,140), D and E (both aspartyl proteases140,141), share the name but have 
no relation to the lysosomal cathepsins. The research herein, the term “cathepsin” will 
refer to lysosomal cysteine proteases, unless otherwise stated. There are 11 lysosomal 
cathepsins in the human genome: B, C, F, H, K, L, O, S, V, X and W142. 
 
The cathepsins share a similar structure with the mature forms being composed of two 
domains of similar size with a total molecular weight of around 30 kDa. The two domains 
are referred to as the “left” and “right” domains with the left domain being formed by 
mainly the N-terminal half of the enzyme and vice versa, though the actual N-terminus is 
located in the right domain and the C-terminus is located in the left domain143. The left 
domain is composed of three helical regions, the longest of which contains the catalytic 
cysteine residue (position 25 in papain), whereas the right domain consists of a β-barrel 
structure made up of 5 or 6 strands. The structure is stabilised by two disulphide bonds in 
the left domain and a single disulphide bond in the right domain143. 
 
 Catalytic mechanism 
Cysteine proteases are thought to utilise a similar proteolytic mechanism to that of serine 
proteases, however it is not as well understood. Initial work undertaken on the 
prototypical cysteine protease, papain, identified a catalytic triad mechanism consisting 
of cysteine-25 in the left domain, with histidine-159 and asparagine-175 in the right 
domain144. Site-directed mutagenesis of the asparagine-175 to an alanine however 
suggested that this amino acid is not directly involved in catalysis as catalytic activity was 
partly retained, exhibiting an activity 150-fold lower than the wild type145. Mutating 
asparagine-175 to a glutamine however has little effect on catalysis, so it is thought that 
position 175 forms a hydrogen bond with histidine-159. This would fix the histidine 
residue in an orientation positioning its imidazole group in the proper position to act to 
deprotonate the sulphur on the cysteine, allowing it to act as a nucleophile able to attack 
the carbonyl carbon on the substrate145,146 (Figure 1.14).  
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 Regulation of activity 
 Activation 
As cathepsins are synthesised as inactive pre-pro zymogens, they require activation to 
yield catalytic activity. The pre (signal) peptide is removed during intracellular trafficking 
while the enzymes are undergoing post-translational modifications and proper folding147. 
Insights to the pro-peptide inhibitory mechanism have been observed by the X-ray 
crystallography of several pro-cathepsins including human pro-cathepsin B148, human 
pro-cathepsin L149 and human pro-cathepsin K150,151, which showed that the pro-domain 
physically blocks the properly-formed active site by simply running along the cleft 
(Figure 1.15). 
Figure 1.14: Cysteine protease catalytic mechanism 
Cysteine proteases utilise a catalytic diad in which the imidazole group on a histidine is able to deprotonate the 
sulphur on a cysteine, allowing it to act as a nucleophile, able to attack the carbonyl group at the scissile bond on 
the substrate. Diagram taken from Erez et al., (2009). 
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Our understanding of the activation mechanisms of the cathepsins is incomplete, and 
variations between individual enzymes exist, but generally are thought to be a result of 
both proteolytic activities from other enzymes and autocatalytic activation. Insights into 
activation mechanisms have been obtained with work on pro-cathepsin B, which has been 
shown to have a low level of endogenous catalytic activity when exposed to low pH (as 
would be found in the lysosomes) presumably due to movement of the pro-domain from 
its normal inhibitory position. This partially active pro-cathepsin B is subsequently 
hypothesised to trans-activate other partially active pro-cathepsin B molecules by 
enzymatic cleavage of their pro-domains in a multi-step mechanism152. It is thought that 
this auto-activation mechanism is able to account in part for the activation of 
endopeptidase cathepsins (such as cathepsins B, H, K, L and S), however exopeptidase 
cathepsins (such as C and X) are unable to activate without the presence of an 
endopeptidase (such as L or S)153,154. 
Figure 1.15: Crystal structure of pro-cathepsin B 
Crystal structure highlighting the pro-domain (blue and red) over the mature domain of the enzyme (grey). The 
pro-domain sits in the active-site cleft blocking catalytic activity. The active site cysteine and histidine are coloured 
yellow and green, respectively. Taken from Turk et al. (2012). 
27 
 
 Inhibition 
Cathepsins are broad-spectrum proteases at very high concentrations within the 
lysosomes. As such, excessive activity of these enzymes can be potentially very damaging 
to cells. Cathepsin activity is curtailed by a variety of endogenous protein inhibitors such 
as cystatins, thyropins138 and to a lesser extent, serpins155. 
 
 Cathepsin B 
Cathepsin B was one of the first identified cathepsins, and as such is one of the best 
described in this family138. Under normal physiological conditions, the activity of 
cathepsin B is tightly regulated, however there are multiple pathlogical conditions where 
this is no longer the case. The pathological condition most associated with cathepsin B is 
cancer, where overexpression is observed in malignancies such as brain, lung, prostate, 
breast and colorectal cancer. Indeed, the expression of cathepsin B correlates with 
invasive and metastatic cancers156. Cathepsin B is thought to exert both intra- and extra-
cellular roles in cancer, such as promoting autophagy intracellularly157, and activating 
important enzymes such as proMMPs via uPA158 and degrading TIMP1 and TIMP2 
extracellularly159. 
 
 Cathepsin K 
Cathepsin K is best known as an osteoclast-expressed collagenolytic enzyme with a key 
role in bone remodelling, however it is also expressed in cells such as macrophages, 
synovial fibroblasts, chondrocytes, and at sites of wound-healing and inflammation160. In 
osteoclasts, cathepsin K represents 4% of all mRNA, and constitutes around 98% of 
expressed cysteine proteases161. Despite the cathepsins being known as lysosomal 
proteases, cathepsin K can be secreted. In terms of bone remodelling, it carries out its 
function in resorption lacunae – a specialised compartment between the cell and the bone 
with conditions which are favourable for bone resorption – where it acts as a very potent 
collagenase breaking down the type I collagen of the bone160. 
 
The ability for cathepsin K to degrade triple helical collagen is unique among the 
cathepsins, and indeed unique amongst all known human proteases bar the collagenase 
MMPs and neutrophil elastase162. As with the collagenase MMPs, Cathepsin K is able to 
cleave both type I and type II collagens, however unlike the MMPs which cleave at a 
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specific site yielding characteristic ¼ and ¾ fragments, cathepsin K cleaves collagen at 
multiple sites163. In contrast with many cathepsins which are negatively charged overall, 
cathepsin K has several positively charged basic residues (lysine and arginine) which are 
on the opposite side of the enzyme to the active site (Figure 1.16). It is thought that these 
charges allow for interactions with the negatively charged GAGs of the ECM164. Indeed, 
cathepsin K exosite interactions with GAG are absolutely vital for collagenolytic 
activity165 leading to the targeting of this region for the design of selective cathepsin K 
collagenase activity inhibitors such as ortho-dihydrotanshinone (DHT1) which do not 
inhibit cleavage of other cathepsin K substrates166. 
 
 Cathepsin S 
Cathepsin S is expressed mainly in cells of the immune system, namely antigen presenting 
cells (APCs) such as B cells, macrophages and dendritic cells where it has a vital role in 
antigen presentation167. During antigen presentation, the antigen presenting class II MHC 
molecules are expressed on the cell surface, containing a random peptide for presentation 
to other cells of the immune system. Class II MHC consists of αβ dimers, however in 
order to successfully form and then traffick to endosomes, they are associated with a 
chaperone known as the invariant chain which sits where eventually the presented peptide 
will sit. In order to successfully present antigen, lysosomal cathepsin S degrades the 
invariant chain from class II MHC which allows peptide antigen to bind it167. 
 
Uncommonly for lysosomal proteases, cathepsin S is highly active and stable at more 
neutral pHs168, indeed it is the only cathepsin which is able to auto-activate at neutral pH 
as well as low pH169, suggesting roles outside of lysosomal compartments. For example 
Figure 1.16: Surface charges of cathepsins K and L 
Cathepsin L shares the most sequence homology to cathepsin K (60%) however cathepsin K has a region of net 
positive charge (blue) on the side furthest from its active site, whereas as with most cathepsins, cathepsin L has 
more net negative charge (red). Image taken from Lacaille et al., (2008). 
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cathepsin S is known to be a potent elastinolytic enzyme at neutral pH with implications 
for ECM degradation170. Cathepsin S has been implicated in the pathogenesis of a number 
of conditions such as RA171, multiple sclerosis (MS)172 and asthma173. 
 
 Cathepsins L and V 
Cathepsin L has had multiple intra- and extra-cellular physiological functions identified 
including lysosomal protein turnover, regulation of cell cycle and MHC class II 
processing, and has also been implicated in the pathogenesis of multiple malignancies174.  
 
Cathepsin V shares a high degree of homology with cathepsin L (78% homology, 
compared to <40% for the other cathepsins), indeed upon discovery it was named 
cathepsin L2175. A major difference between cathepsin V and cathepsin L is a much more 
restricted tissue distribution of cathepsin V, which is mainly expressed in the testes and 
thymus176.  
 
In terms of enzyme specificity, cathepsin V has a broader specificity in its S1 and S3 sites, 
compared to cathepsin L which has a preference for positively charged residues in these 
sites177. 
 
 Cathepsins in Osteoarthritis 
The cathepsins have been strongly implicated in arthritic diseases including RA and OA. 
Despite being best known as lysosomal proteases with optimal activity and stability at 
lower pH values, several of the family have also been shown to have activity at more 
neutral pH levels. Cathepsin S is well established to maintain its activity and stability at 
neutral pH with extracellular roles in degrading ECM components168. Cathepsin B, whilst 
most active at lower pH, is still thought to retain activity at neutral pH178 and has also 
exhibited activity at cleaving ECM components179. As mentioned previously, cathepsin 
K is well established as being able to cleave triple helical collagen160. Cathepsin K has an 
optimal activity at pH 6, however is also fully active at neutral pH, but lacks stability and 
will rapidly lose activity180. Cathepsin L is thought to be one of the most unstable 
cathepsins at neutral pH181, however it will exhibit short-term activity at more neutral pH 
levels176,182. Like cathepsin L, cathepsin V is most stable at more acidic pH levels, but 
will also exhibit activity at more neutral pH levels with a loss of stability176.  
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As well as evidence of cathepsin activity at more neutral pH levels, there is also evidence 
of reduced pH levels in OA cartilage183, which would theoretically allow for more stable 
active cathepsin enzymes. Indeed, cathepsin K degradation of type II collagen has been 
detected in human OA cartilage184. 
 
The first cathepsin to be implicated in OA was cathepsin B185, where enzyme activity was 
found to correlate with disease activity186. In partial medial meniscectomy-induced 
arthritis in rabbits, cathepsin B expression is up-regulated in the synovium, but not in 
chondrocytes187. IL-1β stimulation of rabbit chondrocytes did however increase protein 
expression of cathepsin B187. The exact role for cathepsin B in OA is not fully understood. 
Cathepsin B has been shown to cleave aggrecan at the “MMP-specific” site between 
asparagine-341 and phenylalanine-342188. Cathepsin B has also been shown to cleave and 
reduce the activity of the protein deacetylase SirT1, an anti-inflammatory regulator in 
chondrocytes, following treatment by TNFα189. Interestingly, this role for cathepsin B is 
thought to occur within the nucleus189. 
 
Cathepsin S expression has also been shown to be induced by pro-inflammatory 
stimulation of chondrocytes by TNFα and IL-1β, with subsequent secretion of active 
enzyme, detectable in the conditioned medium190. Activity of both cathepsin S and 
cathepsin B has been detected in conditioned medium from OA cartilage in explant 
culture and in regions of degraded cartilage from patients191. 
 
Cathepsins V, L, K, B and S have all had multiple ECM substrates identified, including 
OA-relevant aggrecan and collagen. As mentioned previously, cathepsin B has 
aggrecanase activity, however cathepsins K, L and S have all also been shown to degrade 
aggrecan192. As discussed previously, cathepsin K is a well-established collagenase and 
the only cathepsin to cleave triple helical collagen. Cathepsins B, L and S have also been 
shown to have the ability to cleave collagen sequences, all being able to cleave the 
collagen non-helical telopeptide region162,180. Several other ECM substrates for these five 
cathepsins have also been identified, including elastin, fibronectin and type IV collagen, 
however these hold less relevance for OA. For an excellent review on cathepsin cleavage 
of ECM components, see Fonovic et al., (2014)193. 
 
Several animal models have implicated cathepsin K in the pathogenesis of OA, with most 
of the evidence suggesting a role in the progression of the disease. Mice constitutively 
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overexpressing cathepsin K spontaneously develop synovitis and exhibit degradation of 
articular cartilage194, whereas cathepsin K protein and cathepsin K neo-epitopes were 
identified from post-mortems of horses which had naturally occurring OA, compared to 
healthy195. The inhibition of cathepsin K with the small molecule inhibitor SB-553484 
following partial medial meniscectomy in a canine model of OA shows protective effects 
in terms of reduced cartilage degradation196. 
 
Studies undertaken in rabbits has described opposing effects. In one study, following 
anterior cruciate ligament transection-induced disease, cathepsin K expression was 
elevated in rabbits, however when the disease was induced following cathepsin K siRNA 
knockdown, disease progression was observed to be quicker, suggesting a protective 
effect by cathepsin K197. In a conflicting study, the inhibition of cathepsin K by a small 
molecule inhibitor, L-006235, protected against OA in the same anterior cruciate 
ligament transection model in rabbits198. In comparing these two studies, it is likely that 
the latter had a better methodology to ascertain the role of cathepsin K in OA. The use of 
siRNA in in vivo studies is known to have limitations, such as the ability to activate innate 
immunity199, and is unlikely to be as efficient at inhibition as small molecule inhibitors. 
Furthermore, the latter study is more in line with the other literature regarding a role for 
cathepsin K in OA. 
 
 
 Protease-activated receptor 2 (PAR2) 
 The PAR family 
The PAR family are unique amongst the G-protein coupled receptors (GPCRs) in that 
they are activated in vivo by an irreversible proteolytic cleavage event of their 
extracellular domain. Their peptide ligand is located within their extracellular domain, 
however upon cleavage, the neoepitope is able to bind to the active site of the receptor – 
this is known as a tethered ligand. The PARs are generally known as receptors for serine 
proteases. There are four members in the PAR family, PAR1, PAR3 and PAR4 which are 
known as thrombin receptors, and PAR2 which is a trypsin receptor. All four PAR 
members have, however, had additional agonist proteases identified200. 
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The four PAR family members share a high degree of homology. PAR1 (F2R), PAR2 
(F2RL1) and PAR3 (F2RL2) are located in a gene cluster of chromosome 5q13, whereas 
PAR4 (F2RL3) is located on chromosome 19p12201. As is conserved within the GPCR 
superfamily, the PARs are “7-TM” receptors containing 7 transmembrane helices. 
Furthermore, they have an N-terminal extracellular domain, three extracellular loops 
(ECL1-3), three intracellular loops (ICL1-3) and a C-terminal intracellular domain200. 
PAR1 and PAR3 further contain a hirudin-like motif within their extracellular domains 
to facilitate thrombin binding202. 
 
Following cleavage and removal of the N-terminal region, the tethered ligands of the PAR 
receptors are thought to interact primarily with ECL2, which results in a conformational 
change of the receptor and subsequent activation200 (Figure 1.20). Following activation, 
the induced signalling cascades are typical for GPCRs in that they are mediated by 
association with heterotrimeric G-proteins. Heterotrimeric G-proteins consist of an α 
subunit (Gα) which associates with a βγ dimer (Gβγ). Multiple Gα proteins have been 
identified, which mediate different downstream signalling pathways203. The PARs have 
been shown to couple with multiple Gα subunits, including Gαq, Gαi, Gαs and Gα12/13204. 
Furthermore, the PARs can also signal through Gβγ-dependent pathways200 as well as G-
protein-independent pathways such as β-arrestin signalling204 (Figure 1.17). Our 
understanding of PAR2 signal transduction is incomplete, and further description is 
beyond the scope of this chapter. For an excellent review, the reader is directed to Soh et 
al. (2010)204. 
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 PAR2 agonists and antagonists 
PAR2 is best known as a receptor for trypsin, which cleaves PAR2 after arginine-36 to 
reveal the tethered ligand SLIGKV and instigate full activation of PAR2 in what is known 
as canonical signalling205. Multiple other proteases have been identified to cleave PAR2 
at this site, including coagulation factors X and VII127, tryptase206, trypsin IV207, 
Granzyme A208, kallikrein-2, -4209, -5, -6 and -14210, TMPRSS2211, acrosin212, human 
airway trypsin-like protease213. Of greatest interest to this study, matriptase has also been 
identified as a potent activator of PAR2115. In a challenge to the previous held dogma that 
thrombin was an agonist for PAR1, PAR3 and PAR4 but not PAR2, thrombin has in fact 
recently also been shown to have the ability to induce canonical PAR2 activation214. 
 
Figure 1.17: PAR2 activation mechanism and induced signalling pathways 
The PAR family of GPCRs, including PAR2 as shown in the diagram, is activated by proteolytic cleavage in their 
extracellular domain which reveals a tethered ligand, for example SLIGKV in the case of PAR2. The tethered 
ligand then binds to and activates the receptor, and stimulates various signalling pathways. PAR2 signals through 
coupled G proteins, including various Gα proteins, as well as βγ dimers. PAR2 also signals independently of G 
proteins by β-arrestin signalling. 
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As well as the endogenous activators of PAR2, several exogenous activators have also 
been identified. The serine protease Pen c 13 is an allergen expressed by Penicillium 
citrinum (a mould) and has been found to induce canonical PAR2 activation, with 
associated pro-inflammatory outcomes215. The dust mite allergens and serine proteases 
Der P3 and Der P9 have also been shown to cleave and activate PAR2 at the canonical 
activation site216. Furthermore, the cysteine protease dust mite allergen Der P1 has also 
been shown to activate PAR2 and stimulate inflammatory responses217,218. A bacterial 
cysteine protease, arginine-specific gingipain from Porphyromonas gingivalis has been 
demonstrated to induce canonical PAR2 activation219,220, as has a chitinase from the 
bacterium Streptomyces griseus221. 
 
A commonly used tool in PAR2 research is the use of synthetic peptides corresponding 
to the tethered ligand, either SLIGKV or SLIGRL, corresponding to the human or 
rat/mouse sequence, respectively. These peptides mimic the effect of canonical PAR2 
activation, and by using mutant versions of them, much has been deduced about PAR2 
agonist requirements. This is discussed in more detail in chapter 5.3. A modified synthetic 
peptide, 2-furoyl-LIGRLO-NH2, where O corresponds to the non-proteinogenic amino 
acid, ornithine, is used as a synthetic PAR2 agonist with greater potency and 
bioavailability than SLIGKV/SLIGRL222,223. 
 
As well as the multitude of proteases identified as canonical activators of PAR2, several 
other proteases have also been identified as cleaving PAR2 at distinct sites. Some of these 
proteases can disarm the receptor by removing the extracellular domain and preventing 
the canonical cleavage producing the tethered ligand. Other proteases have, however, 
been identified as able to induce biased agonism, partially activating PAR2 by cleavage 
at a distinct site and either revealing a different tethered ligand or stimulating a 
conformational change of the receptor independently of a tethered ligand. Following 
cleavage by proteases able to induce biased signalling, a subset of PAR2 downstream 
signalling pathways are induced. 
 
One of the first proteases identified as a disarmer for PAR2 was neutrophil elastase, which 
was found to disarm against trypsin-mediated Ca2+ mobilisation (a marker of Gαq 
activation)224. Subsequent work however identified elastase as able to induce biased 
signalling, in terms of ERK1/2 phosphorylation in a Gα12/13-mediated Rho kinase 
activation mechanism225. It is thought that elastase acts as a biased agonist without the 
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need for a tethered ligand, rather directly activating the receptor by inducing a 
conformational change after cleavage. Elastase cleaves PAR2 after serine-68, resulting in 
an extracellular domain only 9 amino acids long, likely too short to act as a ligand. 
Furthermore, peptide agonists corresponding to the new N-terminus do not mimic the 
effect of the enzyme, as would be expected based on other activator peptides used in 
PAR2 research225. 
 
The serine proteases cathepsin G and proteinase 3 are both thought to be disarmers of 
PAR2 with no current evidence for biased agonism. Cathepsin G cleaves after 
phenylalanine-65 and proteinase 3 cleaves after valine-62, which as with elastase removes 
the majority of the extracellular domain, preventing canonical activation225. 
 
The cysteine protease cathepsin S has been identified as a biased agonist for PAR2226. 
Cathepsin S cleaves PAR2 after glutamic acid-56, revealing the tethered ligand 
TVFSVDEFSA. Cathepsin S is able to disarm against trypsin-mediated Ca2+ 
mobilisation, but induces cAMP formation, as a result of inducing coupling to Gαs, but 
not Gαq. The effects of cathepsin S are mimicked by TVFSVDEFSA which shows a 
tethered ligand mechanism is responsible for the activation. 
 
 PAR2 activation and termination  
As previously mentioned, the PARs including PAR2 transduce signals via the coupling 
with various G alpha proteins. PAR2 is unique amongst the PAR family in that it also has 
the ability to bind to β-arrestins, which function to transduce G-protein independent 
signalling pathways (such as G-protein independent ERK1/2 signalling), as well as 
termination of PAR2 signalling227. PAR2 is also the only PAR that has been shown to 
interact with Jun activating binding protein 1 (Jab1), a protein involved in the activation 
of the AP-1 transcription factor228. 
 
Considering the unique activation mechanism of the PARs, it is clear that following 
activation, they cannot be “reactivated” due to the cleavage having already occurred. 
Following activation, PAR2 is therefore internalised and new PAR2 trafficked to the cell 
surface. PAR2 signalling is terminated by the phosphorylation of serine and threonine 
residues on the intracellular domain which aids the recruitment of β-arrestin 1 and β-
arrestin 2229, proteins which are essential for the termination of PAR2 signalling and 
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subsequent internalisation227. β-arrestin recruitment for internalisation is not unique to 
PAR2, rather is a common mechanism for GPCR inactivation and internalisation230. 
 
Following PAR2 internalisation, cell surface PAR2 is rapidly replenished by trafficking 
intracellular stores to the cell membrane. It is thought multiple stores of PAR2 are present 
within cells, at different stages of the secretion pathway. Following activation, PAR2 can 
quickly be trafficked from endosomal stores to the cell surface, and if activated again, 
further PAR2 can be trafficked from the Golgi. Additional activation would likely require 
de novo protein synthesis to replenish surface PAR2231. Recent work has shown that 
PAR2 Gβγ signalling leading to an activation of protein kinase D (PKD) is involved in 
the trafficking of PAR2 from the Golgi to the cell surface membrane232. 
 
There is currently no PAR2 crystal structure available, however structural models have 
been produced based on homology with other GPCRs (human PAR1, bovine rhodopsin 
and human ORL-1)233. 
 
 Physiological and Pathological roles of PAR2 
Roles for PAR2 in both normal physiology and pathological conditions have been 
identified in multiple tissues and systems, including the cardiovascular system, the 
respiratory system, the nervous system, gastrointestinal tissues, the renal system, and the 
musculoskeletal system200. A role for PAR2 is also implicated in various cancers and 
inflammatory conditions200.  
 
The physiological roles of PAR2 are complex and vary from cell type. Canonical PAR2 
activation is pro-inflammatory in nature, resulting in the release of a host of inflammatory 
mediators such as various cytokines and chemokines. For a detailed description of the 
role of PAR2 in the aforementioned systems, the reader is directed to the review by 
Adams et al. (2011)200. 
 
 PAR2 in Osteoarthritis 
A role for PAR2 in OA was first speculated in the mid-2000s when the level of PAR2 
gene expression was found to be elevated in OA chondrocytes compared to normal 
chondrocytes, and that pro-inflammatory (IL-1β or TNFα) stimulation of both normal or 
diseased chondrocytes increased PAR2 expression128,234. 
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The canonical activation of PAR2 is known to induce the expression of the key catabolic 
mediators of articular cartilage, MMP1 and MMP13128, and the PAR2 activator 
matriptase was found to also be significantly up-regulated in OA vs control cartilage1. 
Matriptase is thought to act in OA pathogenesis via PAR2 as it is unable to directly 
breakdown collagen, however its addition to OA cartilage in explant culture leads to 
enhanced collagenolysis which was found to be dependent on MMP activity1. Matriptase 
is able to induce MMP-1, -3 and -13 expression in OA cartilage, and subsequently it is 
able to activate proMMP-1 and proMMP-3 (with active MMP-3 further being able to 
activate proMMP-1 and proMMP-13)1. 
 
A role for PAR2 in OA pathogenesis is supported in mouse models where PAR2- 
deficient mice are protected in both the medial meniscotibial ligament disection 
(MMTL)235 and destabilisation of the medial meniscus (DMM)236 models of the disease. 
Further mouse studies have implicated PAR2 in some of the pathological changes 
observed in the joint, such as the formation of osteophytes and disease-related pain237. 
 
 
 Scope of this thesis  
Cartilage breakdown in OA is known to be a result of proteolytic cleavage mediated by 
proteases synthesised and secreted by the only resident cell within cartilage, the 
chondrocyte. The traditional view that metalloproteinases, specifically the collagenases 
and the aggrecanases, are the key enzymes in OA is looking increasingly simplistic, with 
increasing evidence that other families of enzymes such as the serine proteases and the 
cysteine proteases also having roles in OA. Whilst some of these enzymes, such as 
cathepsin K184, may exert their role in OA by direct breakdown of cartilage, the role for 
other proteases are not so clear and likely exert their roles indirectly. 
 
As described in this chapter, serine proteases partake in multiple complex networks of 
proteolysis, such as coagulation and complement activation, and many have roles in the 
regulation of protease activity, such as proMMP activation. Serine proteases are also able 
to regulate cell behaviour by direct receptor activation, such as uPA activation of uPAR 
and multiple serine proteases with the ability to activate protease-activated receptors, with 
PAR2 activation by matriptase of particular interest to this study. 
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Understanding how proteases can regulate chondrocyte behaviour is essential for 
understanding the molecular mechanisms underlying OA. Recent work has shown that 
the cysteine protease cathepsin S has the ability to activate certain PAR2 responses226, 
challenging the dogma of this receptor being a receptor for trypsin-like serine proteases. 
Indeed, MMP-1 and MMP-13 can activate PAR1, highlighting the complexity of biology 
and the over simplification of considering PAR1 a “thrombin receptor” or PAR2 a 
“trypsin receptor”. A multitude of proteases are expressed in cartilage in both normal 
physiological turnover and pathological OA121, and how the majority of these interact 
with PAR2 is currently unknown. To date, no large scale screen of PAR2 cleavage by 
cartilage-expressed proteases has been performed, therefore this project aims to identify 
novel cleavages of PAR2. It is likely the in vivo situation is much more complicated than 
matriptase activation of PAR2 leading to an induction of MMP1 and MMP13. 
 
On the one hand it is of importance to understand how proteases can regulate chondrocyte 
behaviour, however since chondrocytes are the only cell type within the cartilage, it is 
also of importance to understand how protease expression is regulated in these cells. Pro-
inflammatory stimulation is known to induce the expression of multiple proteases, and 
many studies have been undertaken to further understand this regulation. Mechanical 
loading of chondrocytes has also long been thought to be important in the regulation of 
chondrocyte function, including expression of various mechanosensitive genes, including 
MMP expression22. Matriptase is known to have an elevated expression level in OA1, 
however it is unknown how its expression is regulated, therefore this project also aims to 
explore whether mechanical loading is involved in matriptase regulation.  
 
 
 Aims 
 To explore the expression of matriptase and PAR2 in chondrocytes by mechanical 
loading.  
 
 To perform a screen of cartilage and OA-expressed proteases for the ability to 
cleave PAR2. 
 
 To explore the role of any novel cleavages of PAR2. 
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2. Chapter 2. Materials and Methods 
 Materials 
 Antibodies 
Table 2.1: Antibodies used throughout this project  
Antibody Source Manufacturer 
Product 
Code 
GAPDH Mouse monoclonal Abcam, Cambridge, UK ab8245 
Matriptase Rabbit polyclonal 
Merck Millipore, St Louis, 
USA 
IM1014 
Hepsin Rabbit polyclonal 
Cayman Chemical 
Company, Ann Arbor, USA 
100022 
Phospho-p38 Rabbit monoclonal 
Cell Signalling Technology, 
Danvers, USA 
4511 
p38 Rabbit polyclonal 
Santa Cruz Biotechnology, 
Dallas, USA 
SC-535 
Phospho-Erk1/2 Rabbit polyclonal  
Cell Signalling Technology, 
Danvers, USA 
 
#9101 
Erk1/2 Rabbit polyclonal #9102 
PAR-2 Rabbit polyclonal 
Santa Cruz Biotechnology, 
Dallas, USA 
SC-5597 
MMP-1 Mouse monoclonal In-house RRU-CL1 
 
 Recombinant Proteinases 
  
 Table 2.2: Recombinant proteases used throughout this project     
Proteinase Source Manufacturer Product Code 
proMMP-1 High Five™ Insect Cells Produced In-house N/A 
proMMP-8 Mouse myeloma cell line, NS0-derived R&D Biosystems, Minneapolis, USA 908-MP-010 
proMMP-13 High Five™ Insect Cells Produced In-house N/A 
uPA Purified from human urine Merck Millipore, St Louis, USA 672112-10KU 
HTRA1 Rosetta™(DE3)pLysS E. coli Prof. Michael Ehrmann, University of Duisberg-Essen, 
Germany 
N/A 
HTRA3 Rosetta™(DE3)pLysS E. coli N/A 
Cathepsin G Purified from human sputum leucocytes 
Elastin Products Company, Owensville, USA 
SG623 
Neutrophil elastase Purified from human sputum leucocytes SE563 
Hepsin Drosophila S2 insect cells Prof. Richard Leduc, University of Sherbrooke, Canada N/A 
Matriptase E. coli Prof. Alastair Hawkins, Newcastle University, UK N/A 
Factor I Purified from human serum 
CompTech, Tyler, USA 
A138 
Factor D Purified from human serum A136 
ADAMTS-5 HEK 293-EBNA Cells Prof. Hideaki Nagase, University of Oxford N/A 
Thrombin Purified from bovine serum Merck Millipore, St Louis, USA 605157-1KU 
Cathepsin V Pichia pastoris 
Prof. Dieter Brömme, University of British Columbia, Canada 
N/A 
Cathepsin K Pichia pastoris N/A 
   
Cathepsin S E. coli Merck Millipore, St Louis, USA 219323 
Cathepsin B Mouse myeloma cell line, NS0-derived 
R&D Biosystems, Minneapolis, USA 
953-CY-010 
Cathepsin L Mouse myeloma cell line, NS0-derived 952-CY-010 
PCSK9 Mouse myeloma cell line, NS0-derived 3888-SE-010 
FAP 
Spodoptera frugiperda, Sf 21 
(baculovirus)-derived 
3715-SE-010 
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 Synthetic peptides 
Table 2.3: Synthetic peptides used throughout this project   
Peptide Sequence (N  C) Source 
PAR2 42mer 
H-
RSSKGRSLIGKVDGTSHVTGKG
VTVETVFSVDEFSASVLTGK-
OH 
Dr. Hiroki 
Shimizu, AIST 
Hokkaido, Japan 
PAR2 Trypsin AP H-SLIGKV-NH2 
Abcam, 
Cambridge, UK 
PAR2 MMP AP H-LIGKVD-NH2 
Peptide Synthetics, 
Fareham, UK 
PAR2 MMP AP Reverse H-DVKGIL-NH2 
Cathepsin S/V/L 10mer H-TVFSVDEFSA-NH2 
Cathepsin S/V/L 6mer H-TVFSVD-NH2 
Cathepsin K 6mer H-KVDGTS-NH2 
VETV Abz-VETV-Y(3-NO2) 
FSVD Abz-FSVD-Y(3-NO2) 
SY-9 peptide Abz-SKGRSLIG-Y(3-NO2) 
GL Biochem, 
Shanghai, China 
 
 
 Molecular Biology Reagents 
For plasmid preparation, mini-prep kits were obtained from either GE Healthcare (Little 
Chalfont, UK) for illustra plasmidPrep Mini spin kit or Qiagen  (Hilden, Germany) for 
QIAprep Spin Miniprep Kit. Maxi-prep kits were obtained from either Qiagen (Plasmid 
Maxi Kit) or Promega  (Madison, USA) for PureYield™ Plasmid Maxiprep System.  
 
For Polymerase Chain Reaction (PCR) amplification, Q5® High-Fidelity DNA 
Polymerase from New England Biolabs (Ipswich, USA) and  Pfx50™ DNA Polymerase 
from Thermo Fisher (Waltham, USA)  were used. 
 
All custom primer oligos were synthesised by Sigma-Aldrich (St. Louis, USA). Plasmid 
sequencing was undertaken by Source Bioscience (Nottingham, UK). 
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For molecular cloning, all restriction endonucleases and their buffers were obtained from 
Thermo Fisher. Ligation was undertaken using an In-Fusion HD kit from Clontech 
(Mountain View, USA). For transient and stable transfection, the mammalian expression 
plasmid pcDNA3.1 (Thermo Fisher) was used and FuGene HD transfection reagent 
(Promega) was used for transfection. 
 
 Cell culture reagents 
Interleukin (IL)-1α was provided by Dr Keith Ray at GlaxoSmithKline (Stevenage, UK) 
and is dissolved in Dulbecco's Modified Eagle's medium (DMEM), sterile filtered with a 
0.22 µm polyethersulfone (PES) filter and stored at -20°C.  
 
Oncostatin M (OSM) was produced in-house as previously described238, and is dissolved 
in Dulbecco’s Phosphate-buffered Saline (PBS) with 0.1% (w/v) Bovine serum albumin 
(BSA), sterile filtered with a 0.22 µm PES filter and stored at -80°C. 
 
 Chemicals 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich. 
 
Unless otherwise stated, all cell culture medium was obtained from Thermo Fisher. 
 
Dulbecco’s PBS was obtained from both Sigma-Aldrich and Thermo Fisher. 
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 Protease inhibitors 
Table 2.4: Protease inhibitors used throughout this project 
Protease Inhibitor Source 
E64 Cysteine proteases Sigma-Aldrich 
AEBSF Serine proteases Sigma-Aldrich 
DFP Serine proteases Sigma-Aldrich 
TIMP-1 MMPs Prof. Hideaki Nagase 
MMP-8 inhibitor I MMP-8 Merck Millipore 
CL-82198 MMP-13 Sigma-Aldrich 
 
 
 Consumables 
Unless otherwise stated, all consumables were obtained from Sigma-Aldrich. 
 
Unless otherwise stated, all cell culture dishes, flasks and plates were manufactured by 
Corning (New York, USA) and purchased from Sigma-Aldrich or VWR International 
(Radnor, USA). 
 
 Bovine Nasal Chondrocyte Extraction 
Primary chondrocytes were extracted from bovine nasal septa using a sequential digestion 
method. Bovine nasal septa were obtained from a local abbatoir. 
 
Reagents: 
 Antibiotic-supplemented PBS: Dulbecco’s PBS, supplemented with 200 IU/mL 
penicillin, 200 ug/mL streptomycin and 40 IU/mL Nystatin. 
 DMEM-F12, supplemented with 10% Foetal Bovine Serum (FBS), 200 IU/mL 
penicillin, 200 µg/mL streptomycin and 40 IU/mL Nystatin: “Complete DMEM-
F12”. 
 Hyaluronidase (1 mg/mL in supplemented PBS, 4 mL/g cartilage). 
 Trypsin (2.5 mg/mL in PBS, 4 mL/g cartilage). 
 Collagenase (2 mg/ml in supplemented DMEM-F12, 3 mL/g cartilage). 
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Method: The nasal septum was isolated and removed from the nose and a scalpel was 
used to remove any non-cartilaginous material. The cartilage was then cut into small 
pieces and washed 3 x 5 minutes in antibiotic-supplemented PBS. The cartilage pieces 
were then weighed and no more than 5 g added to multiple 50 ml Falcon tubes. The 
cartilage was then incubated with hyaluronidase for 15 minutes at 37ºC with rotation. The 
hyaluronidase-containing supernatant was removed and the cartilage was washed 3 times 
with supplemented PBS. The cartilage was then incubated with trypsin for 30 minutes at 
37ºC with rotation. The supernatant was removed and the cartilage washed 3 times with 
complete DMEM-F12, before incubating with collagenase for 15-20 hours at 35ºC with 
rotation. Following the collagenase digest, cells were allowed to settle and the 
chondrocyte-containing supernatant was passed through a 0.2 µm cell strainer to remove 
any undigested material. The cell solution was then centrifuged at 1100 x g and the pellet 
resuspended in growth medium and the cells counted. 
 
 Monolayer Cell Culture 
 SW1353 cell line 
SW1353 cells are a chondrosarcoma immortal cell line purchased from American Type 
Culture Collection (ATCC) (Manassas, USA) and cryopreserved in SW1353 culture 
medium supplemented with 10% DMSO. 
 
Reagents: 
 SW1353 (complete) culture medium: DMEM-F12, supplemented with 10% FBS, 
2 mM L-glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin. 
 
SW1353 cells were resurrected from cryopreservation in liquid nitrogren, by rapidly 
thawing at 37°C, before adding drop-wise to 9 mL SW1353 complete culture medium 
and centrifuging at 1100 x g for 5 minutes before resuspending the pellet in 12 mL fresh 
SW1353 complete culture medium and seeding in a T75 flask. The SW1353 cell line was 
mainained in T75 flasks, passaging at a 1:6 ratio when reaching 90% confluency (roughly 
every 3-4 days) and plating cells for experiments as required. The cells were incubated at 
37°C in 5% CO2 in a humidified incubator. 
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In order to passage the cells, the cells were first washed with 10 mL Dulbecco’s PBS, 
before incubating for 5 minutes at 37°C with 2 mL trypsin-EDTA solution (0.05% porcine 
trypsin and 0.02% (w/v) EDTA in HBSS) to dislodge the adhered cells. The trypsin was 
then inhibited by the addition of 8 mL SW1353 culture medium and the cells transferred 
to a 25 mL universal tube and centrifuged at 1100 x g for for 5 minutes. The cells were 
then resuspended and either counted for plating out experiments, and/or used to seed a 
new T75 to continue the cell line. SW1353 cells were typically utilised for 15-20 passages 
before resurrecting new cells. 
 
In order to count cells, 10 µL of cell suspenstion was mixed with 10 µL of trypan blue 
solution (0.4% sterile-filtered) and well mixed. The 20 µL mixture was then added into 
the chamber of a Fuchs-Rosenthal haemocytometer and cells were counted under a 
microscope by averaging the counts obtained from three squares. Following counting, 
cells were plated according to experimental requirements. 
 
 Bovine nasal chondrocytes (BNC) 
BNC are a primary chondrocyte cell type extracted from bovine nasal septa as outlined 
in chapter 2.2. 
 
Reagents: 
 BNC complete culture medium: DMEM-F12, supplemented with 10% FBS, 2 
mM L-glutamine, 200 IU/mL penicillin, 200 µg/mL streptomycin and 40 IU/mL 
Nystatin 
 
Following the counting step in chapter 2.2, cells were seeded into 96-well plates at a 
density of 1 x 105 cells per well in BNC complete culture medium. Cells were then 
incubated at 37°C in 5% CO2 overnight before serum starving overnight in serum-free 
BNC culture medium and subsequently undertaking experiments. 
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 3-Dimensional Cell Culture 
Reagents: 
 2.5% SeaPlaque™ Agarose from Lonza (Basel, Switzerland). Made up in 
nanopure water and autoclaved. 
 1 M HEPES (Thermo Fisher)  
 DMEM-F12 powder (Thermo Fisher)  
 Insulin-Transferrin-Selenium (ITS -G) (Thermo Fisher)  
 (+)-Sodium L-ascorbate 
 5x DMEM-F12 prepared using DMEM-F12 powder and supplemented with 10% 
FBS, 500 IU/ml penicillin, 500 ug/ml streptomycin and 50 mM HEPES. 
 
Method: The 2.5% agarose was melted by heating in boiling water and then placed in a 
water bath set to 42ºC until the agarose reached 42ºC. Supplemented 5x DMEM-F12 is 
also heated to 42ºC and then mixed with the agarose in a 1:4 ratio to yield 2% Agarose 
and 1x culture medium. It is vital not to allow the temperature to drop in order to avoid 
premature gelling, the agarose/ medium solution is therefore kept at 42ºC until the cells 
are added. The cells are prepared by suspending the required cells and centrifuging to 
form a pellet. The pellet is then resuspended in the minimum possible amount of complete 
DMEM-F12, typically 500 µL. The concentrated cell solution is then added to the 
agarose/ medium solution and mixed taking care to avoid bubble formation. The solution 
is then placed in a 100 mm cell culture dish and quickly incubated at 4ºC for 2 minutes 
followed by 15 minutes at room temperature in order to allow the mixture to set. 
 
Once set, the base of a sterile 5 ml micropipette tip is used to punch out discs of 13 mm 
diameter. Between 20 and 22 discs are obtained from a single 100 mm dish depending on 
the size of the meniscus around the edge and the presence of bubbles. It is important to 
avoid the meniscus and bubbles in order for the discs to have uniform thickness across 
the entire diameter. The discs which are destined to undergo loading are then carefully 
placed within the foam ring in the centre of each well of  BioPress™ Compression Plates  
from Flexcell International Corporation (Burlington, USA). The corresponding unloaded 
controls are placed in regular 6-well cell culture dishes. “Day 0” (4 mL) culture medium 
(table 2.5) is then added to each well, and the plates incubated at 37ºC 5% CO2. Culture 
medium is subsequently changed daily with the medium outlined in table 2.5, according 
to the method of Bougault et al., (2009)239. The benefits of this cell culture regimen are 
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twofold. Firstly, FBS is removed preventing adverse effects on downstream analysis, with 
the ITS being used to supplement for the lack of FBS. Secondly, the increasing levels of 
ascorbic acid help the cells to secrete a PCM/ECM239. 
 
In order to test for the secretion of PCM/ECM by the chondrocytes, the agarose-
chondrocyte constructions either at day 0 or day 6 were fixed in 10% Formalin (Cellpath, 
Newtown, UK) for at least 24 hours before washing in 70% ethanol and embedding in 
paraffin wax (performed by the Newcastle University BioBank). Embedded constructs 
were then sliced and stained for ECM components using histological staining methods 
(performed by Sharon Watson). 
 
Table 2.5: Progressive serum starvation and supplementation timetable for 
chondrocytes in 3D-agarose culture 
Day FBS (%) HEPES (mM) Ascorbic Acid (µg/ml) ITS (%) 
0 10 10 0 0 
1 10 10 0 0 
2 5 20 5 0 
3 5 20 10 1 
4 1 30 15 1 
5 0 30 20 1 
6 0 30 20 1 
 
 
 Cell loading studies using Flexcell® Compression System 
Reagents: 
 Laemmli buffer: 62.5 mM Tris-HCl pH 6.8, 5% (v/v) glycerol, 2.5% (w/v) 
Sodium dodecyl sulphate (SDS), 0.025% Bromophenol blue. Made fresh from a 
4x stock and then β-mercaptoethanol added to 3% (v/v). 
 
Method: Medium from each well of the BioPress plates was replaced with 3 ml of “day 
6” medium. Stationary platens (Flexcell International Corporation) were sterilised in 70% 
ethanol and then prepared for  compression by adjusting the centre screws so that the base 
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of the screw was at the same level as the base of the platen. A stationary platen was added 
to each well of the BioPress plates, and the centre screw adjusted so that it touched the 
top of the gel. The amount to adjust the screws can be calculated based on the known 
thickness of the gels using the following equation: 
 
𝑥 =
(3.11 − ℎ)
0.62
 
 
Where x is the number of 180º clockwise turns required so that the bottom of the centre 
screw is in contact with the gel, and h is the known height of the chondrocyte-agarose 
construct in millimetres. 
 
Following the preparation of the BioPress plates with the stationary platen, the plates 
were placed in the Flexcell® FX-5000™ Compression System (Flexcell International 
Corporation) by centering the plates over the gaskets in the baseplate and clamping the 
plates using the wing nuts on the clamping system until an airtight seal is formed between 
the BioPress plate and the baseplate of the Flexcell system. The Flexcell computer 
software is then used to create and run a regimen for cell loading. The system works by 
increasing air pressure in the baseplate below the BioPress plate, forcing the flexible 
bottom of the BioPress plate to rise and compressing the chondrocyte-agarose construct 
against the stationary platen. 
 
A 30 minute loading regimen of 20-40 kPa with a square waveform with 1 second of 20 
kPa for every 2 seconds of 40 kPa was utilised (Figure 2.1). Following the 30 minute 
loading regiment (referred hereafter as time point 0 minutes), the gels are processed for 
further analysis. For histological analysis, gels were fixed in 10% formalin, washed in 
70% ethanol and embedded in paraffin wax as described in chapter 2.4. For protein 
analysis, gels are placed in a 15 ml Falcon tube and snap frozen in liquid nitrogen and 
stored at -80ºC before lyophilisation using a freeze-dryer. Following lyophilisation, the 
gels are resuspended in 200 µL Laemmli buffer and heated to 100ºC for 5 minutes. The 
gels were allowed to set at room tempterature and transferred to a minispin filter paper 
column with a 10 µm pore size and cut up with a spatula. The gels were then centrifuged 
at 12,000 x g for 1 hour at room temperature. This separates Laemmli buffer containing 
proteins in the filtrate from bits of agarose which cannot pass the 10 µm pores. 20 µL of 
filtrate is then used as loading samples for SDS-PAGE. 
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 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Background: SDS-PAGE is a commonly used laboratory technique in which samples 
containing proteins are separated in a size-dependent manner. Protein samples are 
denatured by heating to 98-105ºC in a buffer containing SDS.  Under native conditions, 
proteins vary in net charge which would affect separation in electrophoretic techniques. 
The presence of SDS negates this variability in protein charges by binding the denatured 
polypeptide chains and giving all proteins a net negative charge and a uniform charge 
density thus allowing them to migrate in a manner relative to their size. The reducing 
agent β-mercaptoethanol may also be added to the sample, reducing disulphide bonds and 
further disrupting any tertiary structure. 
 
The gel is placed in a tank containing a tris-glycine240, or less commonly a tris-tricine241, 
running buffer. An electric current is applied across the gel from negative at the top, to 
positive at the bottom, allowing anions to migrate down through the gel. There are three 
anions in SDS-PAGE: the negatively charged SDS/protein complexes, as well as chloride 
ions from the gel and glycine/tricine from the running buffer. 
 
The polyacrylamide gel contains an upper “stacking gel” and a lower “resolving gel” 
which differ in pH, ionic content and acrylamide concentration. The different migratory 
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Figure 2.1: Loading regimen 
Cells were loaded with a loading regimen of 20-40 kPa with a square waveform with 1 second of 20 kPa for 
every 2 seconds of 40 kPa. 
For 30  mins 
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properties of the stacking gel allow the loaded sample to concentrate (or stack) into a 
single tight band before entering the resolving gel. This permits the proteins to commence 
separating according to their mass at the same starting point. The stacking gel has a larger 
pore size (typically resulting from a lower percentage acrylamide content) which allows 
larger proteins to move quicker and stack with smaller proteins. When a current is applied, 
the three anions enter the stacking gel, however they move at different speeds. The 
chloride ions move the quickest and the glycine/tricine moves slightly slower than the 
proteins. This traps the proteins between the chloride ions and the glycine/tricine, with 
the glycine/tricine “pushing” the proteins into the desired narrow bands. The lower pH 
(6.8) of the stacking gel is key, as this phenomenon is dependent on the pH. When the 
anions reach the higher pH of the resolving gel (pH 8), the glycine/tricine becomes more 
ionised and therefore, along with the chloride ions, migrates quicker than the protein. This 
allows the SDS-protein complexes to migrate based on size as a result of the pores in the 
acrylamide and not a result of their charge. 
 
 Tris-Glycine System 
Method: Tris-glycine SDS-PAGE gels were cast with a either a 10 or12% resolving gel 
and (depending on the mass of protein of interest) a 4% stacking gel. Gels were loaded 
into gel running apparatus (Bio-Rad Mini-PROTEAN Tetra cell), and running buffer 
added. 
 
SDS-PAGE samples are prepared by mixing 4 parts sample with 1 part 5x laemmli buffer. 
For denatured samples, a hotblock was used to heat at 100ºC for 3 minutes. 
 
Prepared samples (10-25 µL) are then loaded into the SDS-PAGE gel at ran at 100 V for 
10 minutes to allow the samples to stack, and then 160-190 V until the bromophenol blue 
dye front reached the bottom of the gel. 
 
Protein was subsequently visualised by either Coomassie staining, silver staining or 
Western blot (chapter 2.6.3, 2.6.4 and 2.6.5, respectively). 
 
Lower Gel 
375 mM Tris pH 8, 0.1% (w/v) SDS, 10 or 12% (v/v) Acrylamide/Bis 
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Upper Gel 
125 mM Tris pH 6.8, 0.1% (w/v) SDS, 4% (v/v) Acrylamide/Bis 
 
Ammonium Persulphate (APS) 
0.2% (w/v) APS 
 
5x Laemmli (Sample) Buffer 
625 mM Tris pH 6.8, 50% (v/v) Glycerol, 10% (w/v) SDS, 5% (v/v) β mercaptoethanol, 
0.025% Bromophenol blue 
 
Running buffer 
25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS 
 
 Tris-Tricine System 
Method: Tris-tricine SDS-PAGE gels were cast with a 20% resolving gel and a 4% 
stacking gel. Once cast, gels were either used or stored wrapped in damp blue roll at 4°C 
overnight. Gels were loaded into gel running apparatus (Bio-Rad Mini-PROTEAN Tetra 
cell), and running buffer added with the cathode buffer going between the the two gels 
and the anode buffer filling the rest of the tank. The tank was placed in a tray of ice prior 
to running to prevent overheating. 
 
Samples were prepared by mixing in equal parts with 2x sample buffer, and heating to 
60°C for 3 minutes. Samples were loaded into the gel, 10 µL per well. Gels were ran at 
200 V until the dye front reached the bottom of the gel, typically 2 hours. 
 
Tris-tricine gels were analysed by silver staining as described in chapter 2.6.4. 
 
Lower Gel 
1 M Tris pH 8.45, 333 mM HCl, 0.1% (w/v) SDS, 20% (v/v) Acrylamide/Bis 
 
Upper Gel 
1 M Tris pH 8.45, 333 mM HCl, 0.1% (w/v) SDS, 4% (v/v) Acrylamide/Bis 
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Ammonium Persulphate (APS) 
0.1% (w/v) APS 
 
2x Sample Buffer 
150 mM Tris pH 7, 30% (v/v) Glycerol, 12% (w/v) SDS, 0.05% Coomassie G-250  
 
Running buffer - Anode 
100 mM Tris pH 8.9, 22.5 mM HCl 
 
Running buffer - Cathode 
100 mM Tris pH 8.25, 100 mM Tricine, 0.1% (w/v) SDS 
 
 Coomassie Staining 
Background: Coomassie Brilliant Blue refers to two similar dyes, R-250 and G-250, 
which differ by the presence of two additional methyl groups on G-250. Despite both 
being blue dyes, G-250 has a more green tint whereas R-250 has a more red tint. Both 
dyes can be used to stain proteins, and this project utilised G-250. Coomassie dyes are 
able to bind to proteins through non-covalent interactions between sulphonic groups in 
the dye and amine groups within the protein. 
 
Method: Following SDS-PAGE, the gels are briefly rinsed in ddH2O and placed directly 
into Coomassie stain for 1 hour at room temperature on a rocker. There is no need for 
fixation as the stain contains the fixative, acetic acid. 
 
Following staining, the gel is placed into destain solution for at least 1 hour with multiple 
changes of solution, until background staining is removed and the bands are clearly 
visible. 
 
Coomassie Stain 
50% (v/v) methanol, 10% (v/v) acetic acid, 0.25% (w/v) Brilliant Blue G-250 
 
Destain Solution 
40% (v/v) methanol, 5% (v/v) acetic acid 
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 Silver Staining 
Background: Silver staining is a sensitive method to stain for all proteins on a gel, 
typically 10-100 times more sensitive than Coomassie staining. The principle behind the 
stain is that silver ions from the silver nitrate solution are able to bind to various side 
groups in various amino acids, which are then reduced to elemental silver during 
development. The reaction can be stopped by introducing EDTA which can chelate any 
unreduced silver ions. 
 
Method: Following SDS-PAGE, the gels are briefly rinsed in ddH2O and placed in fixing 
solution for 1 hour. Following fixation, the gels are place in sensitising solution for an 
hour before rinsing 3 times for 5 minutes each. The gels are then placed in the silver 
nitrate solution for 30 minutes, before rinsing twice for 1 minute each and placing in 
developing solution. The gels are allowed to develop until clear bands are observed and 
then the reaction is stopped to prevent excessive background. All steps were undertaken 
at room temperature on a rocker. 
 
Fixing solution 
For Tris-Glycine gels: 40% (v/v) ethanol, 10% (v/v) acetic acid in ddH2O 
For Tris-Tricine gels: 12% (w/v) trichloroacetic acid (TCA), 30% (v/v) methanol in 
ddH2O 
 
Sensitising solution 
30% (v/v) ethanol, 6.8% (w/v) sodium acetate, 0.2% (w/v) sodium carbonate, 0.125%  
(v/v) glutaraldehyde in ddH2O 
 
Silver nitrate solution 
0.25% (v/v) silver nitrate, 0.0148% (v/v) formaldehyde in ddH2O 
 
Developing solution 
2.5% (w/v) sodium carbonate, 0.029% (v/v) formaldehyde in ddH2O 
 
Reaction stopping solution 
1.5% (w/v) EDTA in ddH2O 
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 Western blotting 
Background: Western blotting is a protein visualation technique which utilises 
antibodies to specifically stain for target proteins of interest, unlike Coomassie or silver 
staining which simply stain for all present proteins. Following SDS-PAGE, the separated 
proteins are transferred from the gel to a membrane (either Polyvinylidene fluoride 
(PVDF) or nitrocellulose) which is then blocked with protein (usually BSA or milk 
proteins) before “probing” with a primary antibody specific to a protein of interest. After 
the primary antibody is allowed to bind to its target protein and excess is washed away, 
the antibody is detected. The most common detection method is to use a secondary 
antibody conjugated to horseradish peroxidase (HRP) enzyme which is specific to the 
species of primary antibody, for example “anti-mouse-HRP” or “anti-rabbit-HRP”. After 
the secondary antibody is bound to the primary antibody and the excess washed away, 
the HRP is detected by a method known as enhanced chemiluminescence (ECL). HRP is 
able to convert the chemiluminescent substrate luminol into oxidised luminol in the 
presence of hydrogen peroxide, a chemical reaction that produces light which can be 
observed on X-ray film on in an imaging hood. The amount of light observed is relative 
to the amount of protein in the band, therefore Western blotting is a semi-quantitative 
method within a specific blot. 
 
Method: A semi-dry transfer method was utilised in the project. Following SDS-PAGE, 
the gel was equilibrated in transfer buffer for two minutes before placement in a transfer 
stack. The transfer stack consists of two pieces of transfer buffer-soaked blotting paper, 
methanol-activated PVDF membrane, the polyacrylamide gel, and two more pieces of 
transfer buffer-soaked blotting paper. The stack was placed in an electroblotter from Bio-
Rad (Hercules, USA) and the electroblotting was undertaken at 80 mA per gel for 1.5 
hours. 
 
Following transfer, the PVDF membrane was blocked for 1 hour at room temperature in 
either 5% BSA in Tris-buffered saline (TBS)-Tween (T) or 5% nonfat dry milk (Marvel 
brand) in TBS-T, depending on antibody preferences. Typically, 5% BSA was only used 
for antibodies which recognised phosphorylated proteins. 
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The membranes were subsequently incubated overnight at 4°C with the primary antibody 
at the manufacturer-recommended concentration, before washing in TBS-T and 
incubating with the appropriate HRP-conjugated secondary antibody (Dako, Agilent 
Technologies, Santa Clara, USA) for 1 hour at room temperature. Membranes were then 
washed in TBS-T prior to ECL detection using an ECL kit (GE Healthcare). The blots 
were then visualised using a Gbox EF Gel Documentation System with Genesnap 
software by Syngene (Cambridge, UK).  
 
Tris Buffered Saline – Tween (TBS-T) 
10 mM Tris pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween 20 
 
Transfer buffer 
39 mM Glycine, 48 mM Tris, 0.0325% (w/v) SDS and 20% (v/v) methanol 
 
 Densitometric analysis (densitometry) 
Densitometric analysis of Western blot allows for semi-quantification of band intensity 
and statisitical analysis to be undertaken. For analysis, high quality exported Tagged 
Image File Format (TIFF) were loaded into ImageJ software (National Institutes of 
Health, Bethesda, USA). Individual lanes were subsequently highlighted, background 
removed, and relative band intensity calculated. Intensities were normalised to 
appropriate loading control, typically GAPDH. 
 
 Agarose gel electrophoresis 
Background: Agarose gel electrophoresis is used to visualise double-stranded DNA by 
first separating out different sized DNA in a sample by electrophoresis, and then 
visualising the gel by methods such as staining with a UV-sensitive dye (e.g. ethidium 
bromide) which can intercalate with double-stranded DNA. 
 
Method: For a 1% gel, 1 g of agarose was measured out and dissolved in 100 mL TAE 
buffer and dissolved by microwaving until boiling. The liquid agarose solution was 
allowed to cool for 5-10 minutes and 1 µL ethidium bromide (at 10 mg/mL) was added 
and mixed. The solution was then placed into a gel tray and an appropriate comb added 
to form the wells. Once fully cooled, the gel set and was placed into a running tank and 
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filled with TAE buffer and the comb removed. Additional ethidium bromide (1 µL per 
100 mL TAE) was added to the TAE buffer in the running tank and the samples loaded 
into the appropriate wells. The lid was then placed on the tank, and the gel ran at 80-110 
V for 30-60 minutes, or until the dye front migrated an appropriate distance. 
 
The gels were then visualised using a Gbox EF Gel Documentation System with 
Genesnap software (Syngene). 
 
TAE buffer 
40 mM Tris-base, 0.11% (v/v) Acetic acid, 1 mM EDTA in ddH2O 
 
 Reverse-Transcription (RT) Real-time (q)PCR 
 mRNA extraction from monolayer cell culture 
Background: In order to measure gene expression from cells in culture, the cells must 
first be lysed and the mRNA stabilised. Multiple methods exist to extract mRNA from 
cells, such as phenol-chloroform extraction or commercially available cell lysis and 
mRNA stabilisation buffers. 
 
Reagents: 
 Cells-to-cDNA II Cell Lysis Buffer (Thermo Fisher) 
  
Method: For gene expression experiments, cells were typically cultured in 96-well plates. 
For mRNA extraction, all steps were performed on ice. Culture medium was aspirated 
from the cells, and each well washed with 200 µL of ice-cold PBS. After aspirating off 
the PBS, 30 µL of Cells-to-cDNA II Cell Lysis Buffer was added per well. Lysis was 
assisted by scratching with pipette tips on a multichannel pipette, before transferring the 
buffer/lysate mixture to a 96-well PCR plate. The lysates are then heated at 75°C for 10 
minutes in a PCR thermocycler. Lysates were then stored at -80°C until required.  
 
 mRNA extraction from 3D cell culture 
See chapter 3.2.2 
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 Reverse Transcription 
Background: In order to quantify gene expression, the extracted mRNA must first be 
converted into complementary (c)DNA, which is the DNA equivalent of the mRNA 
transcripts, thus differs from the genomic (g)DNA in that the introns have been spliced 
out.  
 
Reagents: 
 Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV RT), 200 
units/µL (Thermo Fisher) 
 Random Hexamers (NNN NNN), 0.2 µg/µL (Integrated DNA Technologies, 
Coralville, USA) 
 dNTPs, 2.5 mM each 
 100 mM Dithiothreitol (DTT) (Thermo Fisher) 
 5x First Strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM 
Magnesium Chloride) (Thermo Fisher) 
 RNaseOUT™ Recombinant Ribonuclease Inhibitor, 40 units/µL (Thermo Fisher) 
 
Method: Mix 1 (3 µL dNTPs, 1 µL random hexamers per well) and mix 2 (4 µL 5x first 
strand buffer, 2 µL DTT, 0.125 µL RNase OUT, 0.5 µL MMLV, 1.375 µL ddH2O per 
well) made up for the required number of wells and placed on ice. 4 µL of mix 1 was 
added per well of a 96-well PCR plate, followed by 8 µL per well of cell lysates from 
chapter 2.8.1. The mixture was then incubated in a thermocycler at 70ºC for 5 minutes. 
The PCR plate was then instantly placed on ice and incubated for 2 minutes before adding 
8 µL of mix 2 per well. The mixture plate was then centrifuged at 300 x g for 30 seconds 
to mix and the reverse transcription reaction undertaken in a thermocyler: 37°C for 50 
minutes, followed by 70°C for 15 minutes. The resulting cDNA was then stored at -20°C 
(long-term) or 4°C (short-term). Prior to use in quantitative (q)PCR assays, the cDNA 
was diluted by adding 30 µL ddH2O per well. 
 
 TaqMan® qPCR 
Background: The TaqMan method of qPCR utilises a sequence-specific probe of the 
amplicon. The probe is a short oligonucleotide sequence with a fluorophore coupled to 
the 5’ end and a fluorescence quencher molecule at the 3’ end. The qPCR machine uses 
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a laser to excite the fluorophore, however when the probe is intact, the quencher quenches 
the emitted light and no fluorescence is observed. The probe binds to the template strand 
of cDNA and as the Taq polymerase extends the new strand, its 5’ to 3’ exonuclease 
activity cleaves the probe, thus separating the fluorophore from the  quencher and a signal 
can be detected. The accumulated fluorescence is therefore directly proportional to the 
amount of generated product in the qPCR reaction. 
 
Reagents: 
 TaqMan® Gene Expression Master Mix (Applied Biosystems, Thermo Fisher) 
 TaqMan™ Fast Advanced Master Mix (Applied Biosystems, Thermo Fisher) 
 
Method: A mastermix for the required number of wells is made containing 4.5 µL of 
either Taqman gene expression mastermix (2x) (normal assay) or Fast Advanced Master 
Mix (2x) (fast assay), 0.2 µL of each forward and reverse primer (30 µM) and 0.1 µL 
probe (10 µM) per reaction. 5 µL of mastermix was added per well of an optical bottom 
96-well qPCR plate (Applied Biosystems, Thermo Fisher). 5 µL of cDNA was then added 
per well and the plate given a 30 second spin at 300 x g to mix. 
 
Cycling conditions (normal assay): 
1. Initial denaturation stage of 95ºC 10 minutes 
2. 40 cycles of 95ºC for 15 seconds, 60ºC for 60 seconds 
Cycling conditions (fast assay): 
1. Initial denaturation stage of 95ºC 30 seconds 
2. 40 cycles of 95ºC for 1 second, 60ºC for 15 seconds 
 
Table 2.6: Primers and probes for TaqMan assays, human genes 
Gene Sequence (5’ -  3’) 
 Forward: CGAATGGCTCATTAAATCAGTTATGG 
18S Reverse: TATTAGCTCTAGAATTACCACAGTTATCC 
 Probe: Fam-TCCTTTGGTCGCTCGCTCCTCTCCC-Tamra 
 Forward: GTGAACCATGAGAAGTATGACAAC 
GAPDH Reverse: CATGAGTCCTTCCACGATACC 
 Probe: Fam-CCTCAAGATCATCAGCAATGCCTCCTG-Tamra 
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 Forward: AAGATGAAAGGTGGACCAAAATT 
MMP1 Reverse: CCAAGAGAATGGCCGAGTTC 
 Probe: Fam-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-Tamra 
 Forward: AAATTATGGAGGAGATGCCCATT 
MMP13 Reverse: TCCTTGGAGTGGTCAAGACCTAA 
 Probe: Fam-CTACAACTTGTTTCTTGTTGCTGCGCATGA-Tamra 
 Forward: TTTGCCATCCAGAACAAGC 
ATF3 Reverse: CATCTTCTTCAGGGGCTACCT 
 Probe: Probe #53 (Roche Probe Library, Roche, Basel, Switzerland) 
 Forward: AGACAGCAGAGCACACAAGC 
CXCL8 Reverse: AGGAAGGCTGCCAAGAGAG 
  Probe: Probe #72 (Roche Probe Library) 
 
For bovine HPN and ST14, TaqMan gene expression assay on demands were utilised. 
 
 SYBR green qPCR 
Background: In contrast to the TaqMan method of qPCR where a sequence-specific 
probe is utilised to monitor the PCR amplification, SYBR green is a dye that simply binds 
to any double stranded DNA as is generated by the PCR reaction. As such, SYBR green 
PCR is not as specific as TaqMan, and more care must be taken to validate assays. This 
validation is in the form of a dissociation curve which occurs at the end of the 
amplification. The dissociation, or melt, curve gives an indication of the number of 
amplification products (there should only be one) and also indicates whether primer-
dimers have occurred. The thermocycler begins the curve at a temperature below the Tm, 
and gradually increases to 95°C, the idea being that different products will melt at 
different temperatures thereby confirming the presence of a single amplicon.  
 
SYBR green qPCR was utilised to measure expression levels of bovine genes in this 
project. 
 
Reagents: 
 Platinum® SYBR® Green qPCR SuperMix-UDG (Thermo Fisher) 
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Method: A mastermix for the required number of wells is made containing 10 µL 
Platinum® SYBR® Green qPCR SuperMix-UDG (2x), 0.4 µL of each forward and 
reverse primer (10 µM) and 5.2 µL H2O per reaction. 16 µL of mastermix was added per 
well of an optical bottom 96-well qPCR plate. cDNA (4 µL) was then added per well and 
the plate given a 30 second spin at 300 x g to mix. 
 
Cycling conditions: 
1. UDG incubation stage of 50ºC 2 minutes 
2. Initial denaturation stage of 95ºC 2 minutes 
3. 40 cycles of 95ºC for 15 seconds, 60ºC for 60 seconds 
4. Melt curve analysis 
 
Table 2.7: Primers SYBR green assays, bovine genes 
Gene Sequence (5’ -  3’) 
GAPDH Forward: CCATCTTCCAGGAGCGAGAT 
 Reverse: TCACGCCCATCACAAACATG 
FOS Forward: AAACCATGACAGGAGGCAGA 
 Reverse: TCTAGTTGGTCTGTCTCCGC 
JUN Forward: TATGCTCAGGGAACAGGTGG 
 Reverse: TCTGTTTCCCTCTCGCAACT 
CSRNP1 Forward: TCACTCCCCTGTCCATTCTG 
 Reverse: GCTTGCTCCTGGGTAAACTC 
EGR2 Forward: AGGCCGTAGACAAAATCCCA 
 Reverse: GTTGATCATGCCATCTCCGG 
ATF3 Forward: CCTGCAGAAAGAGTCGGAGA 
 Reverse: GGTTCCTCTCATCTTCCGGA 
MMP1 Forward: TACACCCCAGACCTGTCAAG 
 Reverse: TGTCACGATGATCTCCCCTG 
MMP13 Forward: AGTCTCTCTATGGTCCAGGA 
 Reverse: CATAGGCGGCATCAATACGG 
F2RL1 Forward: CCGTCCCAGGAAACAAGTCT 
  Reverse: CGGGGTGCTTCTTCTTTGTT 
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 LIVE/DEAD® Viability/Cytotoxicity Assay 
To test viability of cells following loading, a LIVE/DEAD® Viability/Cytotoxicity Kit 
for mammalian cells (Molecular Probes, Thermo Fisher) was utilised. 
 
Background: The assay consists of two probes to simultaneously stain for both live and 
dead cells within a population. Live cells are measured by calcein-AM, a non-fluorescent 
precursor which can enter cells but is only cleaved to fluorescent calcein (λex ~494 nm, 
λem ~517 nm) by intracellular esterase in cells which are alive. Dead cells are measured 
by ethidium homodimer (EthD-1), which can enter only cells with damaged membranes 
and fluoresces (λex ~528 nm, λem ~617 nm) when bound to nucleic acid. 
 
 3D cell culture 
Method: Prior to carrying out the assays on loaded cells, the concentrations of calcein-
AM and EthD-1 required to stain BNCs in agarose to give optimal signal were determined 
experimentally, testing a range of concentrations of both probes (0.1 µM to 10 µM) on 
both live cells and cells killed using 70% methanol. Both probes were added to cells 
separately in PBS and incubated for 45 minutes at 37ºC. 
 
Using this method, the optimal concentrations of probe to stain BNCs in agarose were 0.5 
µM calcein-AM and 1 µM EthD-1 (data not shown). To expore the effect of loading on 
cell death, a small sample of the loaded construct was removed and washed in PBS, and 
subsequently incubating in PBS containing 0.5 µM calcein-AM and 1 µM EthD-1 for 45 
minutes at 37ºC. Fluorescence was measured on a Zeiss Axiovert 200M inverted 
microscope (Carl Zeiss AG, Oberkochen, Germany). 
 
 Monolayer cell culture 
Cells were plated in black-walled clear bottom 96-well plates. Cells were treated 
according to the conditions to be tested in terms of other assays of interest. To measure 
cell viability, only live cells were assayed using calcein-AM. 
 
Cells to be assayed were PBS-washed, and 100 µL per well of 2.5 µM calcein-AM in 
PBS was added. The plate was placed into a FLUOstar Optima fluorometer (BMG 
labtech, Ortenberg, Germany) set to 37°C. The assay was carried out, monitoring 
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fluorescence progress at λex 480 nm and λem 520 nm. The slope was taken for each 
condition and normalised to the negative control. As a positive control, cells were pre-
treated for 30 minues with 70% methanol. 
 
 
 PAR2 overexpression in SW1353 cells 
 Stable transfection with expression plasmid 
Background: The production of cell lines which express an expression plasmid in a 
stable manner is a commonly used laboratory technique with major advantages over the 
transient transfection of cells. The plasmid is transfected into the cells, where a selection 
marker, normally antibiotic restistance, is utilised to select only cells integrating the 
plasmid, killing off cells which have not integrated it. The major advantage over transient 
transfection is that low transfection efficiency is overcome by removing untransfected 
cells, resulting in a population of cells all of which overexpress the gene of interest. 
Futhermore, the cells subsequently behave like normal cells and can be passaged and 
plated out as such, without the need for repeated transient transfections, saving on time 
and expensive transfection reagents. 
 
 Cloning of FLAG-PAR2 into pcDNA3.1(+) vector 
In order to clone the PAR2 gene (F2RL1) into the pcDNA3.1(+) vector, In-Fusion cloning 
was utilised (Clontech). Primers were designed in order to amplify the full-length F2RL1 
gene whilst simultaneously adding an N-terminal FLAG tag and overhangs with the 
plasmid cut sites. The pcDNA3.1 vector contains an ampicillin resistance gene for 
bacterial selection, and a neomycin resistance gene for mammalian cell selection. 
 
The full-length F2RL1 gene was obtained commercially (R&D Biosystems, Minneapolis, 
USA, catalogue #RDC0166) stored in a shuttle vector. A cloning strategy was developed 
by designing primers containing an overhang for the pcDNA3.1(+) vector, a kozak 
sequence in the forward primer, a FLAG tag in the forward primer and then an overhang 
for the F2RL1 gene starting at the second amino acid position. 
 
 
 
64 
 
Primers: 
Forward 5’ to 3’:  
TACCGAGCTCGGATC-GCCACC-ATGGACTACAAGGATGACGATGACAAG-
CGAAGTCCTAGTGCT 
 
Reverse 5’ to 3’:  
AAACGGGCCCTCTAG-TTAATAGGAGGTCTTAACAG 
 
The sequences are coloured orange for pcDNA3.1(+) overhang, blue for kozak sequence, 
purple for FLAG tag, and green for F2RL1 gene overhang. 
 
Using the above primers, the F2RL1 gene was amplified using Q5 polymerase (New 
England Biolabs) by performing a reaction containing 1 ng of template DNA (the F2RL1 
gene), 0.2 mM dNTPs, 0.5 µM of each forward and reverse primer and 0.5 units of Q5 
polymerase, in Q5 polymerase buffer.  
 
Cycling conditions: 
1. Initial denaturation stage of 98ºC 30 seconds 
2. 30 cycles of 98ºC for 10 seconds, 56ºC for 15 seconds and 72ºC for 15 seconds 
3. Final elongation of 72ºC for 2 minutes 
 
The pcDNA3.1(+) vector was double digested with the restriction enzymes XbaI and 
BamHI by incubating 1 µg of the vector with 20 units each restriction enzyme in 50 µL 
reactions with NEB buffer 3.1 at 37°C for 4 hours. Single digest control reactions were 
also carried out. 
 
Following the restriction digests and PCR, samples were subjected to agarose gel 
electrophoresis to confirm successful digest and amplification (Figure 2.2), and the 
products were subsequently purified using a PCR clean up kit (Qiagen). 
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The kozak-FLAG-F2RL1 insert was ligated into the digested pcDNA3.1(+) vector using 
an In-Fusion cloning kit (Clontech) by incubating 50 ng of cut vector and 100 ng of insert 
with the kit components in a 10 µL reaction at 50°C for 15 minutes, according to the 
manufacturer’s instructions. 
 
The product was then transformed into “Stellar” E. coli (Clontech), by adding 2.5 µL of 
product into 50 µL of bacteria, and incubating for 30 minutes on ice. The transformation 
was then undertaken by heat shock (incubation at 42°C for 45 seconds), and then placed 
back on ice for 2 minutes. SOC medium (500 µL) (Clontech) prewarmed to 37°C was 
then added and the cells incubated at 37°C for 1 hour at 225 RPM in an orbital incubator. 
The bacteria were then incubated on LB agar plates supplemented with 100 µg/mL 
ampicillin overnight at 37°C. A control transformation was also undertaken. 
 
Colony PCR reactions were performed to screen colonies for successful ligation 
reactions. Fourteen colonies were selected, and samples were obtained by touching the 
colony with a 20 µL pipette tip and then placing the tip in an Eppendorf tube containing 
100 µL sterile water. The tubes were then heated for 3 minutes at 98°C to lyse the bacteria 
and release the DNA. 
 
PCR reactions were set up by creating a mastermix and then adding 1 µL of the bacterial 
DNA-containing water to each reaction. The final reaction components per reaction were 
0.3 mM dNTPs, 0.5 µM of each forward and reverse primers, 1.5 mM MgCl2, 0.25 units 
recombinant Taq polymerase (Thermo Fisher)  in the supplied buffer. The primers were 
Figure 2.2: pcDNA3.1(+) digests and F2RL1 insert 
1% Agarose gel with pcDNA3.1(+) uncut (A), BamHI/XbaI double digest (B), BamHI single digest (C), XbaI 
single digest (D) and the PCR product encoding the kozak-FLAG-F2RL1 insert (E). 
 
bp 
 
 
 
5000 - 
 
 
1500 - 
 
1000 - 
A          B            C           D          E 
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mismatched between the pcDNA3.1(+) vector (T7 promoter) and the F2RL1 gene so that 
products would indicate successful ligation. 
 
Primers: 
Forward 5’ to 3’:  
TAATACGACTCACTATAGGG 
Reverse 5’ to 3’: 
AGAGAGGAGGTCAGCCAAGG 
 
Cycling conditions: 
1. Initial denaturation stage of 94ºC 2 minutes 
2. 35 cycles of 94ºC for 45 seconds, 42ºC for 30 seconds and 72ºC for 90 seconds 
3. Final elongation of 72ºC for 10 minutes 
 
 
 
The colony PCR yielded three successful ligation bands (Figure 2.3), and colonies 5 and 
12 were selected to further grow up and maxiprep. LB medium (250 mL) supplemented 
with 100 µg/mL amplicillin innoculated by each colony was grown overnight at 37°C at 
225 RPM in an orbital incubator. Plasmid DNA was extracted using the PureYield™ 
Plasmid Maxiprep System (Promega) according to the manufacturer’s instructions. A 
sample of each clone was sent for sequencing (Source Bioscience) which confirmed 
successful inframe cloning. 
 
 Optimisation of G418 concentration 
In order to optimise the concentration of G418 to utilise on SW1353 cells, a kill curve 
was generated. SW1353 cells were cultured in black walled clear bottom 96-well plates 
and a titration of G418 100-1000 µg/mL was performed.  
 
Figure 2.3: Colony PCR of pcDNA3.1(+)-FLAG-F2RL1 
A 1% Agarose gel was run with the 14 colony PCR reaction products. The expected band size for successful 
ligation is 469bp, as observed in lanes 5, 12 and 13. 
 
1      2     3      4      5      6     7      8     9     10    11   12   13     14  
bp 
 
 
 
500 - 
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Reagents: 
 DMEM-F12, supplemented with 10% FBS and 2 mM L-glutamine but no 
antibiotics. 
 G418, stored dessicated then made up to 50 mg/mL in ddH2O, filtered with 0.22 
µm PES filter and stored at 4ºC for up to 3 months. 
 
G418 was made up in DMEM-F12 at the desired concentration and 200 µL added per 
well. Cells were cultured at 37ºC in 5% CO2 for either 3, 7, 10 or 14 days with medium 
replaced with freshly made medium at each time point. 
 
In order to measure cell survival, a calcein-AM assay was undertaken as in chapter 2.9.2. 
Data were normalised to the negative control which was assumed to have 100% survival. 
A dose of 400 µg/mL was chosen based on the pcDNA3.1 vector manufacturer manual 
which stated that the minimum dose of G418 that kills the cells after 7 days should be 
used (Figure 2.4). 
 
 
 
 
Figure 2.4: SW1353 sensitivity to G418 
G418 was titrated onto SW1353 cells and cultured for up to 14 days. Cell survival was measured using a calcein-
AM. 
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 Stable transfection of pcDNA3.1_FLAG-PAR2 
Reagents: 
 DMEM-F12, supplemented with 10% FBS and 2 mM L-glutamine but no 
antibiotics. 
 G418, stored desiccated then made up to 50 mg/mL in ddH2O, filtered with 0.22 
µm PES filter and stored at 4ºC for up to 3 months. 
 
In order to create a stable cell line with pcDNA3.1, the plasmid was first linearised by 
digestion with BglII, as this restriction site is not located in an important region of the 
plasmid. A 100 µL reaction was set up containing 10 µg of pcDNA3.1_FLAG-PAR2 and 
50 units of BglII in buffer 3 (New England Biolads, Ipswich, USA) which was incubated 
for 4 hours at 37°C. A 1% agarose gel was run to confirm successful digestion and the 
product was purified using a PCR clean up kit (Qiagen). 
 
Two 60 mm dishes were plated with 2x105 SW1353 cells each, and incubated overnight, 
before transfection was undertaken. Cells were transfected using FuGene HD transfection 
reagent according to the manufacturer’s instructions. Plasmid DNA (2.75 µg) was used 
at a 1:3 ratio with 8.25 µL FuGene HD. A control transfection was also undertaken with 
water:Fugene HD. 
 
Medium was replaced with fresh SW1353 cell culture medium 24 hours post-transfection, 
and with selective medium (400 µg/mL G418 in DMEM-F12, supplemented with 10% 
FBS and 2 mM L-glutamine but no antibiotics), 48 hours post-transfection. Selective 
medium was replaced every 2-3 days until the control transfection cells were all dead, 
and the pcDNA3.1_FLAG-PAR2 cells were 90% confluent. The dish was split 1:6 into 6 
wells of a 6-well plate, and allowed to grow to 90% confluence. Each well was split into 
a T25 flask which was allowed to grow to 90% confluence, and then each flask was split 
into a T75 flask. A sample of each of the 6 clones was taken and lysed, and PAR2 Western 
blot analysis performed. The clone with the highest expression of PAR2 was selected for 
use in this project (data not shown). 
 
 Transient transduction with leniviral vector 
Background: Lentiviral vectors use a highly modified version of the HIV-1 virus to 
introduce foreign DNA into the genome of cells. Numerous modifications have been 
69 
 
made on the native HIV-1 virus for use in gene delivery, removing multiple hazards 
including pathogenicity. 
 
The majority of modern lentiviral expression systems are referred to as being either 
“second”- or “third”-generation. These are both highly safe and efficient lentiviral 
systems, however the third-generation introduces additional safety features, although they 
are more difficult to work with. As such, this project utilised a second-generation system. 
 
A second-generation lentiviral expression system consists of three plasmids: an 
expression plasmid, in which the gene to be overexpressed is cloned into, a packaging 
plasmid (e.g. pCMV-dR8.91) and an envelope plasmid (e.g. pMD2.G) which produce 
virion proteins (the third-generation system splits the packaging components into three 
plasmids). The three plasmids are co-transfected into HEK293T cells, which then 
package live viral particles, which may then be collected and concentrated for subsequent 
use in lentiviral transduction experiments. 
 
The PAR2-expressing and empty vector control lentiviruses were provided by Dr Chun 
Ming Chan, Newcastle University. The lentiviral expression plasmid utilised to construct 
the virus was pHR’-SINcPPT-SIEW (hereafter pSIEW). The vector drives gene of 
interest expression via a spleen focus-forming virus (SFFV) promoter, and also expresses 
enhanced green fluorescent protein (EGFP), produced as a separate protein from a single 
transcript as a result of an internal ribosome entry site (IRES) between the cloning site 
and the EGFP gene. The vector also contains other lentiviral elements, such as a central 
polypurine tract (cPPT), a Woodchuck hepatitis virus post-transcriptional Regulatory 
Element (WPRE), and the HIV Rev response element (RRE). Lentiviruses expressing 
either PAR2 (pSIEW_PAR2) or empty vector control (pSIEW_Empty) were produced 
by co-transfecting HEK293T cells with plasmids containing the remaining components 
required for producing active virion particles. Active virus was harvested, concentrated 
and stored at -80°C. 
 
Reagents: 
 Polybrene, 8 mg/mL, stored at -20°C 
 Heat-inactivated (HI)-FBS, made by heating FBS at 56°C for 30 minutes 
 Complete HI-DMEM-F12, supplemented with 10% HI-FBS, 100 IU/mL 
penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine 
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 SFM, DMEM-F12, supplemented with 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 2 mM L-glutamine 
 
Method: SW1353 cells were seeded into appropriate cell culture plate at a seeding 
density of 30,000 cells/cm3 and allowed to adhere overnight. On the day of transduction, 
cells were expected to be at 50% confluency. Transduction was undertaken by 
supplementing complete HI-DMEM-F12 with 4 µg/mL polybrene, then thawing out 
lentivirus and diluting in the supplemented medium at 1:200. The mixture was then added 
to the cells at an appropriate volume for the plate used (100 µL/well in 96-well plate and 
1000 µL/well in 12-well plate). Cells were then cultured for 48 hours at 37°C, 5% CO2 
before checking EGFP expression using an inverted fluorescence microscope. Following 
confirmation of successful transduction by EGFP expression, cells were serum-starved 
overnight in SFM and subsequently used for experimentation. 
 
 Calcium mobilisation assay 
Background: Activation of Gαq-coupled GPCRs results in Ca2+ flux which acts as a 
second messenger to transduce signal downstream within the cells. In order to assay for 
GPCR activation, Ca2+ flux can be measured utilising fluorescent Ca2+-binding probes. 
Multiple probes exist, and this project utilised Rhod-4 AM, a fluorescent probe with 
excitation and emission wavelengths towards the red end of the spectrum. This probe was 
chosen as the lentiviral construct expresses GFP which would interfere with assays in the 
green part of the spectrum (such as Fluo-4 AM). 
 
Reagents: 
 Hank's Balanced Salt Solution (HBSS) 
 1 M HEPES, pH 7 in ddH2O 
 HEPES-buffered Hank's Balanced Salt Solution (HHBS), HBSS supplemented 
with 20 mM HEPES, pH 7 
 2 M CaCl2 in ddH2O 
 HHBS (2 mM Ca2+), HHBS supplemented with 2 mM CaCl2 
 25 mM Probenecid (Santa Cruz Biotechnology, Dallas, USA), 72 mg dissolved in 
300 µL 1 M NaOH, made up to 10 mL with HHBS (2 mM Ca2+) 
 20% Pluronic F-127 (Thermo Fisher), in DMSO 
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2.5 mM Rhod-4 AM (Santa Cruz Biotechnology), in DMSO, stored at -20ºC, protected 
from light 
2 mM Ionomycin (Santa Cruz Biotechnology), in DMSO 
 
Method: Cells transduced with PAR2-expressing lentivirus (chapter 2.10.2) in a black-
walled clear bottom 96-well plate were washed with 200 µL HHBS (2 mM Ca2+). Rhod-
4 AM was made up to 5 µM in HHBS (2 mM Ca2+) supplemented with 2.5 mM 
probenecid and 0.02% pluronic F-127. Pluronic F-127 helps to increase the solubility of 
the probe, whereas probenecid is an inhibitor of organic-anion transporters within the cell 
membrane and thus helps to prevent the export, and therefore loss, of the probe. Rhod-4 
AM (50 µL) was added to each well and the plate incubated at room temperature in the 
dark for 45 minutes. 
 
Following Rhod-4 AM loading, the cells were washed with 200 µL HHBS (2 mM Ca2+), 
and then incubated in 100 µL HHBS (2 mM Ca2+) for 20 minutes at room temperature to 
allow for complete de-esterfication of the probe. Meanwhile, the flourometer (FLUOstar 
OPTIMA, BMG labtech) was prepared for the assay. Both injection pumps were primed 
with 2 mL of HHBS (2 mM Ca2+), before priming in 1 mL of test compounds. Test 
compound in pump A was always at 2x final concentration, whereas test compound in 
pump B was at 3x final concentration. 
 
Following de-esterfication of the probe, each well was replaced with 30 µL HHBS (2mM 
Ca2+), and placed in the fluorometer pre-heated to 37ºC. The flurometer was programmed 
to read in single-well mode with a reading taken every second at λex 520 nm and λem 590 
nm. Per well, a baseline was established for 10 seconds before 30 µL from pump A was 
injected, then at 90 seconds, 30 µL from pump B was injected. Readings were taken up 
to 120 seconds before moving onto the next well. 
 
 PAR-2 Activation and Disarming Assays 
To test the effect of proteases and peptides on PAR2-expressing SW1353 cells, activation 
and disarming experiments were undertaken, measuring various downstream outcomes. 
 
Cells were seeded according to the requirements of the experiment and the method of 
over expression. For gene expression studies by RT-qPCR and calcium mobilisation 
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assays, cells were plated in 96-well plates. For experiments requiring Western blotting, 
either 6 or 12-well plates were used. Prior to carrying out experiment, cells were serum-
starved overnight. 
 
Reagents: 
 SFM, DMEM-F12, supplemented with 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 2 mM L-glutamine 
 HEPES-buffered Hank's Balanced Salt Solution (HHBS), HBSS supplemented 
with 20 mM HEPES, pH 7 
 
 Matriptase and SLIGKV activation assays 
Matriptase and SLIGKV activation assays consisted of simulating PAR2-overexpressing 
cells which had been serum-starved overnight, with either matriptase or SLIGKV and 
analysing by various methods. 
 
For all assays except those measuring calcium mobilisation, matriptase or SLIGKV was 
diluted into SFM at the appropriate concentration and pre-heated to 37°C. Medium was 
aspirated from the cell culture plates, and the matriptase or SLIGKV in SFM added to the 
cells. Typically, 50 µL was utilised for 96-well plates, and 500 µL for 12-well plates. The 
cells were incubated for varying durations depending on the assay, and then harvested by 
either extracting protein or mRNA as previously described. 
 
For experiments measuring calcium mobilisation, SLIGKV or matriptase was diluted into 
HHBS at twice the final assay concentration, and then used to prime the fluorimeter 
pump. The cells were then aspirated, and HHBS added to each well. The amount of HHBS 
added depended on the final assay concentration for that well. For example, if 20 µM 
SLIGKV was primed into the pump, then by placing 30 µL of HHBS on the cells and 
injecting 30 µL in the assay would result in final stimulation of 10 µM.  
 
 Cathepsin V disarming assays 
PAR2 disarming assays consisted of pre-incubating PAR2-expressing SW1353 cells with 
a cathepsin and then measuring a PAR2 activation readout following matriptase or 
SLIGKV stimulation. These assays were performed in 96-well plates, and consisted of 
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either measuring calcium mobilisation or gene expression by RT-qPCR of PAR2-
responsive genes. 
 
Experiments were performed following overnight serum starvation of the cells. For 
measuring calcium mobilisation as a read out, the cells were first loaded with calcium 
indicator as outlined in chapter 2.11.  
 
The cathepsin enzymes were activated by diluting 1:10 in activation buffer, then further 
diluting to final concentration in assay buffer, and 50 µL was added to each appropriate 
well. Cells were incubated with cathepsin for 10 minutes at 37°C, before being washed 
in assay buffer (calcium mobilisation) or SFM (qPCR). For measuring calcium 
mobilisation, the plates were then directly placed in the fluorometer, and the assay 
undertaken by injecting PAR2 agonist using the fluorometer pumps. When using qPCR 
as a read out, the PAR2 activator was diluted into SFM and added to the cells before 
further incubating at 37°C for the required time. 
 
Cathepsin V, K, S, L activation buffer 
100 mM Sodium acetate pH 5.5, 2.5 mM DTT, 2.5 mM EDTA 
 
Calcium assay buffer 
HHBS (2 mM Ca2+) 
 
 Enzymatic digestion of PAR2 42mer 
Background: In order to screen proteases for their ability to cleave PAR2, incubations 
were carried out with various proteases of interest and a 42 amino acid peptide (hereafter 
“PAR2 42mer”) consisting of the extracellular region of PAR2 that all previously 
identified cleavages have occurred (see chapter 4.1.2.1) . 
 
Reagents: 
 PAR2 42mer, at 100 µM in 0.1% TFA in ddH2O, stored at -80°C. 
 Various recombinant and purified proteases, see chapter 2.1.2. 
 
Method: Reactions were set up using the buffer conditions recommend for the specific 
protease. Typically, the experiments were set up by making dilutions of PAR2 42mer at 
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20 µM and protease at 2x final concentration (typically in the range of 0.1 nM to 200 nM) 
before mixing together in equal parts (typically 20-40 µL) yielding a final peptide 
concentration of 10 µM. Reactions were incubated at 37°C for varying amounts of time. 
 
Following enzymatic digests, the reactions were either analysed by tris-tricine SDS-
PAGE (chapter 2.6.2), HPLC (chapter 2.14.1) or nanoLCMS (chapter 2.14.3). 
 
Cathepsin V, K, S, L buffer 
100 mM Sodium acetate pH 5.5, 2.5 mM DTT, 2.5 mM EDTA, 0.05% (w/v) Brij 35 
 
Cathepsin B buffer 
25 mM MES pH 5, 5 mM DTT, 0.05% (w/v) Brij 35 
 
MMP-1, -8, -13 and ADAMTS5 buffer 
100 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM CaCl2, 0.05% (w/v) Brij 35, 0.01% 
(w/v) PEG 6000. 
 
Matripase, Hepsin buffer 
100 mM Tris pH 8.5, 150 mM NaCl, 0.01% Brij-35 
 
Neutrophil elastase, Cathepsin G, FAP buffer 
100 mM Tris pH 7.5, 150 mM NaCl, 0.01% Brij-35 
 
Thrombin, uPA buffer 
100 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Brij-35 
 
HTRA1, HTRA3, Factor I, Factor D buffer 
50 mM Tris pH 8, 150 nM NaCl, 0.01% Brij-35 
 
PCSK9 buffer 
50 mM Sodium Citrate pH 5, 75 mM NaCl, 2 mM CaCl2, 0.01% Brij-35 
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 Mass Spectrometry of PAR2 42mer digestion products 
Background: In order to identify specific cleavage sites of enzymatic cleavages of 
PAR2, mass spectrometry (MS) was used. Samples were either separated by HPLC and 
ionised in direct-infusion MS, or the reaction mixture was directly subjected to 
nanoLCMS. 
 
 High Performance Liquid Chromatography  
High performance liquid chromatograpgy (HPLC) was used to examine the enzymatic 
digestion products and to subsequently isolate specific products for MS. 
 
An autosampler was used to inject either 10 µL or 30 µL of digestion reaction for 
analytical or preparative HPLC, respectively, onto an ACE 3 C18 column (Advanced 
Chromatography Technologies, Aberdeen, UK) fitted to an 1100 series HPLC system 
(Agilent Technologies). The 5% to 60% acetonitrile gradient was run as detailed below. 
Gradients were run at 35°C at a flow rate of 0.2 mL/min. 
 
Run conditions: 
1. 5% to 60% buffer B in 27 minutes 
2. 60% to 100% buffer B in 1 minute 
3. 100% to 5% buffer B in 2 minutes 
4. Re-equilibration at 5% buffer B for 15 minutes 
 
Buffer A 
0.1% Formic acid in ddH2O 
 
Buffer B 
0.1% Formic acid in acetonitrile 
 
 Direct-infusion MS 
Samples fractionated by HPLC were loaded onto a TriVersa NanoMate (Advion, Ithaca, 
USA) and electrosprayed into a Thermo Finnigan LTQ FT Ultra High Performance Mass 
Spectrophotometer (Thermo Fisher) using a 2.4 kV voltage. 
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 NanoLCMS 
For nanoLCMS, an Acquity UPLC system (Waters, Elstree, UK) was connected to the 
Thermo Finnigan LTQ FT. 
 
Samples were diluted 1:10 in 0.1% Formic acid and loaded into the autosampler. Sample 
(1 µL) was injected onto the system and gradients were run on an in-house packed column 
(Dr. Joe Gray) of 20 cm length x 0.1 mm width, with 5 µm partical size at 5 µL/min. 
 
Run conditions: 
1. 5% to 55% buffer B in 35 minutes 
2. 55% to 85% buffer B in 3 minute 
3. 85% to 5% buffer B in 2 minutes 
 
Products were trapped using an Agilent ion trap (Agilent Technologies) at 0.4 µL/min 
and sprayed using a PicoTip silica tip (New Objective, Woburn, USA).  
 
Buffer A 
0.1% Formic acid in ddH2O 
 
Buffer B 
0.1% Formic acid in Acetonitrile 
 
 Data analysis 
NanoLCMS identifies all cleavages within a sample and thus the data required analysis 
to identify the cleavages and order the relative abundance of products. 
 
Firstly, the NanoLCMS traces were loaded onto Xcalibur™ Software (Thermo Fisher), 
and all the data between 10 and 50 minutes on the gradient were compiled. These times 
were chosen as they avoid the injection peaks at the start and the acetonitrile peak at the 
end. After compiling the data from this timespan, a list of the 20 most abundant masses 
was acquired. Subsequently, a search was undertaken using Mascot software (Matrix 
Science, Boston, USA) where the peptide sequence was uploaded into the database, and 
the raw nanoLCMS data file uploaded and cross-checked with the peptide sequence. This 
resulted in a list of peptide fragments identified as belonging to the PAR2 42mer peptide, 
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which was then cross-referenced with the top 20 list obtained from the Xcalibur™ 
Software, to give the top cleavages generated by each enzyme. 
 
 Enzyme Activity Assays 
Background: Enzymatic reactions can be explored using quenched-fluorescent 
substates. These substrates are composed of short peptide sequences, specific for various 
protease preferences, as well as a quencher group and a fluorophore. In its intact state, the 
quencher prevents the observation of the fluorophore emission following excitation, 
however when the protease cleaves the substrate, the quencher spatially moves from the 
fluorophore allowing fluorescence to be observed (Figure 2.5). Some fluorescent peptide 
substrates, such as Boc-QAR-AMC, do not require a quencher as the binding of the AMC 
flurophore to an amino acid results in quenching, and fluorescence is observed when the 
AMC is cleaved away from the peptide. 
 
 
 
S K G R S L I G 2-Abz 
3-
nitrotyrosine 
S K G R 2-Abz 
Trypsin, Matriptase 
Figure 2.5: Example of a quenched-fluorescent substrate: SY-9 PAR2 activation peptide 
Quenched-fluorescent peptides are composed of a specific peptide sequence, with a quencher group as well as a 
flurophore. For example, the PAR2 activation peptide, SY9, consists of 8 amino acids around the canonical 
activation site, as well as a 2-aminobenzyl flurophore and a trinitrotyrosine quencher. 
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 FS-6 assay 
Background: FS-6 is a quenched-fluorescent hexapeptide with the sequence AMC-Lys-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 where AMC is the fluorophore 7-amino-4-
methylcoumarin, and Dpa is quencher N-3-(2,4-dinitrophenyl)l-α,β-diaminopropionyl. 
FS-6 is a general MMP substrate cleaved by several MMPs including all MMPs utilised 
in this project. 
 
Reagents: 
 FS-6 substrate at 5 mM in DMSO, stored at -20ºC protected from light 
 AMC standard at 5 mM in methanol, stored at -20ºC protected from light 
 
Method: 50 µL of MMP-containing sample made up to 1-5 nM (2x active concentration) 
in assay buffer was added to two wells of a white-walled white bottom 96-well plate 
(Perkin Elmer, Waltham, USA) per sample (two technical repeats). FS-6 substrate was 
diluted to 20 µM (2x final concentration) in assay buffer, and 120 µL added to a third 
well parallel to the assay samples. The plates were pre-incubated for at least 10 minutes 
at 37ºC to allow the reagents to reach assay temperature. Fluorescence was kept below 
10% substrate hydrolysis using AMC standard at 1 µM. A multichannel pipette was then 
used to add 50 µL substrate to each sample well as quickly as possible to ensure that 
enzymatic reactions commenced essentially at the same time. Final substrate 
concentration was 10 µM, and fluorescence increase was monitored in the form of a 
progress curve on a FLUOstar Optima fluorometer (BMG labtech), at λex 325 nm and λem 
405 nm. 
 
FS-6 Assay buffer 
100 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM CaCl2, 0.05% (w/v) Brij 35, 0.01% 
(w/v) PEG 6000 
 
 Boc-QAR-AMC assay 
Background: Boc-QAR-AMC is a fluorescent substrate for trypsin-like serine proteases 
with the sequence Boc-Gln-Ala-Arg-AMC, where Boc is N-tert-butoxycarbonyl, a 
blocking group. 
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Reagents: 
 Boc-QAR-AMC substrate at 25 mM in methanol, stored at -20ºC protected from 
light 
 AMC standard at 5 mM in methanol, stored at -20ºC protected from light 
 
Method: Serine protease-containing sample made up to 1-5 nM (2x active concentration) 
in assay buffer, and 50 µL added to two wells of a white-walled white bottom 96-well 
plate (Perkin Elmer) per sample (two technical repeats). Boc-QAR-AMC substrate was 
diluted to 20 µM (2x final concentration) in assay buffer, and 120 µL added to a third 
well parallel to the assay samples. The plates were pre-incubated for at least 10 minutes 
at 37ºC to allow the reagents to reach assay temperature. Fluorescence was kept below 
10% substrate hydrolysis using AMC standard at 1 µM. A multichannel pipette was then 
used to add 50 µL substrate to each sample well, as quickly as possible to ensure that 
enzymatic reactions commence as close to each other as possible. Final substrate 
concentration was 10 µM, and fluorescence increase was monitored in the form of a 
progress curve on a FLUOstar Optima fluorometer (BMG labtech), at λex 360 nm and λem 
460 nm. 
 
Assay buffer 
100 mM Tris pH 8.5, 150 mM NaCl, 0.01% Brij-35 
 
 Z-FR-AMC assay 
Background: Z-FR-AMC is a fluoroescent substrate for papain-like cysteine proteases 
with the sequence Z-Phe-Arg-AMC, where Z is blocking group benzyloxycarbonyl. This 
substrate was used for all cathepsins in this project. 
 
Reagents: 
 Z-FR-AMC (Bachem, Bubendorf, Switzerland) at 20 mM in methanol, stored at 
-20ºC protected from light 
 
Method: Cathepsin enzymes were stored in their pro-form and required activation by 
exposing to reducing conditions, as provided by DTT in their assay buffers. To activate, 
pro-cathepsins were typically diluted 1:10 in assay buffer and incubated at room 
temperature for 10 minutes. Cathepsin-containing samples were made up to 1-5 nM (2x 
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active concentration) in assay buffer, and 50 µL added to two wells of a white-walled 
white bottom 96-well plate (Perkin Elmer) per sample. Z-FR-AMC substrate was diluted 
to 20 µM (2x final concentration) in assay buffer, and 120 µL added to a third well parallel 
to the assay samples. The plates were pre-incubated for at least 10 minutes at 37ºC to 
allow the reagents to reach assay temperature. Fluorescence was kept below 10% 
substrate hydrolysis using AMC standard at 1 µM. A multichannel pipette was then used 
to add 50 µL substrate to each sample well, as quickly as possible to ensure that enzymatic 
reactions commence as close to each other as possible. Final substrate concentration was 
10 µM, and fluorescence increase was monitored in the form of a progress curve on a 
FLUOstar Optima fluorometer (BMG labtech), at λex 380 nm and λem 460 nm. 
 
Cathepsin V, K, S, L assay buffer 
100 mM Sodium acetate pH 5.5, 2.5 mM DTT, 2.5 mM EDTA, 0.05% (w/v) Brij 35 
 
Cathepsin B assay buffer 
25 mM MES pH 5, 5 mM DTT, 0.05% (w/v) Brij 35 
 
 Michaelis-Menten Kinetics 
Background: Michaelis-Menten kinetics is a commonly used model of enzyme kinetics, 
able to relate the rate of reaction or velocity (V) with the concentration of substrate, [S]. 
Using Michaelis-Menten kinetics to explore how proteases can cleave their substrate, 
several important kinetic constants can be calculated which can give insight into their 
biochemistry. 
 
The pioneering work by Leonor Michaelis and Maud Menten proposed a model for 
enzymatic reactions where enzyme (E) is able to bind to substrate (S) to form an enzyme-
substrate complex (ES) which is a reversible reaction. The enzyme is then able to 
irreversibly catalyse the substrate to product (P) and release itself from the complex, able 
to catalyse another reaction (E): 
 
𝐸 + 𝑆 ⇌ 𝐸𝑆
𝑘𝑐𝑎𝑡
→  𝐸 + 𝑃 
 
With certain assumptions, the Michaelis-Menten equation can be derived as: 
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𝑉 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 + [𝑆]
 
 
Where Vmax is the maximal velocity, and Km is the Michealis-Menten constant. The Km 
is the substrate concentration at half Vmax and is considered an inverse measure of the 
affinity of the enzyme for the substrate, thus a lower Km is considered to be a higher 
affinity and thus the velocity will reach Vmax more quickly. It is important to note that Km 
is a kinetic constant and not an equilibrium constant (which would be the dissociation 
constant Kd for affinity). Using Kd to describe enzymatic affinity for substrate can be 
complicated since the enzyme also degrades the substrate rather than reaching a 
dissociation/association equilibrium. Under certain circumstances, Km may be equal to 
Kd (when the rate of formation of the ES complex is much faster than the formation of E 
and P from ES)242. 
 
kcat is known as the turnover number, and is a measure of the number of substrate 
molecules which are converted to product per active site per unit time. This can be 
calculated by knowing the active-site concentration of the enzyme at T=0 (E0): 
 
𝑘𝑐𝑎𝑡 =
𝑉𝑚𝑎𝑥
𝐸0
 
 
As both kcat and Km give information about the relationship between enzyme and 
substrate, it is common to quote catalytic efficiency as: 
 
𝑘𝑐𝑎𝑡
𝐾𝑚
 
 
If an enzyme has a high turnover number as well as a high affinity for a substrate, then 
the catalytic efficiency will be very high, and a high value for kcat/Km would express this. 
 
In order to generate kinetic constants experimentally, increasing concentrations of 
substrate are incubated with a constant concentration of enzyme, and the velocities are 
observed. The velocities will increase with substrate concentration until the system 
becomes saturated and Vmax is reached. Velocity is plotted against substrate 
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concentration, and constants can be derived by methods such as Lineweaver-Burk plots, 
or by computer software. 
 
  PAR2 peptide kinetics 
Background: In order to explore the enzyme kinetics for various proteases for PAR2, 
quenched-fluorescent substrates for three regions of PAR2 were utilised. 
 
Reagents: 
 SY-9 peptide at 1.748 mM in 20% (v/v) acetonitrile, stored at -20ºC protected 
from light. 
 VETV peptide at 10 mM in DMSO, stored at -20ºC protected from light. 
 FSVD peptide at 10 mM in DMSO, stored at -20ºC protected from light. 
 
Method: Serial dilutions of the PAR2 peptides were undertaken in assay buffer, resulting 
in a series of enzyme concentrations at 2x final concentration. Each concentration was 
placed into duplicate wells of a white-walled, white-bottom 96-well plate (Perkin Elmer), 
50 µL per well, and the plate pre-heated to 37ºC. Meanwhile, the enzyme was prepared 
in assay buffer at 2x final concentration and 120 µL added to a third well parallel to the 
assay wells. A multichannel pipette was then used to transfer 50 µL of 2x enzyme stock 
to each well of the substrate, and the reaction monitored in a FLUOstar OPTIMA 
fluorimeter at λex 320 nm and λem 420 nm. 
 
Velocities were taken in the linear phase at the start of the reaction, and plotted against 
substrate concentration. Velocity in arbitrary fluorescence units was converted to 
concentration of substrate per unit time by using a total hydrolysis standard curve (see 
Appendix 4). A plate was set up with concentration of substrate as used for kinetic 
determination, enzyme was added, but instead of measuring velocity, the plate was 
incubated for 2-4 hours at 37ºC before measuring fluorescence at total hydrolysis. The 
straightline equation was then used to relate arbitrary fluorescence to substrate hydrolysis. 
A different standard curve was used for each different buffer system. 
 
To determine kinetic constants, non-linear regression analysis of velocities was 
performed using GraphPad Prism software. Vmax and Km. kcat could then be determined 
based on the known active concentration of enzyme used. 
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Cathepsin V, K, S, L assay buffer 
100 mM sodium acetate pH 5.5, 2.5 mM DTT, 2.5 mM EDTA, 0.05% (w/v) Brij 35 
 
Cathepsin B assay buffer 
25 mM MES pH 5, 5 mM DTT, 0.05% (w/v) Brij 35 
 
Matriptase assay buffer 
100 mM Tris pH 8.5, 150 mM NaCl, 0.01% Brij-35 
 
MMP-1, -8, -13 assay buffer 
100 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM CaCl2, 0.05% (w/v) Brij 35, 0.01% 
(w/v) PEG 6000. 
 
 Active-site titration 
Background: Throughout this project, quoted enzyme concentrations refer to the protein 
concentration of enzyme, however the enzyme might not be fully active. In order to 
calculate accurate kinetic constants to compare enzymes, an accurate active-site 
concentration must be obtained. In order to active-site titrate an enzyme, an inhibitor with 
1:1 binding stoichiometry is required, and is titrated to a range of concentrations against 
a constant enzyme concentration. When plotted with velocity on the Y axis, and inhibitor 
concentration on the X axis, the X-intercept is the active concentration of enzyme. 
 
 Cathepsin active-site titration with E64 
Background: trans-Epoxysuccinyl-L-leucylamido(4-guanidino)butane (E64) is an 
epoxide small molecule inhibitor of cysteine proteases, which exerts its effect by being 
able to bind to the active-site cysteine residue as a result of nucleophilic attack from its 
thiol group. It is commonly used to active-site titrate various cathepsins243, including all 
cathepsins used in this project. 
 
Reagents: 
 Z-FR-AMC (Bachem) at 20 mM in methanol, stored at -20ºC protected from light. 
 E64, at 1 mM in ddH2O, stored at -20ºC 
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Method: Pro-cathepsins were activated by diluting 1:10 in their assay buffer and 
incubating at room temperature for 10 minutes. Subsequently, they were diluted to 3x 
final concentration (typically 1-5 nM) and 33 µL was added to 2 wells of a white-walled 
white bottom 96-well plate (Perkin Elmer) per sample. E64 was diluted in the same assay 
buffer, and a range of dilutions undertaken by either serial or parallel dilution. Typically, 
concentrations ranging from 10-fold lower to 10-fold higher than the enzyme 
concentration were used. 33 µL of each E64 concentration was added to the enzymes in 
the plate and incubated for 30 minutes at 37ºC to allow complete inhibition. Substrate Z-
FR-AMC was diluted to 30 µM (3x final concentration) and 80 µL was added to a third 
well parallel to the assay wells. A multichannel pipette was then used to add 33 µL 
substrate to each sample well, as quickly as possible to ensure that enzymatic reactions 
commence as close to each other as possible. Final substrate concentration was 10 µM, 
and fluorescence increase was monitored in the form of a progress curve on a FLUOstar 
Optima fluorimeter (BMG labtech), at λex 380 nm and λem 460 nm. 
 
Cathepsin V, K, S, L assay buffer 
100 mM sodium acetate pH 5.5, 2.5 mM DTT, 2.5 mM EDTA, 0.05% (w/v) Brij 35 
 
Cathepsin B assay buffer 
25 mM MES pH 5, 5 mM DTT, 0.05% (w/v) Brij 35 
 
 MMP active-site titration with TIMP1 
Background: As described in chapter 1.4.1.6, MMPs are inhibited by their endogenous 
inhibitors which bind with 1:1 stoichiometry. This property can be exploited to active-
site titrate MMPs, by titrating with a known concentration of TIMP. This project utilised 
TIMP1 as it is able to inhibit all the used MMPs. MMPs are produced recombinantly in 
their pro-form, thus require activating before carrying out the assay. They can be activated 
in vitro in the presence of 4-aminophenylmercuric acetate (APMA). 
 
Reagents: 
 TIMP1 at 5.6 µM, stored at -80°C. 
 AMPA stock solution at 10 mM, made by dissolving 35.2 mg APMA in 200 µL 
DMSO, then made up to 10 mL in 100 mM Tris pH 8.5 stored at 4ºC protected 
from light for up to 3 months 
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Methods: Pro-MMPs were first activated by diluting 1:10 in their assay buffer with 1 
mM APMA and incubating at 37ºC for 30 minutes (proMM13), 1 hour 30 minutes 
(proMMP8) or 3 hours (proMMP1). Subsequently, they were diluted to 3x final 
concentration (typically 1-5 nM) and 33 µL was added to 2 wells of a white-walled white 
bottom 96-well plate (Perkin Elmer) per sample. TIMP1 was diluted in the same assay 
buffer, and a range of dilutions undertaken by either serial or parallel dilution. Typically, 
concentrations ranging from 10-fold lower to 10-fold higher than the enzyme 
concentration were used. Each TIMP1 concentration was added (33 µL) to the enzymes 
in the plate and incubated for 30 minutes at 37ºC to allow complete inhibition. Substrate 
FS6 was diluted to 30 µM (3x final concentration) and 80 µL was added to a third well 
parallel to the assay wells. Subsequently, 33 µL of substrate was added to each sample 
well as quickly as possible. Final substrate concentration was 10 µM, and fluorescence 
increase was monitored in the form of a progress curve on a FLUOstar Optima fluorimeter 
(BMG labtech), at λex 325 nm and λem 405 nm. 
 
FS-6 Assay buffer 
100 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM CaCl2, 0.05% (w/v) Brij 35, 0.01% 
(w/v) PEG 6000. 
 
 Gene expression microarray 
Background: A gene expression (or DNA) microarray is a powerful method for 
exploring the genome-wide gene expression status of a sample, utilising a chip containing 
thousands of oligomeric probes. High purity mRNA is extracted from a source such as a 
tissue or cells, which is then reverse-transcribed to cDNA, which is then hybridised to the 
chip and measured. 
 
Method: SW1353 cells were seeded into a 6-well plate at a seeding density of 30,000 
cells/cm3 before transducing with pSIEW_PAR2 lentivirus as outlined in chapter 2.10.2 
and cultured for 48 hours at 37°C 5% CO2. The cells were serum-starved overnight, and 
stimulated with 10 nM matriptase, 100 µM SLIGKV (both dissolved in SFM) or 
unstimulated (SFM only). Stimulation was undertaken for either 90 minutes or 24 hours 
before extracting mRNA using an RNeasy kit (Qiagen). The mRNA was sent to the 
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Central Biotechnology Services at Cardiff University School of Medicine for gene 
expression analysis. 
 
The microarray utilised a HumanHT-12 v4 Expression BeadChip Kit (Illumina Inc., San 
Diego, USA), able to measure 12 samples on a single chip, with 47,000 probes per 
sample. Samples were randomised over two chips. 
 
The raw microarray data were analysed by the Musculoskeletal Research Group 
Bioinformatics Support Unit at Newcastle University. Pathway analysis was undertaken 
using Ingenuity Pathway Analysis software (Qiagen). 
 
 Statistical Analysis 
Statistical differences between two parametric groups were compared using a student’s 
two-tailed t-test. Where multiple comparisons were made within one experiment, a one-
way analysis of variance (ANOVA) was performed. Graphpad Prism 5.0 software or 
Microsoft Excel were used to undertake statistical analysis. The significance levels used 
were: * = p<0.05, ** = p<0.01 and *** = p<0.001. 
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3. Chapter 3. Mechanical Loading of Chondrocytes 
 Introduction 
As described in chapter 1, chondrocytes are cells which respond to mechanical load in a 
variety of manners, such as altered growth, metabolism and gene expression. Of particular 
interest to this project is the fact that various MMPs are known to be regulated by 
mechanical loading, such as MMP-1, -2, -3, -9 and -1322 – which include the two key 
collagenases implicated in OA, MMP-1 and 13. Matriptase has been shown to be up-
regulated in OA patients1, however very little is currently understood about the 
mechanisms behind this up-regulation. This chapter aims to explore whether matriptase 
expression may be regulated by mechanical loading. 
 
 Chapter Aims 
 To develop a system by which to encapsulate chondrocytes in a 3D hydrogel and 
to expose them to mechanical load, and to extract mRNA and protein for further 
analysis. 
 To explore whether matriptase, and other serine proteases of interest such as 
hepsin, are regulated by abnormal loading. 
 To further aim to understand genes regulated by mechanical loading in 
chondrocytes in the context of catabolism. 
 
 Results 
 Comparison of Bovine Nasal Chondrocytes with SW1353 cells 
In order to test the mechanical loading of chondrocytes, a source of appropriate cells is 
required. Due to the relatively large numbers of cells required per experiment (5-10x106 
cells), the utilisation of human articular chondrocytes (HAC) harvested from joint 
replacement patients would be inappropriate as these typically yield below 1x106 cells 
(unpublished observations). A comparison of a human chondrocytic cell line, SW1353, 
and primary bovine nasal chondrocytes (BNC) was therefore undertaken. 
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10x106 cells (either SW1353 or BNC) were utilised to make agarose/cell constructs and 
cultured for 6 days with progressive serum starvation and supplementation in order to 
allow the cells to secrete a PCM (chapter 2.2.8). Following day 6, histological staining 
was performed. These results clearly showed that BNCs, but not SW1353 cells, were able 
to synthesise and secrete proteoglycans in the pericellular space (Figure 3.1 C, D, G and 
H) as shown by Alcian Blue and Safranin O staining. 
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Figure 3.1: Histological staining of SW1353 cells and BNCs following 6 day culture 
Chondrocyte/agarose constructs containing either SW1353 (A-D) or BNCs (E-H) were cultured for 6 days 
according to the method described in chapter 2.2.8, before fixing in formalin, embedding in paraffin wax and 
staining with H&E (A, E), Masson’s Trichrome (B,F), Alcian Blue (C,G) or Safranin O (D, H). Scale bar = 100 
µm. 
A B 
C D 
E F 
G H 
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Having ascertained whether the two cell types are able to secrete a PCM, their basic 
responses to loading were examined. It has been described in the literature that p38 is 
rapidly phosphorylated in response to loading239,244-247. Both SW1353 and BNC agarose 
constructs were therefore loaded with identical loading regimens and their responses 
examined by western blotting. Following a 30 minute loading regimen of 20-40 kPa at 
0.33 Hz, the chondrocyte/agarose constructs were snap frozen in liquid nitrogen and 
processed for SDS-PAGE analysis, in a method designed to maintain the phosphorylated 
status of proteins in the cells239. Following mechanical loading, SW1353 cells did not 
appear to respond in terms of p38 phosphorylation (Figure 3.2). For BNCs however, there 
was a clear phosphorylation of p38 (Figure 3.3). When BNCs were loaded after two days 
in culture (before they had secreted a PCM), they did not respond to mechanical loading 
(Figure 3.4A). It appears that prior to secretion of PCM, there appears to be a space 
between the cell and the surrounding agarose matrix (Figure 3.4B-E). 
 
 
 
Phospho-p38 
0              15            60             0             15             60 
Unloaded Loaded 
Minutes post loading 
Total p38 
Figure 3.2: Western blot for SW1353 cells following dynamic loading 
SW1353 cells encapsulated in agarose underwent 30 minutes of dynamic loading (20-40kPa at 0.33Hz), following 
which the gels were frozen in liquid nitrogen at 0, 15 or 60 minutes post-loading. Following processing, SDS-
PAGE gels were run and Western blots for phospo-p38 and native p38 were undertaken. 
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Figure 3.3: Western blot for BNC following dynamic loading 
Following 7 days in culture, BNCs encapsulated in agarose underwent 30 minutes of dynamic loading (20-40kPa 
at 0.33Hz), following which the gels were frozen in liquid nitrogen at 0, 15 or 60 minutes post-loading. A: SDS-
PAGE gels were run and western blots for phospo-p38 and total p38 were undertaken. Blot shown is representative 
of n=5 independent experiments with constructs generated from 5 bovine noses. B: Densitometric analysis of p38 
phosphorylation was undertaken on the n=5 separate blots. Density is relative to appropriate total p38 time point 
(mean ± S.E.M; where *** p < 0.001 by two-way ANOVA comparing unloaded and loaded samples). 
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Figure 3.4: Histology and FOS expression post-loading after 2 days in culture 
BNCs encapsulated in agarose were cultured for 2 days following seeding before either undergoing loading or 
processing for histological analysis. Loaded cells underwent dynamic loading (20-40kPa at 0.33Hz for 30 minutes) 
before extracting mRNA immediately post-loading, reverse transcribing to cDNA and running qPCR analyses for 
FOS (A). For histological analysis, BNC/agarose constructs were fixed in formalin, embedded in paraffin wax, 
sectioned and stained with Alcian Blue (B), Safranin O (C), H&E (D) or Masson;s Trichrome (E). c = cell, s = 
space between cell and agarose matrix, b = boundary between space and agarose matrix. qPCR data pooled from 
two separate chondrocyte populations. Cells selected for figure are representative of all cells on the slides. 
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 Development of a method to extract RNA from chondrocytes embedded in 
agarose 
In order to define the effects of mechanical loading on cells at the gene expression level, 
the ability to extract abundant and high quality RNA is of utmost importance. The 
extraction of RNA from cells embedded in agarose requires the dissolution of the agarose, 
the lysis of the cells and stabilisation of the RNA, whilst avoiding the interference of 
additional components of the gel, such as culture medium. As such, extraction of RNA 
from cells in agarose is known to be a relatively difficult process. Several methods, 
however, have been published with various levels of success. A selection of these 
methods were attempted to extract RNA, such as Bougault et al. (2009)239, Wang & 
Stegemann (2010)248 and Mio et al. (2006)249, however none of these resulted in 
successful RNA extraction. A scouting experiment was undertaken based on the work of 
Mio et al. (2006)249 where a range of extraction conditions were tested. Two key variables 
are considered to be vital in the extraction of RNA when utilising a Qiagen RNeasy kit, 
namely the amount of lysis buffer RLT used to dissolve the gel, and the final pH of the 
dissolved gel prior to loading onto the silica membrane of the Qiagen column. SW1353 
cells were seeded into 13mm agarose gel discs at a density of 666 cells/µl. These 
constructs were dissolved in a range of buffer RLT volumes, 500-2000 µl. Following 
dissolution, the cells were homogenised by pipetting up and down, and then varying 
amounts of 2M Sodium Acetate (pH 5.5) were added, 5-50 µl. 0.71 volumes (of buffer 
RLT) of absolute ethanol was added, and the mixture loaded to a Qiagen RNeasy column. 
The subsequent method was as described by the manufacturer, including an on-column 
DNase digest. The RNA was eluted in 50 µl RNase-free H2O, and concentrations 
measured. 
 
It was evident that lower volumes of buffer RLT resulted in significantly higher yields of 
RNA, with a slight trend between RNA yield and pH within each buffer RLT group 
(Figure 3.5). These results disagree with Mio et al. (2006), who found that lower volumes 
of buffer RLT resulted in lower yields of RNA. Their optimum volume of buffer RLT 
was 1540 µl, which when taken into account with their agarose construct volume of 440 
µl is 3.5 volumes of RLT to agarose/cell construct. The cell/agarose constructs utilised in 
this work have an estimated volume of 360 µl, of which the optimum volume of RLT 500 
µl, or a 1:1.39 ratio. 
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SW1353 cells were utilised in the optimisation of RNA extraction rather than BNCs due 
to the ease of obtaining the large quantities of cells required to test all possible conditions. 
After ascertaining the optimal conditions to extract RNA from SW1353 cells, it was 
important to carry out a similar experiment with BNCs due to potential differences in 
optimal conditions. As 500 and 1000 µl of buffer RLT were the only volumes to result in 
good yields of RNA from SW1353 cells, only these two volumes were tested in BNCs. 
As with SW1353 cells, using 500 µl of buffer RLT to dissolve the construct resulted in a 
significantly better yield of RNA compared to dissolving in a higher volume (1000 µl) 
(Figure 3.6). Furthermore, varying amounts of sodium acetate pH 5.5 were added to alter 
the pH of the solution prior to loading on the RNeasy column. Despite not being 
statistically significant, there was a trend of 30 µl sodium acetate pH 5.5 resulting in a 
better yield. These conditions were therefore chosen to be used in subsequent studies: 
dissolving the construct in 500 µl buffer RLT before adjusting the pH with 30 µl 2 M 
sodium acetate pH 5.5. 
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Figure 3.5: Optimisation of conditions to extract RNA from cells embedded in agarose 
SW1353 cells were embedded in 2% agarose at a concentration of 666 cells/µl, prior to dissolution in 500-2000 µl 
Qiagen lysis buffer RLT, alteration of pH using 2M sodium acetate (pH 5.5) and addition of 0.71 volumes absolute 
ethanol before loading onto a Qiagen RNeasy column and subsequent clean-up, DNase step and elution (mean ± 
S.E.M; where ** p < 0.01; *** p < 0.001 by two-tailed unpaired T-test comparing the means of all the data for 
each buffer RLT value independent of sodium acetate amount). RNA extracted from n=2 gels from the same 
chondrocyte population per tested condition. 
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Figure 3.6: Optimisation of conditions to extract RNA from BNCs embedded in agarose 
BNCs were embedded in 2% agarose at a concentration of 228 cells/µl, prior to dissolution in 500 or 1000 µl 
Qiagen lysis buffer RLT, alteration of pH using 2 M Sodium Acetate (pH 5.5) and addition of 0.71 volumes 
absolute ethanol before loading onto a Qiagen RNeasy column and subsequent clean-up, DNase step and elution 
(mean ± S.E.M; where * p < 0.05 by two-tailed unpaired T-test comparing the means of all the data for each buffer 
RLT value independent of sodium acetate amount). RNA extracted from n=3 gels from the same chondrocyte 
population per tested condition. 
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 Exploration of the effect of mechanical loading on the regulation of 
matriptase and hepsin 
Based on the results obtained in section 3.2.1, it was decided to focus solely on BNCs for 
the following work. After ascertaining that the mechanical loading of BNCs clearly 
results in the induction of certain early response genes, it was of interest to explore 
whether other known regulators of osteoarthritis were also differentially regulated 
following loading. Although matriptase was recently identified by this group as a key 
regulator in OA1, little is known about the regulation of matriptase expression in cartilage. 
It was therefore of interest to explore whether the gene might be mechanically sensitive. 
 
BNCs were loaded using the same regimen used to confirm the phosphorylation of p38, 
however different time points were chosen working under the assumption that new 
protein synthesis of a protease would require more than 60 minutes. The expression of 
matriptase following loading gave rise to mixed results with both striking up-regulation 
and no regulation or even down-regulation observed. When pooling together the data 
from densitometric analysis of the western blots from 5 independent experiments, there 
was no significant regulation of matriptase by loading observed (Figure 3.7 A). Hepsin is 
another serine protease of potential interest in OA, and its expression following load was 
also assessed. As with matriptase, no significant trends with loading were observed 
(Figure 3.7 B). To further validate the experimental set up, the expression of MMP-1, a 
protease previous described to be mechanically regulated, was examined. These results 
(Figure 3.7 C) suggest that MMP-1 is indeed regulated by loading, with significant 
increases in expression over time. Interestingly, the significant increases commenced 
immediately post-loading. Taken together, these data suggest that neither matriptase nor 
hepsin are mechanically regulated under tested conditions.  
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Figure 3.7: Exploration of MMP1, matriptase and hepsin expression following mechanical load 
BNCs encapsulated in agarose underwent 30 minutes of dynamic loading (20-40kPa at 0.33Hz), following which the gels were frozen in liquid nitrogen at 0, 3, 6 or 24 hours post-loading. SDS-PAGE 
gels were run and western blots for matriptase (A), hepsin (B) and MMP1 (C) were undertaken. The blots were re-probed with GAPDH as a loading control and densitometric analysis was undertaken. 
Density is relative to appropriate GAPDH time point (mean ± SD; where * p < 0.05; ** p < 0.01, by unpaired two-tailed T Test compared to corresponding unloaded time point). Data generated from 
n=4 (MMP1) or n=5 (matriptase and hepsin) independent experiments from independent populations of chondrocytes. 
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With the western blotting data on matriptase regulation by loading being inconclusive, 
the effect on gene expression was explored. BNCs were loaded and mRNA was extracted 
0, 6 and 24 hours post-loading and qPCRs were undertaken for ST14 (matriptase), F2RL1 
(PAR2) and HPN (hepsin) (Figure 3.8). At 24 hours post-loading, there was a trend of up 
regulation of ST14 though this was not statistically significant (p=0.07) and an up 
regulation of F2RL1. HPN however appeared to be down-regulated post-loading, but it is 
important to note that this gene had a very low expression level and thus very high cycle 
threshold (Ct) values making data analysis less robust. 
 
It was observed that the Ct values for the housekeeping gene loading control GAPDH 
were higher at later time points post-loading (namely 24 hours) compared to earlier time 
points, implying a lower amount of starting cDNA. The average Ct value for GAPDH at 
24 hours post-loading across four independent experiments was 22.3, whereas the average 
value for unloaded control, 0 and 6 hours post-load (pooled) for the same experiments 
was 19.2 – suggesting around 8.5 fold less GAPDH and thus starting mRNA. This raised 
concerns that the viability of the cells could be adversely affected by the loading regimen. 
Previously, cell viability in agarose culture had been ascertained indirectly by observing 
successful secretion of PCM and the observation of cell division by microscopy, however 
no assays had been undertaken to measure cell viability post-loading. 
 
In order to explore cell viability post-loading, LIVE/DEAD® assays were undertaken on 
loaded constructs (see chapter 2.2.10) (Figure 3.9). Despite being unable to quantify cell 
death, it was clear that following loading there was cell death with the effects more 
pronounced at 24 hours post-loading. This increase in cell death correlates with the 
observed higher Ct values on qPCR undertaken at this point.  
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Figure 3.8: Exploration of ST14, F2RL1 and HPN expression following mechanical loading 
BNCs encapsulated in agarose underwent 30 minutes of dynamic loading (20-40kPa at 0.33Hz).  Following loading, mRNA was extracted as described in chapter 3.2.2 and reverse transcribed to 
cDNA. qPCRs were undertaken for various indicated genes, normalised to GAPDH housekeeping gene (mean ± SD; where * p < 0.05, by unpaired two-tailed T Test compared to basal expression, 
unloaded control). Data pooled from four separate chondrocyte populations, and significant outliers were identified by a Grubb’s test and removed from the analysis. 
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Figure 3.9: Exploration of cell death in BNCs following mechanical load 
BNCs encapsulated in agarose underwent 30 minutes of dynamic loading (20-40kPa at 0.33Hz), following which a sample was taken to perform a LIVE/DEAD® assay as described in chapter 2.2.9. 
Calcein-AM stains only live cells, whereas EthD-1 stains only dead cells. Constructs were generated from BNCs obtained from two bovine noses, and each time point for each nose had three technical 
replicates (labelled construct 1, 2 or 3). Calcein-AM and EthD-1 images from corresponding sample are taken on the same field of view, simply taking images with different fluorescent filters. 
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Based on these results, it was difficult to draw firm conclusions on gene expression at 
later time points following loading, thus making this loading regimen inappropriate for 
exploring the effect of loading on the expression of genes such as ST14 and HPN. Despite 
the utilised loading regimen having being previously described in the literature, regimens 
of lower pressures were tested to explore whether FOS could be up-regulated retaining 
greater cell viability. A loading regimen of 10-30 kPa at 0.33 Hz for 30 minutes was 
sufficient to upregulate FOS expression (Figure 3.8), however LIVE/DEAD staining 
revealed that cell death also increased following load (data not shown). Reducing the 
loading regimen to 0-20kPa at 0.33Hz for 30 minutes resulted in better cell viability 
immediately post-loading (data not shown), however the up regulation of FOS was at a 
much lower level, with a fold change of 1.46 compared fold changes of 7.42 and 5.73 for 
20-40 kPa and 10-30 kPa regimens, respectively (Figure 3.10). This small fold-change 
was statistically significant, however due to its small magnitude it was decided not to 
pursue this regimen because of potential issues with sensitivity and resolution of other 
genes. 
 
 
Based on these issues with long-term viability of cells following loading, it was decided 
to examine gene expression changes at earlier time points post-loading when viability 
was not compromised. 
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Figure 3.10: FOS expression following differing loading regimens 
BNCs encapsulated in agarose underwent 30 minutes of dynamic loading of different loading regimens (20-40kPa, 
10-30kPa or 0-20kPa, all at 0.33Hz).  Immediately post-loading, mRNA was extracted as described in chapter 2.2.8 
and reverse transcribed to cDNA. A qPCRs were undertaken for FOS, and normalised to GAPDH housekeeping 
gene (mean ± SD; where ** p < 0.01; *** p < 0.001, by unpaired two-tailed T Test compared to basal expression, 
unloaded control). Data pooled from either two (10-30kPa and 0-20kPa) or four (unloaded and 20-40kPa) separate 
chondrocyte populations. 
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 Assessment of mechanical loading on known regulators of collagenase 
expression 
Previous work in our group has identified key regulatory components of collagenase 
expression in chondrocytes following pro-inflammatory IL-1+OSM stimulation in HAC. 
It was hypothesised that abnormal loading on chondrocytes results in phenotypical 
changes similar to pro-inflammatory stimulation, therefore it was of interest to ascertain 
whether these regulatory components followed similar expression patterns following 
loading, to IL-1+OSM stimulation. Importantly, these regulators are thought to be slow 
immediate early genes (IEG), and thus are expressed in the first few hours of IL-1+OSM 
stimulation in HAC, and therefore are better candidates for study using the Flexcell 
BioPress system. 
 
As prior work on these regulatory components was performed in HAC, it was of initial 
interest to explore the kinetics of gene expression following IL-1+OSM stimulation in 
BNC in monolayer culture before subsequently comparing the effect of loading (Figures 
3.11 and 3.12). As expected, FOS expression is significantly elevated 1 hour following 
IL-1+OSM stimulation, before rapidly returning to lower levels. As in HAC, ATF3, 
CSRNP1 and EGR2 were all also rapidly up-regulated in BNC. Following the expression 
of these early response genes to pro-inflammatory stimulation, collagenase (MMP1 and 
MMP13) expression gradually increases over the 24-hour time-course. Based on the data 
obtained from stimulating BNC in monolayer, it was clear that the first 3 hours of the 
time-course are of greatest interest for ATF3, CSRNP1 and EGR2 so a time-course of this 
length was undertaken following BNC loading. Furthermore, prior data (Figure 3.9) 
suggest that cell viability is higher in these early time points.  
 
Interestingly, FOS expression hit a peak at 1-hour post-loading, reaching a fold increase 
of 38 compared to unloaded samples, whereas immediately post-loading, the fold increase 
was 10. Previously, FOS expression had been examined immediately post-loading for 
validating the compression system, as this was the time point utilised in the 
literature239,244,245. ATF3 expression reached maximal expression immediately post-load, 
reducing but remaining significantly elevated for the remainder of the time-course, a 
similar profile to pro-inflammatory stimulation. CSRNP1 and EGR2 had highly similar 
expression profiles to each other, with maximum expression 2 hours post-load, which 
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differs from their expression following IL-1+OSM stimulation where their expression is 
more similar to FOS, reaching maximum expression early at 1 hour, before lowering 1.25 
hours onwards. Based on the earlier concerns with cell viability, later time points were 
not examined, thus there is no examination of MMP expression at 6-24 hours, however 
protein expression data described in chapter 3.2.3 do suggest that MMP-1 protein 
expression is indeed elevated at 6 and 24 hours. Cell viability was also examined for the 
duration of this time-course, which appeared good for the duration with no observable 
cell death (data not shown). 
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Figure 3.11: Exploration of gene expression changes following IL-1+OSM stimulation 
BNCs seeded at a density of 10x104 cells per well in a 96-well plate were cultured for 3 days before serum starving 
overnight and stimulating with IL-1 at 0.5ng/mL and OSM at 30ng/mL for varying lengths. Following stimulation, 
mRNA was extracted and reverse transcribed to cDNA and qPCRs were undertaken for various indicated genes, 
normalised to GAPDH housekeeping gene (mean ± SD; where * p < 0.05; ** p < 0.01; *** p < 0.001, by unpaired 
two-tailed T Test compared to basal expression, T=0). Data pooled from two separate chondrocyte populations. 
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Figure 3.12: Exploration of gene expression changes following mechanical load 
BNCs encapsulated in agarose underwent 30 minutes of dynamic loading (20-40 kPa at 0.33 Hz).  Following 
loading, mRNA was extracted as described in chapter 3.2.2 and reverse transcribed to cDNA. qPCRs were 
undertaken for various indicated genes, normalised to GAPDH housekeeping gene (mean ± SD; where * p < 0.05; 
** p < 0.01; *** p < 0.001, by unpaired two-tailed T Test compared to basal expression, unloaded control). Data 
pooled from two separate chondrocyte populations. 
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After showing that ATF3 expression was increased post-loading, ATF3 expression was 
examined at the protein level also. Expression of ATF3 was clearly induced by 
mechanical loading in a time dependent manner (Figure 3.13), however as with the earlier 
protein expression experiments (chapter 3.2.3), there was variability between 
experiments, thus only densitometric analysis is presented here. CSRNP1 and EGR2 
expression could not be examined due to lack of antibody cross reactivity with bovine 
proteins. 
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Figure 3.13: ATF3 expression following mechanical load 
BNCs encapsulated in agarose underwent 30 minutes of dynamic loading (20-40 kPa at 0.33 Hz), following which 
the gels were frozen in liquid nitrogen at indicated time points post-loading. SDS-PAGE gels were run and western 
blots for ATF3 were undertaken. The blots were re-probed with GAPDH as a loading control and densitometric 
analysis was undertaken. Density is relative to appropriate GAPDH time point (mean ± S.E.M; where *** p < 
0.001 by two-way ANOVA comparing all unloaded and loaded samples). Data generated from n=5 independent 
experiments from independent populations of chondrocytes. 
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 Discussion 
In this chapter, a method by which to explore the effect of mechanical loading of cells 
cultured in agarose was developed and optimised. Overall, data presented in this chapter 
suggest that the system has severe limitations in terms of cell viability over 24 hours, 
however this system was best suited over shorter term experiments. 
 
A large amount of initial work using the Flexcell BioPress system was based on the 
methods described by Bougault et al (2009) in their detailed published protocols. Their 
methods for initial cell culture to produce PCM proved successful, and their loading 
regimen proved successful in BNCs, but not SW1353 cells. Their method to extract 
protein for SDS-PAGE also worked, however their method for RNA extraction was 
unsuccessful despite multiple attempts. Further published methods to extract RNA (for 
example, Wang & Stegemann (2010)248 and Mio et al. (2006)249) were attempted, 
however no success was achieved with any of these methods. Subsequently, a condition 
scouting experiment was performed based on the method of Mio et al. (2006)249 as their 
method appeared the most promising. Optimal conditions for the extraction of RNA from 
SW1353 cells which differed from that of Mio et al. (2006) was identified in dissolution 
of the construct in 500 µl Qiagen buffer RLT, as opposed to 1320 µl which their paper 
would suggest to be optimal for the construct size in the present study. Their paper also 
suggested a correlation between pH and RNA yield, where better yields were obtained 
when lowering pHs. Lower pH values act to neutralise electrostatic repulsion between the 
negatively charged silica membrane and negatively charged nucleic acid, thus resulting 
in higher RNA yields binding to the column250. 
 
A trend of increasing yields with lowering pH in the 1000 µl buffer RLT group was 
observed, however no such trend existed in the optimal 500 µl group. Extraction 
conditions for BNC/agarose constructs were further optimised as these were the cells to 
be utilised in subsequent gene expression experiments. As with SW1353 cells, the optimal 
volume of buffer RLT for dissolution was 500 µl and the optimal amount of sodium 
acetate pH 5.5 added appeared to be 30 µl, however this was not significantly higher than 
20 µl (p = 0.22). The trend that 30 µl sodium acetate pH 5.5 resulted in a better yield in 
BNC whereas in SW1353 cells sodium acetate pH 5.5 appeared to make no difference 
could be explained by the fact that BNCs produce a PCM when cultured in agarose. This 
PCM stained positive for GAG, which is negatively charged and would therefore 
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contribute to the net negative charge of the lysis solution prior to column loading. It is 
possible that the higher volume of sodium acetate pH 5.5 required to optimise RNA yield 
from BNC reflects this GAG. These conditions were therefore used for subsequent RNA 
extractions. 
 
It is difficult to explain the observed differences in optimal extraction conditions with 
Mio et al.249, however differences in experimental setup are the likely reason. They 
observed agarose in the eluted RNA when using less than 840 µl buffer RLT, however 
samples in the present study were clear. A key difference in the experimental designs are 
that they used 1% agarose whereas 2% agarose was used in the present study, however 
this does not logically explain the observed differences. It would be reasonable to assume 
that the higher concentration of agarose would be more likely to result in carryover 
agarose in the eluted RNA, which did not prove to be the case. 
 
A comparison of the human chondrosarcoma cell line SW1353 with BNCs was performed 
in order to decide which would be more suited to this research. SW1353 cells clearly did 
not secrete a PCM, nor were they responsive to loading in terms of p38 phosphorylation. 
It is known that the PCM plays an important role in the mechanical transmission of 
loading stimuli251, therefore the fact that SW1353 cells did not respond to load could 
possibly be explained as such. SW1353 cells are a commonly used cell line for research 
on chondrocytes, however their use has several limitations. A comparison between 
SW1353 cells and HAC has revealed multiple differences in gene expression profiles 
between the two cell types252. Of greatest interest is the fact that SW1353 cells express 
very low levels of SOX9, a vital “master” transcription factor for all stages of 
chondrogenesis and chondrocyte function253-256. SOX9 is required for the formation of 
cartilage in terms of collagen type II expression254, as well as aggrecan expression257,258. 
Staining for both collagen (Masson’s Trichrome) and proteoglycans (Safranin O and 
Alcian Blue) show no matrix secretion, which could be a result of low SOX9 expression. 
SW1353 cells also express low levels of SOX5 and SOX6, which are two other SOX 
transcription factors important in cartilage, and have been shown to be important in the 
expression of aggrecan258. Reflecting this low expression of SOX genes, expression of 
key matrix genes such as collagen type II and aggrecan were hardly detectable in SW1353 
cells252. Interestingly, when SOX9 is overexpressed in SW1353 cells, their ACAN 
(aggrecan) expression also increases (David Young, personal communication). 
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After 6 days in agarose culture, BNCs did however secrete a PCM, which appeared to 
contain proteoglycans but not collagen, perhaps reflecting the additional time a collagen 
matrix requires to form259,260. This PCM was shown to be necessary for responding to 
loading in terms of FOS induction by testing the loading of BNCs after only 2 days in 
culture. The chondrocyte with its surrounding PCM is known as a chondron261 and these 
are known to have a proteoglycan-rich matrix7, a characteristic shared with the BNCs 
cultured in agarose in the present study. The PCM is thought to anchor the chondrocyte 
to the surrounding tissue by a network of type VI collagen262 and is considered to act as 
a transducer of mechanical stimuli from the external environment of the tissue into the 
cell263,264. As such, it is perhaps unsurprising that when undertaking loading experiments 
on the BNCs before they secrete a PCM, there is no observed up-regulation of FOS 
expression. Indeed, on close examination, it appears that the cells are in limited contact 
with the agarose until they form a PCM (Figures 3.1 and 3.4). It is possible that the BNCs 
are suspended in an aqueous solution when first seeded in the agarose, which is gradually 
replaced by PCM over the 6 days. This aqueous space would not appear on the 
histological analysis, and appear as empty space under the microscope. When cells in this 
form are subjected to compressive load, they are likely protected from the compressive 
forces and do not have the forces applied to the agarose transmitted to the cell and thus 
there is no up-regulation of FOS. 
 
After confirming that BNCs respond to mechanical loading by looking at previously 
described markers such as p38 phosphorylation and FOS induction239,244,245, the key aims 
of this chapter were addressed – to explore the effect of mechanical loading on matriptase 
and hepsin expression. As proteinase expression is usually expected at later time points 
post-stimulus, a 24-hour time-course was decided upon. The effect of loading on 
matriptase and hepsin expression gave rise to mixed results. The experiment was repeated 
several times with chondrocytes extracted from multiple bovine nasal septa. Down and 
up-regulation of both proteinases was observed in these studies, and when densitometric 
analysis was undertaken and the data pooled, no significant effect of loading (up-
regulation nor down-regulation) was observed. To validate the experiments, the 
expression of MMP-1 was assessed, and this was indeed significantly up-regulated in a 
time-dependent manner over the time-course. MMP-1 expression has been shown to be 
up-regulated in a variety of models including tensile strain of rabbit knee articular 
chondrocytes in monolayer culture265; unconfined compression of femoropatellar 
cartilage disks in explant culture266; and dynamic compression of calf femoropatellar 
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chondrocytes seeded in a poly(ethylene glycol) dimethacrylate hydrogel267. However, it 
is important to note that not all loading regimens result in MMP-1 up-regulation, as down-
regulation has also been observed following cyclic tensile strain of rabbit knee and 
shoulder chondrocytes268. To our knowledge, this is the first study to describe MMP-1 
up-regulation in chondrocytes cultured in agarose, but based on the literature, this result 
is likely to be expected. Taken together, these data suggest that the tested loading regimen 
successfully applies mechanical loading to the chondrocytes and results in elevated levels 
of MMP-1, however matriptase and hepsin expression are not regulated by this loading.  
 
An interesting observation was that there was a significant increase in MMP-1 expression 
immediately post-loading, as well as some individual blots for matriptase and hepsin 
showing a similar effect. 30 minutes of loading would not allow for sufficient time for de 
novo protein synthesis of proteases such as MMP-1, matriptase or hepsin, so another 
explanation must be sought. A potential explanation could be that rather than being an 
up-regulation of the gene, there is in fact a reduction in protein turnover by loading, thus 
the observed increase in protease on the blot, though there is limited evidence in the 
literature to support this theory. There is however some evidence that protein turnover 
can be regulated by mechanical loading in muscle cells. For example actin269, myosin270 
and collagen271 have all been shown to have reduced protein turnover when undergoing 
mechanical strain. It is important to note that these three examples are all structural 
proteins, thus their mechano-regulation is not necessarily a surprise. Interestingly, 
proteases such as MMP-1 are key regulators of structural proteins, in that they cleave 
components such as collagen. 
 
It is important to stress the fact that this is not a definite conclusion on the hypothesis of 
whether matriptase and hepsin are mechanosensitive, as there are a huge range of other 
loading regimens that could be tested if time and resources were not a limiting factor. 
What can be concluded is that under the tested conditions, where MMP-1 is clearly 
induced, matriptase and hepsin expression was more variable. Across the experiments, 
variation in responses was observed. In terms of causes, biological variability is a 
possibility, indeed it is known that the breed of cattle utilised, the Hereford, exhibits 
significant genetic variation within the breed272 and the genetic diversity within the breed 
is considered to be as great as exists within human populations273. 
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Another potential cause for variability is the Flexcell BioPress system itself. The 
preparation of the BioPress plates for loading requires the adjustment of the stationary 
platen to rest directly on top of the gel. As described in chapter 2.5, this can be calculated 
by knowing the accurate height of the gel. However, the “starting” position of the platen 
can only be set by eye and by touch, which is not a very scientific method as small 
discrepancies between platens can lead to differences in the loads given to each gel. If the 
platen is slightly too far away from the gel, but slightly too close to another gel – 
differences that the human eye cannot see – then both gels will receive different loads. 
As there are a limited number of gels obtained per bovine nasal septum, the protein 
expression experiments are undertaken with only a single technical replicate, which 
means that any variations within a time point will not be cancelled out. 
 
Due to initial difficulties in extracting the RNA from the agarose constructs, the 
experiments exploring gene expression were undertaken after the experiments exploring 
protein expression. Based on the concerns with variability between experiments 
potentially being caused by the Flexcell system itself, the experiments exploring gene 
expression were designed to contain three technical replicates at each time point with the 
hope of generating more robust data. The expression of ST14, HPN and F2RL1 were 
explored post-loading and there were hints that ST14 and F2RL1 might be up-regulated 
at 24 hours post-loading. In undertaking these experiments it was observed that the Ct 
values for GAPDH were higher at 24 hours post-loading compared to earlier time points 
and unloaded controls. This raised concerns that the cell viability over time might be 
affected by the application of load. To address this, cell viability assays were performed 
which suggested that the cells were indeed losing their viability over the time-course with 
the effect more pronounced at 24 hours post-loading. 
 
It was not ascertained whether the cells are undergoing necrosis or apoptosis. As the cells 
appear to take time to die post-loading, apoptosis is the more likely culprit as if the cell 
loading machine was physically compressing the cells to death, then one would expect 
cell death to be observed earlier. Furthermore, following loading, the cells have a similar 
appearance compared to unloaded control cells, with no obvious signs of physical 
deformation. In terms of the causes of cell death, there is evidence in the literature that 
suggests c-Fos may act as a pro-apoptotic molecule in various cell types274-277 and loading 
resulted in high expression levels of FOS, with a fold increase level of expression 
reaching 38 times that of basal (unloaded) levels 1-hour post-loading. This was a much 
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larger induction of FOS than was induced by IL-1+OSM stimulation which only reached 
an induction of 4.5 fold higher than basal (unstimulated). It is possible that this very high 
“dose” of FOS could be lead to apoptosis. Indeed, there are positive correlations between 
c-Fos expression levels and amount of apoptosis previously described278,279. 
 
Since it was possible cell death was linked to cell loading in a dose-dependent manner, 
other dynamic loading regimens with a lower pressure – 10-30 kPa and 0-20 kPa were 
tested, both for the same length and frequency as the previous experiments (30 minutes 
at 0.33 Hz). The 10-30 kPa also stimulated FOS at a slightly lower level than 20-40 kPa, 
however this did not result in better cell viability. The 0-20 kPa, however resulted in only 
a very small induction of FOS expression which would likely result in lower resolution 
of downstream genes of interest, so it was decided to be inappropriate to further test. 
These three tested regimens were all 30 minutes long, with the same dynamic waveforms 
(0.33 Hz, square waveform). There are a large range of other loading regimens possible 
to utilise by varying the conditions, using a different waveform, different frequency, 
different length etc. It is possible that there are loading regimens which would stimulate 
BNCs but not kill the cells. Unfortunately, due to the time-consuming nature of these 
experiments, it was not possible to explore further loading regimens. 
 
The loading regimen used in this study has previously been described in the literature 
with no mention of adverse effect on cell viability239,244,245, however these studies utilised 
a different type of chondrocyte – embryonic mouse chondrocytes. Bovine nasal septum 
cartilage does not undergo mechanical loading in vivo. A comparison of bovine nasal and 
articular chondrocytes with respect to loading as not been undertaken to date, however it 
is possible that BNCs are less able to tolerate mechanical loading. It has been shown that 
other non-loading cartilage, for example auricular cartilage, has different responses to 
articular cartilage differ in responses following dynamic loading in terms of collagen type 
I and II and aggrecan expression with articular cartilage showing greater increases in 
expression, although viability was not explored280. It is known that BNCs differ to bovine 
articular chondrocytes (BACs) (metacarpophalangeal) in that articular chondrocytes 
express more type II collagen and aggrecan, whereas BNCs express more type I 
collagen281. Furthermore, the response of BNCs and BACs to pro-inflammatory cytokines 
(IL-1α) differ in terms of subsequent ADAMTS4 expression282, and it is highly likely other 
responses differ between the two cell types. Interestingly, a study comparing the use of 
either human nasal or human articular chondrocytes in loading following tissue 
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engineering suggested that nasal chondrocytes were able to respond to and endure various 
loading regimens including a higher expression of matrix protein than articular 
chondrocytes, although cell viability was not explicitly tested nor discussed283.   
 
As cell viability and GAPDH Ct values appeared better at earlier time points post-loading, 
it was decided to look at other genes relevant to OA which would potentially be 
mechanosensitive. Our group has recently identified several transcription factors 
implicated in regulation of MMP-1 and MMP-13 following IL-1+OSM stimulation – 
ATF3, CSRNP1 and EGR2 (Chris MacDonald, unpublished). This prior work was 
performed in HAC, and was first successfully replicated in BNC before exploring in the 
loading model. Following loading the three genes did indeed get up-regulated, however 
the temporal regulation appeared to differ to pro-inflammatory stimulation. Following IL-
1+OSM stimulation, FOS, CSRNP1 and EGR2 had very similar expression profiles of 
reaching peak expression at 1 hour, before beginning to reduce by 1.25 hours whereas 
ATF3 also peaked early, at 1.25 hours. Following loading, however, ATF3 peaked first, 
immediately post-loading, with FOS peaking at 1-hour post-loading whereas EGR2 and 
CSRNP1 peak 2 hours post-loading. It is likely that these slight differences in temporal 
regulation reflect the differing stimuli. 
 
ATF3 has previously been shown to be mechanosensitive to stretch in human bronchial 
epithelial cells284 and rat cardiomyocytes285, whereas EGR2 mechano-sensitivity to 
stretch has been demonstrated in both rat retinal glial cells286 and in mouse osteoblastic 
cell line MC3T3-E1287. EGR2 has also been shown to be mechanosensitive to loading in 
vivo in mouse tibiae288. In terms of mechanical loading in chondrocytes, ATF3 and EGR2 
up-regulation were observed in a gene expression microarray following the loading of 
embryonic mouse chondrocytes with a very similar loading regimen (20-40 kPa for 30 
minutes at 0.5 Hz, compared to 20-40 kPa for 30 minutes at 0.33 Hz in the present study) 
with fold increases of 1.47 and 2.60, respectively, immediately post-loading245. These 
data suggest that EGR2 expression immediately post-loading has not yet significantly 
increased, with no significant effect observed until 1 hour, and then peaking at 2 hours. 
The present study also observed a much larger fold increase of ATF3 compared to theirs, 
potentially reflecting that adult bovine chondrocytes might be more responsive than 
embryonic mouse chondrocytes. Comparing these studies also highlights the importance 
of temporal kinetics of gene expression, and the limitations of only picking a single time 
point for analysis. 
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CSRNP1 (sometimes referred to as AXUD1 in the literature), has been shown to be up-
regulated following 6 hours of “compression” in human primary cementoblasts289, 
however they used a centrifuge to apply the compression, which is less physiologically 
relevant than other systems. To our knowledge, the observation that CSRNP1 is up-
regulated in chondrocytes following mechanical loading is a novel observation. 
 
 
 Summary 
 Chondrocytic cell line SW1353 does not secrete PCM whilst cultured in agarose 
and do not appear responsive to mechanical loading. BNCs however do secrete a 
PCM and do respond to mechanical loading in terms of p38 phosphorylation and 
FOS induction. 
 
 Matriptase and hepsin do not appear to be regulated at the protein level post-
loading, however MMP-1 is. 
 
 Mechanical loading of BNCs appears to result in cell death, an effect pronounced 
with time post-loading. As the later time points are more of interest with regards 
to OA relevant genes, it is difficult to generate confident data with this system. 
The early time points appear more robust. 
 
 The mechanical loading stimulation of BNCs appears to elicit a similar response 
to pro-inflammatory stimulation with IL-1+OSM 
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4. Chapter 4. Screening of novel proteases with the ability to 
cleave PAR2 
 Introduction 
A role for canonical PAR2 activation in the pathogenesis of OA was described in chapter 
1, where matriptase is able to cleave and activate PAR2, both of which have elevated 
expression levels in the disease. This can lead to the induction of many pro-inflammatory 
genes as well as the key collagenases in articular cartilage, MMP-1 and MMP-131. 
 
Cartilage destruction in OA is much more complex than just the action of a single enzyme 
on a single receptor to induce the expression of a few important genes. Many other 
proteases have been identified as having roles in OA and other arthritic diseases. Whilst 
some may directly break down components of the cartilage, such as the aggrecanases 
ADAMTS-4 and ADAMTS-5290, others exert their roles indirectly. For example, many 
enzymes have been identified as part of networks by activating other enzymes. The serine 
protease plasmin has long been known to possess the ability to activate various 
proMMPs291, and subsequently several other proteases including thrombin, neutrophil 
elastase, and cathepsin G have also been found to possess this activation capacity121. 
 
The extracellular milieu of enzymes within cartilage (both normal and in disease) is 
complex, and therefore it is likely there are many unidentified roles for them. This chapter 
therefore aims to screen whether cartilage (and especially OA)-expressed proteases have 
the ability to cleave PAR2. The identification of novel cartilage-expressed proteases with 
the ability to cleave PAR2 could lead to the identification of novel mechanisms in the 
pathogenesis of OA. 
 
 Chapter Aims 
 To develop a method to test protease ability to cleave a PAR2 42mer synthetic 
peptide. 
 To screen for proteases from the serine, cysteine and metalloproteinase families 
for their ability to cleave this PAR2 42mer. 
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 Results 
 Validation of a Tris-Tricine SDS-PAGE and silver staining method to 
visualise PAR2 42mer 
 Design of PAR2 42mer 
A literature search was undertaken to compile a list of all previously identified cleavages 
of PAR2 (appendix 1). This demonstrated that all previously identified cleavages have 
occurred between positions 31 and position 76 of PAR2. The extracellular domain of 
PAR2 ends at amino acid 75, therefore it was decided to design a synthetic peptide ending 
at position 72 as any closer to position 75 would have limited physiological relevance due 
to enzyme not being able to bind to full-length transmembrane PAR2. The PAR2 
sequence from arginine-31 until lysine-72 was therefore kindly synthesised by Dr. Hiroki 
Shimizu (National Institute of Advanced Industrial Science and Technology (AIST), 
Sapporo, Hokkaido, Japan) for use in the protease screen (Figure 4.1). 
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 Optimisation of Tris-Tricine system to separate peptides 
In order to visualise cleavage events of the PAR2 42mer, it was decided to use SDS-
PAGE followed by polypeptide staining. The PAR2 42mer is a peptide of 4324.86 Da 
and is therefore too small to be visualised by “conventional” SDS-PAGE which utilises 
a Tris-Glycine buffer system to separate the proteins. In order to visualise the PAR42mer 
and cleavage products, it was decided to utilise a Tris-Tricine system based on the method 
of Schägger (2006)292. 
 
Firstly, it was important to ascertain whether the Schägger method would be sufficient to 
stain for peptides as small as 4 kDa. SDS-PAGE gels with a 20% acrylamide resolving 
gel and 4% stacking gel were cast, electrophoresed and Coomassie-stained according to 
the Schägger method with a series of protein/peptide standards ranging from 1,060 Da to 
Figure 4.1: Location of PAR2 42mer peptide 
A synthetic peptide corresponding from arginine-31 to lysine-72 (in orange) of PAR2 was designed and 
synthesised. The sites of several key cleavages are also highlighted. 
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26,600. Using this method, the 1,060 and 3,496 Da peptide/proteins did not successfully 
stain (Figure 4.2A). The Schägger method used a fixing solution containing 10% acetic 
acid, and it was hypothesised that this was not a strong enough fixative and the smaller 
peptide/proteins were able to diffuse out of the gel before being fixed. Glutaraldehyde 
was therefore utilised as a stronger fixative, and indeed lower MW peptide/proteins were 
visible following Coomassie staining (Figure 4.2 B). 
 
Despite the tris-tricine system being sufficient to visualise peptide/proteins smaller than 
the PAR2 42mer, Coomassie staining is not sufficiently sensitive to visualise the PAR2 
42mer on an appropriate scale for in vitro digests. Silver staining was therefore used. 
Initially, silver staining following glutaraldehyde fixation was utilised, however this 
resulted in a very high level of background on the gel (data not shown). Trichloroacetic 
acid (TCA) was therefore utilised as a stronger fixative than acetic acid, with a trade off 
against glutaraldehyde: despite poorer fixation, a lower background was observed (Figure 
4.2 C). 
 
 
Figure 4.2: Optimisation of fixation and staining of Tris-Tricine SDS-PAGE gels 
A series of protein/ peptide standards containing (from smallest to largest) bradykinin, bovine insulin chain B, 
bovine aprotinin, bovine alpha-lactalbumin, equine myoglobin, and rabbit triosephosphate isomerase were 
separated by SDS-PAGE. 16% acrylamide tris-tricine gels were cast, electrophoresed and fixed with either 10% 
acetic acid (A) or 5% glutaraldehyde (B) for 1 hour at room temperature before staining with Coomassie G-250. A 
20% acrylamide tris-tricine gel was cast, electrophoresed and fixed with 12% TCA for 1 hour at room temperature 
before silver staining (C). 
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 Screening a panel of proteases known to cleave PAR2 
After optimising SDS-PAGE and silver staining for use with peptides the size of the 
PAR2 42mer, it was of interest to validate a system by which to identify cleavages of the 
peptide. Four proteases previously identified as being able to cleave PAR2 at various 
locations were selected for this: matriptase, hepsin, cathepsin G and neutrophil elastase. 
Matriptase and hepsin are both canonical PAR2 activators cleaving PAR2 at position 36 
between arginine and serine115,293. Cathepsin G has been identified as a disarmer of PAR2, 
cleaving the protein at position 64 between phenylalanine and serine225. Neutrophil 
elastase is thought to be a biased agonist and disarmer of PAR2, cleaving at position 67 
between serine and valine225. 
 
Incubation of hepsin and matriptase with PAR2 42mer resulted in a reduction of parent 
peptide and an accumulation of a single smaller product of >3.5kDa over time (Figure 4.3 
A and D). The expected cleavage of matriptase and hepsin would result in fragments of 
~3650 Da and ~670 Da, thus the observed product is likely to be the ~3650 Da fragment, 
whereas the smaller fragment would be too small to observe by this method. Neutrophil 
elastase and cathepsin G both also cleave the PAR2 42mer (Figure 4.3 B and C), however 
there was no accumulation of product observed, only a loss of the parent peptide, 
implying all fragments are too small to observe by SDS-PAGE.  
 
It is important to note that the PAR2 42mer often runs as a doublet by SDS-PAGE. A 
doublet can be observed in Figure 4.3 D, however one of the gels run in the same 
experiment ran as a singlet (Figure 4.3 A). By running HPLC, it is clear that only a single 
product exists (see Figure 5.1 in chapter 5). It was never ascertained why this occurred, 
and thus it is important to compare the negative control lane to any cleavage lanes. 
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Figure 4.3: Validation of system with proteases known to cleave PAR2 
10 µM PAR2 42mer was incubated with 10 nM of either hepsin (A) or elastase (B), 1 nM cathepsin G (C), or 0.1 
nM matriptase (D) for varying durations before resolving the reaction products on 20% polyacrylamide gels and 
silver staining. All gels representative of 2 independent experiments. 
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 Screen of proteases for ability to cleave PAR2 42mer 
After validating the use of SDS-PAGE to identify the cleavage of the PAR2 42mer with 
enzymes known to cleave PAR2, the system was used to identify novel enzymes for their 
ability to cleave PAR2.  
 
 Serine protease screen 
As PAR2 is considered primarily to be a receptor for serine proteases294, and as a role for 
serine proteases in the pathogenesis of various arthritic diseases, including OA, is 
becoming well established121, it was decided to screen novel serine proteases for their 
ability to cleave PAR2. 
 
In order to keep the serine protease screen relevant to arthritis and in particular OA, a list 
of serine proteases that were found to be significantly dysregulated in OA versus control 
(neck of femur fracture samples) was drawn up (table 4.1), based on low-density array 
data generated during a previous study by our group1. Some of the dysregulated serine 
proteases in the screen are known PAR2 activators, such as matriptase115, hepsin293 and 
coagulation factor X295. 
 
Of the proteases identified in the serine protease screen, complement factor D, 
complement factor I, HTRA1, HTRA3, PCSK9 and FAP were sourced for screening of 
PAR2 cleavage ability. Furthermore, uPA and thrombin were sourced for screening. 
Despite not being identified in this screen, uPA has previously been implicated in arthritis 
pathogenesis296 where its injection into mice joints resulted in rheumatoid arthritis-like 
morphological changes such as synovitis, pannus formation and some cartilage 
destruction. 
 
Thrombin has also been implicated in arthritis. Aside from its role in thrombosis, 
thrombin also activates PAR1 to mediate various other roles including pro-inflammatory 
signalling. PAR1 deficiency in mice confers protection from antigen-induced arthritis, 
including reduced MMP-13 expression125, whereas thrombin inhibition attenuates 
synovial hyperplasia in collagen-induced arthritis in mice126. 
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Table 4.1: Differentially regulated serine proteases in OA, Low-density array 
analysis taken and modified Milner et al., (2010)1 
Gene Protein Fold change 
BF B-factor 0.3 
C2 Complement component 2 7.24 
DF D component of complement 5.08 
DPP4 Dipeptidylpeptidase 4 3.41 
ELANE Neutrophil Elastase 5.94 
F10 Coagulation factor X 17.69 
FAP Fibroblast activation protein 2.36 
GZMA Granzyme A 18.97 
GZMB Granzyme B 3.7 
GZMK Granzyme K 10.81 
HPN Hepsin 0.09 
HTRA1 HtrA serine peptidase 1 3.8 
HTRA2 HtrA serine peptidase 2 0.67 
HTRA3 HtrA serine peptidase 3 4.2 
HTRA4 HtrA serine peptidase 4 20.23 
IF I factor 7.86 
KLK13 Kallikrein 13 21.73 
PCSK1 Proprotein convertase subtilisin/kexin type 1 0.11 
PCSK6 Proprotein convertase subtilisin/kexin type 6 9.98 
PCSK9 Proprotein convertase subtilisin/kexin type 9 14.48 
PLAT Plasminogen activator, tissue 0.22 
PRSS15 Protease, serine, 15 0.57 
PRSS23 Protease, serine, 23 5.89 
PRSS3 Protease, serine, 3 0.24 
ST14 Matriptase 5.92 
TMPRSS4 Transmembrane protease, serine 4 0.02 
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Both uPA and thrombin displayed the ability to cleave the PAR2 42mer at higher 
concentrations after 24 hours (Figure 4.4). Signs of degradation by thrombin were 
observable as low as 10 nM of enzyme, and a dose-response was observed thereafter. It 
appears that thrombin digestion of PAR2 42mer results in a single product. uPA appeared 
less potent at degrading the peptide, however clear digestion was also observed. 
 
 
 
 
As recombinant HTRA1 and HTRA3 preparations were available at very high 
concentrations, PAR2 42mer digestion by a wide range of concentrations was tested. 
HTRA1 had the ability to degrade the PAR2 peptide, with evidence of cleavage as low 
as 20 nM with 500 nM resulting in a complete visual loss of peptide at 24 hours (Figure 
4.5 A). Two bands are visible in the 20-200 nM digestions; thus it is likely multiple 
cleavages occur resulting in products too small to visualise by SDS-PAGE. The high 
concentrations of enzyme result in visual bands from the enzyme preparation visible in 
the gel, as shown in the 10000 nM enzyme only control. There was no evidence of 
HTRA3 being able to cleave PAR2 at all tested concentrations (Figure 4.5 B). 
 
Figure 4.4: uPA and Thrombin cleavage of PAR2 
PAR2 42mer (10 µM) was incubated with increasing concentrations (nM) of either thrombin (A) or uPA (B) for 
24 hours at 37°C before resolving the reaction products on 20% polyacrylamide gels and silver staining. All gels 
representative of 2 independent experiments. 
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The ability of complement factors D and I to cleave PAR2 was examined, and there was 
no evidence of either enzyme exhibiting such activity (Figure 4.6). 
 
 
 
Furthermore, neither PCSK9 or FAP displayed any evidence of being able to cleave the 
PAR2 42mer (Figure 4.7). 
 
Figure 4.5: HTRA1, but not HTRA3, can cleave PAR2 
PAR2 42mer (10 µM) was incubated with increasing concentrations (nM) of either HTRA1 (A) or HTRA3 (B) for 
24 hours at 37°C before resolving the reaction products on 20% polyacrylamide gels and silver staining. All gels 
representative of 2 independent experiments. 
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Figure 4.6: Factor D and Factor I do not cleave PAR2 
PAR2 42mer (10 µM) was incubated with increasing concentrations (nM) of either Factor D (A) or Factor I (B) 
for 24 hours at 37°C before resolving the reaction products on 20% polyacrylamide gels and silver staining. All 
gels representative of 2 independent experiments. 
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 Metalloprotease screen 
The ability of MMPs to modify cell behaviour by cleaving receptors has previously been 
described in the literature with both MMP-1297 and MMP-13298 able to cleave and activate 
the thrombin receptor PAR1. Furthermore, it has been reported that MMP-1 may be able 
to act on PAR2 in an agonistic manner, which is further discussed in chapter 5.3. It was 
therefore of interest to ascertain whether the collagenolytic MMPs would have the ability 
to cleave PAR2, as both the MMPs and PAR2 are known to be involved in arthritis. 
 
The incubation of proMMP-1, -8 and -13 in the presence of APMA with the PAR2 42mer 
for 24 hours resulted in observable cleavage (Figure 4.8). Both MMP-1 and MMP-3 
appear to result in a single product with a dose-response observed, whereas MMP-8 at 
lower concentrations results in a single product, however both this product and the parent 
peptide were lost at higher concentrations. 
 
Figure 4.7: PCSK9 and FAP do not cleave PAR2 
PAR2 42mer (10 µM) was incubated with increasing concentrations (nM) of either PCSK9 (A) or FAP (B) for 24 
hours at 37°C before resolving the reaction products on 20% polyacrylamide gels and silver staining. All gels 
representative of 2 independent experiments. 
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In order to confirm that it was indeed metalloprotease activity responsible for cleavage of 
the peptide, experiments were undertaken in the presence of GM6001, which inhibited 
MMP-1, -8 and -13 cleavage of the PAR2 42mer (data not shown). 
 
 
 Cysteine protease screen 
As described in chapter 1, several lysosomal papain-like cysteine proteases, often referred 
to as the “cathepsins”, have been identified as having extracellular roles and implicated 
in arthritic disease. Furthermore, cathepsin S has been identified as a biased agonist for 
PAR2 activation226. Therefore, the ability of cathepsins V, K, B and L to cleave PAR2 
was explored. 
 
All tested cathepsins were able to digest the PAR2 42mer (Figure 4.9). Of these, cathepsin 
K appeared to result in an observable smaller band, whereas the other cathepsins resulted 
in a loss of PAR2 42mer but no additional bands, thus the product(s) were likely too small 
Figure 4.8: MMP-1, -8 and -13 cleavage of PAR2 42mer 
PAR2 42mer was incubated for 24 hours with either proMMP-1 (A), proMMP-8 (B) or proMMP-13 (C) at various 
concentrations, activated by 1 mM APMA, before resolving the reaction products on 20% polyacrylamide gels and 
silver staining. All gels representative of 2 independent experiments. 
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to be visualised by this technique. The addition of E64 cysteine protease inhibitor resulted 
in the inhibition of PAR2 cleavage for each enzyme, showing that the cleavage of PAR2 
was dependent on cysteine protease activity. 
 
It is important to draw attention to a small band present in all lanes, including the controls. 
This band was not present in experiments undertaken earlier on in the project, thus it 
appears that the peptide was not stable in long-term storage. 
 
 
 
 Discussion 
In this chapter, a synthetic peptide was synthesised corresponding to the extracellular 
region of PAR2 where previously identified cleavages have been identified, and a method 
of visualising this peptide by SDS-PAGE was optimised. Subsequently, this system was 
validated by confirming a series of known PAR2 activators and disarmers could digest 
the peptide. Finally, a series of cartilage and arthritis-relevant proteases from the serine, 
cysteine and metalloprotease families were screened for their ability to cleave PAR2, 
which identified several novel activities of enzymes from these families. 
 
In designing the sequence for the PAR2 42mer synthetic peptide, a list of all previously 
identified PAR2 cleavages was drawn up in order to design a peptide that could “cast the 
largest net” for identifying cleavages, and with consideration that solid-phase synthetic 
peptide synthesis becomes markedly more difficult with each increasing amino acid in 
length299. Indeed, in searching the literature, it appears that 42 amino acids is the longest 
PAR2 peptide sequence utilised for enzyme identification research to date, and previous 
-  +  -  +  -  +  -  +  -  +  -  + 
-  -  V  V  K  K  B  B  S  S  L  L  
Figure 4.9: Cathepsin cleavage of PAR2 is dependent on cysteine protease activity 
10 µM PAR2 42mer was incubated with either 1 nM cathepsin V, 5 nM cathepsin K, 10 nM cathepsin B, 20 nM 
cathepsin S or 0.5 nM cathepsin L 30 minutes at 37°C in the presence or absence of 10 µM E64, before resolving 
the reaction products on 20% polyacrylamide gels and silver staining. Gel representative of 2 independent 
experiments. 
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studies requiring large sequence coverage have utilised overlapping peptides226, or 
otherwise have focused on smaller specific PAR2 regions210,225,300. Moreover, the PAR2 
sequence utilised in this project (arginine-31 to lysine-72) is comparable to the sequence 
utilised in a study by Loew et al. (2000)301 who made an arginine-31 to leucine-79 
sequence, however this was not a synthetic peptide generated by solid-phase synthesis, 
but rather a recombinant protein expressed and purified from E. coli. Sequence analysis 
of PAR2 suggests that the extracellular domain ends at amino acid 75302, thus the 
proteinase 3 and elastase cleavages identified at positions 74, 75 and 76 by Loew et al. 
(2000) are likely to be of low physiological relevance. Terminating the PAR2 42mer 
utilised in the project at lysine-72 was decided to encompass the whole physiologically-
relevant range of residues.  
 
Before screening novel enzymes for the ability to cleave PAR2, the system set up was 
validated by testing four enzymes previously identified as being able to cleave PAR2. 
Matriptase, hepsin, cathepsin G and neutrophil elastase were all tested for their ability to 
cleave PAR2. Matriptase and hepsin are both canonical activators expected to cleave after 
arginine-36115,293, whereas cathepsin G is thought to be a disarmer and neutrophil elastase 
a disarmer of some responses and a biased agonist of others224,225. Multiple cleavage sites 
for cathepsin G and neutrophil elastase have been identified301, however it this thought 
that the most important and physiologically-relevant cleavages are after phenylalanine-
64 and after serine-67, respectively225. 
 
The cleavage of the PAR2 42mer by hepsin and matriptase was evident as early as 30 
minutes, however even when digested for 21 hours, only a single product was observed, 
with no evidence of secondary cleavages or loss of peptide from the visible range of the 
SDS-PAGE system. This observation is in line with the literature where only a single 
cleavage site has been identified for the two enzymes – the canonical site. Electrospray 
MS was undertaken on the digestion product generated by matriptase and hepsin, and this 
confirmed the expected canonical cleavage (data not shown). 
 
Neutrophil elastase and cathepsin G both also cleaved the peptide as expected, however 
this was observed by loss of parent peptide and no product was observed. This would 
imply that the products were too small to observe by SDS-PAGE, or there are multiple 
cleavages which result in multiple small fragments. The expected fragment size from the 
previously described major cleavage site for cathepsin G is 3581.00 Da and 3826.24 Da 
130 
 
for neutrophil elastase (based on the work of Ramachandran et al. 2011225), both would 
be expected to be visible by the SDS-PAGE method utilised. Indeed, the band generated 
by hepsin and matriptase was 3653.10 Da and was clearly detected by this method. Taken 
together, it is likely that multiple digestions have taken place by neutrophil elastase and 
cathepsin G resulting in a series of peptides too small to visualise. Multiple cleavage sites 
on PAR2 have previously been observed by both enzymes225,301, so this observation is in 
line with the literature. 
 
After optimising and validating a method to assess enzymes for their ability to cleave 
PAR2, a screen was undertaken and 9 novel enzymes were identified as being able to 
cleave PAR2 (table 4.2). Three metalloproteases, MMP-1, -8 and -13 were all able to 
cleave PAR2; two serine proteases, uPA and HTRA1 and four cysteine proteases, 
cathepsins V, K, B and L also had this ability. 
 
Table 4.2: List of proteases tested for their ability to cleave PAR2 
 
 Cleavages: Novel 
Cleavages: Not 
Novel 
No Cleavage 
Metalloproteases 
MMP-1*  ADAMTS-5 
MMP-8   
MMP-13   
Serine Proteases 
uPA Thrombin Factor I 
HTRA1 Cathepsin G Factor D 
 Neutrophil elastase HTRA3 
 Hepsin FAP 
 Matriptase PCSK9 
Cysteine 
Proteases 
Cathepsin V Cathepsin S  
Cathepsin K   
Cathepsin B   
Cathepsin L   
*MMP-1 previously suggested to act on PAR2, however no identification of cleavage site nor 
direct evidence of PAR2 cleavage by active MMP-1 observed 303, see chapter 5. 
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It is important to draw attention to the relative concentrations of protease as well as length 
of incubation required to observe PAR2 42mer cleavage. Some proteases, for example 
matriptase, were very potent, able to cleave PAR2 with low concentrations (0.1nM 
matriptase for 30 minutes resulted in about 50% cleavage), whereas proteases such as the 
MMPs were much less potent. MMP-1 and MMP-13 required 400nM of protease for 24 
hours to observe the same level of PAR2 42mer degradation. The cathepsins were 
generally very potent, whereas the other serine proteases exhibited a variable level of 
potency, for example thrombin, uPA and HTRA1 all required high protease concentration 
with a long incubation to observe cleavage. 
 
The observation that HTRA1 was able to cleave PAR2 is an interesting one. This enzyme 
has been linked with multiple musculoskeletal disorders304 including both RA and OA 
where elevated protein levels are observed in synovial fluids305. Furthermore, HTRA1 is 
expressed by chondrocytes, with elevated gene expression levels in OA129 with high 
levels of the protein detected in cartilage extracts306. HTRA1 expression is also elevated 
in antibody-induced arthritis in mice131. The role of HTRA1 in arthritic diseases is 
incompletely understood. Recombinant HTRA1 is able to induce MMP1 and MMP3 
expression in human synovial fibroblasts from both OA and RA patients in a mechanism 
that is thought to involve HTRA1 cleavage of fibronectin and subsequent fibronectin 
fragment induction of MMP expression305. HTRA1 has also been shown to degrade 
various cartilage components such as aggrecan with HTRA1-digested fragments 
identified in OA cartilage133. HTRA1 can also digest soluble type II collagen131, and can 
potentially act to further degrade MMP-digested fibrillar collagen in disease.  
 
Despite being a trypsin-like serine protease, HTRA1 does not have a preference for a 
charged amino acid in the P1 position307, thus is unlikely to be a candidate for being a 
PAR2 canonical activator which would require cleavage after an arginine. HTRA1 prefers 
small- to medium-sized hydrophobic residues, as well as polar threonine and glutamine 
in the P1 position307. The bands observed on the gel suggest that multiple cleavages occur 
as first a single band appears, but at higher concentrations all bands disappear implying 
multiple peptide fragments too small to visualise by this method. 
 
This project had initially included thrombin as part of the screen, which was identified as 
a novel enzyme with the ability to cleave PAR2, but a paper has since been published 
with identifies thrombin as a PAR2 activator214. Indeed, thrombin was identified as 
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cleaving the PAR2 canonical activation site, which is line with the cleavage observed in 
this project as thrombin digestion of the PAR2 42mer resulted in a band of the same size 
as matriptase and hepsin. The fact that the screening method in this project identified a 
cleavage which was subsequently published elsewhere further validates the system as a 
good system to screen PAR2 cleavages. 
 
uPA is best known for its role in fibrinolysis, where it activates plasminogen to plasmin, 
but roles have also been identified in arthritic diseases296 and it is able to activate various 
proMMPs including proMMP-3 and proMMP-13291,308. Interestingly, uPA is already 
known to be able to signal via a cell surface receptor, the uPA receptor (uPAR), which 
can induce multiple cell signalling pathways309. uPA has a preference for a basic arginine 
or lysine in the P1 position, as well as a small glycine or serine in the P2 position310, and 
thus is a candidate for being a canonical PAR2 activator which would require cleavage 
after glycine and arginine. The motif glycine-lysine appears three times in the sequence 
also, so there is also potential for other uPA cleavages within the PAR2 sequence. The 
band observed on the gel appears to be of a similar size to that of hepsin, matriptase and 
thrombin. 
 
Of the serine proteases screened, there was no evidence of factor I, factor D, HTRA3, 
PCSK9 or FAP being able to cleave PAR2. To date, only a single substrate has been 
identified for complement factor D which is complement factor B as part of the 
complement cascade310. Complement factor I, despite having slightly more identified 
substrates than factor D, still has a limited amount of substrates310. The complement 
system has however been linked to arthritic diseases, in particular RA122 with factors I 
and D both being significantly up-regulated in OA compared to control cartilage1. Despite 
these links with arthritis, the known substrate specificities of these enzymes are in line 
with the findings presented here. 
 
FAP is best known as a dipeptidyl peptidase (an exopeptidase which cleaves two amino 
acids from the N-terminus) with a preference for a P1 proline, however it has also been 
shown to exhibit endopeptidase activity311. Thus, it was relevant to include in this PAR2 
cleavage screen. The PAR2 42mer peptide contains no proline residues, and despite being 
some evidence that FAP may also cleave substrates with alanine, arginine, glycine, lysine 
or serine in the P1 position312, it is clear there is a strong preference for a proline in this 
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position313. The failure of FAP to cleave PAR2 means further research is required in order 
to identify potential substrates for this unusual protease. 
 
The three major collagenases, MMP-1, -8 and -13 were all able to cleave PAR2. This was 
a fascinating observation, as it is known that canonical PAR2 activation is able to 
upregulate the expression of many MMPs, including MMP1, MMP3 and MMP131. Data 
presented in this chapter now suggests that active MMPs can act on PAR2, identifying a 
potential feedback system. Due to the vital importance of the collagenases in OA, as well 
as the importance of canonical PAR2 signalling in the disease, further work was 
undertaken on these cleavages, and is presented in chapter 5. 
 
PAR2 has been mainly described as a receptor for trypsin-like serine proteases, however 
a recent paper described biased agonism via activation by the lysosomal cysteine protease 
cathepsin S226. As several other lysosomal cysteine proteases have had extracellular roles 
identified, and have been linked to arthritic diseases, a series of these were also screened. 
Cathepsins B, K, V and L were all identified as novel enzymes with the ability to cleave 
PAR2. These novel observations were very interesting, and opened up PAR2 as 
potentially much more than just a receptor for trypsin-like serine proteases. Therefore, 
more work was undertaken to further understand these cleavages, and is presented in 
chapter 6. 
 
 
 Summary 
 A 42 amino acid peptide corresponding from arginine-31 to lysine-72 of PAR2, 
which contains the vast majority of previously identified PAR2 cleavage sites, 
was designed and synthesised. 
 
 A method to visualise the PAR2 42mer was optimised, comprised of tris-tricine 
SDS-PAGE and silver staining. 
 
 The system was validated by confirming that matriptase, hepsin, cathepsin G and 
neutrophil elastase could cleave the PAR2 42mer. 
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 A screen of novel enzymes from the metalloprotease, serine and cysteine protease 
families was undertaken, identifying 9 novel enzymes with the ability to cleave 
PAR2. 
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5. Chapter 5. Investigation of the role of the collagenolytic 
MMPs 1, 8 and 13 in PAR2 cleavage 
 Introduction 
After identifying that MMP-1, -8 and -13 can enzymatically digest the PAR2 42mer 
peptide, work was performed to further explore these cleavages. To gain initial insights 
into potential roles of cleavages, it is important to know the specific cleavage sites, which 
were obtained by mass spectrometry. Subsequently, further insights into the relevance of 
the cleavages were obtained by generating kinetic parameters for the enzymes for their 
cleavage site. Biochemistry-based assays are useful to give insights into the cleavages, 
but to further to understand the biology, cell work also was performed. 
 
 Chapter Aims 
 To identify the cleavage sites for MMP-1, -8 and -13 cleavage of PAR2. 
 To explore kinetic parameters of MMP-1, -8 and -13 cleavage of PAR2. 
 To explore a functional role for MMP-1, -8 and -13 cleavage of PAR2 in a 
chondrocytic cell culture model. 
 
 Results 
 Identification of PAR2 cleavage sites by MMP-1, -8 and -13 
To identify the cleavage sites, mass spectrometry was used to identify the cleavage 
products generated by MMP cleavage. HPLC was used to remove detergents present in 
the digestion buffer and to visualise the contents of the enzymatic reaction. To be able to 
identify cleavage products, the undigested 42mer peptide was run as a control and the 
elution time noted for comparison with digestion products. The undigested PAR2 42mer 
yielded a single major peak which elutes at around 16.5-17 minutes on the gradient 
(Figure 5.1). 
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To generate robust mass identification by electrospray MS, it is considered that a peak of 
greater than 50 mAU is required (Dr Joe Gray, personal communication). Thus, peaks 
greater than 50 mAU were selected for mass identification. The HPLC separation of a 24-
hour digestion reaction containing 400 nM MMP-1 with 10 µM PAR2 42mer yielded two 
major peaks - a peak at 16.9 minutes which corresponds to the parent peptide, as well as 
a peak with a later elution time at 18.4 minutes (Figure 5.2). The peak was collected and 
the mass obtained by electrospray MS (an example MS trace is presented in appendix 2), 
yielding 3564.9 Da. FindPept software (ExPASy) was used to identify all possible 
cleavage sites on the PAR2 42mer, which identified a single site corresponding to the 
observed mass, which was a cleavage between serine-7 and leucine-8 of the peptide (and 
thus serine-37 and leucine-38 in full length PAR2). A small peak was also observed at 
16.3 minutes, but it was below the sensitivity for electrospray MS. 
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Figure 5.1: Reversed-phase HPLC trace for PAR2 42mer undigested 
The PAR2 42mer peptide was diluted to 10 µM in 0.1% TFA and 30 µL was injected onto an ACE 3 C18 HPLC 
column. A gradient of 5-60% acetonitrile was run over 27 minutes at 35°C using a flow rate of 0.2 mL/min. The 
peptide elutes at around 16.9 minutes on the gradient. Chromatogram representative of three independent 
experiments. 
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A similar experiment using 20 nM MMP-8 resulted in the identification of three major 
peaks – at 16.3, 16.9 and 18.4 minutes (Figure 5.3). As previously described, the peak at 
16.9 minutes corresponds to the parent peptide, and the peak observed at 18.4 minutes 
was likely to be the same product as observed by MMP-1 cleavage. A small peak at 16.3 
minutes had been observed by MMP-1 cleavage of the PAR2 42mer (Figure 5.2), 
however it was too small to run by MS. The 16.3 and 18.4 minute peaks generated by 
MMP-8 cleavage were subjected to electrospray MS, and as expected, the peak at 18.4 
minutes was the same product as generated by MMP-1. The peak at 16.3 minutes yielded 
a product of 3924.1 Da, which corresponded to a cleavage between valine-38 and leucine-
39 of the peptide (valine-68 / leucine-69 in full length PAR2). 
Figure 5.2: Reversed-phase HPLC trace for PAR2 42mer following MMP-1 digestion 
PAR2 42mer (10 µM) was incubated with 400 nM MMP-1 for 24 hours at 37°C. 30 µL was injected to the HPLC 
system and ran through an ACE 3 C18 column on a 5-60% acetonitrile gradient over 27 minutes at 35°C using a 
flow rate of 0.2 mL/min. Peaks were collected manually for further analysis by electrospray MS. 
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The HPLC trace of the digestion of PAR2 42mer by 200 nM MMP-13 resulted in a 
chromatogram with many peaks (Figure 5.4). As insufficient peptide was used in the 
digestion for all the peaks to be product from the PAR2 42mer, it was hypothesised that 
MMP-13 had undergone autolysis as it is known to lack stability68, thus resulting in 
observation of MMP-13 fragments. This was confirmed by running a HPLC trace of 200 
nM MMP-13 following 24-hour incubation in the absence of PAR2 42mer (data not 
shown). The peaks at 17.9 and 18.4 minutes were selected for electrospray MS. There 
was no evidence of the parent peptide remaining in the chromatogram. As with MMP-1 
and -8, the peak at 18.4 yielded the same product resulting from a cleavage between 
serine-7 and leucine-8 of the PAR2 42mer. The peak at 17.9 yielded a product with a 
mass of 3165.6 Da, which interestingly corresponded to a second cleavage event. This 
Parent 
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Ser-37 / Leu-38 
Figure 5.3: Reversed-phase HPLC trace for PAR2 42mer following MMP-8 digestion 
PAR2 42mer (10 µM) was incubated with 20 nM MMP-8 for 24 hours at 37°C. 30 µL was injected to the HPLC 
system and ran through an ACE 3 C18 column on a 5-60% acetonitrile gradient over 27 minutes at 35°C using a 
flow rate of 0.2 mL/min. Peaks were collected manually for further analysis by electrospray MS. 
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product was a result of the previously observed cleavage at serine-7 and leucine-8, as well 
as a cleavage of its C-terminal fragment at valine-38 and leucine-39 – one of the cleavages 
observed by MMP-8 digestion of PAR2 42mer. 
 
It was not possible at this stage to deduce which was the primary cleavage, however the 
fact that the 3564.9 Da peak was the larger peak, and the fact that the serine-7 and leucine-
8 cleavage is present in both peaks, suggests that this is likely to be the case. 
 
 
 
 
Figure 5.4: Reversed-phase HPLC trace for PAR2 42mer following MMP-13 digestion 
PAR2 42mer (10 µM) was incubated with 200 nM MMP-13 for 24 hours at 37°C. 30 µL was injected to the HPLC 
system and ran through an ACE 3 C18 column on a 5-60% acetonitrile gradient over 27 minutes at 35°C using a 
flow rate of 0.2 mL/min. Peaks were collected manually for further analysis by electrospray MS. 
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Table 5.1: Identification of cleavage sites, highlighting the observed product in black 
Protease 
Mass 
(Observed) 
(Da) 
Mass 
(Expected) 
(Da) 
Sequence 
MMP-1 3564.9 3564.9 
(RSSKGRS)LIGKVDGTSHVTGKGVTVETVF
SVDEFSASVLTGK 
MMP-8 3924.1 3924.0 
RSSKGRSLIGKVDGTSHVTGKGVTVETVFS
VDEFSASV(LTGK) 
MMP-8 3564.9 3564.9 
(RSSKGRS)LIGKVDGTSHVTGKGVTVETVF
SVDEFSASVLTGK 
MMP-13 3165.6 3165.6 
(RSSKGRS)LIGKVDGTSHVTGKGVTVETVF
SVDEFSASV(LTGK) 
MMP-13 3564.9 3564.9 
(RSSKGRS)LIGKVDGTSHVTGKGVTVETVF
SVDEFSASVLTGK 
 
 
To ascertain which of the cleavages was the primary cleavage event, limited digests were 
undertaken at 3 and 6 hours for 200 nM MMP-13. At 3 hours, the parent peptide is still 
present, and approximately half had been converted to the 3564.9 Da peak, corresponding 
to the serine-7 and leucine-8 cleavage (Figure 5.5 A). By 6 hours, there is much less 
parent peptide remaining, having mostly been converted to the 3564.9 Da peak (Figure 
5.5 B). Furthermore, at 6 hours the 3165.6 Da peak corresponding to the valine-38 and 
leucine-39 of the peptide begins to appear. Taken together, these data strongly suggest 
that for MMP-13, the primary cleavage is between serine-7 and leucine-8, and the 
secondary cleavage is between valine-38 and leucine-39. 
 
MMP-1, -8 and -13 all cleave at an MMP-specific site which is one amino acid 
downstream of the canonical activation site of PAR2, which results from a cleavage with 
leucine in the P1’ position yielding a new product with an N-terminal leucine (Figure 
5.6). 
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Figure 5.5: Reversed-phase HPLC trace for PAR2 42mer following MMP-13 digestion at 3 and 6 hours 
PAR2 42mer (10 µM) was incubated with 200 nM MMP-13 for either 3 hours or 6 hours at 37°C. 30 µL was 
injected to the HPLC system and ran through an ACE 3 C18 column on a 5-60% acetonitrile gradient over 27 
minutes at 35°C using a flow rate of 0.2 mL/min. Peaks were identified based on their elution time. 
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 Kinetic parameters of MMP-1, -8 and -13 for PAR2 substrate 
Following the identification of an MMP cleavage site between serine-37 and leucine-38 
of| PAR2, kinetic parameters were generated and compared to matriptase. For this work 
the SY-9 peptide was used, a quenched-fluorescent peptide containing 8 amino acids with 
the sequence SKGRSLIG, corresponding to P4 to P4’ of the canonical cleavage site where 
matriptase and trypsin cleave. As the MMP cleavage site is only a single amino acid 
downstream from the canonical site, this peptide can also be used as a substrate for 
MMPs, and their kinetics directly compared to matriptase. 
 
Michaelis-Menten kinetic experiments were undertaken for MMP-1, -8 and -13 (Figure 
5.7), as well as for matriptase. By active-site titrating the enzymes (appendix 3), turnover 
numbers (kcat) were able to be calculated for each one. Taken in combination with the Km, 
Figure 5.6: Summary of MMP cleavage sites on PAR2 
Representation of the structure of the PAR2, highlighting the primary MMP cleavage site at serine-37 / leucine-
38, and the secondary MMP cleavage site at valine-68 / leucine-69 as well as the canonical site for comparison. 
Trypsin 
Matriptase 
MMP-1 
MMP-8 
MMP-13 
MMP-8 
MMP-13 
Primary Cleavage: 
Secondary 
Cleavage 
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“enzymatic efficiency” was calculated for each enzyme in terms of kcat/Km. For further 
information regarding derivation of constants, see chapter 2.15.4. 
 
Figure 5.7: MMP-1, -8 and -13 Michaelis-Menten curves for SY-9 substrate 
Michaelis-Menten curves for MMP-1, -8 and -13. Increasing concentrations of 2Abz-SKGRSLIG-3NY (SY-9) 
peptide were incubated with MMP. MMP-1 was at 400.4nM (A), MMP-8 was at 172.8nM (B) and MMP-13 was 
at 9.088nM (C). The fluorescence was measured at λex 320 nm and λem 420 nm and the linear reaction velocities 
were obtained from linear gradients of the fluorescence progress curves at early timepoints. The hydrolysis of 
substrate was quantified (nM.s-1) using a standard curve generated by total substrate hydrolysis. Graphpad Prism 5 
software was used to plot velocity against substrate concentration and non-linear regression was used to generate 
constants Km and Vmax. kcat was calculated from Vmax and enzyme active concentration. Curves shown are n=3 
independent experiments, mean ± SD. 
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The kinetic constants for MMP-1, -8, -13 and matriptase are outlined in table 5.2. As 
expected, matriptase had a much higher kcat than any of the MMPs with the ability to 
turnover 1720 molecules of substrate per minute per active site, compared to MMP-13 
which can turnover 5.62. MMP-1 and -8 are however much less active on this substrate 
than MMP-13, with kcat values of 0.03 and 0.14, respectively. In terms of Michaelis 
constant, an indicator of enzyme affinity for substrate, all four enzymes have comparable 
values, with MMP-13 having the lowest Km. Taken together, these data suggest that the 
three MMPs have a similar affinity to matriptase for binding to the substrate SY-9, 
however are much less active at turning it over. In terms of kcat/Km, matriptase is two 
orders of magnitude more efficient than MMP-13 (6.13 x 105 M-1.s-1 and 2.6 x 103 M-1.s-
1 , respectively), which is in turn an order of magnitude more efficient than MMP-1 and 
-8 (0.09 x 102 M-1.s-1 and 0.47 x 102 M-1.s-1, respectively). 
 
Table 5.2: Kinetic constants for MMP-1, -8, -13 and matriptase digestion of 
PAR2 peptide SY-9 
Enzyme kcat (min
-1) Km (µM) kcat/Km (M
-1.s-1) 
MMP-1 0.03 ± 0.002 52.52 ± 5.73 0.09 x 102 
MMP-8 0.14 ± 0.005 48.47 ± 4.10 0.47 x 102 
MMP-13 5.62 ± 0.32 36.07 ± 4.89 2.6 x 103 
Matriptase 1720 ± 113.90 46.73 ± 6.71 6.13 x 105 
 
 
 Exploration of the role of MMP-1, -8 and -13 in PAR2 cleavage 
Identification of cleavage sites for MMP-1, -8 and -13 and subsequent deduction of 
kinetic constants for their cleavage site on PAR2 gives initial insights onto the role of 
these enzymes into PAR2 biology, however to further explore potential roles, cell culture 
work was undertaken. 
 
 Do MMP C-terminal domains (CTDs) act as competitive inhibitors of 
matriptase-induced PAR2 activation? 
 
As MMP-1, -8 and -13 have relatively low turnover numbers for their PAR2 substrate, 
yet also have low Michaelis constants, it was hypothesised that the MMPs may be acting 
as competitive antagonists. If an MMP is bound to and cleaving PAR2 at position 37, 
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then it is unlikely the canonical site at position 36 can be also be cleaved to activate the 
receptor. 
 
To test this hypothesis, a large quantity of MMP was required, however this represented 
a technical difficulty, therefore MMP C-terminal domains (CTDs) were used in lieu of 
full-length enzyme. These MMP CTDs are recombinant proteins consisting of the entire 
haemopexin-like domain of the MMP as well as a part of the linker domain. It is well 
established that the hameopexin-like domains play key roles in MMP binding to ligand64, 
therefore it is possible that they could play a role in PAR2 binding and thus be able to 
block subsequent matriptase action. 
 
Before testing the addition of matriptase on PAR2 in the presence of MMP CTD, it was 
important to make sure that matriptase does not directly act on CTD and thus give false 
results. Firstly, matriptase was incubated with either 10- or 100-fold excess MMP-1, -8 
or -13 CTD and incubated for 3 hours. The reactions were separated out by SDS-PAGE 
and silver stained, which showed no evidence of matriptase digesting CTD (Figure 5.8 
A). Secondly, the effect of CTD was tested on matriptase enzyme activity. Matriptase 
activity assays (Boc-QAR-AMC assays) were undertaken, in which a 1-1000-fold excess 
range of MMP-1, -8 and -13 CTDs were included in the assay. Once again, there was no 
evidence of MMP CTD interfering with the enzyme activity of matriptase (Figure 5.8 B). 
Taken together, these data suggest that matriptase had no interaction with MMP CTD in 
the absence of PAR2 and retains full activity; therefore, subsequent experiments could be 
undertaken. 
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To test the hypothesis that MMP CTD can act antagonistically to PAR2 activation by 
matriptase, an experiment was undertaken where PAR2-overexpressing SW1353 cells 
(see chapter 2.10) were pre-incubated with MMP-1, -8 or -13 CTD for 30 minutes. The 
cells were then stimulated with 10 nM matriptase in a calcium mobilisation assay. The 
presence of both MMP-1 and -13 CTD appeared to have a small antagonistic effect on 
calcium mobilisation following matriptase stimulation (Figure 5.9). When this effect was 
quantified, 1000 nM of MMP-1 CTD resulted in 91% of maximal calcium mobilisation, 
and 1000 nM MMP-13 CTD resulted in 82% of maximal calcium mobilisation (Figure 
5.10). These two reductions were both statistically significant to p <0.05, and were the 
only significant results from this experiment, despite a trend of reduction for 100 nM 
MMP-13 CTD. 
Figure 5.8: Incubation of MMP-1, -8 and -13 CTDs with matriptase 
(A) MMP-1, -8 and -13 CTDs at either 100 or 1000 nM were incubated with Matriptase at 10 nM for 3 hours, after 
which samples were separated by SDS-PAGE and silver stained. Gel representative of n=2 independent 
experiments. (B) Boc-QAR-AMC assays were undertaken with 1 nM matriptase in the presence of CTDs at various 
molar excesses. Activity assay n=3 independent experiments. 
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Figure 5.9: Calcium mobilisation following matriptase stimulation with MMP-1, -8 and -13 CTD pre-
incubation 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing lentivirus 
before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM fluorescent 
calcium indicator and placed in a fluorimeter where the assays were undertaken. The cells were pre-incubated for 
30 minutes with either MMP-1, -8 or -13 CTDs. Fluorescence was observed following 10 nM matriptase 
stimulation (M), and 5 µM ionomycin stimulation (I). Data shown are mean of n=2 independent experiments. 
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Figure 5.10: Calcium mobilisation following matriptase stimulation with MMP1, 8 and 13 CTD pre-
incubation 
Maximal calcium response (average calcium response in the 10 seconds immediately following stimulation) 
obtained from the data in figure 5.9 and normalised to the no CTD pre-treatment in PAR-2 expressing cells as 
100% response. PAR2 expressing cells are black bars whereas empty vector control cells are grey bars. Mean ± 
S.E.M; where * p < 0.05 by unpaired T-test between 1000 nM pre-treatment group and no pre-treatment group in 
PAR2 expressing cells. Data shown is mean of n=2 independent experiments.  
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 Testing putative MMP cleavage revealed tethered ligand, LIGKVD, for IL-8 
expression 
 
In order to study PAR2 biology, the synthetic peptide SKIGKV-NH2 (hereafter SLIGKV) 
is commonly used as an agonistic “activator peptide” which mimics PAR2 canonical 
activation by trypsin314. Other activator peptides have been utilised in the literature, 
corresponding to other PAR2 cleavage sites, for example TVFSVDEFSA-NH2 which is 
revealed by cathepsin S226. It was hypothesised that should MMP cleavage of PAR2 be 
agonistic for the receptor, then the revealed ligand would commence with leucine-37. The 
synthetic peptide LIGKVD-NH2 (hereafter LIGKVD) was therefore synthesised and 
utilised as a putative MMP activator peptide. The reverse sequence peptide DVKGIL was 
used as a negative control. 
 
Interleukin-8 (IL-8, gene CXCL8) is well established as a pro-inflammatory chemokine 
induced by canonical PAR2 signalling315,316. To explore whether LIGKVD might 
instigate pro-inflammatory PAR2 signalling, CXCL8 expression was examined and 
compared with canonical SLIGKV stimulation. Both peptides were added to PAR2-
overexpressing cells in increasing concentrations (10 to 300 µM) and stimulated for three 
hours, after which CXCL8 expression was examined. As expected, there was a robust 
upregulation of IL-8 with all tested SLIGKV concentrations, however there was no effect 
by LIGKVD (Figure 5.11 A). Taking the concentration of SLIGKV as low as 1 µM still 
resulted in IL-8 upregulation significant to p < 0.001 (Figure 5.11 B). 
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Figure 5.11: IL-8 expression following 3 hour SLIGKV, LIGKVD and DVKGIL stimulation in 
SW1353_FLAG-PAR2 cells 
SW1353_FLAG-PAR2 cells were seeded in 96-well plates and stimulated for 3 hours with increasing 
concentrations of either 10-300 µM SLIGKV and LIGKVD (A) or 1-100 µM SLIGKV, LIGKVD and DVKGIL 
(B), as well as 10 nM matriptase as a positive control. Following stimulation, mRNA was extracted and reverse 
transcribed to cDNA. qPCR was were undertaken for IL-8 (CXCL8), normalised to 18S  ribosomal RNA (mean ± 
SEM; where ** p < 0.01 and *** p < 0.001 , by unpaired two-tailed T Test compared to basal expression, 
unstimulated control). Data pooled from n=2 separate independent experiments. 
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 Testing putative MMP cleavage revealed tethered ligand, LIGKVD, on calcium 
mobilisation 
 
IL-8 is a useful readout for assessing canonical PAR2 activation, as instigated by 
matriptase or SLIGKV stimulation. The lack of response by LIGKVD suggests that it is 
not a canonical agonist, therefore other signalling pathways further upstream than IL-8 
were investigated. 
 
Firstly, calcium mobilisation assays were undertaken with increasing concentrations of 
SLIGKV on PAR2-overexpressing cells, and there were good responses at all tested 
concentrations from 0.2 to 20 µM (Figure 5.12). When undertaking similar experiments 
with LIGKVD concentrations up to 100 µM, there was no calcium response (Figure 5.13 
A). The small “response” observed with the 100 µM sample is in fact a buffer injection 
artefact as a result of injecting a large volume on the cells and is often observed at the top 
concentration of such dose-response studies. This effect is also observed injecting 100 
µM LIGKVD on the empty vector control cells. The reverse control peptide, DVKGIL, 
also had no effect on calcium mobilisation (Figure 5.13 B). 
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Figure 5.12: Calcium mobilisation following SLIGKV (canonical activating peptide) titrations 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing 
lentivirus before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM 
fluorescent calcium indicator and placed in a fluorimeter where the assays were undertaken. Titrations of 
SLIGKV peptide were undertaken using either 0-20 µM (A) or 0-2 µM (B) peptide. Fluorescence was observed 
following SLIGKV stimulation (S), and 5 µM ionomycin stimulation (I). Data shown is mean of two independent 
experiments. 
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Figure 5.13: Calcium mobilisation following putative MMP activating peptide (LIGKVD) and reverse 
control peptide (DVKGIL) titrations 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing 
lentivirus before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM 
fluorescent calcium indicator and placed in a fluorimeter where the assays were undertaken. Titrations of 0-100 
µM for either putative MMP activating peptide LIGKVD (A) or reverse control peptide DVKGIL (B) were 
undertaken. Fluorescence was observed following LIGKVD (L) or DVKGIL (D) stimulation, and 5 µM 
ionomycin stimulation (I). Data shown is mean of two independent experiments. 
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 Testing putative MMP cleavage revealed tethered ligand, LIGKVD, on MAPK 
activation 
 
Following the observation that LIGKVD does not stimulate calcium mobilisation, the 
activation of p38 and ERK1/2 MAPK signalling pathways was explored. It is known that 
both p38 and ERK1/2 are phosphorylated in response to PAR2 canonical activation, 
including activation by matriptase317. 
 
A time-course experiment was undertaken to explore the dynamics of both p38 and 
ERK1/2 phosphorylation in PAR2-overexpressing SW1353 cells following either 10 nM 
matriptase or 100 µM SLIGKV stimulation (Figure 5.14). As expected, both proteins are 
phosphorylated, with ERK1/2 reaching peak phosphorylation earlier than p38, after 5 
minutes for matriptase, and 10 minutes for SLIGKV. p38 reached maximal 
phosphorylation at 40 minutes for both agonists (however the time-course was terminated 
thereafter, thus it is possible maximal p38 phosphorylation was later). 
 
The same experiment was undertaken by stimulating the cells with either 100 µM 
LIGKVD or DVKGIL. Interestingly, the addition of LIGKVD resulted in a marked 
phosphorylation of ERK1/2 which mimics the phosphorylation observed following 
SLIGKV stimulation (Figure 5.15 A). These cells however had no evidence of p38 
phosphorylation, indicating that biased signalling is occurring following LIGKVD 
stimulation. There was no evidence of MAPK phosphorylation following control peptide 
DVKGIL stimulation (Figure 5.15 B). 
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Figure 5.14: ERK1/2 and p38 phosphorylation following Matriptase and SLIGKV stimulation 
SW1353 cells were transduced with pSIEW_PAR2 or pSIEW_Empty expressing lentivirus before culturing for 48 
hours then serum starving overnight. A time course was undertaken by stimulating with either 10 nM matriptase 
(A) or 100 µM SLIGKV (B) and cells were lysed and proteins separated by SDS-PAGE before probing for either 
phospho-ERK1/2, native ERK1/2, phospho-p38 or native p38. Blots shown are representative of two independent 
experiments. 
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ERK1/2 has previously been shown to be involved in the positive regulation of MMP-1 
expression in various cell types318,319, including chondrocytes320. Therefore, the 
regulation of MMP1 by LIGKVD was explored. 
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Figure 5.15: ERK1/2 and p38 phosphorylation following LIGKVD and DVKGIL stimulation 
SW1353 cells were transduced with pSIEW_PAR2 or pSIEW_Empty expressing lentivirus before culturing for 48 
hours then serum starving overnight. A time course was undertaken by stimulating with either 100 µM LIGKVD 
(A) or 100 µM DVKGIL (B) and cells were lysed and proteins separated by SDS-PAGE before probing for either 
phospho-ERK1/2, native ERK1/2, phospho-p38 or native p38. Blots shown are representative of two independent 
experiments. 
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As expected, SLIGKV resulted in significant upregulation of MMP1 expression at all 
tested peptide concentrations, and control peptide DVKGIL had no effect. However, there 
was no evidence of LIGKVD regulating MMP1 expression, even at the very high 
concentration of 500 µM (Figure 5.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: MMP1 expression following SLIGKV, LIGKVD or DVKGIL stimulation 
PAR2-overexpressing cells were stimulated for 24 hours with 0-500 µM SLIGVD, LIGKVD or DVKGIL. 
Following stimulation, mRNA was extracted and reverse transcribed to cDNA. qPCR was were undertaken for 
MMP1, normalised to GAPDH  (mean ± SEM; where ** p < 0.01 and *** p < 0.001 , by unpaired two-tailed T 
Test compared to basal expression, unstimulated control). n=1 independent experiments. 
 
 
0 25 50 10
0
25
0
50
0
0
5
10
15
20
25
DVKGIL
SLIGKV
LIGKVD
Peptide (M)
M
M
P
1
/G
A
P
D
H
 (
F
o
ld
 c
h
a
n
g
e
 v
s
 b
a
s
a
l)
*** 
*** 
*** 
*** 
** 
158 
 
 MMP activity in IL-1+OSM-stimulated bovine nasal cartilage conditioned 
medium is able to cleave SY-9 
 
The stimulation of bovine nasal cartilage with IL-1 in combination with OSM results in 
an MMP-dependent degradation of cartilage321, a system used as a model for enzyme-
mediated degradation of cartilage1,322,323. 
 
In order to test whether active MMP generated from this model would be able to cleave 
PAR2, conditioned medium was used in a SY-9 activity assay. It was clear that there was 
SY-9 degrading activity within the conditioned media, and this was clearly a result of 
MMP activity, as the effect was completely blocked by GM6001. The inhibition of serine 
proteases with DFP and cysteine proteases with E64 had no effect on the cleavage of SY-
9 (Figure 5.17 A). 
 
To ascertain specific MMPs involved in this activity, a selective MMP-8 inhibitor (MMP-
8 inhibitor I) and a selective MMP-13 inhibitor (CL-82198) were utilised. This 
experiment suggests that the SY-9 cleaving activity is mainly as a result of MMP-13. CL-
82198 inhibits MMP-13 with an IC50 of 3.2 µM
324, and 10 µM in this assay was able to 
almost inhibit all the SY-9 degrading activity of the bovine cartilage conditioned medium 
whereas 100 µM resulted in total inhibition (Figure 5.17 B). MMP-8 inhibitor I has an 
IC50 of 4 nM for MMP-8
325, and 10 nM had no effect on SY-9 degradation, whereas 100 
nM only had a very small effect, however statistical analysis was not able to be 
undertaken (Figure 5.17 B). 
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Figure 5.17: MMP activity in IL-1+OSM stimulated bovine nasal cartilage conditioned medium contains 
MMP activity able to digest SY-9 peptide 
100 µL reactions containing 5 µL day 14 conditioned medium from an IL-1+OSM-stimulated bovine nasal 
cartilage explant experiment were incubated with 10 µM SY-9 peptide in the presence or absence of either 100 µM 
GM6001, 10 µM E64 or 2 mM DFP. Assays were undertaken in a fluorimeter to monitor SY-9 cleavage and 
velocities were obtained from the resulting progress curves. Data was normalised to the control wells, given as 
100% activity (A). n=2 independent experiments with conditioned medium from different donors. Subsequently, a 
similar experiment was undertaken with MMP-13 inhibitor CL-82198 or MMP-8 inhibitor I (B). n=1 independent 
experiment. 
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 Discussion 
In this chapter, the specific cleavage sites generated by MMP-mediated PAR2 digestion 
outlined in chapter 4 were identified and subsequently the functional roles of these 
cleavages were explored. Overall, these results suggest that there might be a blocking 
effect of canonical signalling mediated by MMPs and that MMPs might be biased 
agonists of PAR2. 
 
HPLC was undertaken on the products resulting from MMP-1, -8 and -13 digestion of the 
PAR2 42mer. Of these, MMP-1 yielded the “cleanest” digestion with a single major 
product, whereas MMP-8 and -13 yielded two major products. MS analysis of these 
products identified the cleavage sites as being serine-37 / leucine-38 for all three 
proteases, as well as valine-68 / leucine-69. Both these cleavage sites result from a leucine 
in the P1’ position and a glycine in the P3’ position, however the P2’ position varies with 
an isoleucine at position 39 and a threonine at position 69. The collagenolytic MMPs have 
a preference for a hydrophobic amino acid at the P1’ position, a basic or hydrophobic 
amino acid at the P2’ position and a small amino acid (alanine, glycine or serine) at the 
P3’ position326,327. Furthermore a search of these three proteases in the MEROPS database 
(which collates all previously identified MMP cleavage sites) indicates that the 
hydrophobic amino acid leucine is the preferred P1’ amino acid for them310. The three 
proteases, in particular MMP-8 and -13, also have a preference for a glycine the P3’ 
position of their substrate, which is also found in both sites identified on PAR2. 
 
When comparing the two identified cleavage sites, the literature supports the observation 
that serine-37 / leucine-38 is the likely major cleavage event as the P1’ – P2’ – P3’ 
positions are all chemical preferences for the collagenases, whereas the P2’ for the valine-
68 / leucine-69 cleavage site is a polar uncharged amino acid in threonine as opposed to 
the preferred basic or hydrophobic residue in that position. The observation that MMP-8 
and -13 both cleaved in the additional site that MMP-1 did not, could possibly reflect the 
higher specificity for P3’ glycine for MMP-8 and -13 compared to MMP-1310. It is likely 
that MMP-1 does indeed also cleave that site as a small peak was observed at the correct 
retention time by HPLC, but under tested conditions this was below the sensitivity range 
of electrospray MS. 
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In order to ascertain the relative importance of the two observed cleavages for MMP-8 
and -13, a restricted digest experiment was undertaken using MMP-13. This clearly 
demonstrated that serine-37 / leucine-38 was the initial cleavage event, followed by 
valine-68 / leucine-69. It is well established that PAR2 activation is rapid following 
canonical activation, as demonstrated in this chapter by measuring calcium mobilisation 
following matriptase stimulation. It therefore follows that any activation by MMP-
mediated cleavage at serine-37 / leucine-38 would likely be instigated before cleavage 
occurs at valine-68 / leucine-69. The second cleavage could also have a potential role as 
a limiting factor in any MMP-mediated activation. Indeed, mast cell tryptase has been 
identified as a canonical activator of PAR2, however its activation potential is limited by 
a secondary cleavage downstream of the canonical site206. 
 
In order to gain initial insights of the relevance of this MMP cleavage site on PAR2, 
enzyme kinetics were studied. As the SY-9 peptide substrate encompasses P4-P4’ for 
matriptase and P5-P3’ for the MMPs, it could be used to directly compare the kinetics for 
PAR2 cleavage by all the enzymes. Unsurprisingly, all three MMPs were far less efficient 
at cleaving the substrate compared to matriptase. Matriptase is known as a very potent 
PAR2 activator293, and has previously had its cleavage of the SY-9 peptide explored. 
Béliveau et al. (2009)328, found that matriptase cleaved PAR2 with a kcat/Km of 3.1 X 10
5 
M-1.s-1, which is a Figure in the same order of magnitude as obtained in this study, 6.13 x 
105 M-1.s-1. It is important to address the limitations of small peptide substrate 
experiments such as this, as they are unlikely to allow for exosite interactions, such as 
with MMP haemopexin domains, and thus the physiological enzymatic efficiencies are 
likely to be different. It is interesting to compare the kinetics for PAR2 cleavage by 
matriptase, and PAR1 activation by thrombin (the archetypal protease-mediated receptor 
activation). Thrombin cleaves PAR1 with a kcat/Km of 1.2 X 10
7 M-1.s-1, two orders of 
magnitude more efficiently than matriptase cleavage of PAR2202. 
 
When considering the enzyme kinetics for the collagenases, it is important to note that 
this projected utilised APMA-activated enzyme, however this is not considered to be fully 
active. When activated by either APMA or trypsin, the pro-collagenases are activated 
only to 10-25% of maximal activation. This results from cleavage within the bait region 
of the pro-domain, however for fully active enzyme, the whole pro-domain requires 
removal, which can be performed by enzymes such as MMP-3329. It is therefore possible 
that the kinetic data presented within this chapter underestimates the physiological 
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relevance of these cleavages, and the utilisation of MMP-3-activated collagenase would 
likely give higher kcat values. 
 
The relatively low kcat/Km values for MMPs on SY-9 are a result mainly of their low kcat 
values, whereas their Km values are comparable to matriptase. These low Km values 
suggest a relatively high affinity for the substrate. Taking these data together, a hypothesis 
was developed where MMPs might act as competitive antagonists for PAR2 canonical 
activation. In a system where PAR2, matriptase and MMPs are all expressed, such as 
cartilage, it is possible that MMPs and matriptase compete for binding to PAR2. In such 
a system, irrespective of the subsequent functional role of the MMP cleavage and revealed 
ligand, canonical PAR2 activation by matriptase would be attenuated. The presence of 
MMP at its cleavage site would render it very unlikely to allow matriptase to bind there 
due to steric hindrance. 
 
To test this hypothesis in a cell culture model, a blocking experiment utilising MMP 
CTDs was undertaken. MMP CTDs were utilised due to a lack of recombinant full-length 
MMPs and time constraints for producing sufficient quantities. The MMP CTDs consist 
of the entire haemopexin-like domain as well as part of the linker domains of MMP. It is 
well established that MMP haemopexin-like domains play key roles in substrate 
recognition and binding of MMP to substrate64, therefore it is possible that this is true of 
MMP cleavage of PAR2. Whilst the haemopexin-like domain will not be binding to the 
cleavage site on PAR2, it is possible that it will be able to bind sufficiently close to also 
result in steric hindrance. 
 
This experiment showed a modest blocking effect of MMP-1 and -13 CTDs on calcium 
mobilisation triggered by canonical matriptase activation of PAR2. A 100-fold excess of 
MMP-1 and -13 CTD over matriptase resulted in 91% and 82% of maximal calcium 
mobilisation, respectively. Background work suggested that this effect was not a result of 
interference by CTD on matriptase activity. Were this a result of CTD binding and 
blocking matriptase from fully activating the receptor, the modest effect does not reflect 
the Km values for matriptase and MMP-1 and -13 could be a result of not using full-length 
MMP. Depending on where the CTD binds to PAR2, matriptase was not fully blocked 
from activating the receptor. It would be important in future work to utilise full-length 
MMP in similar experiments. Should the effect observed by CTD be a result of blocking 
the receptor, then utilising full-length MMP should result in a stronger blocking effect. 
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After exploring the effect of MMP CTD on canonical PAR2 signalling, an exploration of 
the potential role of the MMP cleavage and its revealed ligand was undertaken. The MMP 
cleavage site of PAR2 is downstream of the canonical activation site meaning it can either 
be a disarmer, a full agonist or a biased agonist. Unfortunately, sufficient quantity of 
active MMP was unable to be sourced for this work, so instead a synthetic peptide 
corresponding to the putative revealed tethered ligand, LIGKVD, was used. 
 
This tethered ligand was compared to matriptase and SLIGKV canonical activation of 
PAR2, and it was found that LIGKVD was unable to activate the pathways resulting in 
IL-8 expression, as well as being unable to stimulate calcium mobilisation. When looking 
at MAPK signalling, LIGKVD was able to stimulate ERK1/2 phosphorylation, but not 
p38 phosphorylation, as opposed to the canonical activators which stimulated both. 
 
Previous work has been undertaken on the canonical activator peptide, SLIGKV, 
exploring key residues for PAR2 activation. Al-Ani et al. (2004)330 created a series of 
mutants substituting alanine into each position from 37 to 42 of full-length PAR2 for cell 
culture work, as well as synthetic peptides. As their work used rat cells, the canonical 
activator peptide was SLIGRL. Interestingly, when measuring calcium mobilisation, their 
ALIGRL mutant resulted in 95% activity in cell culture work following trypsin activation, 
whereas the synthetic ALIGRL peptide resulted in 9.5% residual activation in the same 
cells. In their study, substituting the P2’ leucine for an alanine had a much larger reducing 
effect resulting in only 14% activation for trypsin activation, and no activity for the 
synthetic peptide SAIGRL. Taken together with their other mutants, it was concluded that 
the serine and leucine at the P1’ and P2’ position are key to activating PAR2, with leucine 
of particular importance. This leucine is present in the putative MMP activator peptide 
used in this study as the P1’ position. This peptide however did not exhibit any stimulation 
of calcium mobilisation, despite being tested at a concentration of 500 times higher than 
for the observed calcium mobilisation by SLIGKV. The fact that LIGKVD in this study 
exhibited no calcium mobilisation whereas ALIGRL did in the Al-Ani et al. (2004)330 
study could reflect a species difference between rat and human, or the fact that despite 
leucine at P2’ being more important than serine at P1’, there is a requirement for the 
presence of an amino acid there, such as alanine. Indeed this is supported by the 
observation that synthetic PAR2 agonist 2-furoyl-LIGKV-OH (also known as ASKH95) 
is able to fully activate PAR2, including calcium mobilisation331. The 2-furoyl-LIGKV-
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OH peptide was developed as a PAR2 agonist with a longer biological half-life than 
canonical activator peptide SLIGKV-NH2, and has a higher affinity for PAR2 than the 
canonical activator314. Whilst the 2-furoyl group is not an amino acid, it is a similar size 
to an amino acid, and therefore could act to keep the leucine in the P2’ position. 
 
A subsequent study found that the peptide SLAAAA was able to stimulate ERK1/2 
phosphorylation without stimulating calcium mobilisation, as observed with LIGKVD in 
this study but unfortunately they did not measure p38 MAPK332. It is thought that there 
is a requirement of a basic amino acid in position 5 of the tethered ligand/ activator peptide 
for triggering calcium mobilisation – lysine in the human sequence or arginine in the rat 
sequence333. The LIGKVD peptide used in this project has this basic lysine in position 4, 
and position 5 is subsequently occupied with a hydrophobic valine. It is unknown how 
the canonical peptide or LIGKVD docks into the active site of PAR2, however this loss 
of basic residue could contribute to the loss of calcium mobilisation observed. 
 
An interesting study by Lin et al. (2008)334, compared the rat activator peptide SLIGRL 
with a truncated version, LIGR and explored various signalling pathways. As with the 
peptide LIGKVD utilised in this study, LIGR was shown to instigate biased signalling. 
As with LIGKVD, LIGR was unable to stimulate calcium mobilisation, IL-8 induction or 
p38 MAPK phosphorylation, however unlike LIGKVD, there was no phosphorylation of 
ERK1/2 either. The biased signalling induced by LIGR involved activation of the Rho 
family of GTPases as measured by an increase in GTP-bound Rho. 
 
Despite being able to induce the phosphorylation of ERK1/2, LIGKVD was unable to 
induce MMP1 expression. Cell signalling is complex with much cross-talk between 
pathways. Whilst the inhibition of ERK1/2 will result in a suppression of MMP1 
expression following canonical PAR2 activation (Dr Chun Chan, unpublished), the 
suppression is not total, implying other pathways are also involved. Indeed, following IL-
1β stimulation of chondrocytes, ERK1/2 inhibition will reduce MMP1 expression, 
however so will p38 inhibition, albeit to a lesser extent320. In this study it is likely that 
despite inducing ERK1/2 phosphorylation, other pathways required for MMP1 expression 
are not induced. 
 
The observation that cell surface receptors may be activated by collagenolytic MMPs has 
previously been described. Both MMP-1 and MMP-13 have been shown to be able to 
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activate the PAR1 receptor. MMP-1 cleaves PAR1 two amino acids upstream of its 
canonical activation site, and results in an extended tethered ligand297, whereas MMP-13 
cleaves a single amino acid downstream of the canonical site298. Both MMP-1 and -13 
are agonistic to PAR1, with some evidence of biased signalling generated by these 
cleavage sites297,298. 
 
Furthermore, Li and Tai (2013) published work that described MMP-1 acting on cells in 
a PAR2-dependent manner, by upregulating monocyte chemoattractant protein-1 (MCP-
1) protein. Their work utilised A549 cells which are not as responsive to canonical PAR2 
signalling as lentiviral overexpressed PAR2 nor PAR2 stable cell line (unpublished 
observations). The fact their paper observed a PAR2 activation effect with 5nM MMP-1 
does not fit with data presented in this project. In this project, 5nM matriptase would be 
a low concentration to be used to activate PAR2 in highly expressing cells. Kinetic data 
presented here shows that matriptase is around 68000-fold more efficient at cleaving 
PAR2 than MMP-1 is based on respective kcat/Km values, therefore it is very unlikely that 
5 nM MMP-1 would be sufficient to activate PAR2. Furthermore, to activate MMP-1 
they used 10 µg/mL trypsin, which is approximately 416 nM, followed by subsequent 
inhibition with soybean trypsin inhibitor. Trypsin is difficult to completely inhibit 
(unpublished observations), and this paper failed to provide MMP inhibitor (e.g. 
GM6001) experiments, nor a trypsin/trypsin soybean inhibitor-only control to confirm 
that it was indeed MMP-mediated cleavage and not trypsin contamination responsible for 
the observed effect. 
 
Both PAR2234 and matriptase1 are expressed significantly higher in OA chondrocytes than 
in normal chondrocytes, and it is known that canonical PAR2 activation results in MMP1 
and MMP13 expression128. When recombinant matriptase is added to OA cartilage 
explant cultures, there is an enhanced level of collagen breakdown which is dependent on 
MMP activity and attenuated by PAR2 antagonists1. Matriptase is then subsequently able 
to directly activate proMMP-1, and indirectly activate proMMP-13 (by activating 
proMMP-3 which is able to activate proMMP-13) which is responsible for the observed 
collagenolysis in the explant experiments1. Data presented in this chapter further suggests 
that these active MMPs may be able to also act on PAR2 in a feedback loop (summarised 
in Figure 5.18). Further work will be required to elucidate the exact role of MMP cleavage 
of PAR2.  
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It remains to be deduced as to whether this feedback loop impacts negatively (i.e. prevents 
further PAR2 signalling) or positively (i.e. perpetuates PAR2 signalling) on ECM 
remodelling in OA. In either case, the findings of this chapter further highlight the 
inherent complexity regarding proteolysis and cell signalling in a disease setting. 
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2. proMMP-1, -13 
↑ MMP1, MMP13 
1. Matriptase 
3. Matriptase 
4. MMP-1, -13 
Figure 5.18: Chapter Summary 
Both matriptase and PAR2 are more highly expressed in OA cartilage. It has previously been shown that PAR2 
activation by matriptase results in the upregulation of MMP1, MMP3 and MMP13, which are then secreted and can 
also be activated by matriptase directly (MMP-1 and MMP-3) or indirectly (MMP-13, via MMP-31). Work 
presented in this chapter shows that MMP-1 and MMP-13 can both cleave PAR2 in in vitro assays and the putative 
revealed ligand, LIGKVD, is a biased agonist for MAPK signalling. 
RSSKGR SLIGKV RSSKGRS LIGKVD 
ERK1/2? 
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 Summary 
 MMP-1, -8 and -13 primarily cleaved at serine-36 / leucine-37 in PAR2, a single 
amino acid to the C-terminus of the canonical activation site. 
 
 MMP-13 was the most catalytically efficient enzyme to cleave PAR2 followed by 
MMP-8 and then MMP-1, however all three were markedly less efficient than 
matriptase. 
 
 The three collagenases had a similar affinity for PAR2 substrate, and using the C-
terminal domains of MMP-1 and -13 resulted in small antagonistic effects on 
matriptase stimulation of PAR2. 
 
 The putative MMP-revealed ligand, LIGKVD, was unable to stimulate IL-8 
expression, calcium mobilisation, or p38 MAPK phosphorylation, however was 
able to stimulate ERK1/2 phosphorylation. 
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6. Chapter 6 - Investigation of the role of cathepsin-mediated 
PAR2 cleavage 
 Introduction 
Data presented in chapter 4 identified a novel activity for four cathepsin enzymes in the 
ability to cleave PAR2. Furthermore, the previously described activity of PAR2 cleavage 
by cathepsin S was confirmed226,300. Data presented in this chapter aims to follow a similar 
work flow to the data presented in chapter 5 which explored MMP cleavage of PAR2. In 
order to understand cathepsin cleavage of PAR2, it is important to first identify the 
cleavage sites. Subsequently, generating kinetic parameters for the cleavages provides 
insights into functional relevance. Finally, to gain physiological relevance of the 
cleavages, cell culture-based work was performed to explore functional outcomes of this 
cleavage in PAR2. 
 
 Chapter Aims 
 To identify the sites for cathepsin cleavage of PAR2. 
 To explore kinetic parameters of cathepsin cleavage of PAR2. 
 To explore a functional role for cathepsin cleavage of PAR2 in chondrocytic cells. 
 
 Results 
 Identification of cathepsin-mediated cleavage sites of PAR2 
After identifying the ability of cathepsins V, L, B, S and K to cleave PAR2 in chapter 4, 
work was performed to identify the cleavage sites for these enzymes. For this work, 
nanoLCMS was utilised rather than direct infusion MS as was performed for MMP-
cleavage of PAR2 in chapter 5. The reasons for this change of methodology were that as 
the stock concentrations of the recombinant cathepsins were higher than that of the 
MMPs, and that the cathepsins cleave PAR2 at a much lower concentration, a much larger 
dilution to assay concentration could be performed. The recombinant enzyme stocks all 
contained detergents which interfere with and damage nanoLCMS UPLC columns and 
thus were removed (by HPLC for the MMPs) or diluted out as per the cathepsins (Dr Joe 
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Gray, personal communication). The advantages of using nanoLCMS over direct infusion 
are a higher sensitivity and the ability to identify all cleavages within a sample. 
 
NanoLCMS was performed on the 4 novel PAR2-cleaving cathepsins, as well as with 
cathepsin S (an example trace is presented in appendix 2). Multiple cleavages for each 
enzyme were identified and by using the analysis strategy described in chapter 2.14.3.1, 
these were ordered for each enzyme, and are shown in Figure 6.1 for cathepsins V, K, L 
and S. 
 
The primary cleavage site for cathepsins V, S and L was between glutamic acid-56 and 
threonine-57, with secondary sites for cathepsins V and S between phenylalanine-59 and 
serine-60. A secondary site for cathepsin L was located towards the N-terminus between 
glycine-40 and lysine-41, which also corresponds to the primary site for cathepsin K. 
More minor sites were identified between serine-60 and valine-61 (cathepsins S and L), 
as well as between threonine-54 and valine-55 (cathepsin K). 
 
 
 
Cathepsin B resulted in more cleavages than the other enzymes, and it was more difficult 
to order them using the method utilised for the other cathepsins. Cleavages by cathepsin 
B were identified at all the same sites as for the other cathepsins, as well as several other 
sites (Figure 6.2). 
 
 
72 
Figure 6.1: Cathepsin cleavage sites on PAR2 
Schematic showing the amino acid sequence of the PAR2 42mer peptide, highlighting the identified cleavage 
sites by the cathepsin enzymes in this study, as well as the previously described cathepsin S cleavages of PAR2.  
Cleavage sites are numbered in brackets in order of importance according to nanoLCMS. Quenched-fluorescent 
peptides utilised for kinetic studies in this project are highlighted: red for SY-9 peptide, green for VETV 
substrate, and blue for FSVD substrate. 
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Matriptase 
K(1), L(2) K(3) 
K(2), V(1), S(1), L(1) 
V(2), S(2), L(4) 
Cathepsin S cleavage site 
(Zhao et al., 2014) 
S(3), L(3) 
Cathepsin S cleavage sites 
(Elmariah et al., 2014) 
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As multiple cleavage sites were identified for each enzyme, it was of importance to 
validate the method for ordering the importance of the cleavages. Synthetic substrates 
were therefore designed to compare the potencies of the cathepsin enzymes for each 
cleavage site. It was difficult to design specific substrates for each enzyme, and it was 
decided to utilise two peptides of 4 amino acids each: VETV and FSVD (Figure 6.1). The 
VETV substrate contains the identified primary cleavage site of cathepsins V, S and L 
(glutamic acid-56 / threonine-57), whereas the FSVD peptide contains the site for the 
secondary cathepsin V, S and L cleavage at phenylalanine-59 / serine-60. The SY-9 
peptide was used as the primary cleavage site for cathepsin K and the secondary site for 
cathepsin L (Figure 6.1). 
 
 
 Kinetic parameters of cathepsins V, L, S and K for PAR2 substrates 
Kinetic parameters were generated for the cathepsin enzymes using the VETV, FSVD 
and SY-9 substrates, and compared with matriptase. Cathepsin B did not display 
Michaelis-Menten kinetics and therefore these data are not presented. The Michaelis-
Menten curves for cathepsin V, L, S and K are shown in Figure 6.3, and the Km, kcat and 
kcat/Km values are all outlined in table 6.1. 
 
 
 
 
31 72 
Figure 6.2: Cathepsin B cleavage of PAR2 
PAR2 42mer sequence showing the amino acid sequence of the PAR2 42mer peptide, highlighting the 
identified cleavage sites by cathepsin B. 
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Figure 6.3: Cathepsin V, L, S and K Michaelis-Menten curves 
Michaelis-Menten curves for cathepsins V, L, S and K. Increasing concentrations of VETV, FSVD or SKGRSLIG (SY-9) peptides were incubated with fixed concentrations of cathepsin enzyme. 
Cathepsin V was used at 5.32 nM for VETV, 10.65 nM for FSVD and 266.2 nM for SY-9 (A). Cathepsin L was used at 25 nM for all peptides (B). Cathepsin S was used at 10.77 nM for VETV and 
FSVD and at 21.54 nM for SY-9 (C). Cathepsin K was used at 10.69 nM for all peptides (D). The fluorescence was measured at λex 320 nm and λem 420 nm and the linear reaction velocities were 
obtained from early gradients of  the fluorescence progress curves. The hydrolysis of substrate was quantified (nM.s-1) using a standard curve generated by total substrate hydrolysis. Graphpad Prism 
5 software was used to plot velocity against substrate concentration and non-linear regression used to generate constants Km and Vmax. kcat was calculated from Vmax and enzyme active concentration. 
See Chapter 2.15.4.1 for all experimental conditions. Curves shown are n=3 independent experiments, mean ± SD. 
C Cathepsin S 
D Cathepsin K 
 N/A = No data as enzyme did not cleave substrate 
Table 6.1: Kinetic constants for cathepsin V, L, S and K, and matriptase digestion of PAR2 peptides VETV, FSVD and SKGRSLIG  
Enzyme Peptide Km (µM) kcat (min
-1) kcat/Km (M
-1.s-1) 
 VETV 66.12 ± 4.60 72.95 ± 2.141 1.84 x 104 
Cathepsin V FSVD 56.31 ± 10.61 41.14 ± 3.112 1.22 x 104 
 SKGRSLIG 74.80 ± 6.274 15.32 ± 0.5641 3.41 x 103 
 VETV 63.14 ± 3.966 140.5 ± 3.673 3.71 x 104 
Cathepsin L FSVD 47.46 ± 8.225 92.80 ± 7.611 3.26 x 104 
 SKGRSLIG 12.53 ± 0.9363 13.11 ± 0.3062 1.74 x 104 
 VETV 110.6 ± 13.71 92.79 ± 5.728 1.40 x 104 
Cathepsin S FSVD 57.77 ± 10.91 38.78 ± 2.965 1.12 x 104 
 SKGRSLIG 109.6 ± 6.653 48.78 ± 6.653 7.4 x 103 
 VETV 316 ± 85.99 182.0 ± 33.96 9.60 x 103 
Cathepsin K FSVD 262.8 ± 24.12 117.8 ± 7.046 7.47 x 103 
 SKGRSLIG 78.15 ± 9.129 127.8 ± 8.312 2.73 x 104 
 VETV N/A N/A N/A 
Matripase FSVD N/A N/A N/A 
 SKGRSLIG 46.73 ± 6.711 1720 ± 113.9 6.13 x 105 
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Cathepsin V, S and L all had a primary cleavage site of glutamic acid-56 / threonine-57 
according to the nanoLCMS data, and this was supported by the generated kinetic 
constants. These three enzymes had their highest turnover numbers (kcat) and catalytic 
efficiencies (kcat/Km) for the VETV substrate which corresponds to this cleavage site. 
Cathepsin V, S and L had kcat/Km values of 1.84 x 10
4, 1.40 x 104 and 3.71 x 104 M-1.s-1, 
respectively. Therefore, these three enzymes can be ordered in terms of efficiency for the 
cleavage site as cathepsin L > cathepsin V > cathepsin S. Cathepsin S actually exhibited 
a higher kcat value than cathepsin V (92.79 min
-1 compared to 72.95 min-1), but its lower 
affinity for the substrate resulted in a lower catalytic efficiency. Overall, these three 
proteases exhibited broadly similar kinetics for the VETV substrate. 
 
Interestingly, all three enzymes had a higher affinity (lower Km) for the FSVD substrate 
than the VETV substrate, suggesting they bind this substrate better, but do not cleave it 
as effectively. Both cathepsin V and cathepsin S had a much lower catalytic efficiency 
for the SY-9 substrate, an order of magnitude lower than for VETV and FSVD, though 
for cathepsin S, this was a result of a high Km as its kcat for SY-9 was in fact higher than 
for FSVD. 
 
Cathepsin V and S had their secondary cleavage site based on nanoLCMS as 
phenylalanine-59 / serine-60, which is encompassed in the FSVD substrate. Once again, 
this is supported by the kinetic data which identify this substrate as their secondary 
substrate based on catalytic efficiency. Both these enzymes cleave the SY-9 substrate 
also, despite not being identified as doing so in Figure 6.1. When analysing the 
nanoLCMS data, a cleavage site at glycine-40 / lysine-41 can be observed, but it is not 
one of the top cleavages, thus was not included.  
 
The secondary cleavage site for cathepsin L was glycine-40 / lysine-41, and this is further 
supported by kinetic data showing a higher catalytic efficiency for SY-9 than cathepsin 
V and S do. However, the cathepsin L catalytic efficiency for SY-9 is lower than for 
FSVD, which contains the cathepsin L preferred cleavage sites 3 and 4. 
 
Unlike the other cathepsins, nanoLCMS identified the primary cathepsin K cleavage 
towards the N-terminus at glycine-40 / lysine-41, with secondary and tertiary cleavages 
located within the VETV substrate sequence. This observation is also fully supported by 
the kinetic data, which show that cathepsin K has the highest catalytic efficiency for the 
176 
 
SY-9 peptide compared to VETV and FSVD. Interestingly, cathepsin K has a similar kcat 
value for the three substrates, with a highest value for VETV. The lower catalytic 
efficiency for VETV and FSVD is a result of very high Km values, suggesting a low 
affinity for these substrates. It stands to reason in the cleavage of the PAR2 42mer 
substrate, the higher affinity for the glycine-40 / lysine-41 would result in preferential 
binding and thus cleavage at this location – as observed in the nanoLCMS experiments. 
 
 Cathepsin V and S do not stimulate PAR2 calcium mobilisation 
Cathepsin S has previously been identified as a biased agonist for PAR2 able to stimulate 
cAMP production, but unable to stimulate calcium mobilisation, activate ERK1/2, recruit 
β-arrestins or endocytose PAR2226. As cathepsin V was identified to have a similar 
cleavage profile to cathepsin S, it was of interest to explore whether cathepsin V would 
behave in a similar manner in terms of cellular responses. Despite the majority of 
lysosomal cathepsin enzymes being active at lower pH levels, cathepsin S is known to 
retain activity at neutral pH168. Cathepsin V has been shown to lose stability rapidly at 
more neutral pH levels, being most stable at pH 5.5176. It was therefore important to test 
the stability of recombinant cathepsin V in a buffer system that is compatible with cell 
culture work. 
 
A pH curve was performed testing pH 5.5-7.5 using 100 mM phosphate buffer, 150 mM 
NaCl, 0.01% Brij-35 (Figure 6.4). Under the tested conditions, cathepsin V was in fact 
most active at pH 7, but rapidly lost its activity at all tested pH values. After 15 and 30 
minutes there was a higher residual activity at pH 6.5. Interestingly, under the tested 
conditions, at no time point was pH 5.5 the optimal pH. 
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Even though cathepsin V rapidly lost its activity at neutral pH values, PAR2 responses 
are known to be rapid (see calcium mobilisation assays following matriptase stimulation 
in chapter 5), therefore cathepsin V assays could be performed as there is likely enough 
activity before the enzyme loses its stability. 
 
The effect of cathepsin V on calcium mobilisation was explored, and compared to the 
effect of cathepsin S. Assays were performed with a stock of enzyme in assay buffer being 
prepared and loaded into the fluorimeter to inject onto the cells for the assay. The assay 
took 40 minutes to complete, therefore loss of activity was a concern. pH 6.5 was utilised 
for cathepsin V as there appeared to be the longest stability at this pH. Cathepsin S was 
utilised at pH 7. Neither cathepsin V nor cathepsin S could stimulate calcium mobilisation 
(Figure 6.5). 
Figure 6.4: Cathepsin V pH curve 
Cathepsin V was activated by diluting 1:10 in activation buffer (100 mM sodium acetate pH 5.5, 2.5 mM DTT, 2.5 
mM EDTA) and incubating for 5 minutes at room temperature. Active cathepsin V was then diluted to 2x assay 
concentration in a pH range of 100 mM phosphate buffer, 150 mM NaCl, 0.01% Brij-35, and a Z-FR-AMC assay 
was performed as outlined in chapter 2. Velocities were calculated as change in fluorescence per second, taken 
from linear phase of the assay. n=3, error bars represent SD. 
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After showing that recombinant cathepsin V and S were unable to stimulate calcium 
mobilisation, the experiment was repeated utilising cathepsin-revealed activator peptides. 
The revealed ligand for the primary cathepsin cleavage site of PAR2 between glutamic 
acid-56 and threonine-57 would be TVFSVDEFSA, which is the peptide utilised by Zhao 
et al., (2014)226 to mimic the effects of cathepsin S in their paper. As the canonical 
activator is shorter at 6 amino acids, a 6 amino acid version of the cathepsin activator 
peptide was also synthesised, TVFSVD. As expected, neither of these peptides had the 
ability to stimulate calcium mobilisation (Figure 6.6). 
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Figure 6.5: Calcium mobilisation following Cathepsin V and S titration 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing lentivirus 
before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM fluorescent 
calcium indicator and placed in a fluorimeter where the assays were performed. Titrations of activated cathepsin V 
(A) or cathepsin S (B)  were performed using 0-200 nM enzyme. Fluorescence was observed following cathepsin 
injection stimulation (V or S, respectively), and 5 µM ionomycin stimulation (I). Data shown are mean of n=2 
independent experiments. 
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 Cathepsin V is able to disarm matriptase-induced canonical PAR2 activation 
As cathepsin V was unable to stimulate calcium mobilisation, but is able to cleave PAR2 
downstream of the canonical activation site, it was of interest to explore whether 
cathepsin V could disarm against matriptase-induced canonical PAR2 activation. 
 
Firstly, the disarming of PAR2 by the serine protease cathepsin G was explored to confirm 
that this system could be utilised to measure PAR2 disarming. Cathepsin G has previously 
been described as a PAR2 disarmer by Ramachandran et al., (2011)225, thus their 
methodology was replicated in the SW1353 cell overexpression system utilised in this 
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Figure 6.6: Calcium mobilisation following TVFSVD and TVFSVDEFSA titration 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing lentivirus 
before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM fluorescent 
calcium indicator and placed in a fluorimeter where the assays were performed. Titrations of cathepsin AP 
TVFSVD (A) or TVFSVDEFSA (B) dissolved in HHBS were performed using 0-100 µM peptide. Fluorescence 
was observed following peptide injection stimulation (6mer or 10mer, respectively), and 5µM ionomycin 
stimulation (I). Data shown are mean of n=2 independent experiments. 
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study. Cathepsin G was clearly able to disarm matriptase-induced canonical PAR2 
activation of calcium mobilisation (Figure 6.7), thus the disarming by cathepsin V could 
subsequently be explored. 
 
 
PAR2-expressing SW1353 cells were pre-stimulated for 15 minutes with various 
concentrations of cathepsin V, and subsequently challenged with matriptase. Cathepsin 
V could attenuate matriptase-induced calcium mobilisation in a dose-dependent manner, 
with the highest effect following 200 nM cathepsin V pre-treatment (Figure 6.8 A). The 
experiment was repeated, but instead of injecting ionomycin as a positive control, the 
PAR2 agonist peptide SLIGKV was injected. Cathepsin V-mediated disarming of PAR2 
canonical activation would occur as a result of removal of the tethered ligand sequence 
of PAR2. The SLIGKV peptide activates PAR2 independently of the PAR2 extracellular 
domain by binding directly to the active site. Therefore, as expected, the SLIGKV peptide 
could restore the calcium response following cathepsin V disarming. This was confirmed 
as the control transduction cells did not respond to SLIGKV (Figure 6.8 B). 
 
 
 
Figure 6.7: Cathepsin G disarming of canonical PAR2 activation 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing lentivirus 
before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM fluorescent 
calcium indicator and pre-treated. Cathepsin G was diluted to 0.3 units/mL in HHBS (2 mM Ca2+) and added to 
the cells for 15 minutes before removing, washing in HHBS (2 mM Ca2+) and undertaking the calcium 
mobilisation assay. Data shown is from n=1 experiment. 
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Figure 6.8: Pre-treatment PAR2 expressing cells with cathepsin V disarms canonical PAR2 activation 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing lentivirus 
before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM fluorescent 
calcium indicator and pre-treated (in order to disarm) with 0-200nM activated cathepsin V in 100 mM phosphate 
buffer pH 6, 150 mM NaCl for 15 minutes before placing in a fluorimeter and stimulating with 10nM matriptase 
(A and B), and subsequently stimulating with either 5 µM ionomycin (A) or 10 µM SLIGKV (B). Both n=2 
independent experiments. To quantify disarming, maximal calcium response (average calcium response in the 10 
seconds immediately following stimulation) was obtained from the experiments in A and B (therefore n=4 
independent experiments) (C); where *** p < 0.001 by unpaired T-test between 200 nM pre-treatment group and 
no pre-treatment group in PAR2 expressing cells. 
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Calcium mobilisation was quantified, and statistical analysis performed, which confirmed 
the significant disarming by 200 nM cathepsin V (Figure 6.8 C). 
 
Cathepsin V disarming of calcium mobilisation is an interesting observation, however to 
explore whether this could hold relevance for arthritic diseases, it was of interest to 
examine whether this effect is transmitted downstream to the expression of PAR2-
regulated genes. PAR2-expressing SW1353 cells were disarmed as previously, but 
instead of undertaking calcium mobilisation assays, they were challenged with matriptase 
for 30 minutes, before incubating for 24 hours and gene expression examined for MMP1 
and MMP13. 
 
Only the highest tested concentration of cathepsin V pre-incubation, 200 nM, showed any 
evidence of disarming MMP induction, where MMP1 expression was significantly 
attenuated (Figure 6.9 A). In these assays, it appears that 10 nM matriptase was unable to 
stimulate MMP13 upregulation. As with the calcium mobilisation experiments, the 
cathepsin V disarming of PAR2 followed by stimulation with the SLIGKV peptide did 
not result in any attenuation of MMP1 expression (Figure 6.9 B). 
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Figure 6.9: Cathepsin V can disarm against matriptase-induced MMP expression 
SW1353 cells were transduced with pSIEW_PAR2 and pSIEW control-expressing lentivirus before culturing for 
48 hours then serum starving overnight. Cells were then pre-treated with 0-200 nM activated cathepsin V in 100 
mM phosphate buffer pH 6, 150 mM NaCl for 15 minutes before PBS-washing and stimulated with 10 nM 
matriptase (A) or SLIGKV (B) for 30 minutes, before PBS-washing and culturing in SFM for an additional 24 
hours. Cells were then lysed and mRNA extracted and reverse transcribed to cDNA. MMP1 and MMP13 expression 
was measured by qPCR and normalised to GAPDH. where * p < 0.05 by unpaired T-test between 200 nM pre-
treatment group and no pre-treatment group in PAR2 expressing cells. Data pooled from n=3 independent 
experiments for panel A, n=1 for panel B. 
 
0
n
M
5
0
n
M
1
0
0
n
M
2
0
0
n
M
0
n
M
5
0
n
M
1
0
0
n
M
2
0
0
n
M
0
20
40
60
80
MMP1
MMP13
*
0
n
M
5
0
n
M
1
0
0
n
M
2
0
0
n
M
0
n
M
5
0
n
M
1
0
0
n
M
2
0
0
n
M
0
20
40
60
80
MMP1
MMP13
M
M
P
/G
A
P
D
H
 (
F
o
ld
 c
h
a
n
g
e
 v
s
 B
a
s
a
l)
 
pSIEW_Control 
pSIEW_Control 
pSIEW_PAR2 
pSIEW_PAR2 
Cathepsin V Pre-treatment 
A Matriptase 
B SLIGKV 
184 
 
 
 Putative cathepsin K activator peptide KVDGTS does not mobilise calcium 
Cathepsin K has been shown to have optimal activity at pH 6, but is also nearly fully 
active at pH 7180. Cathepsin K is however much more stable at lower pH values, retaining 
49% of its activity after 1 hour at pH 6.5, but none of its activity at pH 7.5. Cathepsin K 
is most stable at pH 5.5180. 
 
Cathepsin K activity was explored at a range of pH values. Cathepsin K appeared to have 
similar activity levels at pH 5.5 – pH 7 initially, but activity at higher pH levels decline 
by the 30-minute mark, with complete loss of activity at pH 7 but no loss of activity at 
pH 5.5 (Figure 6.10). 
 
 
 
 
The pH of cartilage has been shown to be reduced in OA183, and the activity of cathepsin 
K has been observed in the disease184, therefore cleavage of PAR2 by cathepsin K could 
hold physiological relevance and warrants further investigation. Unfortunately, 
limitations in the availability of sufficient quantities of recombinant cathepsin K meant 
that the required experiments could not be performed within the time frame of this project. 
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Figure 6.10: Cathepsin K pH activity curve 
Cathepsin K was activated by diluting 1:10 in activation buffer (100 mM sodium acetate pH 5.5, 2.5 mM DTT, 2.5 
mM EDTA) and incubating for 5 minutes at room temperature. Active cathepsin K was then diluted to 2x assay 
concentration in a pH range of 100 mM phosphate buffer, 150 mM NaCl, 0.01% Brij-35, and a Z-FR-AMC assay 
was undertaken as outlined in chapter 2. Velocities were calculated as change in fluorescence per second, taken 
from linear phase at beginning of assay. n=3, error bars represent SD. 
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The primary cleavage site for cathepsin K was located between glycine-40 and lysine-41, 
thus should this be an activating cleavage, then the putative revealed ligand would be 
KVDGTS. This putative activator peptide was therefore synthesised and utilised in lieu 
of active cathepsin K. Testing the addition of KVDGTS on PAR2-expressing cells had 
no effect on calcium mobilisation at all tested concentrations (Figure 6.11). 
 
 
 
 Discussion 
All tested cathepsins were found to be able to cleave PAR2 potently, and at multiple sites. 
This is unsurprising due to the intracellular roles of this family of proteases, where they 
are best described as lysosomal proteases responsible for breaking down a wide range of 
proteins and peptides as part of normal protein turnover. Indeed, a search of these 
proteases in the MEROPS database shows little specificity in terms of amino acids able 
to interact within S4-S4’ of the cathepsin active site clefts310. One might therefore ask the 
question of whether cathepsin-mediated cleavage of PAR2 is physiologically relevant or 
merely a product of incubating a protease with low specificity with a polypeptide and 
therefore cleaving the only heterologous protein substrate in the reaction. Indeed, 
cathepsins are likely to be involved in the recycling of PAR2 following canonical 
activation and subsequent internalisation229. This discussion will examine the potential 
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Figure 6.11: Calcium mobilisation following KVDGTS titration 
SW1353 cells were transduced with pSIEW_PAR2 (red lines) and pSIEW_Empty (blue lines) expressing lentivirus 
before culturing for 48 hours then serum starving overnight. Cells were loaded with Rhod-4-AM fluorescent 
calcium indicator and placed in a fluorimeter where the assays were performed. Titrations of putative cathepsin K 
AP were performed using 0-100 µM peptide. Fluorescence was observed following peptide injection stimulation 
(K), and 5 µM ionomycin stimulation (I). Data shown are mean of n=2 independent experiments. 
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physiological relevance of cathepsin-mediated PAR2 cleavage by considering previously 
identified extracellular roles for the cathepsins. 
 
To date, the only cysteine protease identified as being able to cleave PAR2 is cathepsin 
S226,300. Zhao et al., (2014)1 identified a cathepsin S cleavage site between glutamic acid-
56 and threonine-57, which reveals the tethered ligand TVFSVDEFSA. They showed 
cathepsin S to be a biased agonist, able to stimulate cAMP production, but unable to 
stimulate calcium mobilisation, activate ERK1/2, recruit β-arrestins or endocytose PAR2 
in HEK293 cells overexpressing PAR2. Another study by Elmariah et al., (2014)2 found 
cathepsin S to cleave at two locations further towards the N-terminus than the Zhao et al. 
(2014) study: between leucine-38 and isoleucine-39 and between glycine-40 and lysine-
41. The Elmariah et al., (2014)2 study described conflicting signalling outcomes 
following cathepsin S stimulation of PAR2 in that cathepsin S, as well as both putative 
activator peptides IGKVDG and KVDGTS, were all able to stimulate calcium 
mobilisation in HeLa cells overexpressing PAR2. 
 
The reason for the identification of different cleavage sites in the two studies is likely to 
result from the fact that the Elmariah et al., (2014)2 study utilised a shorter synthetic 
peptide to examine cleavage by cathepsin S which terminated at threonine-54, which 
would be too short to observe the Zhao et al., (2014)1-identified cleavage at glutamic 
acid-56. Indeed, data presented within this chapter using a peptide longer than the peptide 
used in both these studies, encompassing the whole region from arginine-31 to lysine-72, 
confirms the presence of the cleavage identified by Zhao et al., (2014)1. No cleavage was 
observed at the two cleavage sites identified by Elmariah et al., (2014)2, however 
cathepsin S could cleave the PAR2 SY-9 peptide substrate, which encompasses the region 
serine-33 to glycine-40. Taken together, it is likely that cathepsin S can indeed cleave all 
the sites identified in both studies, however when presented with the full-length PAR2 
sequence, there is a much stronger preference for the glutamic acid-56 / threonine-57 site, 
but it will cleave between leucine-38 and isoleucine-39 or between glycine-40 and lysine-
41 in the absence of the preferred site as observed by Elmariah et al., (2014)2, and within 
the SY-9 kinetics in the present study. Taken together, the data from these two previous 
studies and the present study, it is likely that the glutamic acid-56 / threonine-57 is the 
predominant cathepsin S cleavage of PAR2 and the most likely to hold physiological 
relevance. 
 
187 
 
As well as confirming the ability for cathepsin S to cleave at glutamic acid-56 / threonine-
57, cathepsins V, L, K and B were all shown to cleave at this location, with this being the 
preferred site in PAR2 for cathepsins V and L, and a secondary site for cathepsin K. Zhao 
et al., (2014)1 did not explore enzyme kinetics for this cleavage, however data presented 
in this chapter show that cathepsin V and L are more potent than cathepsin S at cleaving 
this site on PAR2. When considering the kinetic parameters for the three substrates, 
specificity for the glutamic acid-56 / threonine-57 can be ordered as cathepsin V > 
cathepsin S > cathepsin L. Cathepsin L has cleavage sites at all three sequences identified 
by nanoLCMS and had a similar potency for each site in terms of catalytic efficiency. 
 
In agreement with the Zhao et al., (2014)1 study, cathepsin S was unable to stimulate 
calcium mobilisation in PAR2 overexpressing SW1353 cells. Cathepsin V was also 
unable to do this, which is in line with the similar cleavage profiles observed by both 
enzymes on PAR2. Furthermore, the same activator peptide used in the Zhao et al., 
(2014)1 study, TVSFVDEFSA, was unable to stimulate calcium mobilisation which is in 
agreement with that study. Futher work needs to be performed to explore whether 
cathepsin V, L and S are able to induce the same signalling outcomes in chondrocytes as 
were observed with cathepsin S in HEK293 cells226. 
 
The lack of calcium mobilisation by cathepsin S stimulation of PAR2 is in disagreement 
with Elmariah et al., (2014)2 who observed calcium mobilisation following cathepsin S 
stimulation. It is unclear why calcium mobilisation was observed in their study, and not 
in the present study or the Zhao et al., (2014)1 study, but all three studies utilised different 
cell lines, thus could be a result of different signalling mediators available following 
PAR2 cleavage. Futhermore, a contaminant can not be excluded on the recombinant 
cathepsin S stock utilised by Elmariah et al., (2014)2 as no controls utilising a cathepsin 
S inhibitor were performed confirming the observed calcium mobilisation is indeed a 
result of cathepsin S activity. 
 
Interestingly, the present study did identify a cathepsin cleavage site at glycine-40 / 
lysine-41, which was the primary cleavage site for cathepsin K, and the secondary site 
for cathepsin L. To test the role of this cleavage, the putative activator peptide, KVDGTS, 
was synthesised. This peptide is the same as the peptide utilised by Elmariah et al., 
(2014)2 who incorrectly used it as the cathepsin S activator peptide. In that study, this 
peptide was able to stimulate calcium mobilisation in PAR2-overexpressing HeLa cells. 
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It was therefore hypothesised that cathepsin K and KVDGTS would induce calcium 
moblisation. Limitations in recombinant cathepsin K meant that this hypothesis could not 
be fully tested, however the addition of KVDGTS on PAR2-overexpressing SW1353 
cells had no effect on calcium mobilisation, which is in disagreement with Elmariah et 
al., (2014)2. The reasons for this are unclear, but it could possibly be as a result of different 
cell types, and different availability of required signalling mediators. SW1353 cells 
however clearly have the capacity for inducing calcium mobilisation in a PAR2-
dependent manner as shown with matriptase activation in this study. Despite the 
possibility for non-canonical calcium mobilisation explaining the observed differences, 
the Elmariah et al., (2014)2 study suggests canonical calcium mobilisation occuring as 
measured by inositol monophosphate accumulation, a metabolite of inositol triphosphate 
– the agonist for the calcium channel responsible for canonical GPCR activation335. 
 
Cathepsin V was found to be able to disarm canonical PAR2 activation in terms of 
calcium mobilisation and MMP1 induction. In this study, a pH curve was performed using 
a buffer system amenable to cell culture work, and interestingly, cathepsin V was found 
to be most active at pH 7 initially, and most active at pH 6.5 at the 15 and 30 minute 
marks. Cathepsin V was unstable at all pH values however, quickly reducing in activity. 
This observation conflicts with previous work which shows cathepsin V to be most active 
at pH 5.7, and completely stable for at least 2 hours at pH 5.5 but rapidly losing activity 
at pH 6.5 or 7176. It is extremely likely that these conflicting observations reflect the 
different buffer systems utilised within the two studies, with 100 mM phosphate buffer, 
150 mM NaCl, 0.01% Brij-35 utilised in the present study clearly not an optimal buffer 
system for this enzyme. A trade off was however required to allow for cathepsin V 
activity in cell culture work, and there was clearly a disarming effect observed in the cell 
culture work, suggesting that activity did indeed occur in the cell culture model. 
 
By considering the kinetic data presented in this chapter as well as the previous literature 
regarding cathepsin S cleavage of PAR2, it is reasonable to hypothesise that cathepsins 
V, S and L could hold relevance in PAR2 and OA biology.  
 
Cathepsin V is one of the more recent and less well understood cathepsins, and currently 
there is not a lot of evidence for its expression in cartilage, involvement in OA or 
extracellular functions. Macrophage-expressed Cathepsin V has been shown to have the 
ability to potently digest the ECM-component elastin336, although that study failed to 
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detect secreted cathepsin V, and suggested intracellular digestion of elastin. Other work 
has however shown cathepsin V to be secreted from cells337. Work presented in this 
chapter showed that cathepsin V was able to disarm against matriptase-induced canonical 
PAR2 signalling, including a reduction of MMP1 expression which could hint at a 
protective effect for cathepsin V in OA. More work however needs to be undertaken on 
the role of cathepsin V in cartilage biology. 
 
On the other hand, cathepsin L is a better candidate for having a role in cartilage biology, 
and in arthritis with respect to PAR2 cleavage. Cathepsin L has been detected in synovial 
fluid of patients with RA338 and secretion has been observed in chondrocytes extracted 
from OA cartilage191. The enzyme is expressed in the synovium of both RA and OA 
patients339. Furthermore, cathepsin L has been shown to be able to cleave aggrecan192. 
Future work would need to be undertaken with cathepsin L in cell culture work to 
ascertain putative roles in chondrocyte and PAR2 biology. However, one would 
hypothesise that cathepsin V and L would exert similar effects in vivo.  
 
As previously discussed, cathepsin S has been identified as a biased agonist for PAR2. A 
potential role for cathepsin S cleavage of PAR2 in OA is possible as cathepsin S activity 
has been previously detected in OA cartilage explant culture191, therefore there is 
evidence for the presence of cathepsin S in a tissue and disease where PAR2 is expressed. 
Furthermore, the expression and secretion of cathepsin S from chondrocytes following 
TNFα or IL-1β stimulation has been described190. 
 
As described in chapter 1, a role for cathepsin K in OA is well established. Cathepsin K 
degradation of type II collagen has been detected in human OA cartilage184, therefore the 
presence of cathepsin K in a tissue where PAR2 is expressed suggests potential 
physiological relevance for cathepsin K cleavage of PAR2. Further work will be required 
to ascertain the role for cathepsin K in PAR2 biology. 
 
A role for cathepsin B in OA is also well established as outlined in chapter 1. In terms of 
cathepsin B cleavage of PAR2, there were too many cleavages observed to deduce the 
most physiologically relevent cleavages. Further work would be required untertaking 
more restricted digests to ascertain which cleavages occur first – it remains possible that 
there could be a physiological role for cathepsin B in PAR2 biology. 
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Taken together, there is potential for the cathepsins to have a role in PAR2 activation or 
disarming in OA. In particular, cathepsins S, L and K are strong candidates for this based 
on previously described roles of these enzymes in OA and general extracellular functions.  
 
 
 Summary 
 Cathepsins V, K, L, B and S were all able to cleave PAR2 at multiple sites, with 
a primary cleavage site for cathepsins V, S and L between glutamic acid-56 and 
threonine-57, and a primary cleavage site for cathepsin K between glycine-40 and 
lysine-41. Cathepsin B cleaved at multiple sites along the sequence and cleavages 
were difficult to rank. 
 
 The kinetic parameters for cathepsins V, K, L and S generally correlated with the 
ranking of cleavages as observed by nanoLCMS. 
 
 Cathepsin V, as well as its putative activator peptide, were unable to stimulate 
calcium mobilisation. 
 
 Pre-incubation of SW1353 cells with cathepsin V was able to disarm against 
matriptase-induced canonical activation of PAR2. 
 
 The putative cathepsin K activator peptide was unable to stimulate calcium 
mobilisation. 
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7. Chapter 7 – Canonical PAR2 Activation: Gene Expression 
Microarray 
 Introduction 
Data presented in chapters 4, 5 and 6 have identified and begun to describe the regulation 
of PAR2 activity by extracellular proteolysis mediated by enzymes involved in OA. Data 
presented in chapter 6 have also demonstrated the ability for cathepsin V to “disarm” 
canonical PAR2 activation by matriptase. Taken together, it is likely that a complex 
extracellular environment regulates chondrocyte behaviour in response to PAR2 in both 
the context of disease and normal physiology. It is not possible to understand the full 
relevance of extracellular events in PAR2 biology when intracellular events in terms of 
PAR2 signalling are incompletely understood. A gene expression microarray to assess 
global gene expression changes following canonical PAR2 activation was therefore 
performed.  
 
There has been little work previously performed in chondrocytes with respect to PAR2 
biology, and data presented and discussed in chapter 6 with respect to previously 
published data has suggested possible signalling differences between commonly used cell 
lines in response to PAR2 activation. Only a single study has previously explored global 
gene expression changes following PAR2 canonical activation, and this work was 
undertaken in HEK293 cells340, a cell line with conflicting PAR2 responses as outlined 
in chapter 6. Furthermore, that study utilised both trypsin and the synthetic PAR2 agonist 
2-furoyl-LIGRLO-NH2 to stimulate canonical PAR2 activation. There is evidence that 
such synthetic PAR2 agonists can act on cells in PAR2-independent mechanisms341, and 
that trypsin cleavage of other cell surface proteins may modify cell behaviour342. It was 
therefore of interest to explore global gene expression changes following matriptase and 
SLIGKV stimulation of PAR2 in chondrocytic cells. 
 
Understanding the signalling outcomes of PAR2 activation in chondrocytes, stimulated 
by a physiologically relevant activator in matriptase, is of central importance to this study. 
Furthermore, as PAR2 canonical activation is generally considered to be pro-
inflammatory in nature, it is of interest to compare some of the downstream targets of 
PAR2 activation with the downstream targets identified in chapter 3 of this study, where 
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mechanical loading of cells was found to induce the expression of various pro-
inflammatory regulators such as ATF3, CSRNP1 and EGR2. 
 
 Chapter Aims 
 To optimise time points to explore SW1353 cell gene expression by microarray 
after canonical PAR2 activation. 
 To perform a gene expression microarray following canonical PAR2 activation 
by either SLIGKV or matriptase. 
 To carry out pathway analysis to explore the outcomes of canonical PAR2 
activation. 
 
 Results 
 Optimisation of time points for microarray 
As described in chapter 3.2.4, previous work undertaken in our group explored the 
expression of collagenases following IL-1+OSM stimulation in HAC and identified 
regulators such as ATF3, CSRNP1 and EGR2. Studies undertaken using bovine nasal 
chondrocytes identified some of the same regulators that were mechanosensitive. In order 
to explore global gene expression changes in SW1353 cells, it was of importance to pick 
the most relevant time points for examination, and it was decided that the time required 
for maximal expression of genes such as ATF3 would be of greatest interest. 
 
Firstly, the kinetics of ATF3 and MMP expression were explored following IL-1+OSM 
stimulation is SW1353 cells. ATF3 expression peaked at 1.5 hours post-stimulation, 
reaching statistically significant upregulation at 0.5 hours and remained significantly up-
regulated for the remainder of the time-course, until 24 hours (Figure 7.1 A). As expected, 
MMP1 and MMP13 expression were induced later in the time-course, reaching maximum 
level at the 24-hour mark (Figure 7.1 B). 
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After exploring the kinetics of ATF3 expression in SW1353 cells following IL-1+OSM 
stimulation, it was of interest to see whether PAR2 activation would also induce ATF3 
expression. Despite it being known that MMP expression is induced in chondrocytes 
following PAR2 canonical activation, the signalling pathways involved are not well 
established, and ATF3 has not previously been explored as a PAR2 target. 
 
Figure 7.1: ATF3, MMP1 and MMP13 expression following IL1+OSM stimulation 
SW1353 cells were stimulated with IL-1 at 0.5 ng/mL and OSM at 30 ng/mL for varying lengths of time before 
lysing the cells, extracting the mRNA, reverse transcription and qPCR examining ATF3 (A) or MMP1 and MMP13 
(B) expression. Mean ± S.E.M; where *** p < 0.001 by unpaired T-test between ATF3 or MMP1 basal expression 
(T=0) and time point; †† p < 0.01, ††† p < 0.001 by unpaired T-test between MMP13 basal expression (T=0) and 
time point. Data pooled from n=2 independent experiments. 
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ATF3 expression was indeed robustly induced by canonical PAR2 activation by both 
matriptase and SLIGKV, with maximal induction 1.5-hours post-stimulation (Figure 7.2). 
 
 
 
 
When comparing the IL-1+OSM and PAR2 activation data, it was decided that the use of 
1.5 and 24 hours would be most appropriate for the microarray experiment, as this would 
give coverage for examining earlier expressed genes such as ATF3, as well as later genes 
such as the MMPs. 
 
 Microarray experiment validation 
To generate the mRNA for use in the microarray analysis, three independent experiments 
were undertaken, overexpressing PAR2 in SW1353 cells and then stimulating with either 
100 µM SLIGKV peptide, 10 nM matriptase, or control (serum-free medium), for either 
90 minutes or 24 hours. mRNA was extracted and a small sample was taken to perform a 
reverse transcription to validate the experiments by qPCR. The expression levels for 
ATF3 (90 minutes) or MMP1 (24 hours) were examined at each time point. All three 
Figure 7.2: ATF3 expression following matriptase and SLIGKV stimulation 
SW1353 cells transduced with pSIEW_Empty or pSIEW_PAR2 were stimulated stimulating with either 100 µM 
SLIGKV or 10 nM matriptase for varying lengths of time before lysing the cells, extracting the mRNA, reverse 
transcription and qPCR examining ATF3 expression. Mean ± S.E.M; where ** p < 0.01*** p < 0.001 by unpaired 
T-test between ATF3 basal expression (T=0) and time point following matriptase stimulation; and †† p < 0.01, ††† 
p < 0.001 by unpaired T-test between ATF3 basal expression (T=0) and time point following SLIGKV stimulation. 
Data pooled from n=1 experiment. 
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experimental repeats exhibited successful induction of ATF3 and MMP1 at the expected 
time points (Figure 7.3) and the samples were therefore sent for microarray analysis. 
 
 
 
Figure 7.3: ATF3 and MMP1 expression of samples sent for microarray analysis 
pSIEW_PAR2 transduced SW1353 cells were stimulated with either 100 µM SLIGKV or 10 nM matriptase for 
either 90 minutes (A) or 24 hours (B) before mRNA was extracted by an RNeasy kit. A sample of the mRNA from 
each replicate was reverse transcribed and qPCR was performed for either ATF3 (A) or MMP1 (B). Each bar 
represents a single sample, thus there is no standard deviation for error bars to be added. Each experiment was 
performed independently of each other. 
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 A comparison of matriptase and SLIGKV-mediated canonical activation 
SLIGKV (as well as the equivalent rat sequence, SLIGRL) are commonly used as 
agonists for canonical PAR2 activation, able to activate PAR2 independently of receptor 
cleavage314. There is however evidence that this peptide activates PAR2 via a different 
mechanism to the equivalent sequence as a tethered ligand333, although whether this 
results in different downstream effects is unknown. Furthermore, there is some evidence 
that SLIGRL lacks specificity for PAR2, with an ability to activate the GPCR neurokinin-
1 receptor having been suggested343. It was therefore of interest to examine whether 
global gene expression changes following canonical PAR2 activation by SLIGKV and 
matriptase were similar. 
 
Changes in genes expressed greater than 2-fold (log2 >1) compared to basal, as well as 
genes down-regulated by greater than 2-fold (log2 < -1) were compared for SLIGKV vs 
matriptase stimulation. At 90 minutes, most differentially regulated genes were up-
regulated, and there was a strong correlation between SLIGKV and matriptase, with an 
R2 value of 0.96 (Figure 7.4). 
 
At 24 hours post-stimulation, there was a greater number of down regulated genes, and 
an even stronger correlation between matriptase and SLIGKV, with an R2 value of 0.99 
(Figure 7.5). 
 
Taken together, it was clear that matriptase and SLIGKV exhibited similar effects on gene 
expression changes in SW1353 cells, and thus subsequent analyses were performed 
predominantly on matriptase-stimulated samples, as these hold more physiological 
relevance.  
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Figure 7.4: Scatter plot of matriptase vs SLIGKV induced expression changes 90 minutes post-stimulation 
Scatter plot of matriptase vs SLIGKV gene expression changes (both normalised to unstimulated control) 90 
minutes post-stimulation. Included are all genes with a log2 fold change of -1< and >1. The blue line represents the 
correlation and the grey shading represents the standard deviation. There are a total of 134 genes included in the 
analysis. The R2 value refers to the correlation between the two stimulations. 
 
R2 = 0.96 
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Figure 7.5: Scatter plot of matriptase vs SLIGKV induced expression changes 24 hours post-stimulation 
Scatter plot of matriptase vs SLIGKV gene expression changes (both normalised to unstimulated control) 24 hours 
post-stimulation. Included are all genes with a log2 fold change of -1< and >1. The blue line represents the 
correlation and the grey shading represents the standard deviation. There are a total of 109 genes included in the 
analysis. The R2 value refers to the correlation between the two stimulations. 
 
 
R2 = 0.99 
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 An examination of genes regulated by canonical PAR2 activation in SW1353 
cells 
 90-minute stimulation 
Following 90-minute stimulation of both matriptase and SLIGKV, similar gene 
expression changes were observed with many genes up-regulated (Figure 7.6). 
 
 
Figure 7.6: Volcano plots showing global gene expression changes following 90-minute SLIGKV or 
matriptase stimulation 
Volcano plot of normalised microarray data, comparing either matriptase vs control (A) or SLIGKV vs control (B). 
The vertical red lines mark log2 fold change of -1 and 1 whereas the horizontal red line corresponds to an adjusted 
p-value of <0.05. The red dots therefore correspond to genes significantly expressed at either <0.5 or >2 fold change 
to basal. 
 
A 
B 
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Due to the similar gene expression changes following SLIGKV or matriptase stimulation, 
this chapter will focus predominantly on the expression changes following matriptase-
mediated PAR2 activation as this holds more physiological relevance. Overall, 165 genes 
were significantly (adjusted p-value of p <0.05) up-regulated by greater than 2-fold (log2 
>1) compared to basal, whereas only 3 genes were down-regulated by greater than 2-fold 
(log2 < -1). A list of the top 20 most up-regulated genes is presented in table 7.1. 
 
Table 7.1: Top 20 most up-regulated genes following 90-minute matriptase 
stimulation 
Rank Fold Change Adj. p-value Gene 
1 83.439 2.19441-24 CXCL8 
2 41.279 2.97807-24 CXCL8 
3 25.005 1.3742-21 FOSB 
4 20.718 1.4796-22 FAM90A2P 
5 17.764 3.16567-20 NR4A2 
6 15.656 6.75332-25 TNFAIP3 
7 15.066 2.11741-21 ATF3 
8 13.494 3.58251-22 FOS 
9 13.023 1.16156-18 NR4A2 
10 11.944 4.13924-19 FAM90A5P 
11 10.733 6.59862-22 DUSP1 
12 10.379 6.40802-22 IER3 
13 10.246 4.98809-19 EGR1 
14 10.038 8.02579-19 FAM90A5P 
15 9.631 1.99951-20 KLF2 
16 8.401 1.72447-17 IL11 
17 8.394 1.28431-20 C11orf96 
18 7.643 1.31625-18 CSRNP1 
19 7.596 4.17231-18 NFKBIA 
20 7.319 4.13924-19 EGR2 
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 24-hour stimulation 
Following 24-hour stimulation of both matriptase and SLIGKV, similar gene expression 
changes were observed with many genes both up- and down-regulated (Figure 7.7). 
 
 
 
Figure 7.7: Volcano plots showing global gene expression changes following 24-hour SLIGKV or matriptase 
stimulation 
Volcano plot of normalised microarray data, comparing either matriptase vs control (A) or SLIGKV vs control (B). 
The vertical red lines mark log2 fold change of -1 and 1 whereas the horizontal red line corresponds to an adjusted 
p-value of <0.05. The red dots therefore correspond to genes significantly expressed at either <0.5 or >2 fold change 
to basal. 
A 
B 
202 
 
Following 24-hour matriptase stimulation, 68 genes were significantly (adjusted p-value 
of p >0.05) up-regulated by greater than 2-fold (log2 >1) compared to basal, whereas 48 
genes were down-regulated by greater than 2-fold (log2 < -1). A list of the top 20 most 
up-regulated genes is presented in table 7.2 and list of the 20 most down-regulated genes 
is presented in table 7.3. Furthermore, other genes of interest to this study outside the top 
20 are included in the tables. 
 
Table 7.2: Top 20 most up-regulated genes and other up-regulated genes of interest 
following 24-hour matriptase stimulation 
Rank Fold Change Adj. p-value Gene 
1 18.82546 1.52938-21 KIAA1199 
2 13.42363 3.35334-18 IL11 
3 10.36369 1.1159-15 STC1 
4 9.374547 7.48334-18 CXCL8 
5 5.517051 2.87364-17 IL24 
6 3.545718 1.11196-13 ITGA2 
7 3.372986 1.69786-12 DUSP5 
8 3.31848 4.39336-14 PLAUR 
9 3.152777 4.75277-17 MMP9 
10 3.064465 2.13006-13 PLAUR 
11 3.023068 6.47027-14 IL24 
12 3.001402 2.16994-10 PLAUR 
13 2.93569 6.29343-11 LDLR 
14 2.884798 6.47027-14 ARHGAP22 
15 2.807649 4.29924-12 IL24 
16 2.727704 6.80023-13 SOD2 
17 2.677695 2.04302-08 UPP1 
18 2.654329 1.35243-13 GRAMD1B 
19 2.650923 9.75806-14 DEFB103B 
20 2.640348 7.93367-11 GNG11 
26 2.489293 3.39044-13 SPINK1 
47 2.156543 8.3662-12 SERPINB8 
53 2.105567 1.00703-12 ADAMTS6 
66 2.026306 1.9952-9 CSRNP1 
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Table 7.3: Top 20 most down-regulated genes and other down-regulated genes of 
interest following 24-hour matriptase stimulation 
Rank Fold Change Adj. p-value Gene 
1 4.931793299 5.68228-13 TXNIP 
2 3.418230792 9.75806-14 MAFB 
3 3.305468236 4.09663-12 MYH8 
4 3.234320017 8.74945-12 BMP4 
5 3.22614988 1.2789-15 CNTNAP2 
6 3.103671954 9.03272-13 ID3 
7 3.097001174 8.92322-14 CADM1 
8 3.011349777 1.1159-15 RGCC 
9 2.988116262 2.68475-13 AKR1B10 
10 2.952064379 1.53584-12 ACKR3 
11 2.93761677 1.24726-11 AKR1C3 
12 2.896065984 1.70762-9 RHOBTB3 
13 2.742393287 1.67535-12 ABLIM1 
14 2.727627319 1.11196-13 ACKR3 
15 2.473539313 2.21141-8 NPPB 
16 2.455910271 3.25209-9 COL1A1 
17 2.373306942 3.54222-11 F2RL2 
18 2.367435452 7.49863-10 TLE4 
19 2.305964608 1.33452-10 COL1A2 
20 2.279555578 5.91602-10 ATOH8 
31 2.138721772 1.152-11 F2R 
 
 Pathway Analysis of PAR2 canonical activation 
Ingenuity Pathway Analysis (IPA) was performed on matriptase-induced PAR2 canonical 
activation (samples normalised to controls). IPA is powerful software utilised to analyse 
complex “omic” data, including gene expression microarray data. IPA can perform 
searches for targeted information on gene and protein networks based on interactive 
models of experimental systems previously outlined within the literature. 
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 Canonical Pathways 
Firstly, a canonical pathway analysis was performed, which analyses associations within 
the experimental dataset with previously described signalling pathways. The analysis 
gives an indication of how strongly the pathway is in an activation or inhibitory state (Z 
score), as well as the significance of the association (Figure 7.8). 
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Figure 7.8: Top dysregulated canonical pathways following matriptase stimulation of PAR2 
Ingenuity Pathway Analysis was performed on the microarray data: matriptase normalised to control samples, at 
both 90 minutes (A) and 24 hours (B) examining associated canonical pathways with the data set. The bars on the 
primary x axis represent the -log(p-value) for each pathway, stating the statistical significance for the association 
of that pathway with the microarray data set. The shade of the bar fill (orange for positive regulation, blue for 
negative regulation) shows the strength of the regulation: darker shade for stronger regulation. The line on the 
secondary x axis represent the ratio of regulated genes: the number of genes in the canonical pathway dysregulated 
in the examined data set. 
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At the 90-minute time point, all the associated pathways were in a positive activation 
state, with many on the list being associated with pro-inflammatory responses, such as 
TNF signalling, IL-6 signalling, IL-17 signalling and IL-1 signalling. The most 
statistically associated pathway was TNFR2 signalling, however pathways such as 
HMGB1 and IL-6 had higher Z-scores indicating a stronger level of activation (however 
at lower statistical significance due to fewer genes within the pathway being 
dysregulated). 
 
An initial striking difference at the 24-hour time point was a marked reduction in the 
number of significantly associated pathways. Furthermore, unlike the 90-minute time 
point, there was an association with a negatively associated pathway in protein kinase A 
(PKA) signalling. The most significantly associated pathway at this time point was IL-8 
signalling. 
  
 Upstream Regulators 
As well as exploring canonical pathways by IPA, specific upstream regulators associated 
with the data set were explored. Rather than being a whole pathway, these upstream 
regulators represent specific gene products involved in regulation of multiple downstream 
targets. The analysis explores the activation state of both the upstream regulator and 
downstream targets within the experimental dataset, and then gives an activation Z-score, 
as well as significance for the association. The analysis also states a predicted activation 
state. Strong statistical association with a particular upstream regulator does not 
necessarily result from multiple activated or inhibited targets, but rather can result from 
a mixture. This results in a statistically associated upstream regulator without a predicted 
activation state, as is observed for many of the identified top associations in this study. 
As with the canonical pathway analysis, the upstream regulator analysis is based on 
previous literature for signalling networks. 
 
At the 90-minute time point, the majority of the top 20 most significant upstream 
regulators are in a predicted activation state, with only CD3 being a predicted inhibited 
upstream regulator, and two regulators, NR3C1 and IgG having no predicted activation 
state (table 7.4). The most strongly associated upstream regulator is Platelet-derived 
growth factor (PDGF) – BB chain dimer, followed by TNF and IL-1B. Other 
inflammatory regulators of interest to this project within the top 20 include p38 MAPK, 
NF-kB, Jnk, ERK and ERK1/2. 
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Table 7.4: Top 20 most significantly associated upstream regulator genes with 
microarray data following 90-minute matriptase stimulation 
Rank Gene Z score p-value of overlap Predicted Activation 
1 PDGF BB 5.868 8.38-62 Activated 
2 TNF 5.458 7.91-40 Activated 
3 IL1B 5.874 6.49-39 Activated 
4 NR3C1 0.507 1.67-30  - 
5 CREB1 4.282 5.41-30 Activated 
6 P38 MAPK 4.016 1.55-28 Activated 
7 TREM1 4.452 3.69-26 Activated 
8 
NFkB 
(complex) 
4.339 3.22-25 Activated 
9 Jnk 3.196 3.74-23 Activated 
10 CREM 3.353 5.73-22 Activated 
11 EIF2AK3 2.608 7.92-22 Activated 
12 STAT3 3.780 1.33-20 Activated 
13 ERK 4.164 3.45-20 Activated 
14 CD3 -3.103 9.31-20 Inhibited 
15 ERK1/2 3.049 2.21-19 Activated 
16 ECSIT 3.302 8.00-19 Activated 
17 IgG -1.774 2.94-18  -  
18 FOXL2 3.571 5.13-18 Activated 
19 FOXO3 2.741 2.46-17 Activated 
20 PRKCD 2.688 4.64-17 Activated 
 
By 24 hours, within the top 20 most strongly associated upstream regulators, only three 
have a predicted activation state: TNF, IL-1B and ERBB2 (table 7.5). TNF and IL1-B 
were both strongly associated at the 90-minute time point, however ERBB2 was the 106th 
most associated at this time point. 
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Table 7.5: Top 20 most significantly associated upstream regulator genes with 
microarray data following 24-hour matriptase stimulation 
Rank Gene Z score p-value of overlap Predicted Activation 
1 TGFB1 0.813 2.09-16  - 
2 TP53 -0.609 2.10-13  - 
3 Cg 1.599 1.05-12  - 
4 TNF 3.377 4.80-12 Activated 
5 HIF1A 0.607 1.42-11  - 
6 SP1   4.46-11  - 
7 NEDD9 1.890 1.11-10  - 
8 PRKCD 1.320 5.51-10  - 
9 SP3   5.51-10  - 
10 STAT5A   8.73-10  - 
11 IL1B 3.453 1.35-09 Activated 
12 TGFBR1 -1.195 1.44-09  - 
13 CBX5 0.333 1.49-09  - 
14 JUN 1.675 1.75-09  - 
15 AHR 1.700 2.00-09  - 
16 Ap1   5.01-09  - 
17 NR3C1 -1.497 5.28-09  - 
18 ERBB2 2.474 8.54-09 Activated 
19 KRAS 1.555 1.28-08  - 
20 
estrogen 
receptor 
-1.706 1.70-08  - 
 
The signalling networks of IL-1B and TNF were further explored due to their high Z-
scores and significance at the 90-minute time point; the fact they were also two of the 
three activated regulators at the 24-hour time point; and the fact that as cytokines, TNF 
(specifically TNF-α) and IL-1 are both thought to be involved in OA. 
 
As shown in table 7.4, TNF is a strongly activated upstream regulator, and by examining 
the downstream regulators under regulation by TNF within the microarray, it is clear that 
many of the genes were activated by matriptase (Figure 7.9). Further downstream of the 
regulators, 74 targets were also dysregulated by PAR2 activation. Two of these of 
particular interest, EGR2 and ATF3, were selected for inclusion in the diagram. 
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IL-1B (IL-1β) was another strongly activated upstream regulator, and by examining the 
downstream regulators previously described as under its regulation, many were observed 
as activated within the microarray dataset following matriptase activation of PAR2 
(Figure 7.10). Further downstream of the regulators, 72 targets were also dysregulated by 
PAR2 activation. Three of these were of particular interest: ATF3, CSRNP1 and EGR2, 
and were selected for inclusion in the diagram. 
Figure 7.9: TNF pathway following 90-minute matriptase stimulation 
The signalling network downstream of TNF was examined based on the activation state of the genes within the 
network in the microarray dataset of 90-minute PAR2 stimulation by matriptase. Included are 2 downstream targets 
of interest (out of 74 total targets in the network): EGR2 and ATF3.  
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Figure 7.10: IL-1B pathway following 90 minute matriptase stimulation 
The signalling network downstream of IL-1B was examined based on the activation state of the genes within the 
network in the microarray dataset of 90-minute PAR2 stimulation by matriptase. Included are 3 downstream targets 
of interest (out of 72 total targets in the network): ATF3, CSRNP1 and EGR2. 
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 Discussion 
Work presented in this chapter optimised the time points to be utilised for a gene 
expression microarray following canonical PAR2 activation. The selected time points 
were based on how SW1353 cells responded to IL-1+OSM stimulation in terms of ATF3 
and MMP expression. ATF3 was subsequently identified as a PAR2 target, and 90 minutes 
was chosen as an early time point and 24 hours as a later time point for microarray 
analysis. A gene expression microarray was performed by stimulating PAR2-expressing 
SW1353 cells with either matriptase or SLIGKV, after which these responses were 
compared, and further analysis performed on matriptase-stimulated samples. 
 
In examining the top 20 most up-regulated genes following 90-minute matriptase 
stimulation, a multitude of early response genes (FOSB, FOS, ATF3, IER3, EGR1, EGR2 
and CSRNP1), transcription factors (NR4A2 and KLF2), cyto/chemokines (CXCL8 and 
IL-11) and other inflammatory regulators (NFKBIA and TNFAIP3) were found to be 
significantly up-regulated. An initial and striking observation was that ATF3, EGR2 and 
CSNRP1 were all identified as being robustly up-regulated following PAR2 activation. 
These three genes were explored in chapter 3 as being regulated by the mechanical 
loading of chondrocytes. A previous study has also identified these three genes as key 
regulators of collagenase activation following IL-1+OSM stimulation of chondrocytes 
(Chris MacDonald, unpublished). 
 
The gene with the highest fold increase of expression following 90-minute matriptase 
stimulation was CXCL8 (the gene which encodes IL-8), which validates the use of this 
gene as a readout for canonical PAR2 activation in previous chapters, as well as in 
previous studies315,316. IL-8 has also been implicated in OA pathogenesis. IL-8344 and its 
receptor345 are up-regulated by OA chondrocytes, and whilst this expression of IL-8 has 
not been linked to PAR2, data presented in this study suggests that the involvement of 
PAR2 is a reasonable hypothesis. IL-11 which was also up-regulated at this time point 
has also been implicated in OA, with an elevated expression in OA chondrocytes346. 
However, this is contrary to the pro-inflammatory outcomes of PAR2 signalling, as it is 
suggested that IL-11 is anti-inflammatory in chondrocytes, leading to TIMP-1 
upregulation346. IL-11 has however also been shown to promote MMP expression 
similarly to IL-6 when combined with IL-1 (A.D. Rowan, personal communication). 
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Nuclear receptor subfamily 4, group A, member 2 (NR4A2) had a robustly elevated 
expression level following 90-minute matriptase stimulation. NR4A2 has been identified 
as a transcription factor involved in multiple arthritic diseases, particularly inflammatory 
arthritic diseases347. NR4A2 has however also been shown to have elevated expression in 
OA synovial tissues348. Furthermore, the overexpression of NR4A2 in an immortalised 
synovial fibroblast cell line leads to a synergistic increase in MMP13 expression 
following TNFα stimulation348. 
 
Other genes strongly up-regulated following 90 minutes include various early response 
genes which have been previously implicated in OA. For example, FOSB had the second 
highest fold increase in expression following 90 minutes, and family member FOS was 
also highly up-regulated. The gene products of the FOS family form heterodimers with 
gene products of the JUN family to form the AP-1 transcription factor, which has key 
roles in the transcription of a variety of genes including the collagenolytic MMPs, in a 
response to a variety of stimuli, including cytokines. Indeed, the inhibition of c-Fos (the 
gene product of FOS)/AP-1 results in a reduced induction of MMP13 following IL-1 
stimulation, and was found to be protective against OA in the CIA model of mouse 
disease349.  
 
To our knowledge, this is the first study to identify ATF3 and CSRNP1 as downstream 
targets of PAR2 canonical signalling, however EGR2 has previously been identified as 
being induced following trypsin activation of PAR2 in HEK293 cells, although not as 
robustly as in SW1353 cells340. Little is currently known about the signalling pathways 
involved in matriptase-induced up-regulated expression of collagenases. The observation 
that ATF3, CSRNP1 and EGR2 are all targets of PAR2 signalling is therefore a fascinating 
one, as it suggests the potential for similar and overlapping mechanisms of collagenase 
expression following distinct stimuli, be it IL-1+OSM, abnormal mechanical load, or 
PAR2 activation. It is noteworthy that DNA microarray analysis of SW1353 cells 
following IL-1+OSM identified CXCL8 as the most up-regulated gene, in complete 
agreement with the data presented here350, further suggesting overlapping common 
pathways. 
 
In order to further explore this overlap and association with other defined signalling 
pathways, pathway analysis was undertaken. Unsurprisingly, canonical PAR2 activation 
was strongly associated with a whole host of defined inflammatory canonical pathways, 
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such as TNF signalling, IL-6 signalling, IL-17 signalling, TLR-signalling, IL-1 
signalling, and p38 MAPK signalling. Furthermore, many of these canonical pathways 
have also been associated with OA. For example, IL-1 and TNF have long been strongly 
associated with OA. IL-1 (namely, IL-1β) and TNF are expressed and released by 
multiple cells of the joint, including chondrocytes, cells of the synovial membrane, 
osteoblasts and infiltrated mononuclear cells351. Elevated levels of IL-1β and TNF are 
observed in the synovial fluid and cartilage of patients with OA352, and the receptor for 
IL-1 also exhibits a higher expression level in OA chondrocytes353. These cytokines are 
catabolic in nature, stimulating the expression of multiple genes detrimental to cartilage 
health such as the collagenolyic MMPs351. IL-1B and TNF were both identified in this 
study as very strongly associated upstream regulators within the microarray dataset, 
suggesting several downstream regulators and targets of IL-1β and TNF are also induced 
by canonical PAR2 activation. Multiple other upstream regulators identified in this study 
have also been previously shown to be involved in IL-1β and TNF signalling, such as p38 
MAPK, JUN and STAT3. Furthermore, at 24 hours post-stimulation, IL-1B and TNF 
remained two of the three top upstream regulators which retained a predicted activation 
state, further establishing their association with PAR2 signalling. 
 
Taking together the canonical pathway analysis and the upstream regulator analysis, it is 
clear that canonical PAR2 activation is highly pro-inflammatory in nature, with many 
overlapping pathways with those observed by pro-inflammatory cytokine stimulation. 
Futhermore, IL-6 and IL-17 have also been implicated in OA351, as has TLR signalling354. 
 
The later time point utilised in this study was 24 hours. A striking observation was that 
24 hours post-stimulation there was a more equal number of down and up-regulated 
genes, whereas at 90 minutes, only three genes were significantly down-regulated below 
the threshold of log2 < -1. This was not observed in a previous microarray analysis of 
canonical PAR2 activation340 and could reflect differences in cell line or differences in 
sensitives of the microarray chips utilised. 
 
After 24-hour stimulation, several cytokines remained highly up-regulated, including IL-
8 and IL-11 as observed at 90 minutes, with the addition of IL-24, a cytokine which has 
been associated with RA, however not with OA355. Other genes up-regulated at 24 hours 
post-stimulation include cell surface receptors such as PLAUR, the uPA receptor and 
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LDLR, the Low-Density Lipoprotein receptor. Other cell surface receptors such as F2R 
(PAR1) and F2RL2 (PAR3) were however down-regulated at this time point. 
 
The only proteases to be significantly up-regulated at 24 hours at the set threshold were 
ADAMTS6 and MMP9, despite RT-qPCR clearly showing the upregulation of MMP1 at 
this time point in the same samples. This is likely a reflection of the relative sensitivities 
of DNA microarray analysis and RT-qPCR. Indeed, it is generally accepted that RT-
qPCR is more sensitive than microarray analysis356-358. MMP-9 is a gelatinase which has 
an elevated expression level in OA359,360, whereas ADAMTS-6 is an incompletely 
understood protease with no current link to the disease.  
 
Interestingly, at 24 hours two protease inhibitors were up-regulated: SPINK1 and 
SERPINB8. SPINK1 is a kazal-type serine-protease inhibitor, best known as a pancreatic-
expressed trypsin inhibitor361. To our knowledge, this is the first time SPINK1 has been 
shown to be regulated by PAR2 activation, which might suggest the presence of a 
negative feedback system whereby canonical PAR2 activation can upregulate a trypsin 
inhibitor. Despite being able to inhibit trypsin, there is however evidence that SPINK1 
does not inhibit matriptase362. SERPINB8 is an intracellular serine protease inhibitor and 
is best known as a furin inhibitor363, with no current links to arthritic diseases. 
 
The most down-regulated gene at 24 hours was Thioredoxin-interacting protein (TXNIP), 
which is an interesting observation as this gene has recently been implicated in OA364. 
The regulation of this gene by PAR2 is not a novel observation, and this was indeed also 
the most down-regulated gene observed in a previous microarray analysis of canonical 
PAR2 activation340. TXNIP was found to be expressed at relatively high levels in normal 
human and mouse cartilage, however expression was significantly reduced in both OA, 
and with aging364.  
 
The second most down-regulated gene at 24 hours was MAFB, a transcription factor, 
which has also been implicated in OA. MAFB is regulated by retinoic acid and the genetic 
knockdown of MAFB in chondrocytes however results in an increased expression of 
aggrecan and a decreased expression of MMP3 and MMP13365. MAFB deficiency is 
therefore anabolic, which conflicts with the generally catabolic effects of PAR2 
activation.  
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Another strongly down-regulated gene at 24 hours was bone morphogenic protein 4 
(BMP4), a growth factor from the TGF-β family, which also has a decreased expression 
level in patients with OA366. 
 
Under the criteria used for the pathway analysis, only a single down-regulated canonical 
pathway was associated with the microarray data set, which was protein kinase A (PKA). 
Interestingly, decreased PKA activity has recently been associated with activation of 
another GPCR, GPR22, in chondrocytes367, with GPR22 having previously been linked 
to OA368. 
 
Taking together the data presented within this chapter, it is clear that canonical PAR2 
activation is pro-inflammatory in nature, and multiple genes regulated by PAR2 have 
links to arthritic diseases, with links to OA of particular interest to this study. In exploring 
canonical PAR2 activation on a global level within chondrocytes, many potentially 
interesting novel avenues of exploration have been identified. 
 
 
 Summary 
 ATF3 expression reaches a peak at 1.5 hours post-stimulation when stimulated 
with either IL-1+OSM or via PAR2 activation. 
 
 Matriptase and SLIGKV both induce highly similar gene expression changes in 
SW1353 cells. 
 
 Multiple pathways and upstream regulators are significantly associated with the 
microarray data set, and the responses of PAR2 activation are generally pro-
inflammatory in nature. 
 
 Genes such as ATF3, CSRNP1 and EGR2 are highly induced by PAR2 activation, 
identifying overlaps with chondrocyte responses following PAR2 activation, 
mechanical loading of chondrocytes or IL-1+OSM stimulation. 
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8. Chapter 8 – General Discussion 
 General Perspectives 
OA is a disease which is characterised by the enzymatic breakdown of articular cartilage, 
where the balance between ECM synthesis and degradation is disturbed and proteases 
such as the collagenases, MMP-1 and MMP-13 are up-regulated. It is becoming 
increasingly clear that as important as the collagenases are, many other enzymes have 
roles in cartilage turnover and disease, including metalloproteinases such as the 
aggrecanases - ADAMTS-4 and ADAMTS-542, as well as proteases from the serine and 
cysteine protease families. 
 
Serine proteases have been implicated in OA, from simple associations (e.g. elevated 
expression), to others with more detailed pathogenic mechanisms. The serine protease 
matriptase was identified as having a role in OA. Matriptase has an elevated expression 
level in OA patients, as does the receptor PAR2, which can be potently activated by 
matriptase to induce MMP expression1. Various cysteine proteases have also had roles 
implicated in the disease, with the strongest links being the cathepsin proteases, cathepsin 
B and cathepsin K. 
 
This project had two major aims: to explore how matriptase expression is regulated in 
chondrocytes, and to explore how proteases expressed by chondrocytes interact with 
PAR2 compared to matriptase. Understanding the regulation of previously described 
pathogenic mechanisms such as matriptase-mediated PAR2 activation, as well as the 
discovery of novel mechanisms of disease are important for understanding OA, and the 
development of future therapeutics.  
 
To date, the therapeutic inhibition of active cartilage degrading proteases has been 
unsuccessful. The inhibition of the collagenases or MMP-3 has been shown to be 
protective in preventing cartilage degradation in animal models of OA369,370, however 
when in clinical trials, low selectivity and severe side effects were observed371, 
highlighting the importance of these enzymes in normal physiology. The targeting of 
MMPs in OA has, however, shown that the overall aim: the prevention of MMP-mediated 
cartilage degradation, is a valid target for therapy. Understanding the regulation of MMPs 
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in cartilage, from physiology to pathology, will potentially identify new targets elsewhere 
in the pathway which could prevent specific MMP activity without directly inhibiting any 
MMPs with a small molecule inhibitor. 
 
 
 Regulation of collagenase gene expression 
The initial aims of chapter 3 were to explore whether matriptase was regulated by 
mechanical load. In performing this work, limitations in the model were identified with a 
major issue of long-term viability of BNCs following loading. Data generated at earlier 
time points were however more robust in terms of reproducibility and cell viability, 
therefore the focus of this chapter shifted towards an exploration of genes involved in 
collagenase expression. A previous study performed by our group has identified ATF3, 
CSRNP1 and EGR2 as all having roles in the regulation of collagenase expression 
following pro-inflammatory stimulation by IL-1+OSM, specifically ATF3 and EGR2 in 
the regulation of MMP13 and CSRNP1 in the regulation of MMP1 (C. MacDonald, 
unpublished). As these regulators are induced early following pro-inflammatory 
regulation, they were candidates for exploration with the mechanical loading models. 
This work identified all three of them to be induced by the mechanical loading of 
chondrocytes.  
 
In chapter 7, a gene expression microarray was performed to explore global gene 
expression changes following canonical PAR2 activation. Multiple genes were regulated 
with strong associations to multiple defined pro-inflammatory signalling pathways and 
networks. One of the strongest associations with canonical PAR2 signalling in 
chondrocytes was with IL-1 signalling. Furthermore, ATF3, CSRNP1 and EGR2 were all 
found to be strongly induced by PAR2 activatio. It is well established that mechanical 
loading, PAR2 activation and IL-1+OSM stimulation are all able to robustly induce MMP 
expression, however work presented in this study suggests that the signalling networks 
involved may have overlap (Figure 8.1).  
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The identification of potential overlapping signalling pathways from distinct stimuli is 
interesting, yet not unique in biology. For example, in the context of bone, another tissue 
with important mechanical roles, osteocytes respond to both mechanical loads and 
proMMP-1, -13 
↑ MMP1, MMP13 
Matriptase 
 Matriptase 
 IL-1 
 OSM 
↑ATF 3  ↑EGR2  ↑CSRNP1 
??? 
Abnormal Load 
Figure 8.1: Canonical PAR2 activation, mechanical loading and IL-1+OSM stimulation result in 
collagenase expression 
Work presented in this thesis identified ATF3, EGR2 and CSRNP1 as being regulated by mechanical loading in 
chondrocytes, as well as being downstream targets of PAR2 canonical activation. This follows on from previous 
work by this group which identified them as being collagenase regulators following IL-1+OSM stimulation. 
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hormonal stimulation. Despite being distinct stimuli, many of the downstream signalling 
pathways are known to overlap, such as Wnt signalling and ERK signalling372. Within 
OA, abnormal mechanical load, IL-1 and OSM, and matriptase/PAR2 signalling have all 
been implicated in the disease, and identifying common downstream regulators could 
provide interesting and novel therapeutic targets. As discussed previously, MMP 
inhibition has not yielded success due to the lack of specificity of inhibitors and the 
importance of these proteases in physiology. In understanding further how different 
pathological stimuli can induce MMP expression, it may be possible to identify specific 
regulators in chondrocytes where the different incoming stimuli converge, before 
inducing the expression of MMPs. 
 
 
 PAR2 disarming and biased agonism 
The work presented in this study was performed in the context of cartilage biology and 
OA, however PAR2 and the examined proteases are expressed in multiple tissues. 
Therefore, work presented in this study could hold relevance in other physiological and 
pathological systems. Indeed, despite being identified in this study as having the ability 
to cleave PAR2, one of the identified proteases has limited relevance to cartilage biology 
based on our current understanding of cartilage. As discussed in chapter 6, there is little 
evidence of extracellular proteolysis by cathepsin V and it is not known to be present in 
cartilage. This protease has however been linked to multiple pathological conditions 
including atherosclerosis336, as well as breast and colorectal cancers175, diseases in which 
PAR2 is also implicated200. As there is evidence that cathepsin V can be secreted from 
cells such as a fibrosarcoma cell line337, a role for cathepsin V cleavage of PAR2 under  
certain conditions cannot be excluded. 
 
The other cathepsins identified as able to cleave PAR2 are however better candidates as 
being relevant to cartilage biology. As discussed in chapter 6, cathepsin L has been 
detected in synovial fluid of patients with RA338, secretion has been observed in 
chondrocytes extracted from OA cartilage191, and it has the ability to cleave aggrecan192. 
This places cathepsin L as being expressed and present in the correct compartment to 
cleave PAR2 in a physiological manner. Furthermore, data presented in chapter 6 showed 
that cathepsin L was the most potent cathepsin at PAR2 cleavage. The similar cleavage 
profiles of cathepsins V and L against PAR2 in the present study, as well as the high level 
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of homology between the two enzymes175 mean that it would be reasonable to hypothesise 
that the two enzymes behave similarly. Cathepsin V was able to disarm against 
matriptase-induced canonical PAR2 activation, resulting in an attenuation of collagenase 
expression. Whilst not explored in this study, one could hypothesise that both cathepsins 
V and L would be biased agonists for PAR2 based on previous work with cathepsin S 
which showed induction via Gαs-mediated cAMP accumulation226. 
 
Taken together, it is possible that cathepsin L expression in osteoarthritic cartilage could 
be protective against the disease. Aside from the disarming of PAR2 activation, there 
could be further protection in terms of the biased signalling pathways induced. Should 
cathepsin L prove to mimic the action of cathepsin S on PAR2 activation and result in 
cAMP accumulation, this could further offer protection in OA. The hormone calcitonin, 
which signals via a GPCR (the calcitonin receptor), has been shown to be protective 
against cartilage degradation in a cAMP-dependent mechanism373. MMP expression 
following TNF+OSM cytokine stimulation in bovine articular cartilage explant culture 
was found to be attenuated by cAMP373. It has been suggested that cAMP has anti-
inflammatory properties in arthritic diseases374, and indeed PKA (a downstream target of 
cAMP) activity has recently been found to be reduced in OA367. Interestingly, pathway 
analysis of global gene expression changes following canonical PAR2 activation in 
chapter 7 of this study found PKA activity to be reduced further suggesting links between 
PAR2 activation and previously described outcomes of OA. 
 
Although cathepsin S cleavage of PAR2 was not a novel observation, a role of cathepsin 
S cleavage of PAR2 in cartilage biology has not been explored previously. Cathepsin S 
cleavage of PAR2 is another strong candidate for a pathological mechanism in OA, as 
cathepsin S has well established extracellular roles where it is considered the most stable 
cathepsin at neutral pH levels168. Cathepsin S activity has been detected in OA 
cartilage191, and secreted cathepsin S following TNFα or IL-1β stimulation of 
chondrocytes has been described190. Based on data presented in this study, it is likely 
cathepsin S and L would exert similar signalling and disarming outcomes. 
 
Of the cathepsin enzymes studied, cathepsin K exhibited a markedly different cleavage 
profile of PAR2. Despite also being a lysosomal cathepsin protease, cathepsin K is best 
described as an extracellular-localised ECM degrading protease, and a potent collagenase 
vital in bone remodelling160. The observation that cathepsin K can cleave PAR2 is a 
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fascinating discovery as cathepsin K has been linked to OA with cathepsin K degradation 
of type II collagen being detected in human OA cartilage184. This provides evidence for 
the presence of active cathepsin K in the correct compartment for activity against PAR2. 
The outcomes of cathepsin K cleavage of PAR2 are currently unknown, however work 
presented in chapter 6 with the putative activator peptide suggests that canonical PAR2 
signalling is not induced. Cathepsin K was found to cleave downstream of the canonical 
activation site, therefore it is likely that disarming would occur against canonical 
activation. However, it remains to be elucidated whether cathepsin K can act as a disarmer 
experimentally, or whether cathepsin K can act as a biased agonist for PAR2 responses. 
Cathepsin K has also been implicated in a wide array of cancers with a variety of 
suggested roles, which are generally detrimental such as the enabling of tumour 
metastasis375, a role generally attributed to collagenase activity. The observation that 
cathepsin K can cleave PAR2 could therefore have wider implications outside of arthritic 
diseases. 
 
Data presented in chapter 4 identified the classical collagenases, MMP-1, -8 and -13 as 
having the ability to cleave PAR2. Further work presented in chapter 5 identified an 
MMP-specific cleavage site on PAR2, a single amino acid downstream of the canonical 
site, after leucine-37. Studies performed on the putative activator peptide, LIGKVD, 
suggested that cleavage at this site could result in biased agonism. The only signalling 
pathway identified as being stimulated by this ligand was the phosphorylation of ERK1/2. 
 
Despite ERK1/2 signalling known to be important in MMP1 expression320, LIGKVD was 
unable to stimulate MMP1 expression in the present study. The signalling outcomes 
following LIGKVD-mediated ERK1/2 phosphorylation remain to be elucidated. The 
activation of ERK1/2 signalling is a fairly ubiquitous event following receptor activation, 
and in terms of PAR2 activation, multiple pathways have been identified as being able to 
stimulate ERK1/2 phosphorylation, with a wide range of potential outcomes for cell 
behaviour. ERK1/2 phosphorylation has been identified as a downstream pathway of Gα-
dependent pathways (Gαq, Gα12/13, Gαs); Gβγ-dependent pathways and G protein-
independent pathways200,204,225,227. 
 
It is difficult to speculate the potential roles of MMP-mediated PAR2 “activation”, 
however, it is unlikely to be positive feedback based on the lack of MMP1 expression 
following LIGKVD stimulation. ERK1/2 is involved in a variety of cellular functions, 
222 
 
and has been associated with generally pro-inflammatory processes, however anti-
inflammatory roles for ERK1/2 have also been identified376,377. With respect to PAR2 
biology, ERK1/2 is thought to be important in the internalisation of the receptor following 
activation in a β-arrestin-dependent manner, however this was found to also involve Gαq 
activation and associated Ca2+ mobilisation not observed in the present study378. 
Neutrophil elastase has been identified as a biased agonist able to stimulate ERK1/2 
phosphorylation, but not Ca2+ mobilisation225. However, this neutrophil elastase-
mediated PAR2 biased agonism was suggested to be a result of receptor conformational 
change following cleavage, whereas in the present study the biased signalling observed 
with LIGKVD is unlikely to result from a receptor conformational change as the receptor 
likely remains intact. Depending on the mechanism of ERK1/2 activation by PAR2, 
cellular localisation can be regulated. For example, when interacting with β-arrestin, 
ERK1/2 activity is retained within the cytoplasm, whereas in the absence of β-arrestin, 
ERK1/2 is able to translocate to the nucleus378, thus ERK1/2 has the potential to regulate 
different targets. It is therefore of vital importance to further elucidate the regulation of 
ERK1/2 by LIGKVD/active MMP in order to begin to understand an outcome for the 
cleavage. 
 
In addition to the lack of evidence for a potential positive feedback situation by the 
putative MMP revealed ligand LIGKVD, data presented in chapter 5 highlighted the 
possibility that MMPs might be antagonistic to canonical PAR2 activation by blocking 
matriptase from cleaving PAR2. These experiments were performed with recombinant 
non-catalytic domains of MMP-1 and MMP-13, however there appeared to be a modest 
blocking effect. It would be of interest to explore whether full-length MMP can block 
PAR2 activation by matriptase. Matriptase is a very potent activator of PAR2 which 
results in expression of MMP1 and MMP13, both potent collagenases. All these proteins 
have been implicated in OA, and if the disease pathogenesis were as simple as this 
mechanism, then one could hypothesise a rapid disease progression. OA is however 
generally described as a slowly progressing disease24; thus the underlying pathological 
mechanisms are likely much more complex. Within simplistic pathogenic pathways such 
as the matriptase-PAR2-MMP axis, it is likely that additional levels of regulation are 
present and yet to be elucidated. Work presented in this thesis such as the cleavage of 
PAR2 by the collagenases, and the antagonism of PAR2 activation by MMP-1 and MMP-
13 CTDs, potentially provides indications of some of these unknown levels of regulation, 
and warrants further investigation. 
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 Future Work 
 Mechanical Loading of Chondrocytes 
 Work presented in this chapter provided no evidence that mechanical loading is a 
regulator of matriptase expression, however did show regulation of pro-
inflammatory genes such as CSRNP, ATF3 and EGR2. There were however 
severe limitations in the system, namely the cells had limited viability following 
loading. Furthermore, the loading regimens were not very physiological, nor was 
the “matrix” that the cells were cultured in. There were sufficient results from this 
chapter however to warrant future work in the field of mechanical loading of 
chondrocytes. A better system to explore the mechanical loading of chondrocytes 
would be one which applies mechanical load directly to cartilage in explant 
culture, as the cells will have a physiological matrix to transmit mechanical 
signals, and more physiological loads could be utilised.  
 
 Serine protease cleavage of PAR2 
 Data presented in chapter 4 identified the serine proteases HTRA1 and uPA as 
having the ability to cleave PAR2. Constraints with reagents and time meant that 
these cleavages were not further explored. Both proteases have been implicated 
in OA, and are known to partake in extracellular proteolysis and indeed uPA is 
already known to induce cell signalling by binding its receptor uPAR. A further 
exploration of these proteases and their role in PAR2 cleavage would therefore be 
of interest. 
 
 The role of MMP-mediated PAR2 cleavage 
 The putative MMP cleavage revealed ligand LIGKVD was identified as a biased 
agonist for PAR2, able to stimulate ERK1/2 phosphorylation. It is therefore vital 
to firstly explore whether active MMP is able to induce ERK1/2 phosphorylation 
when added to cell culture. 
 
 LIGKVD was unable to induce calcium mobilisation, therefore the ERK1/2 
activation is unlikely to be a result of Gαq-coupled PAR2 activation and 
subsequent ERK activation by PKC379 or calcium380. ERK signalling however has 
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multiple activators which are known to be targets of PAR2, such as Gαs, Gαi, 
Gαs, Gα12/13, βγ subunit and β-arrestin signalling381. It would therefore be of 
interest to ascertain which pathways are required for the observed LIGVKD-
induced ERK1/2 activation. 
 
 In line with deducing the pathway by which LIGKVD signals, and working under 
the assumption that active MMP also activates ERK signalling, it is of interest to 
ascertain the signalling outcomes of MMP-mediated PAR2 activation and explore 
whether there is a more negative feedback situation of anti-inflammatory 
outcomes, or whether there is a positive feedback situation of more pro-
inflammatory outcomes. 
 
 Experiments performed with the pre-incubation of MMP CTD on PAR2-
expressing cells suggested the potential for a blocking effect by MMP-1 and 
MMP-13 CTDs on matriptase-induced PAR2 activation. This potential 
antagonistic action of MMP CTD warrants further investigation with full-length 
MMP including a catalytically inactive enzyme. 
 
 The role of cathepsin-mediated PAR2 cleavage 
 Cathepsin V was able to disarm against matriptase-induced canonical activation 
of PAR2, however as discussed in chapter 6, cathepsin V is unlikely to hold a 
great deal of physiological relevance in cartilage biology and OA. Cathepsin V 
was used for these assays primarily due to availability of sufficient recombinant 
enzyme, however cathepsins S and L are likely more relevant. Furthermore, 
cathepsin B has associations with OA, and also cleaved multiple downstream sites 
to the canonical site thus is a candidate for being a PAR2 disarmer in cartilage. 
Therefore, future work testing the ability for cathepsins L, S and B to disarm 
against canonical PAR2 activation would be of great interest. 
 
 Cathepsin S is described as a biased agonist in the literature (able to induce Gαs-
mediated cAMP accumulation)365. Data presented in chapter 6 showed that 
cathepsin V, and to some extent cathepsin L, have similar cleavage profiles to 
cathepsin S. It would therefore be of interest to explore whether cathepsins V and 
L are able to act as biased agonists for cAMP accumulation. 
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 Cathepsin K primarily cleaved at a distinct site to the other cathepsin enzymes, at 
a location which makes it a candidate for either biased agonism or disarming. The 
putative activator peptide (KVDGTS) did not induce calcium mobilisation, 
however this is not sufficient to conclude the peptide has no effect (as shown by 
data in chapter 5 with the LIGKVD peptide). Future work would therefore require 
the exploration of other signalling pathways known to be regulated by PAR2. 
Furthermore, for a greater level of physiological relevance, the addition of active 
cathepsin K would need to be tested on cells and compared with KVDGTS. 
 
 Exploration of canonical PAR2 activation in chondrocytes 
 It is known that matriptase-induced PAR2 activation in chondrocytes leads to an 
upregulation of collagenase (MMP1 and MMP13) expression, however little is 
currently known about the signalling pathways involved. This study identified 
several downstream targets of PAR2 activation which are also downstream targets 
of IL-1+OSM stimulation of chondrocytes. It is therefore of interest to further 
examine these and explore whether they are required for collagenase expression. 
For example, experiments such as siRNA knockdown of ATF3, EGR2 and 
CSRNP1 prior to matriptase stimulation of cells would be interesting to perform. 
 
 Studies in chapter 3 was performed in bovine nasal chondrocytes, whereas the 
microarray in chapter 7 was performed in human SW1353 cells. Previous 
investigation with IL-1+OSM was performed in human articular chondrocytes 
(HAC). Despite, ATF3, EGR2 and CSRNP1 being regulated in all three cell types, 
for direct comparison, all studies should be performed on a single cell type. As 
HAC represent the most physiologically relevant cell, the regulation of these 
effectors following PAR2 activation or mechanical loading should be explored in 
them. 
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 Summary 
Data presented in this thesis identified several novel cleavages of PAR2 by proteases from 
the metalloproteinase family (the collagenases: MMP-1, -8 and -13), the cysteine protease 
family (cathepsin V, K, L and B) and the serine protease family (HTRA1, uPA). The 
collagenases were found to cleave PAR2 at a specific site, a single amino acid C-terminal 
to the canonical activation site, to reveal a putative ligand, LIGKVD. When added to cells 
as a synthetic peptide, LIGKVD could induce biased signalling in PAR2-overexpressing 
SW1353 cells as measured by the phosphorylation of ERK1/2, but not p38 MAPK, both 
of which are phosphorylated by canonical PAR2 activation. The cathepsins cleaved at 
multiple sites, however primary sites after glutamic acid-56 for cathepsins V and L, and 
after glycine-40 for cathepsin K, were identified. 
 
A gene expression microarray was performed exploring canonical PAR2 activation in 
SW1353 cells following matriptase stimulation. It was clear that the signalling outcomes 
were pro-inflammatory in nature, with significant overlap with other pathways known to 
be involved in OA. Some of the most up-regulated genes included ATF3, EGR2 and 
CSRNP1, which had already been identified as mechanosensitive in this project, and 
identified as key regulators of collagenase expression following IL-1+OSM stimulation 
by previous study. Data presented in this thesis suggest that disparate stimuli all appear 
to have some common downstream elements that facilitate MMP expression. Further 
elucidation of the signalling networks involved could highlight novel therapeutic targets 
for the treatment of OA.
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9. Appendix 1: Known PAR2 cleavages 
Protein Gene Site 
Cleavage 
sequence 
Evidence Reference 
kallikrein-related 
peptidase 5 
KLK5 31 G-T-N-R↓S-S-K-G SP, RE, MS 
210 
kallikrein-related 
peptidase 6 
 
KLK6 
36 S-K-G-R↓S-L-I-G SP, RE, MS 
210 
41 L-I-G-K↓V-D-G-T SP, RE, MS 
210 
51 V-T-G-K↓G-V-T-V SP, RE, MS 
210 
kallikrein-related 
peptidase 14 
 
KLK14 
 
31 G-T-N-R↓S-S-K-G SP, RE, MS 
210 
36 S-K-G-R↓S-L-I-G SP, RE, MS 
210 
41 L-I-G-K↓V-D-G-T SP, RE, MS 
210 
51 V-T-G-K↓G-V-T-V SP, RE, MS 210 
Trypsin 1 
 
PRSS1 
 
34 R-S-S-K↓G-R-S-L 
rPAR2, RE, 
MS 
301 
36 S-K-G-R↓S-L-I-G 
rPAR2, RE, 
MS 
301 
41 L-I-G-K↓V-D-G-T SP, RE, MS 210 
51 V-T-G-K↓G-V-T-V 
rPAR2, RE, 
MS 
301 
72 L-T-G-K↓L-T-T-V 
rPAR2, RE, 
MS 
301 
Plasmin PLG 
34 R-S-S-K↓G-R-S-L 
rPAR2, RE, 
MS 
301 
36 S-K-G-R↓S-L-I-G 
rPAR2, RE, 
MS 
301 
Tryptase 
alpha/beta-1 
TPSAB1 
36 S-K-G-R↓S-L-I-G SP, RE, MS 206 
41 L-I-G-K↓V-D-G-T SP, RE, MS 206 
Thrombin F2 36 S-K-G-R↓S-L-I-G 
rPAR2, RE, 
MS 
301 
Matriptase ST14 36 S-K-G-R↓S-L-I-G   
Coagulation factor 
X 
F10 36 S-K-G-R↓S-L-I-G SDM, RE 127 
Coagulation factor 
VII 
F7 36 S-K-G-R↓S-L-I-G SDM, RE 127 
Trypsin 
IV/mesotrypsin 
PRSS3 36 S-K-G-R↓S-L-I-G SP, RE, MS 207 
Cathepsin G CTSG 
38 G-R-S-L↓I-G-K-V 
rPAR2, RE, 
MS 
301 
59 E-T-V-F↓S-V-D-E 
rPAR2, RE, 
MS 
301 
64 V-D-E-F↓S-A-S-V 
SP, rPAR2, 
RE, MS 
225,301 
Neutrophil Elastase 
 
ELANE 
 
42 I-G-K-V↓D-G-T-S 
rPAR2, RE, 
MS 
301 
48 T-S-H-V↓T-G-K-G 
rPAR2, RE, 
MS 
301 
53 G-K-G-V↓T-V-E-T 
rPAR2, RE, 
MS 
301 
58 V-E-T-V↓F-S-V-D 
rPAR2, RE, 
MS 
301 
67 F-S-A-S↓V-L-T-G SP, RE, MS 225 
228 
 
74 G-K-L-T↓T-V-F-L 
rPAR2, RE, 
MS 
301 
76 L-T-T-V↓F-L-P-I 
rPAR2, RE, 
MS 
301 
Calpain 1 CAPN1 59 E-T-V-F↓S-V-D-E 
rPAR2, RE, 
MS 
301 
Calpain 2 CAPN2 
45 V-D-G-T↓S-H-V-T 
rPAR2, RE, 
MS 
301 
71 V-L-T-G↓K-L-T-T 
rPAR2, RE, 
MS 
301 
Proteinase 3 PRTN3 
48 T-S-H-V↓T-G-K-G 
rPAR2, RE, 
MS 
301 
55 G-V-T-V↓E-T-V-F 
rPAR2, RE, 
MS 
301 
57 T-V-E-T↓V-F-S-V 
rPAR2, RE, 
MS 
301 
61 V-F-S-V↓D-E-F-S 
SP, rPAR2, 
RE, MS 
225,301 
62 F-S-V-D↓E-F-S-A 
rPAR2, RE, 
MS 
301 
72 L-T-G-K↓L-T-T-V 
rPAR2, RE, 
MS 
301 
74 G-K-L-T↓T-V-F-L 
rPAR2, RE, 
MS 
301 
75 K-L-T-T↓V-F-L-P 
rPAR2, RE, 
MS 
301 
76 L-T-T-V↓F-L-P-I 
rPAR2, RE, 
MS 
301 
Interstitial 
collagenase 
MMP1 N/A N/A 
Indirect: 
MMP-1 
addition to 
A549 cells 
with PAR2 
antagonist 
303 
Chitinase-3-like 
protein 1 
CHI3L1 N/A N/A 
Indirect: cell 
response with 
PAR2 
blocking 
antibody 
382 
Cathepsin S 
 
 
 56 V-T-V-E↓T-V-F-S SP, RE, MS 226 
 38 G-R-S-L↓I-G-K-V SP, RE, MS 300 
 40 S-L-I-G↓K-V-D-G SP, RE, MS 300 
 
rPAR2 = recombinant PAR2, SP = synthetic peptide, RE = recombinant enzyme, MS = 
mass spectrometry, SDM = site-directed mutagenesis 
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10. Appendix 2: Example Mass Spectometry Traces 
Electrospray MS: MMP1 - Ser-37 / Leu-38 
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NanoLCMS: Cathepsin K 
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11. Appendix 3: Active-site titrations 
 
 
Appendix 3.1: MMP active-site titration 
MMP-1 (A), MMP-8 (B) and MMP-13 (C) were active-site titrated by TIMP-1 as outlined in chapter 2.15.5.2. 
Curves shown are n=2 independent experiments, mean ± SD. 
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Appendix 3.2: MMP active-site titration 
Cathepsins B (A),  K (B), V (C), S (D) and L (E) were active-site titrated by E64 as outlined in chapter 2.15.5.1. 
Curves shown are n=2 independent experiments, mean ± SD. 
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12. Appendix 4: Example of raw enzyme kinetic data 
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Appendix 4.1: Example of raw fluorescence data 
Data showing the same enzyme assay before (A) and after (B) using a total hydrolysis standard curve to calculate 
substrate turnover, and thus subsequently being able to perform Michaelis-Menten kinetics. 
  
234 
 
13. References 
1 Milner, J. M., Patel, A., Davidson, R. K., Swingler, T. E., Desilets, A., Young, D. 
A., Kelso, E. B., Donell, S. T., Cawston, T. E., Clark, I. M., Ferrell, W. R., Plevin, 
R., Lockhart, J. C., Leduc, R. & Rowan, A. D. Matriptase Is a Novel Initiator of 
Cartilage Matrix Degradation in Osteoarthritis. Arthritis and Rheumatism 62, 
1955-1966, doi:10.1002/art.27476 (2010). 
2 Roughley, P. J. The structure and function of cartilage proteoglycans. European 
Cells & Materials 12, 92-101 (2006). 
3 Barbara, Y., Lowe, J. S., Stevens, A. & Heath, J. W. Wheater's Functional 
Histology. Fifth edn,  (Elsevier, 2006). 
4 Halloran, J. P., Sibole, S., van Donkelaar, C. C., van Turnhout, M. C., Oomens, 
C. W. J., Weiss, J. A., Guilak, F. & Erdemir, A. Multiscale Mechanics of Articular 
Cartilage: Potentials and Challenges of Coupling Musculoskeletal, Joint, and 
Microscale Computational Models. Annals of Biomedical Engineering 40, 2456-
2474, doi:10.1007/s10439-012-0598-0 (2012). 
5 Heinegard, D. Proteoglycans and more - from molecules to biology. International 
Journal of Experimental Pathology 90, 575-586, doi:10.1111/j.1365-
2613.2009.00695.x (2009). 
6 Buckwalter, J. A., Mow, V. C. & A, R. Restoration of Injured or Degenerated 
Articular Cartilage. Journal of the American Academy of Orthopaedic Surgeons 
2, 192-201 (1994). 
7 Poole, C. A. Articular cartilage chondrons: Form, function and failure. Journal of 
Anatomy 191, 1-13, doi:10.1046/j.1469-7580.1997.19110001.x (1997). 
8 Fosang, A. J. & Beier, F. Emerging Frontiers in cartilage and chondrocyte 
biology. Best Practice & Research in Clinical Rheumatology 25, 751-766, 
doi:10.1016/j.berh.2011.11.010 (2011). 
9 Archer, C. W. & Francis-West, P. The chondrocyte. International Journal of 
Biochemistry & Cell Biology 35, 401-404, doi:10.1016/s1357-2725(02)00301-1 
(2003). 
10 van der Kraan, P. M. & van den Berg, W. B. Chondrocyte hypertrophy and 
osteoarthritis: role in initiation and progression of cartilage degeneration? 
Osteoarthritis and Cartilage 20, 223-232, doi:10.1016/j.joca.2011.12.003 (2012). 
11 Murphy, G. & Nagase, H. Reappraising metalloproteinases in rheumatoid arthritis 
and osteoarthritis: destruction or repair? Nature Clinical Practice Rheumatology 
4, 128-135, doi:10.1038/ncprheum0727 (2008). 
12 Verzijl, N., DeGroot, J., Thorpe, S. R., Bank, R. A., Shaw, J. N., Lyons, T. J., 
Bijlsma, J. W. J., Lafeber, F., Baynes, J. W. & TeKoppele, J. M. Effect of collagen 
turnover on the accumulation of advanced glycation end products. Journal of 
Biological Chemistry 275, 39027-39031, doi:10.1074/jbc.M006700200 (2000). 
13 Thomas, L. Reversible collapse of rabbit ears after intravenous papain, and 
prevention of recovery by cortisone. The Journal of experimental medicine 104, 
245-252, doi:10.1084/jem.104.2.245 (1956). 
14 Shoulders, M. D. & Raines, R. T. in Annual Review of Biochemistry Vol. 78 
Annual Review of Biochemistry   929-958 (2009). 
15 Fields, G. B. Interstitial Collagen Catabolism. Journal of Biological Chemistry 
288, 8785-8793, doi:10.1074/jbc.R113.451211 (2013). 
16 Ikenoue, T., Trindade, M. C. D., Lee, M. S., Lin, E. Y., Schurman, D. J., 
Goodman, S. B. & Smith, R. L. Meehanoregulation of human articular 
chondrocyte aggrecan and type II collagen expression by intermittent hydrostatic 
235 
 
pressure in vitro. Journal of Orthopaedic Research 21, 110-116, 
doi:10.1016/s0736-0266(02)00091-8 (2003). 
17 Valhmu, W. B., Stazzone, E. J., Bachrach, N. M., Saed-Nejad, F., Fischer, S. G., 
Mow, V. C. & Ratcliffe, A. Load-controlled compression of articular cartilage 
induces a transient stimulation of aggrecan gene expression. Archives of 
Biochemistry and Biophysics 353, 29-36, doi:10.1006/abbi.1998.0633 (1998). 
18 Manninen, P., Riihimaki, H., Heliovaara, M. & Suomalainen, O. Physical exercise 
and risk of severe knee osteoarthritis requiring arthroplasty. Rheumatology 40, 
432-437, doi:10.1093/rheumatology/40.4.432 (2001). 
19 Roos, E. M. & Dahlberg, L. Positive effects of moderate exercise on 
glycosaminoglycan content in knee cartilage - A four-month, randomized 
controlled trial in patients at risk of osteoarthritis. Arthritis and Rheumatism 52, 
3507-3514, doi:10.1002/art.21415 (2005). 
20 Loening, A. M., James, I. E., Levenston, M. E., Badger, A. M., Frank, E. H., Kurz, 
B., Nuttall, M. E., Hung, H. H., Blake, S. M., Grodzinsky, A. J. & Lark, M. W. 
Injurious mechanical compression of bovine articular cartilage induces 
chondrocyte apoptosis. Archives of Biochemistry and Biophysics 381, 205-212, 
doi:10.1006/abbi.2000.1988 (2000). 
21 Sun, H. B. in Molecular and Integrative Physiology of the Musculoskeletal System 
Vol. 1211 Annals of the New York Academy of Sciences (eds J. I. Mechanick, L. 
Sun, & M. Zaidi)  37-50 (2010). 
22 Blain, E. J. Mechanical regulation of matrix metalloproteinases. Frontiers in 
Bioscience 12, 507-527, doi:10.2741/2078 (2007). 
23 McInnes, I. B. & Schett, G. The Pathogenesis of Rheumatoid Arthritis. New 
England Journal of Medicine 365, 2205-2219 (2011). 
24 Goldring, M. B. & Goldring, S. R. Osteoarthritis. Journal of Cellular Physiology 
213, 626-634, doi:10.1002/jcp.21258 (2007). 
25 Felson, D. T., Lawrence, R. C., Dieppe, P. A., Hirsch, R., Helmick, C. G., Jordan, 
J. M., Kington, R. S., Lane, N. E., Nevitt, M. C., Zhang, Y., Sowers, M., 
McAlindon, T., Spector, T. D., Poole, A. R., Yanovski, S. Z., Ateshian, G., 
Sharma, L., Buckwalter, J. A., Brandt, K. D. & Fries, J. F. Osteoarthritis: new 
insights. Part 1: the disease and its risk factors. Annals of internal medicine 133, 
635-646 (2000). 
26 Pratta, M. A., Yao, W. Q., Decicco, C., Tortorella, M. D., Liu, R. Q., Copeland, 
R. A., Magolda, R., Newton, R. C., Trzaskos, J. M. & Arner, E. C. Aggrecan 
protects cartilage collagen from proteolytic cleavage. Journal of Biological 
Chemistry 278, 45539-45545, doi:10.1074/jbc.M303737200 (2003). 
27 Hedlund, H., Hedbom, E., Heinegard, D., Mengarelli-Widholm, S., Reinholt, F. 
P. & Svensson, O. Association of the aggrecan keratan sulfate-rich region with 
collagen in bovine articular cartilage. Journal of Biological Chemistry 274, 5777-
5781, doi:10.1074/jbc.274.9.5777 (1999). 
28 Maroudas, A. Balance between swelling pressure and collagen tension in normal 
and degenerate cartilage. Nature 260, 808-809, doi:10.1038/260808a0 (1976). 
29 Aigner, T. & McKenna, L. Molecular pathology and pathobiology of 
osteoarthritic cartilage. Cellular and Molecular Life Sciences 59, 5-18, 
doi:10.1007/s00018-002-8400-3 (2002). 
30 Hollander, A. P., Heathfield, T. F., Webber, C., Iwata, Y., Bourne, R., Rorabeck, 
C. & Poole, A. R. Increased damage to type II collagen in osteoarthritic articular 
cartilage detected by a new immunoassay. Journal of Clinical Investigation 93, 
1722-1732, doi:10.1172/jci117156 (1994). 
31 Hollander, A. P., Pidoux, I., Reiner, A., Rorabeck, C., Bourne, R. & Poole, A. R. 
Damage to type II collagen in aging and osteoarthritis starts at the articular 
236 
 
surface, originates around chondrocytes, and extends into the cartilage with 
progressive degeneration. Journal of Clinical Investigation 96, 2859-2869, 
doi:10.1172/jci118357 (1995). 
32 Kiani, C., Chen, L., Wu, Y. J., Yee, A. J. & Yang, B. B. Structure and function of 
aggrecan. Cell Research 12, 19-32, doi:10.1038/sj.cr.7290106 (2002). 
33 Fosang, A. J., Neame, P. J., Hardingham, T. E., Murphy, G. & Hamilton, J. A. 
Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. 
Journal of Biological Chemistry 266, 15579-15582 (1991). 
34 Fosang, A. J., Neame, P. J., Last, K., Hardingham, T. E., Murphy, G. & Hamilton, 
J. A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, 
gelatinases, and cathepsin B. Journal of Biological Chemistry 267, 19470-19474 
(1992). 
35 Fosang, A. J., Last, K., Knauper, V., Neame, P. J., Murphy, G., Hardingham, T. 
E., Tschesche, H. & Hamilton, J. A. Fibroblast and neutrophil collagenases cleave 
at two sites in the cartilage aggrecan interglobular domain. Biochemical Journal 
295, 273-276 (1993). 
36 Fosang, A. J., Last, K., Knauper, V., Murphy, G. & Neame, P. J. Degradation of 
cartilage aggrecan by collagenase-3 (MMP-13). Febs Letters 380, 17-20, 
doi:10.1016/0014-5793(95)01539-6 (1996). 
37 Sandy, J. D., Flannery, C. R., Neame, P. J. & Lohmander, L. S. The structure of 
aggrecan fragments in human synovial fluid. Evidence for the involvement in 
osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of 
the interglobular domain. Journal of Clinical Investigation 89, 1512-1516, 
doi:10.1172/jci115742 (1992). 
38 Hughes, C. E., Little, C. B., Buttner, F. H., Bartnik, E. & Caterson, B. Differential 
expression of aggrecanase and matrix metalloproteinase activity in chondrocytes 
isolated from bovine and porcine articular cartilage. Journal of Biological 
Chemistry 273, 30576-30582, doi:10.1074/jbc.273.46.30576 (1998). 
39 Tortorella, M. D., Burn, T. C., Pratta, M. A., Abbaszade, I., Hollis, J. M., Liu, R., 
Rosenfeld, S. A., Copeland, R. A., Decicco, C. P., Wynn, R., Rockwell, A., Yang, 
F., Duke, J. L., Solomon, K., George, H., Bruckner, R., Nagase, H., Itoh, Y., Ellis, 
D. M., Ross, H., Wiswall, B. H., Murphy, K., Hillman, M. C., Hollis, G. F., 
Newton, R. C., Magolda, R. L., Trzaskos, J. M. & Arner, E. C. Purification and 
cloning of aggrecanase-1: A member of the ADAMTS family of proteins. Science 
284, 1664-1666, doi:10.1126/science.284.5420.1664 (1999). 
40 Hurskainen, T. L., Hirohata, S., Seldin, M. F. & Apte, S. S. ADAM-TS5, ADAM-
TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases 
- General features and genomic distribution of the ADAM-TS family. Journal of 
Biological Chemistry 274, 25555-25563, doi:10.1074/jbc.274.36.25555 (1999). 
41 Stanton, H., Rogerson, F. M., East, C. J., Golub, S. B., Lawlor, K. E., Meeker, C. 
T., Little, C. B., Last, K., Farmer, P. J., Campbell, I. K., Fourie, A. M. & Fosang, 
A. J. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. 
Nature 434, 648-652, doi:10.1038/nature03417 (2005). 
42 Glasson, S. S., Askew, R., Sheppard, B., Carito, B., Blanchet, T., Ma, H. L., 
Flannery, C. R., Peluso, D., Kanki, K., Yang, Z. Y., Majumdar, M. K. & Morris, 
E. A. Deletion of active ADAMTS5 prevents cartilage degradation in a murine 
model of osteoarthritis. Nature 434, 644-648, doi:10.1038/nature03369 (2005). 
43 Song, R.-H., Tortorella, M. D., Malfait, A.-M., Alston, J. T., Yang, Z., Arner, E. 
C. & Griggs, D. W. Aggrecan degradation in human articular cartilage explants is 
mediated by both ADAMTS-4 and ADAMTS-5. Arthritis and Rheumatism 56, 
575-585, doi:10.1002/art.22334 (2007). 
237 
 
44 Naito, S., Shiomi, T., Okada, A., Kimura, T., Chijiiwa, M., Fujita, Y., Yatabe, T., 
Komiya, K., Enomoto, H., Fujikawa, K. & Okada, Y. Expression of ADAMTS4 
(aggrecanase-1) in human osteoarthritic cartilage. Pathology International 57, 
703-711, doi:10.1111/j.1440-1827.2007.02167.x (2007). 
45 Perez-Silva, J. G., Espanol, Y., Velasco, G. & Quesada, V. The Degradome 
database: expanding roles of mammalian proteases in life and disease. Nucleic 
Acids Research 44, D351-D355, doi:10.1093/nar/gkv1201 (2016). 
46 Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. 
Biochemical and biophysical research communications 27, 157-162, 
doi:10.1016/s0006-291x(67)80055-x (1967). 
47 Pelmenschikov, V., Blomberg, M. R. A. & Siegbahn, P. E. A theoretical study of 
the mechanism for peptide hydrolysis by thermolysin. Journal of Biological 
Inorganic Chemistry 7, 284-298, doi:10.1007/s007750100295 (2002). 
48 Erez, E., Fass, D. & Bibi, E. How intramembrane proteases bury hydrolytic 
reactions in the membrane. Nature 459, 371-378, doi:10.1038/nature08146 
(2009). 
49 Bode, W., Gomisruth, F. X. & Stockler, W. Astacins, serralysins, snake venom 
and matrix metalloproteinases exhibit identical zinc-binding environments 
(HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a 
common family, the metzincins. Febs Letters 331, 134-140, doi:10.1016/0014-
5793(93)80312-i (1993). 
50 Tallant, C., Garcia-Castellanos, R., Baumann, U. & Xavier Gomis-Rueth, F. On 
the Relevance of the Met-turn Methionine in Metzincins. Journal of Biological 
Chemistry 285, 13951-13957, doi:10.1074/jbc.M109.083378 (2010). 
51 Huxley-Jones, J., Clarke, T.-K., Beck, C., Toubaris, G., Robertson, D. L. & Boot-
Handford, R. P. The evolution of the vertebrate metzincins; insights from Ciona 
intestinalis and Danio rerio. Bmc Evolutionary Biology 7, doi:10.1186/1471-
2148-7-63 (2007). 
52 Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissues : a tissue 
culture assay. Proceedings of the National Academy of Sciences of the United 
States of America 48, 1014-1022, doi:10.1073/pnas.48.6.1014 (1962). 
53 Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix 
metalloproteinases and TIMPs. Cardiovascular Research 69, 562-573, 
doi:10.1016/j.cardiores.2005.12.002 (2006). 
54 Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifl, S. & Kuliopulos, A. PAR1 
is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis 
of breast cancer cells. Cell 120, 303-313, doi:10.1016/j.cell.2004.12.018 (2005). 
55 Aimes, R. T. & Quigley, J. P. Matrix metalloproteinase-2 is an interstitial 
collagenase. Journal of Biological Chemistry 270, 5872-5876 (1995). 
56 Bigg, H. F., Rowan, A. D., Barker, M. D. & Cawston, T. E. Activity of matrix 
metalloproteinase-9 against native collagen types I and III. Febs Journal 274, 
1246-1255, doi:10.1111/j.1742-4658.2007.05669.x (2007). 
57 Van Wart, H. E. & Birkedal-Hansen, H. The cysteine switch: a principle of 
regulation of metalloproteinase activity with potential applicability to the entire 
matrix metalloproteinase gene family. Proceedings of the National Academy of 
Sciences of the United States of America 87, 5578-5582 (1990). 
58 Nagase, H., Enghild, J. J., Suzuki, K. & Salvesen, G. Stepwise activation 
mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by 
proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29, 5783-5789, 
doi:10.1021/bi00476a020 (1990). 
59 Pei, D. Q. & Weiss, S. J. Furin-dependent intracellular activation of the human 
stromelysin-3 zymogen. Nature 375, 244-247, doi:10.1038/375244a0 (1995). 
238 
 
60 Yana, I. & Weiss, S. J. Regulation of membrane type-1 matrix metalloproteinase 
activation by proprotein convertases. Molecular Biology of the Cell 11, 2387-2401 
(2000). 
61 Rowan, A. D., Litherland, G. J., Hui, W. & Milner, J. M. Metalloproteases as 
potential therapeutic targets in arthritis treatment. Expert Opinion on Therapeutic 
Targets 12, 1-18, doi:10.1517/14728222.12.1.1 (2008). 
62 Milner, J. M., Rowan, A. D., Elliott, S. F. & Cawston, T. E. Inhibition of furin-
like enzymes blocks interleukin-1 alpha/oncostatin M-stimulated cartilage 
degradation. Arthritis and Rheumatism 48, 1057-1066, doi:10.1002/art.10873 
(2003). 
63 Fingleton, B. Matrix metalloproteinases as valid clinical targets. Current 
Pharmaceutical Design 13, 333-346, doi:10.2174/138161207779313551 (2007). 
64 Piccard, H., Van den Steen, P. E. & Opdenakker, G. Hemopexin domains as 
multifunctional liganding modules in matrix metal loproteinases and other 
proteins. Journal of Leukocyte Biology 81, 870-892, doi:10.1189/jlb.1006629 
(2007). 
65 Troeberg, L. & Nagase, H. Proteases involved in cartilage matrix degradation in 
osteoarthritis. Biochimica Et Biophysica Acta-Proteins and Proteomics 1824, 
133-145, doi:10.1016/j.bbapap.2011.06.020 (2012). 
66 Clark, I. M. & Cawston, T. E. Fragments of human fibroblast collagenase - 
Purification and characterization. Biochemical Journal 263, 201-206 (1989). 
67 Knauper, V., Osthues, A., Declerck, Y. A., Langley, K. E., Blaser, J. & Tschesche, 
H. Fragmentation of human polymorphonuclear-leucocyte collagenase. 
Biochemical Journal 291, 847-854 (1993). 
68 Knauper, V., Cowell, S., Smith, B., LopezOtin, C., Oshea, M., Morris, H., Zardi, 
L. & Murphy, G. The role of the c-terminal domain of human collagenase-3 
(MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue 
inhibitor of metalloproteinase interaction. Journal of Biological Chemistry 272, 
7608-7616 (1997). 
69 Murphy, G., Allan, J. A., Willenbrock, F., Cockett, M. I., Oconnell, J. P. & 
Docherty, A. J. P. The role of the C-terminal domain in collagenase and 
stromelysin specificity. Journal of Biological Chemistry 267, 9612-9618 (1992). 
70 Hirose, T., Patterson, C., Pourmotabbed, T., Mainardi, C. L. & Hasty, K. A. 
Structure-function relationship of human neutrophil collagenase: identification of 
regions responsible for substrate specificity and general proteinase activity. 
Proceedings of the National Academy of Sciences of the United States of America 
90, 2569-2573, doi:10.1073/pnas.90.7.2569 (1993). 
71 Harris, E. D., Jr., Cohen, G. L. & Krane, S. M. Synovial collagenase: its presence 
in culture from joint disease of diverse etiology. Arthritis and rheumatism 12, 92-
102, doi:10.1002/art.1780120206 (1969). 
72 Welgus, H. G., Jeffrey, J. J. & Eisen, A. Z. The collagen substrate specificity of 
human skin fibroblast collagenase. Journal of Biological Chemistry 256, 9511-
9515 (1981). 
73 Hasty, K. A., Jeffrey, J. J., Hibbs, M. S. & Welgus, H. G. The collagen substrate 
specificity of human neutrophil collagenase. Journal of Biological Chemistry 262, 
10048-10052 (1987). 
74 Stremme, S., Duerr, S., Bau, B., Schmid, E. & Aigner, T. MMP-8 is only a minor 
gene product of human adult articular chondrocytes of the knee. Clinical and 
Experimental Rheumatology 21, 205-209 (2003). 
75 Shlopov, B. V., Lie, W. R., Mainardi, C. L., Cole, A. A., Chubinskaya, S. & Hasty, 
K. A. Osteoarthritic lesions - Involvement of three different collagenases. 
Arthritis and Rheumatism 40, 2065-2074, doi:10.1002/art.1780401120 (1997). 
239 
 
76 Tetlow, L. C. & Woolley, D. E. Comparative immunolocalization studies of 
collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by 
human chondrocytes and synoviocytes in vitro. British Journal of Rheumatology 
37, 64-70 (1998). 
77 Lindy, O., Konttinen, Y. T., Sorsa, T., Ding, Y. L., Santavirta, S., Ceponis, A. & 
LopezOtin, C. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid 
synovium. Arthritis and Rheumatism 40, 1391-1399, doi:10.1002/art.1780400806 
(1997). 
78 Knauper, V., LopezOtin, C., Smith, B., Knight, G. & Murphy, G. Biochemical 
characterization of human collagenase-3. Journal of Biological Chemistry 271, 
1544-1550 (1996). 
79 Zhang, L., Yang, M., Yang, D., Cavey, G., Davidson, P. & Gibson, G. Molecular 
Interactions of MMP-13 C-Terminal Domain with Chondrocyte Proteins. 
Connective Tissue Research 51, 230-239, doi:10.3109/03008200903288902 
(2010). 
80 Galasso, O., Familiari, F., De Gori, M. & Gasparini, G. Recent findings on the 
role of gelatinases (matrix metalloproteinase-2 and -9) in osteoarthritis. Advances 
in orthopedics 2012, 834208-834208, doi:10.1155/2012/834208 (2012). 
81 Mohtai, M., Smith, R. L., Schurman, D. J., Tsuji, Y., Torti, F. M., Hutchinson, N. 
I., Stetlerstevenson, W. G. & Goldberg, G. I. Expression of 92-kD type IV 
collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction 
in normal human articular cartilage by interleukin Journal of Clinical 
Investigation 92, 179-185, doi:10.1172/jci116547 (1993). 
82 Soder, S., Roach, H. I., Oehler, S., Bau, B., Haag, J. & Aigner, T. MMP-
9/gelatinase B is a gene product of human adult articular chondrocytes and 
increased in osteoarthritic cartilage. Clinical and experimental rheumatology 24, 
302-304 (2006). 
83 Duerr, S., Stremme, S., Soeder, S., Bau, B. & Aigner, T. MMP-2/gelatinase A is 
a gene product of human adult articular chondrocytes and is increased in 
osteoarthritic cartilage. Clinical and Experimental Rheumatology 22, 603-608 
(2004). 
84 Hulejova, H., Baresova, V., Klezl, Z., Polanska, M., Adam, M. & Senolt, L. 
Increased level of cytokines and matrix metalloproteinases in osteoarthritic 
subchondral bone. Cytokine 38, 151-156, doi:10.1016/j.cyto.2007.06.001 (2007). 
85 Poe, M., Stein, R. L. & Wu, J. K. High pressure gel-permeation assay for the 
proteolysis of human aggrecan by human stromelysin-1: kinetic constants for 
aggrecan hydrolysis. Archives of Biochemistry and Biophysics 298, 757-759, 
doi:10.1016/0003-9861(92)90477-e (1992). 
86 Bord, S., Horner, A., Hembry, R. M. & Compston, J. E. Stromelysin-1 (MMP-3) 
and stromelysin-2 (MMP-10) expression in developing human bone: Potential 
roles in skeletal development. Bone 23, 7-12, doi:10.1016/s8756-3282(98)00064-
7 (1998). 
87 Kevorkian, L., Young, D. A., Darrah, C., Donell, S. T., Shepstone, L., Porter, S., 
Brockbank, S. M. V., Edwards, D. R., Parker, A. E. & Clark, I. M. Expression 
profiling of metalloproteinases and their inhibitors in cartilage. Arthritis and 
Rheumatism 50, 131-141, doi:10.1002/art.11433 (2004). 
88 Barksby, H. E., Milner, J. M., Patterson, A. M., Peake, N. J., Hui, W., Robson, T., 
Lakey, R., Middleton, J., Cawston, T. E., Richards, C. D. & Rowan, A. D. Matrix 
metalloproteinase 10 promotion of collagenolysis via procollagenase activation - 
Implications for cartilage degradation in arthritis. Arthritis and Rheumatism 54, 
3244-3253, doi:10.1002/art.22167 (2006). 
240 
 
89 Knauper, V., Murphy, G. & Tschesche, H. Activation of human neutrophil 
procollagenase by stromelysin 2. European Journal of Biochemistry 235, 187-
191, doi:10.1111/j.1432-1033.1996.00187.x (1996). 
90 Chen, J.-J., Huang, J.-F., Du, W.-X. & Tong, P.-J. Expression and significance of 
MMP3 in synovium of knee joint at different stage in osteoarthritis patients. Asian 
Pacific Journal of Tropical Medicine 7, 297-300, doi:10.1016/s1995-
7645(14)60042-0 (2014). 
91 Murphy, G. & Nagase, H. Localizing matrix metalloproteinase activities in the 
pericellular environment. Febs Journal 278, 2-15, doi:10.1111/j.1742-
4658.2010.07918.x (2011). 
92 Lee, M. H., Rapti, M. & Murphy, G. Unveiling the surface Epitopes that render 
tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix 
metalloproteinase. Journal of Biological Chemistry 278, 40224-40230, 
doi:10.1074/jbc.M305678200 (2003). 
93 Edwards, D. R., Handsley, M. M. & Pennington, C. J. The ADAM 
metalloproteinases. Molecular Aspects of Medicine 29, 258-289, 
doi:10.1016/j.mam.2008.08.001 (2008). 
94 Zack, M. D., Malfait, A.-M., Skepner, A. P., Yates, M. P., Griggs, D. W., Hall, 
T., Hills, R. L., Alston, J. T., Nemirovskiy, O. V., Radabaugh, M. R., Leone, J. 
W., Arner, E. C. & Tortorella, M. D. ADAM-8 Isolated From Human 
Osteoarthritic Chondrocytes Cleaves Fibronectin at Ala(271). Arthritis and 
Rheumatism 60, 2704-2713, doi:10.1002/art.24753 (2009). 
95 Kerna, I., Kisand, K., Laitinen, P., Tamm, A. E., Kumm, J., Lintrop, M. & Tamm, 
A. O. Association of ADAM12-S protein with radiographic features of knee 
osteoarthritis and bone and cartilage markers. Rheumatology International 32, 
519-523, doi:10.1007/s00296-010-1717-6 (2012). 
96 Bohm, B. B., Burkhardt, H., Aigner, T., Blobel, C. P. & Kalden, J. R. 
Upregulation of MDC15 (metargidin) mRNA in human osteoarthritic cartilage. 
Arthritis and Rheumatism 42, S252-S252 (1999). 
97 Bohm, B. B., Aigner, T., Roy, B., Brodie, T. A., Blobel, C. P. & Burkhardt, H. 
Homeostatic effects of the metalloproteinase disintegrin ADAM15 in 
degenerative cartilage remodeling. Arthritis and Rheumatism 52, 1100-1109, 
doi:10.1002/art.20974 (2005). 
98 Reiss, K. & Saftig, P. The "A Disintegrin And Metalloprotease" (ADAM) family 
of sheddases: Physiological and cellular functions. Seminars in Cell & 
Developmental Biology 20, 126-137, doi:10.1016/j.semcdb.2008.11.002 (2009). 
99 Roghani, M., Becherer, J. D., Moss, M. L., Atherton, R. E., Erdjument-Bromage, 
H., Arribas, J., Blackburn, R. K., Weskamp, G., Tempst, P. & Blobel, C. P. 
Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic 
activity. Journal of Biological Chemistry 274, 3531-3540, 
doi:10.1074/jbc.274.6.3531 (1999). 
100 Seals, D. F. & Courtneidge, S. A. The ADAMs family of metalloproteases: 
multidomain proteins with multiple functions. Genes & Development 17, 7-30, 
doi:10.1101/gad.1039703 (2003). 
101 Porter, S., Clark, I. M., Kevorkian, L. & Edwards, D. R. The ADAMTS 
metalloproteinases. Biochemical Journal 386, 15-27, doi:10.1042/bj20040424 
(2005). 
102 Longpre, J.-M., McCulloch, D. R., Koo, B.-H., Alexander, J. P., Apte, S. S. & 
Leduc, R. Characterization of proADAMTS5 processing by proprotein 
convertases. International Journal of Biochemistry & Cell Biology 41, 1116-1126, 
doi:10.1016/j.biocel.2008.10.008 (2009). 
241 
 
103 Gao, G., Plaas, A., Thompson, V. P., Jin, S., Zuo, F. R. & Sandy, J. D. ADAMTS4 
(aggrecanase-1) activation on the cell surface involves C-terminal cleavage by 
glycosylphosphatidyl inositol-anchored membrane type 4-matrix 
metalloproteinase and binding of the activated proteinase to chondroitin sulfate 
and heparan sulfate on syndecan-1. Journal of Biological Chemistry 279, 10042-
10051, doi:10.1074/jbc.M312100200 (2004). 
104 Flannery, C. R., Zeng, W. L., Corcoran, C., Collins-Racie, L. A., Chockalingam, 
P. S., Hebert, T., Mackie, S. A., McDonagh, T., Crawford, T. K., Tomkinson, K. 
N., LaVallie, E. R. & Morris, E. A. Autocatalytic cleavage of ADAMTS-4 
(Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. Journal of 
Biological Chemistry 277, 42775-42780, doi:10.1074/jbc.M205309200 (2002). 
105 Gendron, C., Kashiwagi, M., Lim, N. H., Enghild, J. J., Thogersen, I. B., Hughes, 
C., Caterson, B. & Nagase, H. Proteolytic activities of human ADAMTS-5 - 
Comparative studies with ADAMTS-4. Journal of Biological Chemistry 282, 
18294-18306, doi:10.1074/jbc.M701523200 (2007). 
106 Plaas, A., Osborn, B., Yoshihara, Y., Bai, Y., Bloom, T., Nelson, F., Mikecz, K. 
& Sandy, J. D. Aggrecanolysis in human osteoarthritis: confocal localization and 
biochemical characterization of ADAMTS5 - hyaluronan complexes in articular 
cartilages. Osteoarthritis and Cartilage 15, 719-734, 
doi:10.1016/j.joca.2006.12.008 (2007). 
107 Szabo, R. & Bugge, T. H. Type II transmembrane serine proteases in development 
and disease. International Journal of Biochemistry & Cell Biology 40, 1297-1316, 
doi:10.1016/j.biocel.2007.11.013 (2008). 
108 Miller, G. S. & List, K. The matriptase-prostasin proteolytic cascade in epithelial 
development and pathology. Cell and Tissue Research 351, 245-253, 
doi:10.1007/s00441-012-1348-1 (2013). 
109 Blow, D. M., Birktoft, J. J. & Hartley, B. S. Role of a buried acid group in the 
mechanism of action of chymotrypsin. Nature 221, 337-340, 
doi:10.1038/221337a0 (1969). 
110 Kraut, J. Serine Proteases: Structure and Mechanism of Catalysis. Annual Review 
of Biochemistry 46, 331-358, doi:10.1146/annurev.bi.46.070177.001555 (1977). 
111 List, K., Haudenschild, C. C., Szabo, R., Chen, W. J., Wahl, S. M., Swaim, W., 
Engelholm, L. H., Behrendt, N. & Bugge, T. H. Matriptase/MT-SP1 is required 
for postnatal survival, epidermal barrier function, hair follicle development, and 
thymic homeostasis. Oncogene 21, 3765-3779, doi:10.1038/sj/onc/1205502 
(2002). 
112 List, K., Szabo, R., Wertz, P. W., Segre, J., Haudenschild, C. C., Kim, S. Y. & 
Bugge, T. H. Loss of proteolytically processed filaggrin caused by epidermal 
deletion of matriptase/MT-SP1. Journal of Cell Biology 163, 901-910, 
doi:10.1083/jcb.200304161 (2003). 
113 Basel-Vanagaite, L., Attia, R., Ishida-Yamamoto, A., Rainshtein, L., Ben Amitai, 
D., Lurie, R., Pasmanik-Chor, M., Indelman, M., Zvulunov, A., Saban, S., Magal, 
N., Sprecher, E. & Shohat, M. Autosomal recessive ichthyosis with hypotrichosis 
caused by a mutation in ST14, encoding type II transmembrane serine protease 
matriptase. American Journal of Human Genetics 80, 467-477, 
doi:10.1086/512487 (2007). 
114 Uhland, K. Matriptase and its putative role in cancer. Cellular and Molecular Life 
Sciences 63, 2968-2978, doi:10.1007/s0018-006-6298-x (2006). 
115 Takeuchi, T., Harris, J. L., Huang, W., Yan, K. W., Coughlin, S. R. & Craik, C. 
S. Cellular localization of membrane-type serine protease 1 and identification of 
protease-activated receptor-2 and single-chain urokinase-type plasminogen 
242 
 
activator as substrates. Journal of Biological Chemistry 275, 26333-26342, 
doi:10.1074/jbc.M002941200 (2000). 
116 Cho, E. G., Kim, M. G., Kim, C., Kim, S. R., Seong, I. S., Chung, C. H., Schwartz, 
R. H. & Park, D. N-terminal processing is essential for release of epithin, a mouse 
type II membrane serine protease. Journal of Biological Chemistry 276, 44581-
44589, doi:10.1074/jbc.M107059200 (2001). 
117 Kim, C., Cho, Y. C., Kang, C. H., Kim, M. G., Lee, H. S., Cho, E. G. & Park, D. 
Filamin is essential for shedding of the transmembrane serine protease, epithin. 
Embo Reports 6, 1045-1051, doi:10.1038/sj.embor.7400534 (2005). 
118 Oberst, M. D., Williams, C. A., Dickson, R. B., Johnson, M. D. & Lin, C. Y. The 
activation of matriptase requires its noncatalytic domains, serine protease domain, 
and its cognate inhibitor. Journal of Biological Chemistry 278, 26773-26779, 
doi:10.1074/jbc.M304282200 (2003). 
119 Inouye, K., Yasumoto, M., Tsuzuki, S., Mochida, S. & Fushiki, T. The optimal 
activity of a pseudozymogen form of recombinant matriptase under the mildly 
acidic pH and low ionic strength conditions. Journal of Biochemistry 147, 485-
492, doi:10.1093/jb/mvp190 (2010). 
120 Satomi, S., Yamasaki, Y., Tsuzuki, S., Hitomi, Y., Iwanaga, T. & Fushiki, T. A 
role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. 
Biochemical and Biophysical Research Communications 287, 995-1002, 
doi:10.1006/bbrc.2001.5686 (2001). 
121 Milner, J. M., Patel, A. & Rowan, A. D. Emerging Roles of Serine Proteinases in 
Tissue Turnover in Arthritis. Arthritis and Rheumatism 58, 3644-3656, 
doi:10.1002/art.24046 (2008). 
122 Okroj, M., Heinegard, D., Holmdahl, R. & Blom, A. M. Rheumatoid arthritis and 
the complement system. Annals of Medicine 39, 517-530, 
doi:10.1080/07853890701477546 (2007). 
123 Wang, Q., Rozelle, A. L., Lepus, C. M., Scanzello, C. R., Song, J. J., Larsen, D. 
M., Crish, J. F., Bebek, G., Ritter, S. Y., Lindstrom, T. M., Hwang, I. Y., Wong, 
H. D. H., Punzi, L., Encarnacion, A., Shamloo, M., Goodman, S. B., Wyss-Coray, 
T., Goldring, S. R., Banda, N. K., Thurman, J. M., Gobezie, R., Crow, M. K., 
Holers, V. M., Lee, D. M. & Robinson, W. H. Identification of a central role for 
complement in osteoarthritis. Nature Medicine 17, 1674-U1196, 
doi:10.1038/nm.2543 (2011). 
124 Busso, N. & Hamilton, J. A. Extravascular coagulation and the plasminogen 
activator/plasmin system in rheumatoid arthritis. Arthritis and Rheumatism 46, 
2268-2279, doi:10.1002/art.10498 (2002). 
125 Yang, Y. H., Hall, P., Little, C. B., Fosang, A. J., Milenkovski, G., Santos, L., 
Xue, J., Tipping, P. & Morand, E. F. Reduction of arthritis severity in protease-
activated receptor-deficient mice. Arthritis and Rheumatism 52, 1325-1332, 
doi:10.1002/art.21001 (2005). 
126 Marty, I., Peclat, V., Kirdaite, G., Salvi, R., So, A. & Busso, N. Amelioration of 
collagen-induced arthritis by thrombin inhibition. Journal of Clinical 
Investigation 107, 631-640, doi:10.1172/jci11064 (2001). 
127 Camerer, E., Huang, W. & Coughlin, S. R. Tissue factor- and factor X-dependent 
activation of protease-activated receptor 2 by factor VIIa. Proceedings of the 
National Academy of Sciences of the United States of America 97, 5255-5260, 
doi:10.1073/pnas.97.10.5255 (2000). 
128 Boileau, C., Amiable, N., Martel-Pelletier, J., Fahmi, H., Duval, N. & Pelletier, 
J.-P. Activation of proteinase-activated receptor 2 in human osteoarthritic 
cartilage upregulates catabolic and proinflammatory pathways capable of 
243 
 
inducing cartilage degradation: a basic science study. Arthritis Research & 
Therapy 9, doi:10.1186/ar2329 (2007). 
129 Hu, S. I., Carozza, M., Klein, M., Nantermet, P., Luk, D. & Crowl, R. M. Human 
HtrA, an evolutionarily conserved serine protease identified as a differentially 
expressed gene product in osteoarthritic cartilage. Journal of Biological 
Chemistry 273, 34406-34412, doi:10.1074/jbc.273.51.34406 (1998). 
130 Vande Walle, L., Lamkanfi, M. & Vandenabeele, P. The mitochondrial serine 
protease HtrA2/Omi: an overview. Cell Death and Differentiation 15, 453-460, 
doi:10.1038/sj.cdd.4402291 (2008). 
131 Tsuchiya, A., Yano, M., Tocharus, J., Kojima, H., Fukumoto, M., Kawaichi, M. 
& Oka, C. Expression of mouse HtrA1 serine protease in normal bone and 
cartilage and its upregulation in joint cartilage damaged by experimental arthritis. 
Bone 37, 323-336, doi:10.1016/j.bone.2005.03.015 (2005). 
132 Tocharus, J., Tsuchiya, A., Kajikawa, M., Ueta, Y., Oka, C. & Kawaichi, M. 
Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor 
of TGF-beta signaling. Development Growth & Differentiation 46, 257-274 
(2004). 
133 Chamberland, A., Wang, E., Jones, A. R., Collins-Racie, L. A., LaVallie, E. R., 
Huang, Y., Liu, L., Morris, E. A., Flannery, C. R. & Yang, Z. Identification of a 
novel HtrA1-susceptible cleavage site in human aggrecan: evidence for the 
involvement of HtrA1 in aggrecan proteolysis in vivo. Journal of Biological 
Chemistry 284, 27352-27359, doi:10.1074/jbc.M109.037051 (2009). 
134 Lopez-Otin, C. & Matrisian, L. M. Tumour micro environment - Opinion - 
Emerging roles of proteases in tumour suppression. Nature Reviews Cancer 7, 
800-808, doi:10.1038/nrc2228 (2007). 
135 Berti, P. & Storer, A. Alignment/phylogeny of the papain superfamily of cysteine 
proteases. Journal of Molecular Biology 246, 273-283 (1995). 
136 Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., 
Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., 
Elliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J. F., Egger, L. A., 
Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, 
J. P., Yamin, T. T., Lee, T. D., Shively, J. E., Maccross, M., Mumford, R. A., 
Schmidt, J. A. & Tocci, M. J. A novel heterodimeric cysteine protease is required 
for inteleukin-1 beta processing in monocytes. Nature 356, 768-774, 
doi:10.1038/356768a0 (1992). 
137 Saido, T. C., Sorimachi, H. & Suzuki, K. Calpain: new perspectives in molecular 
diversity and physiological-pathological involvement. Faseb Journal 8, 814-822 
(1994). 
138 Turk, V., Turk, B. & Turk, D. Lysosomal cysteine proteases: facts and 
opportunities. Embo Journal 20, 4629-4633, doi:10.1093/emboj/20.17.4629 
(2001). 
139 Korkmaz, B., Moreau, T. & Gauthier, F. Neutrophil elastase, proteinase 3 and 
cathepsin G: Physicochemical properties, activity and physiopathological 
functions. Biochimie 90, 227-242, doi:10.1016/j.biochi.2007.10.009 (2008). 
140 McDonald, J. & Barrett, A. in Mammalian Proteases Vol. 2    357 (New York: 
Academic, 1986). 
141 Takahashi, T. & Tang, J. Cathepsin D from porcine and bovine spleen. Methods 
in Enzymology 80, 565-581 (1981). 
142 Rossi, A., Deveraux, Q., Turk, B. & Sali, A. Comprehensive search for cysteine 
cathepsins in the human genome. Biological Chemistry 385, 363-372, 
doi:10.1515/bc.2004.040 (2004). 
244 
 
143 McGrath, M. E. The lysosomal cysteine proteases. Annual Review of Biophysics 
and Biomolecular Structure 28, 181-204, doi:10.1146/annurev.biophys.28.1.181 
(1999). 
144 Wang, J., Xiang, Y. F. & Lim, C. THE DOUBLE CATALYTIC TRIAD, CYS25-
HIS159-ASP158 AND CYS25-HIS159-ASN175, IN PAPAIN CATALYSIS - 
ROLE OF ASP158 AND ASN175. Protein Engineering 7, 75-82, 
doi:10.1093/protein/7.1.75 (1994). 
145 Vernet, T., Tessier, D. C., Chatellier, J., Plouffe, C., Lee, T. S., Thomas, D. Y., 
Storer, A. C. & Menard, R. Structural and Functional Roles of Asparagine 175 in 
the Cysteine Protease Papain. Journal of Biological Chemistry 270, 16645-16652 
(1995). 
146 Shokhen, M., Khazanov, N. & Albeck, A. Challenging a paradigm: Theoretical 
calculations of the protonation state of the Cys25-His159 catalytic diad in free 
papain. Proteins-Structure Function and Bioinformatics 77, 916-926, 
doi:10.1002/prot.22516 (2009). 
147 Ishidoh, K. & Kominami, E. Processing and activation of lysosomal proteinases. 
Biological Chemistry 383, 1827-1831, doi:10.1515/bc.2002.206 (2002). 
148 Turk, D., Podobnik, M., Kuhelj, R., Dolinar, M. & Turk, V. Crystal structures of 
human procathepsin B at 3.2 and 3.3 angstrom resolution reveal an interaction 
motif between a papain-like cysteine protease and its propeptide. Febs Letters 
384, 211-214, doi:10.1016/0014-5793(96)00309-2 (1996). 
149 Coulombe, R., Grochulski, P., Sivaraman, J., Menard, R., Mort, J. S. & Cygler, 
M. Structure of human procathepsin L reveals the molecular basis of inhibition by 
the prosegment. Embo Journal 15, 5492-5503 (1996). 
150 Sivaraman, J., Lalumiere, M., Menard, R. & Cygler, M. Crystal structure of wild-
type human procathepsin K. Protein Science 8, 283-290 (1999). 
151 LaLonde, J. M., Zhao, B. G., Janson, C. A., D'Alessio, K. J., McQueney, M. S., 
Orsini, M. J., Debouck, C. M. & Smith, W. W. The crystal structure of human 
procathepsin K. Biochemistry 38, 862-869, doi:10.1021/bi9822271 (1999). 
152 Pungercar, J. R., Caglic, D., Sajid, M., Dolinar, M., Vasiljeva, O., Pozgan, U., 
Turk, D., Bogyo, M., Turk, V. & Turk, B. Autocatalytic processing of 
procathepsin B is triggered by proenzyme activity. Febs Journal 276, 660-668, 
doi:10.1111/j.1742-4658.2008.06815.x (2009). 
153 Dahl, S. W., Halkier, T., Lauritzen, C., Dolenc, I., Pedersen, J., Turk, V. & Turk, 
B. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated 
by cathepsins L and S but not by autocatalytic processing. Biochemistry 40, 1671-
1678, doi:10.1021/bi001693z (2001). 
154 Nagler, D. K., Zhang, R. L., Tam, W., Sulea, T., Purisima, E. O. & Menard, R. 
Human cathepsin X: A cysteine protease with unique carboxypeptidase activity. 
Biochemistry 38, 12648-12654, doi:10.1021/bi991371z (1999). 
155 Schick, C., Pemberton, P. A., Shi, G. P., Kamachi, Y., Cataltepe, S., Bartuski, A. 
J., Gornstein, E. R., Bromme, D., Chapman, H. A. & Silverman, G. A. Cross-class 
inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin 
squamous cell carcinoma antigen 1: A kinetic analysis. Biochemistry 37, 5258-
5266, doi:10.1021/bi972521d (1998). 
156 Gondi, C. S. & Rao, J. S. Cathepsin B as a cancer target. Expert Opinion on 
Therapeutic Targets 17, 281-291, doi:10.1517/14728222.2013.740461 (2013). 
157 Fais, S. Cannibalism: A way to feed on metastatic tumors. Cancer Letters 258, 
155-164, doi:10.1016/j.canlet.2007.09.014 (2007). 
158 Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, 
M., Gunzler, W. A., Janicke, F. & Graeff, H. Cathepsin B Efficiently Activates 
the Soluble and the Tumor Cell Receptor-bound Form of the Proenzyme 
245 
 
Urokinase-type Plasminogen Activator (Pro-uPA). Journal of Biological 
Chemistry 266, 5147-5152 (1991). 
159 Kostoulas, G., Lang, A., Nagase, H. & Baici, A. Stimulation of angiogenesis 
through cathepsin B inactivation of the tissue inhibitors of matrix 
metalloproteinases. Febs Letters 455, 286-290, doi:10.1016/s0014-
5793(99)00897-2 (1999). 
160 Bromme, D. & Lecaille, F. Cathepsin K inhibitors for osteoporosis and potential 
off-target effects. Expert Opinion on Investigational Drugs 18, 585-600, 
doi:10.1517/13543780902832661 (2009). 
161 Drake, F. H., Dodds, R. A., James, I. E., Connor, J. R., Debouck, C., Richardson, 
S., LeeRykaczewski, E., Coleman, L., Rieman, D., Barthlow, R., Hastings, G. & 
Gowen, M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in 
human osteoclasts. Journal of Biological Chemistry 271, 12511-12516 (1996). 
162 Garnero, P., Borel, O., Byrjalsen, I., Ferreras, M., Drake, F. H., McQueney, M. 
S., Foged, N. T., Delmas, P. D. & Delaisse, J. M. The collagenolytic activity of 
cathepsin K is unique among mammalian proteinases. Journal of Biological 
Chemistry 273, 32347-32352, doi:10.1074/jbc.273.48.32347 (1998). 
163 Kafienah, W., Bromme, D., Buttle, D. J., Croucher, L. J. & Hollander, A. P. 
Human cathepsin K cleaves native type I and II collagens at the N-terminal end 
of the triple helix. Biochemical Journal 331, 727-732 (1998). 
164 Lecaille, F., Broemme, D. & Lalmanach, G. Biochemical properties and 
regulation of cathepsin K activity. Biochimie 90, 208-226, 
doi:10.1016/j.biochi.2007.08.011 (2008). 
165 Aguda, A. H., Panwar, P., Du, X., Nguyen, N. T., Brayer, G. D. & Broemme, D. 
Structural basis of collagen fiber degradation by cathepsin K. Proceedings of the 
National Academy of Sciences of the United States of America 111, 17474-17479, 
doi:10.1073/pnas.1414126111 (2014). 
166 Panwar, P., Soe, K., Guido, R. V. C., Bueno, R. V. C., Delaisse, J.-M. & 
Broemme, D. A novel approach to inhibit bone resorption: exosite inhibitors 
against cathepsin K. British Journal of Pharmacology 173, 396-410, 
doi:10.1111/bph.13383 (2016). 
167 Gupta, S., Singh, R. K., Dastidar, S. & Ray, A. Cysteine cathepsin S as an 
immunomodulatory target: present and future trends. Expert Opinion on 
Therapeutic Targets 12, 291-299, doi:10.1517/14728222.12.3.291 (2008). 
168 Liuzzo, J. P., Petanceska, S. S., Moscatelli, D. & Devi, L. A. Inflammatory 
mediators regulate cathepsin S in macrophages and microglia: A role in 
attenuating heparan sulfate interactions. Molecular Medicine 5, 320-333 (1999). 
169 Vasiljeva, O., Dolinar, M., Pungercar, J. R., Turk, V. & Turk, B. Recombinant 
human procathepsin S is capable of autocatalytic processing at neutral pH in the 
presence of glycosaminoglycans. Febs Letters 579, 1285-1290, 
doi:10.1016/j.febslet.2004.12.093 (2005). 
170 Xin, X. Q., Gunesekera, B. & Mason, R. W. The specificity and elastinolytic 
activities of bovine cathepsins S and H. Archives of Biochemistry and Biophysics 
299, 334-339, doi:10.1016/0003-9861(92)90283-3 (1992). 
171 Nakagawa, T. Y., Brissette, W. H., Lira, P. D., Griffiths, R. J., Petrushova, N., 
Stock, J., McNeish, J. D., Eastman, S. E., Howard, E. D., Clarke, S. R. M., 
Rosloniec, E. F., Elliott, E. A. & Rudensky, A. Y. Impaired invariant chain 
degradation and antigen presentation and diminished collagen-induced arthritis in 
cathepsin S null mice. Immunity 10, 207-217, doi:10.1016/s1074-7613(00)80021-
7 (1999). 
172 Beck, H., Schwarz, G., Schroter, C. J., Deeg, M., Baier, D., Stevanovic, S., Weber, 
E., Driessen, C. & Kalbacher, H. Cathepsin S and an asparagine-specific 
246 
 
endoprotease dominate the proteolytic processing of human myelin basic protein 
in vitro. European Journal of Immunology 31, 3726-3736, doi:10.1002/1521-
4141(200112)31:12<3726::aid-immu3726>3.0.co;2-o (2001). 
173 Fajardo, I., Svensson, L., Bucht, A. & Pejler, G. Increased levels of hypoxia-
sensitive proteins in allergic airway inflammation. American Journal of 
Respiratory and Critical Care Medicine 170, 477-484, doi:10.1164/rccm.200402-
1780C (2004). 
174 Lankelma, J. M., Voorend, D. M., Barwari, T., Koetsveld, J., Van der Spek, A. 
H., De Porto, A. P. N. A., Van Rooijen, G. & Van Noorden, C. J. F. Cathepsin L, 
target in cancer treatment? Life Sciences 86, 225-233, 
doi:10.1016/j.lfs.2009.11.016 (2010). 
175 Santamaria, I., Velasco, G., Cazorla, M., Fueyo, A., Campo, E. & Lopez-Otin, C. 
Cathepsin L2, a novel human cysteine proteinase produced by breast and 
colorectal carcinomas. Cancer Research 58, 1624-1630 (1998). 
176 Bromme, D., Li, Z. Q., Barnes, M. & Mehler, E. Human cathepsin V functional 
expression, tissue distribution, electrostatic surface potential, enzymatic 
characterization, and chromosomal localization. Biochemistry 38, 2377-2385, 
doi:10.1021/bi982175f (1999). 
177 Puzer, L., Cotrin, S. S., Alves, M. F. M., Egborge, T., Araujo, M. S., Juliano, M. 
A., Juliano, L., Bromme, D. & Carmona, A. K. Comparative substrate specificity 
analysis of recombinant human cathepsin V and cathepsin L. Archives of 
Biochemistry and Biophysics 430, 274-283, doi:10.1016/j.abb.2004.07.006 
(2004). 
178 Werle, B., Julke, B., Lah, T., Spiess, E. & Ebert, W. Cathepsin B fraction active 
at physiological pH of 7.5 is of prognostic significance in squamous cell 
carcinoma of human lung. British Journal of Cancer 75, 1137-1143, 
doi:10.1038/bjc.1997.196 (1997). 
179 Buck, M. R., Karustis, D. G., Day, N. A., Honn, K. V. & Sloane, B. F. Degradation 
of extracellular-matrix proteins by human cathepsin B from normal and tumour 
tissues. Biochemical Journal 282, 273-278 (1992). 
180 Bromme, D., Okamoto, K., Wang, B. B. & Biroc, S. Human cathepsin O-2, a 
matrix protein-degrading cysteine protease expressed in osteoclasts - Functional 
expression of human cathepsin O-2 in Spodoptera frugiperda and characterization 
of the enzyme. Journal of Biological Chemistry 271, 2126-2132 (1996). 
181 Turk, B., Dolenc, I., Turk, V. & Bieth, J. G. Kinetics of the pH-induced 
inactivation of human cathepsin L. Biochemistry 32, 375-380, 
doi:10.1021/bi00052a046 (1993). 
182 Dehrmann, F. M., Coetzer, T. H. T., Pike, R. N. & Dennison, C. Mature cathepsin 
L is substantially active in the ionic milieu of the extracellular medium. Archives 
of Biochemistry and Biophysics 324, 93-98, doi:10.1006/abbi.1995.9924 (1995). 
183 Konttinen, Y. T., Mandelin, J., Li, T. F., Salo, J., Lassus, J., Liljestrom, M., 
Hukkanen, M., Takagi, M., Virtanen, I. & Santavirta, S. Acidic cysteine 
endoproteinase cathepsin K in the degeneration of the superficial articular hyaline 
cartilage in osteoarthritis. Arthritis and Rheumatism 46, 953-960, 
doi:10.1002/art.10185 (2002). 
184 Dejica, V. M., Mort, J. S., Laverty, S., Percival, M. D., Antoniou, J., Zukor, D. J. 
& Poole, A. R. Cleavage of type II collagen by cathepsin K in human osteoarthritic 
cartilage. American Journal of Pathology 173, 161-169, 
doi:10.2353/ajpath.2008.070494 (2008). 
185 Bayliss, M. T. & Yousufali, S. Studies on cathepsin B in human articular cartilage. 
Biochemical Journal 171, 149-154 (1978). 
247 
 
186 Baici, A., Horler, D., Lang, A., Merlin, C. & Kissling, R. Cathepsin B in 
osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. 
Annals of the Rheumatic Diseases 54, 281-288, doi:10.1136/ard.54.4.281 (1995). 
187 Mehraban, F., Tindal, M. H., Proffitt, M. M. & Moskowitz, R. W. Temporal 
pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and 
synovium from rabbit knees with experimental osteoarthritis: Gene expression in 
chondrocytes in response to interleukin-1 and matrix depletion. Annals of the 
Rheumatic Diseases 56, 108-115, doi:10.1136/ard.56.2.108 (1997). 
188 Mort, J. S., Magny, M. C. & Lee, E. R. Cathepsin B: an alternative protease for 
the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. 
Biochemical Journal 335, 491-494 (1998). 
189 Dvir-Ginzberg, M., Gagarina, V., Lee, E. J., Booth, R., Gabay, O. & Hall, D. J. 
Tumor Necrosis Factor alpha-Mediated Cleavage and Inactivation of SirT1 in 
Human Osteoarthritic Chondrocytes. Arthritis and Rheumatism 63, 2363-2373, 
doi:10.1002/art.30279 (2011). 
190 Caglic, D., Repnik, U., Jedeszko, C., Kosec, G., Miniejew, C., Kindermann, M., 
Vasiljeva, O., Turk, V., Wendt, K. U., Sloane, B. F., Goldring, M. B. & Turk, B. 
The proinflammatory cytokines interleukin-1 alpha and tumor necrosis factor 
alpha promote the expression and secretion of proteolytically active cathepsin S 
from human chondrocytes. Biological Chemistry 394, 307-316, doi:10.1515/hsz-
2012-0283 (2013). 
191 Ben-Aderet, L., Merquiol, E., Fahham, D., Kumar, A., Reich, E., Ben-Nun, Y., 
Kandel, L., Haze, A., Liebergall, M., Kosinska, M. K., Steinmeyer, J., Turk, B., 
Blum, G. & Dvir-Ginzberg, M. Detecting cathepsin activity in human 
osteoarthritis via activity-based probes. Arthritis Research & Therapy 17, 
doi:10.1186/s13075-015-0586-5 (2015). 
192 Hou, W. S., Li, Z. Q., Buttner, F. H., Bartnik, E. & Bromme, D. Cleavage site 
specificity of cathepsin K toward cartilage proteoglycans and protease complex 
formation. Biological Chemistry 384, 891-897, doi:10.1515/bc.2003.100 (2003). 
193 Fonovic, M. & Turk, B. Cysteine cathepsins and extracellular matrix degradation. 
Biochimica Et Biophysica Acta-General Subjects 1840, 2560-2570, 
doi:10.1016/j.bbagen.2014.03.017 (2014). 
194 Morko, J., Kiviranta, R., Joronen, K., Saamanen, A. M., Vuorio, E. & Salminen-
Mankonen, H. Spontaneous development of synovitis and cartilage degeneration 
in transgenic mice overexpressing cathepsin K. Arthritis and Rheumatism 52, 
3713-3717, doi:10.1002/art.21423 (2005). 
195 Vinardell, T., Dejica, V., Poole, A. R., Mort, J. S., Richard, H. & Laverty, S. 
Evidence to suggest that cathepsin K degrades articular cartilage in naturally 
occurring equine osteoarthritis. Osteoarthritis and Cartilage 17, 375-383, 
doi:10.1016/j.joca.2008.07.017 (2009). 
196 Connor, J. R., LePage, C., Swift, B. A., Yamashita, D., Bendele, A. M., Maul, D. 
& Kumar, S. Protective effects of a cathepsin K inhibitor, SB-553484, in the 
canine partial medial meniscectomy model of osteoarthritis. Osteoarthritis and 
Cartilage 17, 1236-1243, doi:10.1016/j.joca.2009.03.015 (2009). 
197 Takahashi, D., Iwasaki, N., Kon, S., Matsui, Y., Majima, T., Minami, A. & Uede, 
T. Down-Regulation of Cathepsin K in Synovium Leads to Progression of 
Osteoarthritis in Rabbits. Arthritis and Rheumatism 60, 2372-2380, 
doi:10.1002/art.24718 (2009). 
198 Hayami, T., Zhuo, Y., Wesolowski, G. A., Pickarski, M. & Duong, L. T. 
Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate 
ligament transection rabbit and murine models of osteoarthritis. Bone 50, 1250-
1259, doi:10.1016/j.bone.2012.03.025 (2012). 
248 
 
199 Robbins, M., Judge, A. & MacLachlan, I. siRNA and Innate Immunity. 
Oligonucleotides 19, 89-101, doi:10.1089/oli.2009.0180 (2009). 
200 Adams, M. N., Ramachandran, R., Yau, M.-K., Suen, J. Y., Fairlie, D. P., 
Hollenberg, M. D. & Hooper, J. D. Structure, function and pathophysiology of 
protease activated receptors. Pharmacology & Therapeutics 130, 248-282, 
doi:10.1016/j.pharmthera.2011.01.003 (2011). 
201 Kahn, M. L., Hammes, S. R., Botka, C. & Coughlin, S. R. Gene and locus 
structure and chromosomal localization of the protease-activated receptor gene 
family. Journal of Biological Chemistry 273, 23290-23296, 
doi:10.1074/jbc.273.36.23290 (1998). 
202 Nieman, M. T. & Schmaier, A. H. Interaction of thrombin with PAR1 and PAR4 
at the thrombin cleavage site. Biochemistry 46, 8603-8610, 
doi:10.1021/bi700597p (2007). 
203 Sprang, S. R. & DeCamp, D. L. in Encyclopedia of the Neurological Sciences 
(Second Edition)     560–563 (2014). 
204 Soh, U. J. K., Dores, M. R., Chen, B. & Trejo, J. Signal transduction by protease-
activated receptors. British Journal of Pharmacology 160, 191-203, 
doi:10.1111/j.1476-5381.2010.00705.x (2010). 
205 Nystedt, S., Emilsson, K., Larsson, A. K., Strombeck, B. & Sundelin, J. Molecular 
cloning and functional expression of the gene encoding the human proteinase-
activated receptor 2. European Journal of Biochemistry 232, 84-89, 
doi:10.1111/j.1432-1033.1995.tb20784.x (1995). 
206 Molino, M., Barnathan, E. S., Numerof, R., Clark, J., Dreyer, M., Cumashi, A., 
Hoxie, J. A., Schechter, N., Woolkalis, M. & Brass, L. F. Interactions of mast cell 
tryptase with thrombin receptors and PAR-2. Journal of Biological Chemistry 
272, 4043-4049 (1997). 
207 Knecht, W., Cottrell, G. S., Amadesi, S., Mohlin, J., Skaregarde, A., Gedda, K., 
Peterson, A., Chapman, K., Hollenberg, M. D., Vergnolle, N. & Bunnett, N. W. 
Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to 
induce inflammation and hyperalgesia. Journal of Biological Chemistry 282, 
26089-26100, doi:10.1074/jbc.M703840200 (2007). 
208 Hansen, K. K., Sherman, P. M., Cellars, L., Andrade-Gordon, P., Pan, Z. Y., 
Baruch, A., Wallace, J. L., Hollenberg, M. D. & Vergnolle, N. A major role for 
proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of 
infectious colitis. Proceedings of the National Academy of Sciences of the United 
States of America 102, 8363-8368, doi:10.1073/pnas.0409535102 (2005). 
209 Mize, G. J., Wang, W. & Takayama, T. K. Prostate-specific kallikreins-2 and-4 
enhance the proliferation of DU-145 prostate cancer cells through protease-
activated receptors-1 and-2. Molecular Cancer Research 6, 1043-1051, 
doi:10.1158/1541-7786.mcr-08-0096 (2008). 
210 Oikonomopoulou, K., Hansen, K. K., Saifeddine, M., Tea, I., Blaber, M., Blaber, 
S. I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G. S., Bunnett, N. W., 
Diamandis, E. P. & Hollenberg, M. D. Proteinase-activated receptors, targets for 
kallikrein signaling. Journal of Biological Chemistry 281, 32095-32112, 
doi:10.1074/jbc.M513138200 (2006). 
211 Wilson, S., Greer, B., Hooper, J., Zijlstra, A., Walker, B., Quigley, J. & 
Hawthorne, S. The membrane-anchored serine protease, TMPRSS2, activates 
PAR-2 in prostate cancer cells. Biochemical Journal 388, 967-972, 
doi:10.1042/bj20041066 (2005). 
212 Smith, R., Jenkins, A., Lourbakos, A., Thompson, P., Ramakrishnan, V., 
Tomlinson, J., Deshpande, U., Johnson, D. A., Jones, R., Mackie, E. J. & Pike, R. 
N. Evidence for the activation of PAR-2 by the sperm protease, acrosin: 
249 
 
expression of the receptor on oocytes. Febs Letters 484, 285-290, 
doi:10.1016/s0014-5793(00)02146-3 (2000). 
213 Miki, M., Nakamura, Y., Takahashi, A., Nakaya, Y., Eguchi, H., Masegi, T., 
Yoneda, K., Yasuoka, S. & Sone, S. Effect of human airway trypsin-like protease 
on intracellular free Ca2+ concentration in human bronchial epithelial cells. The 
journal of medical investigation : JMI 50, 95-107 (2003). 
214 Mihara, K., Ramachandran, R., Saifeddine, M., Hansen, K. K., Renaux, B., 
Polley, D., Gibson, S., Vanderboor, C. & Hollenberg, M. D. Thrombin-Mediated 
Direct Activation of Proteinase-Activated Receptor-2: Another Target for 
Thrombin Signaling. Molecular Pharmacology 89, 606-614, 
doi:10.1124/mol.115.102723 (2016). 
215 Chiu, L.-L., Perng, D.-W., Yu, C.-H., Su, S.-N. & Chow, L.-P. Mold allergen, Pen 
c 13, induces IL-8 expression in human airway epithelial cells by activating 
protease-activated receptor 1 and 2. Journal of Immunology 178, 5237-5244 
(2007). 
216 Sun, G., Stacey, M. A., Schmidt, M., Mori, L. & Mattoli, S. Interaction of mite 
allergens Der P3 and Der P9 with protease-activated receptor-2 expressed by lung 
epithelial cells. Journal of Immunology 167, 1014-1021 (2001). 
217 Asokananthan, N., Graham, P. T., Stewart, D. J., Bakker, A. J., Eidne, K. A., 
Thompson, P. J. & Stewart, G. A. House dust mite allergens induce 
proinflammatory cytokines from respiratory epithelial cells: The cysteine protease 
allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates 
PAR-1. Journal of Immunology 169, 4572-4578 (2002). 
218 Kauffman, H. F., Tamm, M., Timmerman, J. A. B. & Borger, P. House dust mite 
major allergens Der p 1 and Der p 5 activate human airway-derived epithelial cells 
by protease-dependent and protease-independent mechanisms. Clinical and 
molecular allergy : CMA 4, 5-5, doi:10.1186/1476-7961-4-5 (2006). 
219 Lourbakos, A., Potempa, J., Travis, J., D'Andrea, M. R., Andrade-Gordon, P., 
Santulli, R., Mackie, E. J. & Pike, R. N. Arginine-specific protease from 
Porphyromonas gingivalis activates protease-activated receptors on human oral 
epithelial cells and induces interleukin-6 secretion. Infection and Immunity 69, 
5121-5130, doi:10.1128/iai.69.8.5121-5130.2001 (2001). 
220 Uehara, A., Muramoto, K., Imamura, T., Nakayama, K., Potempa, J., Travis, J., 
Sugawara, S. & Takada, H. Arginine-specific gingipains from Porphyromonas 
gingivalis stimulate production of hepatocyte growth factor (scatter factor) 
through protease-activated receptors in human gingival fibroblasts in culture. 
Journal of Immunology 175, 6076-6084 (2005). 
221 Hong, J. H., Hong, J. Y., Park, B., Lee, S.-I., Seo, J. T., Kim, K.-E., Sohn, M. H. 
& Shin, D. M. Chitinase Activates Protease-Activated Receptor-2 in Human 
Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular 
Biology 39, 530-535, doi:10.1165/rcmb.2007-0410OC (2008). 
222 Hollenberg, M. D., Renaux, B., Hyun, E., Houle, S., Vergnolle, N., Saifeddine, 
M. & Ramachandran, R. Derivatized 2-furoyl-LIGRLO-amide, a versatile and 
selective probe for proteinase-activated receptor 2: Binding and visualization. 
Journal of Pharmacology and Experimental Therapeutics 326, 453-462, 
doi:10.1124/jpet.108.136432 (2008). 
223 McGuire, J. J., Saifeddine, M., Triggle, C. R., Sun, K. & Hollenberg, M. D. 2-
Furoyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 
agonist. Journal of Pharmacology and Experimental Therapeutics 309, 1124-
1131, doi:10.1124/jpet.103.064584 (2004). 
224 Dulon, S., Cande, C., Bunnett, N. W., Hollenberg, M. D., Chignard, M. & Pidard, 
D. Proteinase-activated receptor-2 and human lung epithelial cells - Disarming by 
250 
 
neutrophil serine proteinases. American Journal of Respiratory Cell and 
Molecular Biology 28, 339-346, doi:10.1165/rcmb.4908 (2003). 
225 Ramachandran, R., Mihara, K., Chung, H., Renaux, B., Lau, C. S., Muruve, D. 
A., DeFea, K. A., Bouvier, M. & Hollenberg, M. D. Neutrophil Elastase Acts as 
a Biased Agonist for Proteinase-activated Receptor-2 (PAR(2)). Journal of 
Biological Chemistry 286, 24638-24648, doi:10.1074/jbc.M110.201988 (2011). 
226 Zhao, P., Lieu, T., Barlow, N., Metcalf, M., Veldhuis, N. A., Jensen, D. D., Kocan, 
M., Sostegni, S., Haerteis, S., Baraznenok, V., Henderson, I., Lindstrom, E., 
Guerrero-Alba, R., Valdez-Morales, E. E., Liedtke, W., McIntyre, P., Vanner, S. 
J., Korbmacher, C. & Bunnett, N. W. Cathepsin S Causes Inflammatory Pain via 
Biased Agonism of PAR(2) and TRPV4. Journal of Biological Chemistry 289, 
27215-27234, doi:10.1074/jbc.M114.599712 (2014). 
227 Stalheim, L., Ding, Y., Gullapalli, A., Paing, M. M., Wolfe, B. L., Morris, D. R. 
& Trejo, J. Multiple independent functions of arrestins in the regulation of 
protease-activated receptor-2 signaling and trafficking. Molecular Pharmacology 
67, 78-87, doi:10.1124/mol.104.006072 (2005). 
228 Luo, W. B., Wang, Y. F., Hanck, T., Stricker, R. & Reiser, G. Jab1, a novel 
protease-activated receptor-2 (PAR-2)-interacting protein, is involved in PAR-2-
induced activation of activator protein-1. Journal of Biological Chemistry 281, 
7927-7936, doi:10.1074/jbc.M510784200 (2006). 
229 Ricks, T. K. & Trejo, J. Phosphorylation of Protease-activated Receptor-2 
Differentially Regulates Desensitization and Internalization. Journal of 
Biological Chemistry 284, 34444-34457, doi:10.1074/jbc.M109.048942 (2009). 
230 Kang, D. S., Tian, X. & Benovic, J. L. Role of beta-arrestins and arrestin domain-
containing proteins in G protein-coupled receptor trafficking. Current Opinion in 
Cell Biology 27, 63-71, doi:10.1016/j.ceb.2013.11.005 (2014). 
231 Bohm, S. K., Khitin, L. M., Grady, E. F., Aponte, G., Payan, D. G. & Bunnett, N. 
W. Mechanisms of desensitization and resensitization of proteinase-activated 
receptor-2. Journal of Biological Chemistry 271, 22003-22016 (1996). 
232 Jensen, D. D., Zhao, P., Jimenez-Vargas, N. N., Lieu, T., Gerges, M., Yeatman, 
H. R., Canals, M., Vanner, S. J., Poole, D. P. & Bunnett, N. W. Protein Kinase D 
and G Subunits Mediate Agonist-evoked Translocation of Protease-activated 
Receptor-2 from the Golgi Apparatus to the Plasma Membrane. Journal of 
Biological Chemistry 291, 11285-11299, doi:10.1074/jbc.M115.710681 (2016). 
233 Perry, S. R., Xu, W. J., Wirija, A., Lim, J. X., Yau, M. K., Stoermer, M. J., Lucke, 
A. J. & Fairlie, D. P. Three Homology Models of PAR2 Derived from Different 
Templates: Application to Antagonist Discovery. Journal of Chemical 
Information and Modeling 55, 1181-1191, doi:10.1021/acs.jcim.5b00087 (2015). 
234 Xiang, Y., Masuko-Hongo, K., Sekine, T., Nakamura, H., Yudoh, K., Nishioka, 
K. & Kato, T. Expression of proteinase-activated receptors (PAR)-2 in articular 
chondrocytes is modulated by IL-1 beta, TNF-alpha and TGF-beta. Osteoarthritis 
and Cartilage 14, 1163-1173, doi:10.1016/j.joca.2006.04.015 (2006). 
235 Ferrell, W. R., Kelso, E. B., Lockhart, J. C., Plevin, R. & McInnes, I. B. Protease-
activated receptor 2: a novel pathogenic pathway in a murine model of 
osteoarthritis. Annals of the Rheumatic Diseases 69, 2051-2054, 
doi:10.1136/ard.2010.130336 (2010). 
236 Amiable, N., Martel-Pelletier, J., Lussier, B., Tat, S. K., Pelletier, J.-P. & Boileau, 
C. Proteinase-activated Receptor-2 Gene Disruption Limits the Effect of 
Osteoarthritis on Cartilage in Mice: A Novel Target in Joint Degradation. Journal 
of Rheumatology 38, 911-920, doi:10.3899/jrheum.100710 (2011). 
237 Huesa, C., Ortiz, A., Dunning, L., McGavin, L., Bennett, L., McIntosh, K., Crilly, 
A., Kurowska-Stolarska, M., Plevin, R., van 't Hof, R., Rowan, A. D., McInnes, 
251 
 
I. B., Goodyear, C., lockhart, J. C. & Ferrell, P. W. Proteinase-activated receptor 
2 modulates OA-related pain, cartilage and bone pathology. Ann Rheum Dis In 
Press (2015). 
238 Staunton, D., Hudson, K. R. & Heath, J. K. The interactions of the cytokine-
binding homology region and immunoglobulin-like domains of gp130 with 
oncostatin M: implications for receptor complex formation. Protein Engineering 
11, 1093-1102, doi:10.1093/protein/11.11.1093 (1998). 
239 Bougault, C., Paumier, A., Aubert-Foucher, E. & Mallein-Gerin, F. Investigating 
conversion of mechanical force into biochemical signaling in three-dimensional 
chondrocyte cultures. Nature Protocols 4, 928-938, doi:10.1038/nprot.2009.63 
(2009). 
240 Laemmli, U. K. Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4. Nature 227, 680-&, doi:10.1038/227680a0 (1970). 
241 Schagger, H. & Vonjagow, G. Tricine–sodium dodecyl sulfate polyacrylamide 
gel electrophoresis for the separation of proteins in the range from 1–100 kDa. 
Analytical Biochemistry 166, 368-379, doi:10.1016/0003-2697(87)90587-2 
(1987). 
242 Matthews, J. in Fundamentals of Receptor, Enzyme, and Transport Kinetics     
(CRC Press, 1993). 
243 Barrett, A. J., Kembhavi, A. A., Brown, M. A., Kirschke, H., Knight, C. G., 
Tamai, M. & Hanada, K. L-trans-Epoxysuccinyl-leucylamido(4-
guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases 
including cathepsins B, H and L. Biochemical Journal 201, 189-198 (1982). 
244 Bougault, C., Paumier, A., Aubert-Foucher, E. & Mallein-Gerin, F. Molecular 
analysis of chondrocytes cultured in agarose in response to dynamic compression. 
Bmc Biotechnology 8, doi:10.1186/1472-6750-8-71 (2008). 
245 Bougault, C., Aubert-Foucher, E., Paumier, A., Perrier-Groult, E., Huot, L., Hot, 
D., Duterque-Coquillaud, M. & Mallein-Gerin, F. Dynamic Compression of 
Chondrocyte-Agarose Constructs Reveals New Candidate Mechanosensitive 
Genes. Plos One 7, doi:10.1371/journal.pone.0036964 (2012). 
246 Fanning, P. J., Emkey, G., Smith, R. J., Grodzinsky, A. J., Szasz, N. & Trippel, S. 
B. Mechanical regulation of mitogen-activated protein kinase signaling in 
articular cartilage. Journal of Biological Chemistry 278, 50940-50948, 
doi:10.1074/jbc.M305107200 (2003). 
247 Li, K. W., Wang, A. S. & Sah, R. L. Microenvironment regulation of extracellular 
signal-regulated kinase activity in chondrocytes - Effects of culture configuration, 
interleukin-1, and compressive stress. Arthritis and Rheumatism 48, 689-699, 
doi:10.1002/art.10849 (2003). 
248 Wang, L. & Stegemann, J. P. Extraction of high quality RNA from polysaccharide 
matrices using cetlytrimethylammonium bromide. Biomaterials 31, 1612-1618, 
doi:10.1016/j.biomaterials.2009.11.024 (2010). 
249 Mio, K., Kirkham, J. & Bonass, W. A. Tips for extracting total RNA from 
chondrocytes cultured in agarose gel using a silica-based membrane kit. 
Analytical Biochemistry 351, 314-316, doi:10.1016/j.ab.2005.12.031 (2006). 
250 Melzak, K. A., Sherwood, C. S., Turner, R. F. B. & Haynes, C. A. Driving forces 
for DNA adsorption to silica in perchlorate solutions. Journal of Colloid and 
Interface Science 181, 635-644, doi:10.1006/jcis.1996.0421 (1996). 
251 Knight, M. M., Lee, D. A. & Bader, D. L. The influence of elaborated pericellular 
matrix on the deformation of isolated articular chondrocytes cultured in agarose. 
Biochimica Et Biophysica Acta-Molecular Cell Research 1405, 67-77, 
doi:10.1016/s0167-4889(98)00102-5 (1998). 
252 
 
252 Gebauer, M., Saas, J., Sohler, F., Haag, J., Soder, S., Pieper, M., Bartnik, E., 
Beninga, J., Zimmer, R. & Aigner, T. Comparison of the chondrosarcoma cell line 
SW1353 with primary human adult articular chondrocytes with regard to their 
gene expression profile and reactivity to IL-1 beta. Osteoarthritis and Cartilage 
13, 697-708, doi:10.1016/j.joca.2005.04.004 (2005). 
253 Akiyama, H., Chaboissier, M. C., Martin, J. F., Schedl, A. & de Crombrugghe, B. 
The transcrintion factor Sox9 has essential roles in successive steps of the 
chondrocyte differentiation pathway and is required for expression of Sox5 and 
Sox6. Genes & Development 16, 2813-2828, doi:10.1101/gad.1017802 (2002). 
254 Bi, W. M., Deng, J. M., Zhang, Z. P., Behringer, R. R. & de Crombrugghe, B. 
Sox9 is required for cartilage formation. Nature Genetics 22, 85-89 (1999). 
255 Zhao, Q., Eberspaecher, H., Lefebvre, V. & deCrombrugghe, B. Parallel 
expression of Sox9 and Col2a1 in cells undergoing chondrogenesis. 
Developmental Dynamics 209, 377-386, doi:10.1002/(sici)1097-
0177(199708)209:4<377::aid-aja5>3.0.co;2-f (1997). 
256 Ng, L. J., Wheatley, S., Muscat, G. E. O., ConwayCampbell, J., Bowles, J., 
Wright, E., Bell, D. M., Tam, P. P. L., Cheah, K. S. E. & Koopman, P. SOX9 
binds DNA, activates transcription, and coexpresses with type II collagen during 
chondrogenesis in the mouse. Developmental Biology 183, 108-121, 
doi:10.1006/dbio.1996.8487 (1997). 
257 Sekiya, I., Tsuji, K., Koopman, P., Watanabe, H., Yamada, Y., Shinomiya, K., 
Nifuji, A. & Noda, M. SOX9 enhances aggrecan gene promoter/enhancer activity 
and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. Journal 
of Biological Chemistry 275, 10738-10744, doi:10.1074/jbc.275.15.10738 
(2000). 
258 Han, Y. & Lefebvre, V. L-Sox5 and Sox6 drive expression of the aggrecan gene 
in cartilage by securing binding of Sox9 to a far-upstream enhancer. Molecular 
and Cellular Biology 28, 4999-5013, doi:10.1128/mcb.00695-08 (2008). 
259 Mwale, F., Stachura, D., Roughley, P. & Antoniou, J. Limitations of using 
aggrecan and type X collagen as markers of chondrogenesis in mesenchymal stem 
cell differentiation. Journal of Orthopaedic Research 24, 1791-1798, 
doi:10.1002/jor.20200 (2006). 
260 Xu, J., Wang, W., Ludeman, M., Cheng, K., Hayami, T., Lotz, J. C. & Kapila, S. 
Chondrogenic differentiation of human mesenchymal stem cells in three-
dimensional alginate gels. Tissue Engineering Part A 14, 667-680, 
doi:10.1089/tea.2007.0272 (2008). 
261 Poole, C. A., Flint, M. H. & Beaumont, B. W. Chondrons in cartilage: 
ultrastructural analysis of the pericellular microenvironment in adult human 
articular cartilages. Journal of Orthopaedic Research 5, 509-522, 
doi:10.1002/jor.1100050406 (1987). 
262 Marcelino, J. & McDevitt, C. A. Attachment of articular cartilage chondrocytes 
to the tissue form of type VI collagen. Biochimica Et Biophysica Acta-Protein 
Structure and Molecular Enzymology 1249, 180-188, doi:10.1016/0167-
4838(95)00026-q (1995). 
263 Guilak, F., Alexopoulos, L. G., Upton, M. L., Youn, I., Choi, J. B., Cao, L., Setton, 
L. A. & Haider, M. A. in Skeletal Development and Remodeling in Health, 
Disease, and Aging Vol. 1068 Annals of the New York Academy of Sciences (ed 
M. Zaidi)  498-512 (2006). 
264 Vincent, T. L., McLean, C. J., Full, L. E., Peston, D. & Saklatvala, J. FGF-2 is 
bound to perlecan in the pericellular matrix of articular cartilage, where it acts as 
a chondrocyte mechanotransducer. Osteoarthritis and Cartilage 15, 752-763, 
doi:10.1016/j.joca.2007.01.021 (2007). 
253 
 
265 Honda, K., Ohno, S., Tanimoto, K., Ijuin, C., Tanaka, N., Doi, T., Kato, Y. & 
Tanne, K. The effects of high magnitude cyclic tensile load on cartilage matrix 
metabolism in cultured chondrocytes. European Journal of Cell Biology 79, 601-
609, doi:10.1078/0171-9335-00089 (2000). 
266 Pufe, T., Lemke, A., Kurz, B., Petersen, W., Tillmann, B., Grodzinsky, A. J. & 
Mentlein, R. Mechanical overload induces VEGF in cartilage discs via hypoxia-
inducible factor. American Journal of Pathology 164, 185-192, 
doi:10.1016/s0002-9440(10)63109-4 (2004). 
267 Nicodemus, G. D. & Bryant, S. J. Mechanical loading regimes affect the anabolic 
and catabolic activities by chondrocytes encapsulated in PEG hydrogels. 
Osteoarthritis and Cartilage 18, 126-137, doi:10.1016/j.joca.2009.08.005 (2010). 
268 Xu, Z. F., Buckley, M. J., Evans, C. H. & Agarwal, S. Cyclic tensile strain acts as 
an antagonist of IL-1 beta actions in chondrocytes. Journal of Immunology 165, 
453-460 (2000). 
269 Sharp, W. W., Terracio, L., Borg, T. K. & Samarel, A. M. Contractile activity 
modulates actin synthesis and turnover in cultured neonatal rat heart cells. 
Circulation Research 73, 172-183 (1993). 
270 Byron, K. L., Puglisi, J. L., Holda, J. R., Eble, D. & Samarel, A. M. Myosin heavy 
chain turnover in cultured neonatal rat heart cells: Effects of Ca2+ (i) and 
contractile activity. American Journal of Physiology-Cell Physiology 271, C1447-
C1456 (1996). 
271 Flynn, B. P., Bhole, A. P., Saeidi, N., Liles, M., DiMarzio, C. A. & Ruberti, J. W. 
Mechanical Strain Stabilizes Reconstituted Collagen Fibrils against Enzymatic 
Degradation by Mammalian Collagenase Matrix Metalloproteinase 8 (MMP-8). 
Plos One 5, doi:10.1371/journal.pone.0012337 (2010). 
272 Blott, S. C., Williams, J. L. & Haley, C. S. Genetic variation within the Hereford 
breed of cattle. Animal Genetics 29, 202-211 (1998). 
273 Gibbs, R. A., Taylor, J. F., Van Tassell, C. P., Barendse, W., Eversoie, K. A., Gill, 
C. A., Green, R. D., Hamernik, D. L., Kappes, S. M., Lien, S., Matukumalli, L. 
K., McEwan, J. C., Nazareth, L. V., Schnabel, R. D., Taylor, J. F., Weinstock, G. 
M., Wheeler, D. A., Ajmone-Marsan, P., Barendse, W., Boettcher, P. J., Caetano, 
A. R., Garcia, J. F., Hanotte, O., Mariani, P., Skow, L. C., Williams, J. L., Caetano, 
A. R., Diallo, B., Green, R. D., Hailemariam, L., Hanotte, O., Martinez, M. L., 
Morris, C. A., Silva, L. O. C., Spelman, R. J., Taylor, J. F., Mulatu, W., Zhao, K., 
Abbey, C. A., Agaba, M., Araujo, F. R., Bunch, R. J., Burton, J., Gill, C. A., Gorni, 
C., Olivier, H., Harrison, B. E., Luff, B., Machado, M. A., Mariani, P., Morris, C. 
A., Mwakaya, J., Plastow, G., Sim, W., Skow, L. C., Smith, T., Sonstegard, T. S., 
Spelman, R. J., Taylor, J. F., Thomas, M. B., Valentini, A., Williams, P., Womack, 
J., Wooliams, J. A., Liu, Y., Qin, X., Worley, K. C., Gao, C., Gill, C. A., Jiang, 
H., Liu, Y., Moore, S. S., Nazareth, L. V., Ren, Y., Song, X.-Z., Bustamante, C. 
D., Hernandez, R. D., Muzny, D. M., Nazareth, L. V., Patil, S., Lucas, A. S., Fu, 
Q., Kent, M. P., Moore, S. S., Vega, R., Abbey, C. A., Gao, C., Gill, C. A., Green, 
R. D., Matukumalli, L. K., Matukumalli, A., McWilliam, S., Schnabel, R. D., 
Sclep, G., Ajmone-Marsan, P., Bryc, K., Bustamante, C. D., Choi, J., Gao, H., 
Grefenstette, J. J., Murdoch, B., Stella, A., Villa-Angulo, R., Wright, M., Aerts, 
J., Jann, O., Negrini, R., Sonstegard, T. S., Williams, J. L., Taylor, J. F., Villa-
Angulo, R., Goddard, M. E., Hayes, B. J., Barendse, W., Bradley, D. G., 
Boettcher, P. J., Bustamante, C. D., da Silva, M. B., Lau, L. P. L., Liu, G. E., 
Lynn, D. J., Panzitta, F., Sclep, G., Wright, M. & Dodds, K. G. Genome-Wide 
Survey of SNP Variation Uncovers the Genetic Structure of Cattle Breeds. 
Science 324, 528-532, doi:10.1126/science.1167936 (2009). 
254 
 
274 Smeyne, R. J., Vendrell, M., Hayward, M., Baker, S. J., Miao, G. G., Schilling, 
K., Robertson, L. M., Curran, T. & Morgan, J. I. Continuous c-fos expression 
precedes programmed cell death in vivo. Nature 363, 166-169, 
doi:10.1038/363166a0 (1993). 
275 Marti, A., Jehn, B., Costello, E., Keon, N., Ke, G., Martin, F. & Jaggi, R. Protein 
kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse 
mammary epithelial cells. Oncogene 9, 1213-1223 (1994). 
276 Preston, G. A., Lyon, T. T., Yin, Y. X., Lang, J. E., Solomon, G., Annab, L., 
Srinivasan, D. G., Alcorta, D. A. & Barrett, J. C. Induction of apoptosis by c-Fos 
protein. Molecular and Cellular Biology 16, 211-218 (1996). 
277 Zhang, X., Zhang, L., Yang, H., Huang, X., Otu, H., Libermann, T. A., DeWolf, 
W. C., Khosravi-Far, R. & Olumi, A. F. c-Fos as a proapoptotic agent in TRAIL-
induced apoptosis in prostate cancer cells. Cancer Research 67, 9425-9434, 
doi:10.1158/0008-5472.can-07-1310 (2007). 
278 Liang, Y., Jorgensen, A., Kaestel, C. G., Wiencke, A. K., Lui, G. M., la Cour, M., 
Ropke, C. & Nissen, M. H. Bcl-2, Bax, and c-Fos expression correlates to RPE 
cell apoptosis induced by UV-light and daunorubicin. Current Eye Research 20, 
25-34 (2000). 
279 Yu, R.-A., He, L.-F. & Chen, X.-M. Effects of cadmium on hepatocellular DNA 
damage, proto-oncogene expression and apoptosis in rats. Biomedical and 
environmental sciences : BES 20, 146-153 (2007). 
280 Chung, C., Erickson, I. E., Mauck, R. L. & Burdick, J. A. Differential behavior of 
auricular and articular chondrocytes in hyaluronic acid hydrogels. Tissue 
Engineering Part A 14, 1121-1131, doi:10.1089/ten.tea.2007.0291 (2008). 
281 Boutell, J., Maciewicz, R. A. & Parker, A. E. Cartilage ECM molecules are 
differentially expressed between nasal and articular bovine chondrocytes. Int J 
Exp Pathol 81, A7-A8 (2000). 
282 Arai, M., Anderson, D., Kurdi, Y., Annis-Freeman, B., Shields, K., Collins-Racie, 
L. A., Corcoran, C., DiBlasio-Smith, E., Pittman, D. D., Dorner, A. J., Morris, E. 
& LaVallie, E. R. Effect of adenovirus-mediated overexpression of bovine 
ADAMTS-4 and human ADAMTS-5 in primary bovine articular chondrocyte 
pellet culture system. Osteoarthritis and Cartilage 12, 599-613, 
doi:10.1016/j.joca.2004.05.001 (2004). 
283 Candrian, C., Vonwil, D., Barbero, A., Bonacina, E., Miot, S., Farhadi, J., Wirz, 
D., Dickinson, S., Hollander, A., Jakob, M., Li, Z., Alini, M., Heberer, M. & 
Martin, I. Engineered cartilage generated by nasal chondrocytes is responsive to 
physical forces resembling joint loading. Arthritis and Rheumatism 58, 197-208, 
doi:10.1002/art.23155 (2008). 
284 Dos Santos, C., Akram, A., Masoom, H., Han, B., Haitsma, J. J., Peng, C., Shan, 
Y., Zhang, H., Liu, M., Hai, T. & Slutsky, A. S. ATF3 is activated in ventilator 
induced lung injury. Faseb Journal 24 (2010). 
285 Koivisto, E., Acosta, A. J., Moilanen, A.-M., Tokola, H., Aro, J., Pennanen, H., 
Sakkinen, H., Kaikkonen, L., Ruskoaho, H. & Rysa, J. Characterization of the 
Regulatory Mechanisms of Activating Transcription Factor 3 by Hypertrophic 
Stimuli in Rat Cardiomyocytes. Plos One 9, doi:10.1371/journal.pone.0105168 
(2014). 
286 Wang, X., Fan, J., Zhang, M., Sun, Z. & Xu, G. Gene Expression Changes under 
Cyclic Mechanical Stretching in Rat Retinal Glial (Muller) Cells. Plos One 8, 
doi:10.1371/journal.pone.0063467 (2013). 
287 Ott, C.-E., Bauer, S., Manke, T., Ahrens, S., Roedelsperger, C., Gruenhagen, J., 
Kornak, U., Duda, G., Mundlos, S. & Robinson, P. N. Promiscuous and 
Depolarization-Induced Immediate-Early Response Genes Are Induced by 
255 
 
Mechanical Strain of Osteoblasts. Journal of Bone and Mineral Research 24, 
1247-1262, doi:10.1359/jbmr.090206 (2009). 
288 Zaman, G., Sunters, A., Galea, G. L., Javaheri, B., Saxon, L. K., Moustafa, A., 
Armstrong, V. J., Price, J. S. & Lanyon, L. E. Loading-related Regulation of 
Transcription Factor EGR2/Krox-20 in Bone Cells Is ERK1/2 Protein-mediated 
and Prostaglandin, Wnt Signaling Pathway-, and Insulin-like Growth Factor-I 
Axis-dependent. Journal of Biological Chemistry 287, 3946-3962, 
doi:10.1074/jbc.M111.252742 (2012). 
289 Diercke, K., Kohl, A., Lux, C. J. & Erber, R. Compression of human primary 
cementoblasts leads to apoptosis A possible cause of dental root resorption? 
Journal of Orofacial Orthopedics-Fortschritte Der Kieferorthopadie 75, 430-445, 
doi:10.1007/s00056-014-0237-5 (2014). 
290 Verma, P. & Dalal, K. ADAMTS-4 and ADAMTS-5: Key Enzymes in 
Osteoarthritis. Journal of Cellular Biochemistry 112, 3507-3514, 
doi:10.1002/jcb.23298 (2011). 
291 Werb, Z., Mainardi, C. L., Vater, C. A. & Harris, E. D. Endogenous activiation of 
latent collagenase by rheumatoid synovial cells. Evidence for a role of 
plasminogen activator. New England Journal of Medicine 296, 1017-1023, 
doi:10.1056/nejm197705052961801 (1977). 
292 Schaegger, H. Tricine-SDS-PAGE. Nature Protocols 1, 16-22, 
doi:10.1038/nprot.2006.4 (2006). 
293 Camerer, E., Barker, A., Duong, D. N., Ganesan, R., Kataoka, H., Cornelissen, I., 
Darragh, M. R., Hussain, A., Zheng, Y.-W., Srinivasan, Y., Brown, C., Xu, S.-
M., Regard, J. B., Lin, C.-Y., Craik, C. S., Kirchhofer, D. & Coughlin, S. R. Local 
Protease Signaling Contributes to Neural Tube Closure in the Mouse Embryo. 
Developmental Cell 18, 25-38, doi:10.1016/j.devcel.2009.11.014 (2010). 
294 Hollenberg, M. D., Mihara, K., Polley, D., Suen, J. Y., Han, A., Fairlie, D. P. & 
Ramachandran, R. Biased signalling and proteinase-activated receptors (PARs): 
targeting inflammatory disease. British Journal of Pharmacology 171, 1180-
1194, doi:10.1111/bph.12544 (2014). 
295 Tanaka, M., Arai, H., Liu, N., Nogaki, F., Nomura, K., Kasuno, K., Oida, E., Kita, 
T. & Ono, T. Role of coagulation factor Xa and protease-activated receptor 2 in 
human mesangial cell proliferation. Kidney International 67, 2123-2133, 
doi:10.1111/j.1523-1755.2005.00317.x (2005). 
296 Jin, T., Tarkowski, A., Carmeliet, P. & Bokarewa, M. Urokinase, a constitutive 
component of the inflamed synovial fluid, induces arthritis. Arthritis Research & 
Therapy 5, R9-R17, doi:10.1186/ar606 (2003). 
297 Trivedi, V., Boire, A., Tchemychev, B., Kaneider, N. C., Leger, A. J., 
O'Callaghan, K., Covic, L. & Kuliopulos, A. Platelet Matrix Metalloprotease-1 
Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site. Cell 137, 
332-343, doi:10.1016/j.cell.2009.02.018 (2009). 
298 Jaffre, F., Friedman, A. E., Hu, Z., Mackman, N. & Blaxall, B. C. beta-Adrenergic 
Receptor Stimulation Transactivates Protease-Activated Receptor 1 via Matrix 
Metalloproteinase 13 in Cardiac Cells. Circulation 125, 2993-+, 
doi:10.1161/circulationaha.111.066787 (2012). 
299 Albericio, F. Developments in peptide and amide synthesis. Current Opinion in 
Chemical Biology 8, 211-221, doi:10.1016/j.cbpa.2004.03.002 (2004). 
300 Elmariah, S. B., Reddy, V. B. & Lerner, E. A. Cathepsin S Signals via PAR2 and 
Generates a Novel Tethered Ligand Receptor Agonist. Plos One 9, 
doi:10.1371/journal.pone.0099702 (2014). 
301 Loew, D., Perrault, C., Morales, M., Moog, S., Ravanat, C., Schuhler, S., Arcone, 
R., Pietropaolo, C., Cazenave, J. P., van Dorsselaer, A. & Lanza, L. O. Proteolysis 
256 
 
of the exodomain of recombinant protease-activated receptors: Prediction of 
receptor activation or inactivation by MALDI mass spectrometry. Biochemistry 
39, 10812-10822, doi:10.1021/bi0003341 (2000). 
302 KB, U. UniProtKB - P55085 (PAR2_HUMAN), 
<http://www.uniprot.org/uniprot/P55085> (2016). 
303 Li, X. & Tai, H.-H. Thromboxane A(2) Receptor-Mediated Release of Matrix 
Metalloproteinase-1 (MMP-1) Induces Expression of Monocyte Chemoattractant 
Protein-1 (MCP-1) by Activation of Protease-Activated Receptor 2 (PAR2) in 
A549 Human Lung Adenocarcinoma Cells. Molecular Carcinogenesis 53, 659-
666, doi:10.1002/mc.22020 (2014). 
304 Tiaden, A. N. & Richards, P. J. The Emerging Roles of HTRA1 in 
Musculoskeletal Disease. American Journal of Pathology 182, 1482-1488, 
doi:10.1016/j.ajpath.2013.02.003 (2013). 
305 Grau, S., Richards, P. J., Kerr, B., Hughes, C., Caterson, B., Williams, A. S., 
Junker, U., Jones, S. A., Clausen, T. & Ehrmann, M. The role of human HtrA1 in 
arthritic disease. Journal of Biological Chemistry 281, 6124-6129, 
doi:10.1074/jbc.M500361200 (2006). 
306 Wu, J., Liu, W., Bemis, A., Wang, E., Qiu, Y., Morris, E. A., Flannery, C. R. & 
Yang, Z. Comparative proteomic characterization of articular cartilage tissue from 
normal donors and patients with osteoarthritis. Arthritis and Rheumatism 56, 
3675-3684, doi:10.1002/art.22876 (2007). 
307 Eigenbrot, C., Ultsch, M., Lipari, M. T., Moran, P., Lin, S. J., Ganesan, R., Quan, 
C., Tom, J., Sandoval, W., Campagne, M. v. L. & Kirchhofer, D. Structural and 
Functional Analysis of HtrA1 and Its Subdomains. Structure 20, 1040-1050, 
doi:10.1016/j.str.2012.03.021 (2012). 
308 Carmeliet, P., Moons, L., Lijnen, H. R., Baes, M., Lemaitre, V., Tipping, P., Drew, 
A., Eeckhout, Y., Shapiro, S., Lupu, F. & Collen, D. Urokinase-generated plasmin 
activates matrix metalloproteinases during aneurysm formation. Nature Genetics 
17, 439-444, doi:10.1038/ng1297-439 (1997). 
309 Smith, H. W. & Marshall, C. J. Regulation of cell signalling by uPAR. Nature 
Reviews Molecular Cell Biology 11, 23-36, doi:10.1038/nrm2821 (2010). 
310 Rawlings, N. D., Barrett, A. J. & Finn, R. Twenty years of the MEROPS database 
of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Research 44, 
D343-D350, doi:10.1093/nar/gkv1118 (2016). 
311 Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J. & 
Rettig, W. J. Fibroblast activation protein, a dual specificity serine protease 
expressed in reactive human tumor stromal fibroblasts. Journal of Biological 
Chemistry 274, 36505-36512, doi:10.1074/jbc.274.51.36505 (1999). 
312 Aggarwal, S., Brennen, W. N., Kole, T. P., Schneider, E., Topaloglu, O., Yates, 
M., Cotter, R. J. & Denmeade, S. R. Fibroblast activation protein peptide 
substrates identified from human collagen I derived gelatin cleavage sites. 
Biochemistry 47, 1076-1086, doi:10.1021/bi701921b (2008). 
313 Huang, C.-H., Suen, C.-S., Lin, C.-T., Chien, C.-H., Lee, H.-Y., Chung, K.-M., 
Tsai, T.-Y., Jiaang, W.-T., Hwang, M.-J. & Chen, X. Cleavage-site specificity of 
prolyl endopeptidase FAP investigated with a full-length protein substrate. 
Journal of Biochemistry 149, 685-692, doi:10.1093/jb/mvr017 (2011). 
314 Kanke, T., Ishiwata, H., Kabeya, M., Saka, M., Doi, T., Hattori, Y., Kawabata, A. 
& Plevin, R. Binding of a highly potent protease-activated receptor-2 (PAR2) 
activating peptide, H-3 2-furoyl-LIGRL-NH2, to human PAR2. British Journal 
of Pharmacology 145, 255-263, doi:10.1038/sj.bjp.0706189 (2005). 
315 Yoshida, N., Katada, K., Handa, O., Takagi, T., Kokura, S., Naito, Y., Mukaida, 
N., Soma, T., Shimada, Y., Yoshikawa, T. & Okanoue, T. Interleukin-8 
257 
 
production via protease-activated receptor 2 in human esophageal epithelial cells. 
International Journal of Molecular Medicine 19, 335-340 (2007). 
316 Tanaka, Y., Sekiguchi, F., Hong, H. & Kawabata, A. PAR2 triggers IL-8 release 
via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochemical 
and Biophysical Research Communications 377, 622-626, 
doi:10.1016/j.bbrc.2008.10.018 (2008). 
317 Seitz, I., Hess, S., Schulz, H., Eckl, R., Busch, G., Montens, H. P., Brandl, R., 
Seidl, S., Schomig, A. & Ott, I. Membrane-type serine protease-1/matriptase 
induces interleukin-6 and-8 in endothelial cells by activation of protease-activated 
receptor-2 - Potential implications in atherosclerosis. Arteriosclerosis Thrombosis 
and Vascular Biology 27, 769-775, doi:10.1161/01.atv.0000258862.61067.14 
(2007). 
318 Deroanne, C. F., Hamelryckx, D., Ho, T. T. G., Lambert, C. A., Catroux, P., 
Lapiere, C. M. & Nusgens, B. V. Cdc42 downregulates MMP-1 expression by 
inhibiting the ERK1/2 pathway. Journal of Cell Science 118, 1173-1183, 
doi:10.1242/jcs.01707 (2005). 
319 Weiss, M. B., Abel, E. V., Mayberry, M. M., Basile, K. J., Berger, A. C. & Aplin, 
A. E. TWIST1 Is an ERK1/2 Effector That Promotes Invasion and Regulates 
MMP-1 Expression in Human Melanoma Cells. Cancer Research 72, 6382-6392, 
doi:10.1158/0008-5472.can-12-1033 (2012). 
320 Raymond, L., Eck, S., Mollmark, J., Hays, E., Tomek, I., Kantor, S., Elliott, S. & 
Vincenti, M. Interleukin-1 beta induction of matrix metal loproteinase-1 
transcription in chondrocytes requires ERK-dependent activation of CCAAT 
enhancer-binding protein-beta. Journal of Cellular Physiology 207, 683-688, 
doi:10.1002/jcp.20608 (2006). 
321 Cawston, T. E., Ellis, A. J., Humm, G., Lean, E., Ward, D. & Curry, V. 
Interleukin-1 and oncostatin-M in combination promotes the release of collagen 
fragments from bovine nasal cartilage in culutre. Biochemical and Biophysical 
Research Communications 215, 377-385, doi:10.1006/bbrc.1995.2476 (1995). 
322 Cleaver, C. S., Rowan, A. D. & Cawston, T. E. Interleukin 13 blocks the release 
of collagen from bovine nasal cartilage treated with proinflammatory cytokines. 
Annals of the Rheumatic Diseases 60, 150-157, doi:10.1136/ard.60.2.150 (2001). 
323 Shingleton, W. D., Ellis, A. J., Rowan, A. D. & Cawston, T. E. Retinoic acid 
combines with interleukin-1 to promote the degradation of collagen from bovine 
nasal cartilage: Matrix metalloproteinases-1 and-13 are involved in cartilage 
collagen breakdown. Journal of Cellular Biochemistry 79, 519-531, 
doi:10.1002/1097-4644(20001215)79:4<519::aid-jcb10>3.0.co;2-u (2000). 
324 Wu, J. J., Rush, T. S., Hotchandani, R., Du, X. M., Geck, M., Collins, E., Xu, Z. 
B., Skotnicki, J., Levin, J. I. & Lovering, F. E. Identification of potent and 
selective MMP-13 inhibitors. Bioorganic & Medicinal Chemistry Letters 15, 
4105-4109, doi:10.1016/j.bmcl.2005.06.019 (2005). 
325 Matter, H., Schwab, W., Barbier, D., Billen, G., Haase, B., Neises, B., Schudok, 
M., Thorwart, W., Schreuder, H., Brachvogel, V., Lonze, P. & Weithmann, K. U. 
Quantitative structure-activity relationship of human neutrophil collagenase 
(MMP-8) inhibitors using comparative molecular field analysis and X-ray 
structure analysis. Journal of Medicinal Chemistry 42, 1908-1920, 
doi:10.1021/jm980631s (1999). 
326 Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease 
cleavage site motifs using mixture-based oriented peptide libraries. Nature 
Biotechnology 19, 661-667, doi:10.1038/90273 (2001). 
258 
 
327 Netzelarnett, S., Fields, G., Birkedalhansen, H. & Vanwart, H. E. Sequence 
Specificities of Human Fibroblast and Neutrophil Collagenases. Journal of 
Biological Chemistry 266, 6747-6755 (1991). 
328 Beliveau, F., Desilets, A. & Leduc, R. Probing the substrate specificities of 
matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent 
peptides. Febs Journal 276, 2213-2226, doi:10.1111/j.1742-4658.2009.06950.x 
(2009). 
329 Nagase, H. & Visse, R. in Extracellular Matrix Degradation Vol. 2   Ch. 5, 95-
122 (2011). 
330 Al-Ani, B., Hansen, K. K. & Hollenberg, M. D. Proteinase-activated receptor-2: 
Key role of amino-terminal dipeptide residues of the tethered ligand for receptor 
activation. Molecular Pharmacology 65, 149-156, doi:10.1124/mol.65.1.149 
(2004). 
331 Ferrell, W. R., Lockhart, J. C., Kelso, E. B., Dunning, L., Plevin, R., Meek, S. E., 
Smith, A. J. H., Hunter, G. D., McLean, J. S., McGarry, F., Ramage, R., Jiang, L., 
Kanke, T. & Kawagoe, J. Essential role for proteinase-activated receptor-2 in 
arthritis. Journal of Clinical Investigation 111, 35-41, doi:10.1172/jci200316913 
(2003). 
332 Ramachandran, R., Mihara, K., Mathur, M., Rochdi, M. D., Bouvier, M., Defea, 
K. & Hollenberg, M. D. Agonist-Biased Signaling via Proteinase Activated 
Receptor-2: Differential Activation of Calcium and Mitogen-Activated Protein 
Kinase Pathways. Molecular Pharmacology 76, 791-801, 
doi:10.1124/mol.109.055509 (2009). 
333 Al-Ani, B., Wijesuriya, S. J. & Hollenberg, M. D. Proteinase-activated receptor 
2: Differential activation of the receptor by tethered ligand and soluble peptide 
analogs. Journal of Pharmacology and Experimental Therapeutics 302, 1046-
1054, doi:10.1124/jpet.302.3.1046 (2002). 
334 Lin, C. B., Chen, N., Scarpa, R., Guan, F., Babiarz-Magee, L., Liebel, F., Li, W. 
H., Kizoulis, M., Shapiro, S. & Seiberg, M. LIGR, a protease-activated receptor-
2-derived peptide, enhances skin pigmentation without inducing inflammatory 
processes. Pigment Cell & Melanoma Research 21, 172-183, doi:10.1111/j.1755-
148X.2008.00441.x (2008). 
335 Foskett, J. K., White, C., Cheung, K.-H. & Mak, D.-O. D. Inositol trisphosphate 
receptor Ca2+ release channels. Physiological Reviews 87, 593-658, 
doi:10.1152/physrev.00035.2006 (2007). 
336 Yasuda, Y., Li, Z. Q., Greenbaum, D., Bogyo, M., Weber, E. & Bromme, D. 
Cathepsin V, a novel and potent elastolytic activity expressed in activated 
macrophages. Journal of Biological Chemistry 279, 36761-36770, 
doi:10.1074/jbc.M403986200 (2004). 
337 Niwa, Y., Suzuki, T., Dohmae, N., Umezawa, K. & Simizu, S. Determination of 
cathepsin V activity and intracellular trafficking by N-glycosylation. Febs Letters 
586, 3601-3607, doi:10.1016/j.febslet.2012.08.001 (2012). 
338 Ikeda, Y., Ikata, T., Mishiro, T., Nakano, S., Ikebe, M. & Yasuoka, S. Cathepsins 
B and L in synovial fluids from patients with rheumatoid arthritis and the effect 
of cathepsin B on the activation of pro-urokinase. The journal of medical 
investigation : JMI 47, 61-75 (2000). 
339 Keyszer, G. M., Heer, A. H., Kriegsmann, J., Geiler, T., Trabandt, A., Keysser, 
M., Gay, R. E. & Gay, S. Comparative analysis of cathepsin L, cathepsin D, and 
collagenase messenger RNA expression in synovial tissues of patients with 
rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis and 
Rheumatism 38, 976-984, doi:10.1002/art.1780380714 (1995). 
259 
 
340 Suen, J. Y., Gardiner, B., Grimmond, S. & Fairlie, D. P. Profiling Gene 
Expression Induced by Protease-Activated Receptor 2 (PAR2) Activation in 
Human Kidney Cells. Plos One 5, doi:10.1371/journal.pone.0013809 (2010). 
341 Stenton, G. R., Nohara, O., Dery, R. E., Vliagoftis, H., Gilchrist, M., Johri, A., 
Wallace, J. L., Hollenberg, M. D., Moqbel, R. & Befus, A. D. Proteinase-activated 
receptor (PAR)-1 and-2 agonists induce mediator release from mast cells by 
pathways distinct from PAR-1 and PAR-2. Journal of Pharmacology and 
Experimental Therapeutics 302, 466-474, doi:10.1124/jpet.302.2.466 (2002). 
342 Huang, H. L., Hsing, H. W., Lai, T. C., Chen, Y. W., Lee, T. R., Chan, H. T., Lyu, 
P. C., Wu, C. L., Lu, Y. C., Lin, S. T., Lin, C. W., Lai, C. H., Chang, H. T., Chou, 
H. C. & Chan, H. L. Trypsin-induced proteome alteration during cell subculture 
in mammalian cells. Journal of Biomedical Science 17, doi:10.1186/1423-0127-
17-36 (2010). 
343 Abey, H. T., Fairlie, D. P., Moffatt, J. D., Balzary, R. W. & Cocks, T. M. Protease-
activated receptor-2 peptides activate neurokinin-1 receptors in the mouse isolated 
trachea. Journal of Pharmacology and Experimental Therapeutics 317, 598-605, 
doi:10.1124/jpet.105.097121 (2006). 
344 Borzi, R. M., Mazzetti, I., Macor, S., Silvestri, T., Bassi, A., Cattini, L. & 
Facchini, A. Flow cytometric analysis of intracellular chemokines in 
chondrocytes in vivo: constitutive expression and enhancement in osteoarthritis 
and rheumatoid arthritis. Febs Letters 455, 238-242, doi:10.1016/s0014-
5793(99)00886-8 (1999). 
345 Borzi, R. M., Mazzetti, I., Cattini, L., Uguccioni, M., Baggiolini, M. & Facchini, 
A. Human chondrocytes express functional chemokine receptors and release 
matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis 
and Rheumatism 43, 1734-1741, doi:10.1002/1529-
0131(200008)43:8<1734::aid-anr9>3.0.co;2-b (2000). 
346 Yan, D. Y., Kc, R., Chen, D., Xiao, G. Z. & Im, H. J. Bovine Lactoferricin-
induced Anti-inflammation Is, in Part, via Up-regulation of Interleukin-11 by 
Secondary Activation of STAT3 in Human Articular Cartilage. Journal of 
Biological Chemistry 288, 31655-31669, doi:10.1074/jbc.M112.440420 (2013). 
347 Ralph, J. A., McEvoy, A. N., Kane, D., Bresnihan, B., FitzGerald, O. & Murphy, 
E. P. Modulation of orphan nuclear receptor NURR1 expression by methotrexate 
in human inflammatory joint disease involves adenosine A2A receptor-mediated 
responses. Journal of Immunology 175, 555-565 (2005). 
348 Mix, K. S., McMahon, K., McMorrow, J. P., Walkenhorst, D. E., Smyth, A. M., 
Petrella, B. L., Gogarty, M., Fearon, U., Veale, D., Attur, M. G., Abramson, S. B. 
& Murphy, E. P. Orphan nuclear receptor NR4A2 induces synoviocyte 
proliferation, invasion, and matrix metalloproteinase 13 transcription. Arthritis 
and Rheumatism 64, 2126-2136, doi:10.1002/art.34399 (2012). 
349 Aikawa, Y., Morimoto, K., Yamamoto, T., Chaki, H., Hashiramoto, A., Narita, 
H., Hirono, S. & Shiozawa, S. Treatment of arthritis with a selective inhibitor of 
c-Fos/activator protein-1. Nature Biotechnology 26, 817-823, 
doi:10.1038/nbt1412 (2008). 
350 Barksby, H. E., Hui, W., Wappler, I., Peters, H. H., Milner, J. M., Richards, C. 
D., Cawston, T. E. & Rowan, A. D. Interleukin-1 in combination with oncostatin 
M up-regulates multiple genes in chondrocytes - Implications for cartilage 
destruction and repair. Arthritis and Rheumatism 54, 540-550, 
doi:10.1002/art.21574 (2006). 
351 Wojdasiewicz, P., Poniatowski, L. A. & Szukiewicz, D. The Role of 
Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of 
Osteoarthritis. Mediators of Inflammation, doi:10.1155/2014/561459 (2014). 
260 
 
352 Melchiorri, C., Meliconi, R., Frizziero, L., Silvestri, T., Pulsatelli, L., Mazzetti, I., 
Borzi, R. M., Uguccioni, M. & Facchini, A. Enhanced and coordinated in vivo 
expression of inflammatory cytokines and nitric oxide synthase by chondrocytes 
from patients with osteoarthritis. Arthritis and Rheumatism 41, 2165-2174, 
doi:10.1002/1529-0131(199812)41:12<2165::aid-art11>3.0.co;2-o (1998). 
353 Martelpelletier, J., McCollum, R., Dibattista, J., Faure, M. P., Chin, J. A., 
Fournier, S., Sarfati, M. & Pelletier, J. P. The interleukin-1 receptor in normal and 
osteoarthritic human articular chondrocytes: identification as the type I receptor 
and analysis of binding kinetics and biologic function. Arthritis and Rheumatism 
35, 530-540, doi:10.1002/art.1780350507 (1992). 
354 Sillat, T., Barreto, G., Clarijs, P., Soininen, A., Ainola, M., Pajarinen, J., 
Korhonen, M., Konttinen, Y. T., Sakalyte, R., Hukkanen, M., Ylinen, P. & 
Nordstrom, D. C. E. Toll-like receptors in human chondrocytes and osteoarthritic 
cartilage. Acta Orthopaedica 84, 585-592, doi:10.3109/17453674.2013.854666 
(2013). 
355 Kragstrup, T. W., Otkjaer, K., Hohn, C., Jorgensen, A., Hokland, M., Iversen, L. 
& Deleuran, B. The expression of IL-20 and IL-24 and their shared receptors are 
increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 41, 16-23, 
doi:10.1016/j.cyto.2007.10.004 (2008). 
356 Raymond, F., Carbonneau, J., Boucher, N., Robitaille, L., Boisvert, S., Wu, W. 
K., De Serres, G., Boivin, G. & Corbeil, J. Comparison of Automated Microarray 
Detection with Real-Time PCR Assays for Detection of Respiratory Viruses in 
Specimens Obtained from Children. Journal of Clinical Microbiology 47, 743-
750, doi:10.1128/jcm.01297-08 (2009). 
357 Allanach, K., Mengel, M., Einecke, G., Sis, B., Hidalgo, L. G., Mueller, T. & 
Halloran, P. F. Comparing microarray versus RT-PCR assessment of renal 
allograft biopsies: Similar performance despite different dynamic ranges. 
American Journal of Transplantation 8, 1006-1015, doi:10.1111/j.1600-
6143.2008.02199.x (2008). 
358 Wang, Y. L., Barbacioru, C., Hyland, F., Xiao, W. M., Hunkapiller, K. L., Blake, 
J., Chan, F., Gonzalez, C., Zhang, L. & Samaha, R. R. Large scale real-time PCR 
validation on gene expression measurements from two commercial long-
oligonucleotide microarrays. Bmc Genomics 7, doi:10.1186/1471-2164-7-59 
(2006). 
359 Zeng, G. Q., Chen, A. B., Li, W., Song, J. H. & Gao, C. Y. High MMP-1, MMP-
2, and MMP-9 protein levels in osteoarthritis. Genetics and Molecular Research 
14, 14811-14822, doi:10.4238/2015.November.18.46 (2015). 
360 Lipari, L. & Gerbino, A. Expression of gelatinases (MMP-2, MMP-9) in human 
articular cartilage. International Journal of Immunopathology and Pharmacology 
26, 817-823 (2013). 
361 Ohmuraya, M., Sugano, A., Hirota, M., Takaoka, Y. & Yamamura, K. Role of 
intrapancreatic SPINK1/Spink3 expression in the development of pancreatitis. 
Frontiers in Physiology 3, doi:10.3389/fphys.2012.00126 (2012). 
362 Yamasaki, Y., Satomi, S., Murai, N., Tsuzuki, S. & Fushiki, T. Inhibition of 
membrane-type serine protease 1/matriptase by natural and synthetic protease 
inhibitors. Journal of Nutritional Science and Vitaminology 49, 27-32 (2003). 
363 Izaguirre, G., Qi, L. X., Lima, M. & Olson, S. T. Identification of Serpin 
Determinants of Specificity and Selectivity for Furin Inhibition through Studies 
of alpha(1) PDX (alpha(1)-Protease Inhibitor Portland)-Serpin B8 and Furin 
Active-site Loop Chimeras. Journal of Biological Chemistry 288, 
doi:10.1074/jbc.M113.462804 (2013). 
261 
 
364 Alvarez-Garcia, O., Olmer, M., Akagi, R., Akasaki, Y., Fisch, K. M., Shen, T., 
Su, A. I. & Lotz, M. K. Suppression of REDD1 in osteoarthritis cartilage, a novel 
mechanism for dysregulated mTOR signaling and defective autophagy. 
Osteoarthritis and Cartilage 24, 1639-1647, doi:10.1016/j.joca.2016.04.015 
(2016). 
365 Zhang, Y. & Ross, A. C. Retinoic acid and the transcription factor MafB act 
together and differentially to regulate aggrecan and matrix metalloproteinase gene 
expression in neonatal chondrocytes. Journal of Cellular Biochemistry 114, 471-
479, doi:10.1002/jcb.24387 (2013). 
366 Bramlage, C. P., Haupl, T., Kaps, C., Ungethum, U., Krenn, V., Pruss, A., Muller, 
G. A., Strutz, F. & Burmester, G. R. Decrease in expression of bone 
morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis 
and rheumatoid arthritis. Arthritis Research & Therapy 8, doi:10.1186/ar1923 
(2006). 
367 Guns, L., Calebiro, D., Lohse, M., Loires, R. & Cailotto, F. The GPR22 receptor, 
genetically linked to osteoarthritis stimulates chondrocyte hypertrophy and 
decreases protein kinase a activity. Ann Rheum Dis 75 (2016). 
368 Kerkhof, H. J. M., Lories, R. J., Meulenbelt, I., Jonsdottir, I., Valdes, A. M., Arp, 
P., Ingvarsson, T., Jhamai, M., Jonsson, H., Stolk, L., Thorleifsson, G., Zhai, G. 
J., Zhang, F., Zhu, Y. Y., van der Breggen, R., Carr, A., Doherty, M., Doherty, S., 
Felson, D. T., Gonzalez, A., Halldorsson, B. V., Hart, D. J., Hauksson, V. B., 
Hofman, A., Ioannidis, J. P. A., Kloppenburg, M., Lane, N. E., Loughlin, J., 
Luyten, F. P., Nevitt, M. C., Parimi, N., Pols, H. A. P., Rivadeneira, F., Slagboom, 
E. P., Styrkarsdottir, U., Tsezou, A., van de Putte, T., Zmuda, J., Spector, T. D., 
Stefansson, K., Uitterlinden, A. G. & van Meurs, J. B. J. A Genome-Wide 
Association Study Identifies an Osteoarthritis Susceptibility Locus on 
Chromosome 7q22. Arthritis and Rheumatism 62, 499-510, 
doi:10.1002/art.27184 (2010). 
369 Lewis, E. J., Bishop, J., Bottomley, K. M. K., Bradshaw, D., Brewster, M., 
Broadhurst, M. J., Brown, P. A., Budd, J. M., Elliott, L., Greenham, A. K., 
Johnson, W. H., Nixon, J. S., Rose, F., Sutton, B. & Wilson, K. Ro 32-3555, an 
orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in 
vivo. British Journal of Pharmacology 121, 540-546, doi:10.1038/sj.bjp.0701150 
(1997). 
370 MacPherson, L. J., Bayburt, E. K., Capparelli, M. P., Carroll, B. J., Goldstein, R., 
Justice, M. R., Zhu, L. J., Hu, S. I., Melton, R. A., Fryer, L., Goldberg, R. L., 
Doughty, J. R., Spirito, S., Blancuzzi, V., Wilson, D., Obyrne, E. M., Ganu, V. & 
Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active 
stromelysin inhibitor that blocks cartilage degradation in rabbits. Journal of 
Medicinal Chemistry 40, 2525-2532, doi:10.1021/jm960871c (1997). 
371 Vandenbroucke, R. E. & Libert, C. Is there new hope for therapeutic matrix 
metalloproteinase inhibition? Nature Reviews Drug Discovery 13, 904-927, 
doi:10.1038/nrd4390 (2014). 
372 Plotkin, L. & Bellido, T. Osteocytic signalling pathways as therapeutic targets for 
bone fragility. Nature Reviews Endocrinology 12, 593–605 (2016). 
373 Karsdal, M. A., Sumer, E. U., Wulf, H., Madsen, S. H., Christiansen, C., Fosang, 
A. J. & Sondergaard, B.-C. Induction of increased cAMP levels in articular 
chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, 
but not aggrecanase-mediated cartilage degradation. Arthritis and Rheumatism 
56, 1549-1558, doi:10.1002/art.22599 (2007). 
374 Morovic-Vergles, J., Culo, M. I., Gamulin, S. & Culo, F. Cyclic adenosine 5 '-
monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis 
262 
 
patients. Rheumatology International 29, 167-171, doi:10.1007/s00296-008-
0663-z (2008). 
375 Verbovsek, U., Van Noorden, C. J. F. & Lah, T. T. Complexity of cancer protease 
biology: Cathepsin K expression and function in cancer progression. Seminars in 
Cancer Biology 35, 71-84, doi:10.1016/j.semcancer.2015.08.010 (2015). 
376 Roux, P. P. & Blenis, J. ERK and p38 MAPK-activated protein kinases: a family 
of protein kinases with diverse biological functions. Microbiology and Molecular 
Biology Reviews 68, 320-+, doi:10.1128/mmbr.68.2.320-344.2004 (2004). 
377 Maeng, Y. S., Min, J. K., Kim, J. H., Yamagishi, A., Mochizuki, N., Kwon, J. Y., 
Park, Y. W., Kim, Y. M. & Kwon, Y. G. ERK is an anti-inflammatory signal that 
suppresses expression of NF-kappa B-dependent inflammatory genes by 
inhibiting IKK activity in endothelial cells. Cellular Signalling 18, 994-1005, 
doi:10.1016/j.cellsig.2005.08.007 (2006). 
378 DeFea, K. A., Zalevsky, J., Thoma, M. S., Dery, O., Mullins, R. D. & Bunnett, N. 
W. beta-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is 
required for intracellular targeting of activated ERK1/2. Journal of Cell Biology 
148, 1267-1281, doi:10.1083/jcb.148.6.1267 (2000). 
379 Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K. & Ohno, S. Protein kinase 
C delta activates the MEK-ERK pathway in a manner independent of Ras and 
dependent on Raf. Journal of Biological Chemistry 271, 23512-23519 (1996). 
380 Schmitt, J. M., Wayman, G. A., Nozaki, N. & Soderling, T. R. Calcium activation 
of ERK mediated by calmodulin kinase I. Journal of Biological Chemistry 279, 
24064-24072, doi:10.1074/jbc.M401501200 (2004). 
381 Eishingdrelo, H. & Kongsamut, S. Minireview: Targeting GPCR Activated ERK 
Pathways for Drug Discovery. Current chemical genomics and translational 
medicine 7, 9-15, doi:10.2174/2213988501307010009 (2013). 
382 Goergens, S. W., Eckardt, K., Elsen, M., Tennagels, N. & Eckel, J. Chitinase-3-
like protein 1 protects skeletal muscle from TNF alpha-induced inflammation and 
insulin resistance. Biochemical Journal 459, 479-488, doi:10.1042/bj20131151 
(2014). 
 
